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Abstract 
 
Epstein-Barr virus (EBV) establishes a lifelong latent infection in the human host. In vitro EBV 
immortalises primary B lymphocytes giving rise to latently infected lymphoblastoid cell lines 
(LCLs). EBV strains are classified as type 1 or type 2 according to the sequence of the EBNA-2 
gene, which expresses a transcription factor that induces viral and cell genes important for B cell 
proliferation. Type 1 EBV transforms primary B lymphocytes into LCLs much more efficiently 
than type 2 EBV, a difference previously mapped to the EBNA-2 locus. 
In this study, the greater transforming activity of type 1 EBV was found to correlate with a 
stronger and more rapid induction of the viral oncogene LMP-1 and the cell gene CXCR7 (which 
are both required for proliferation of EBV-LCLs) during infection of primary B cells with EBV-
BAC recombinant viruses. The enhanced ability of type 1 EBNA-2 to induce LMP-1 and 
CXCR7 genes was also confirmed in Burkitt’s Lymphoma cell lines.  
Although the major sequence differences between type 1 and type 2 EBNA-2 lie in N-terminal 
parts of the protein, the superior ability of type 1 EBNA-2 to sustain proliferation of EBV-LCLs 
is mostly determined by the C-terminal region of the protein. Substitution of the C-terminal third 
of type 1 EBNA-2 into the type 2 protein is sufficient to confer type 1 growth phenotype and 
type 1 expression levels of LMP-1 and CXCR7 in an EREB2.5 cell growth assay. Within this 
region, the RG, CR7 and TAD domains are the minimum type 1 sequences required. Sequencing 
the C-terminal part of EBNA-2 from additional EBV isolates showed high sequence identity 
within type 1 isolates or within type 2 isolates, indicating that the functional differences mapped 
are typical of EBV type sequences.  
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TEMPORALE 
Un bubbolìo lontano. . . 
Rosseggia l'orizzonte, 
come affocato, a mare: 
nero di pece, a monte, 
stracci di nubi chiare: 
tra il nero un casolare: 
un'ala di gabbiano. 
 
 
tratto da “Myricae - Arbusta iuvant humilesque myricae”, di Giovanni Pascoli 
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1  Introduction 
 
1.1  Epstein-Barr Virus: the first candidate human tumour virus 
In 1958, the English surgeon Denis Burkitt first described an endemic lymphoma affecting 
children in equatorial Africa, which he suspected to have a viral aetiology closely associated 
with malaria [1,2]. In 1964, in England, the pathologist Anthony Epstein and his PhD student 
Yvonne Barr succeeded in culturing the lymphoma cells from some of these tumour biopsies and 
identified, by electron microscopy, the presence of herpesvirus-like particles in these cells [3]. 
The virus was named Epstein-Barr virus (EBV) and identified as a new member of the 
herpesvirus family, since it was distinct from other previously described herpesviruses [4]. 
Importantly, soon after its discovery, EBV from Burkitt’s Lymphoma-cultured cells was shown 
to transform resting B lymphocytes in vitro leading to unlimited proliferation of the infected 
cells. This observation was crucial to define EBV as a B lymphotropic oncogenic virus [5,6]. 
Although it was discovered as an agent linked to African tumours, EBV has thereafter been 
associated to a variety of human malignancies. These include, in addition to Burkitt’s 
Lymphoma (BL), Hodgkin’s Lymphoma (HL), post-transplant lymphoproliferative disease 
(PTLD) and X-linked lymphoproliferative disease. Peripheral T cell lymphoma, nasal T or 
natural killer (NK) cell lymphoma (NL), nasopharyngeal carcinoma (NPC) and gastric 
carcinoma have also been associated to EBV, providing evidence of the ability of the virus to 
infect cell types other than B lymphocytes (i.e. T or NK cells and epithelial cells) [7]. Overall, 
1% of malignancies world-wide are associated with EBV. Furthermore EBV has also been 
associated with a benign disease, namely infectious mononucleosis [8].  
EBV infects virtually the whole human population (>95%) and establishes a lifelong latent 
infection in the B cell compartment of the host; therefore the virus is considered as one of the 
most successful human pathogens. Despite its potent transforming ability in vitro and its 
association with several types of cancers, EBV remains benign in most of the infected population 
and tumour development is an epidemiologically rare event.  
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1.2  Oncogenic viruses: mechanisms of cell transformation 
Cancerous cells arise from a multi-step accumulation of genetic or epigenetic alterations. As part 
of their normal life cycle, some viruses have evolved strategies to hijack the same host cell 
pathways that are involved in control of cell proliferation and survival, ultimately leading to 
carcinogenesis. 10-15% of the human cancers world-wide can be linked to viral infection [9]. 
There are several viruses that cause cancer in humans: Hepatitis B (HBV) and C (HCV) viruses, 
EBV, Human Papillomavirus (HPV), Human T-lymphotropic type 1 virus (HTLV-1), Kaposi’s 
Sarcoma-associated Herpesvirus (KSHV), Merkel Cell Polyoma Virus (MCPyV) and possibly 
Xenotropic Murine Leukaemia Virus-related Virus (XMRV). The first oncogenic viruses were 
discovered and studied in experimental animal models during the first half of the twentieth 
century and led to the understanding of many molecular mechanisms involved in cell 
transformation. 
 
1.2.1  Animal tumour viruses 
 
1.2.1.1  Animal retroviruses 
The first animal tumour viruses isolated were the retroviruses of the oncovirus family, which 
include Rous Sarcoma Virus (RSV) and Avian Leukosis Virus (ALV) [10]. Retroviruses share a 
common genomic structure comprising three genes, gag, pol and env, flanked by two long 
terminal repeats (LTRs) containing a potent transcriptional promoter. One mechanism by which 
retroviruses may cause cancer is integration of the viral genome, as part of the normal viral life 
cycle, into the host genome in close proximity to a cell proto-oncogene, such that the viral LTR 
can drive expression of the host oncoprotein and thereby promote cell proliferation. The best 
example is offered by the integration event of chicken, cat or mouse retroviruses near the c-MYC 
oncogene, which causes leukaemia [10]. An additional mechanism of retroviral carcinogenesis 
consists of acquisition of a cell gene, normally involved in cell proliferation, into the viral 
genome by rare recombination events [10]. These integrated genes may often suffer mutations 
such that their expression is deregulated. Therefore if these integrated genes play a role in cell 
proliferation, they might confer potent transforming activity to the virus. Examples of this viral 
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strategy are offered by RSV and Avian Myelocytomatosis Virus, which have acquired the cell 
proto-oncogenes c-SRC and c-MYC respectively and converted them into the viral oncogenes v-
scr and v-myc respectively.  
 
1.2.1.2  Polyomaviruses 
Polyomaviruses are small DNA viruses and include the Simian Vacuolating Virus 40 (SV40) and 
the Murine Polyoma Virus (MPyV). Both have been shown to cause tumours in experimental 
animals and to transform human cells in culture. Because genome replication of these viruses is 
host DNA polymerase-dependent, they have evolved strategies to push infected cells from the G1 
to the S phase of the cell cycle. SV40 is a monkey virus that causes tumours in rodents, where 
infection is non-productive and early genes are continuously expressed. SV40 large T antigen 
binds to two cell tumour-suppressor proteins, pRB and p53 [11]. pRB regulates the cell cycle 
transition from G1 to S phase, whereas p53 activation causes apoptosis and cell cycle arrest. 
Because unscheduled inactivation of pRB normally triggers a strong anti-proliferative response 
mediated by the p53 protein, as a host mechanism to prevent oncogenic transformation, 
simultaneous inactivation of both cell tumour suppressors by SV40 enables the virus to induce 
cell transformation [12]. This strategy is employed also by other tumour viruses, such as 
adenoviruses and papillomaviruses (see sections 1.2.1.3 and 1.2.2.1), to trigger G1/S cell cycle 
transition [11,13]. SV40 large T antigen also inactivates the G1 cyclin-dependent kinases 
inhibitors p27 and p21, a mechanism also exploited by other viral transforming proteins such as, 
adenovirus E1A and human papillomavirus E7 (see sections 1.2.1.3 and 1.2.2.1) [10]. An 
additional mechanism employed by SV40 to induce cell proliferation is inhibition of the cell 
cycle regulator protein phosphatase 2A, through small T antigen [10].  
 
1.2.1.3  Adenoviruses 
Adenoviruses usually cause respiratory infections in humans, which are their natural hosts. 
However, some adenoviruses, when inoculated in newborn rodents, can cause tumours, as in 
these hosts the viral replication cycle is usually abortive and all or part of the genome may be 
integrated into the host DNA, resulting in a latent infection, which may lead to oncogenic 
transformation [14].  
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The transforming genes of this family of viruses, are E1A and E1B. Both genes are able to cause 
cell transformation in vitro upon transfection. E1A protein binds to and inactivates pRB, 
bypassing the G1/S checkpoint, whereas the E1B proteins bind to and inactivates p53 and the 
pro-apoptotic protein BAX, thereby suppressing apoptosis, with the overall result being 
stimulation of cell proliferation [10].  
 
1.2.1.4  Animal herpesviruses: Marek’s Disease Virus and Herpesvirus Saimiri 
Marek’s Disease Virus (MDV) is a herpesvirus that causes T cell lymphomas in chickens. It 
represents a significant farming problem, still not entirely controlled by vaccination. The key 
transforming gene of MDV is Meq: transfection of this gene into rat cells in culture can induce 
transformation and viruses mutated in their Meq gene display an attenuated transformation 
phenotype [10]. Meq codes for a transcription factor of the b-ZIP family; therefore it dimerizes 
with c-jun and other cell bZIP proteins to regulate transcription. Meq also binds to other cell 
proteins involved in proliferation and death, such as CDK2, p53 and pRB [10]. 
Herpesvirus Saimiri (HVS) is a gamma-herpesvirus that can cause T cell lymphomas after 
experimental infection of monkeys, whereas in its natural host, the squirrel monkey, persistent 
infection is asymptomatic. HVS strains are divided into three subgroups (A, B and C). 
Subgroups A and C are highly oncogenic and are able to immortalise common marmoset T 
lymphocytes to IL-2-independent growth in vitro. The transforming genes of HVS are Stp 
(Saimiri transformation-associated protein) and tip (tyrosine kinase-interacting protein). Both 
genes are required for HSV-mediated transforming activity in culture [15]. The transforming 
ability of the Stp protein directly correlates with the oncogenic potential of different viral 
subgroups. Stp C activates cellular RAS and NF-kB pathways, whereas Tip associates with Src 
family tyrosine kinases and with the mRNA export factor Tap and activates the STAT pathway 
[15].  
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1.2.2  Human tumour viruses 
 
1.2.2.1  Human Papillomaviruses (HPVs) 
Human papillomaviruses are members of the papillomaviridae family. As such, they are small, 
non enveloped viruses containing a circular double stranded DNA (dsDNA) genome of around 
8000 base pairs, and infect keratinocytes. HPVs are associated with cervical, anal and skin 
cancer. To date more than 130 subtypes of HPVs have been identified and classified into low- or 
high-risk groups, depending on their likelihood of inducing cervical cancer or persistent infection 
[16]. High-risk HPVs, such as HPV-16, 18 and 31 are associated with more than 90% of cervical 
cancers [16]. Similarly to animal polyomaviruses, HPVs lack a polymerase gene. Therefore 
replication of the viral genome is dependent upon their ability to stimulate DNA synthesis in the 
infected cells. The main transforming activity of HPV-16 resides in the E6 and E7 oncoproteins, 
two multifunctional proteins that can promote cell proliferation by several mechanisms. E6 and 
E7 are able to immortalise cells in vitro in a synergistic manner and induce skin tumours in 
transgenic animals [17]. HPV genomes are frequently integrated into cell chromosomes. To 
achieve this, HPV genome is linearized, causing interruption of the E2 gene, which is a 
transcriptional repressor of the E6 and E7 genes. Hence, this results in increased expression of 
E6 and E7 proteins, an event that is required for continuous growth of cervical cancer cells in 
culture [10]. The E7 protein, similarly to SV40 large T and adenovirus E1A proteins, binds to 
pRB and prevents its checkpoint functions in the G1/S cell cycle phase transition, stimulating S 
phase entry and DNA synthesis, which leads to cell proliferation [10]. E6 protein inactivates p53 
by ubiquitination and subsequent proteasome degradation, an event achieved by interaction of 
the viral transforming protein with the ubiquitin ligase enzyme E6-associated protein (E6-AP) 
[18]. The mechanism of p53 inactivation is different from that used by SV40 large T and 
adenovirus E1B, but the functional outcome (apoptosis prevention) is the same [10]. By 
inactivating p53, E6 can also induce down-regulation of Notch1, a target gene of p53 associated 
with keratinocyte differentiation and growth suppression of cervical cancer cell lines [19]. E6 
can also induce telomerase activity, an event, together with inactivation of p53 and pRB 
pathways, required for immortalisation of human epithelial cells in culture [19]. E6 can 
additionally prevent the production of β-interferon from the infected cells, by modulating the 
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interferon regulatory factor 3 (IRF-3) and can also bind to the pro-apoptotic BAK protein. Both 
E7 and E6 induce genomic instability, which leads to accumulation of alterations in chromosome 
number and structure and is likely to play a role in cancer development [19].  
 
1.2.2.2  Human T cell Leukaemia Virus Type 1 (HTLV-1) 
HTLV-1 is a human oncogenic retrovirus that infects human CD4+ T lymphocytes. Infection 
with HTLV-1 is life-long. Most infected subjects remain asymptomatic but in a small minority 
(<5%) of infected individuals, the virus can cause a malignancy called adult T cell leukaemia 
(ATL) or a condition known as HTLV-1-associated myelopathy or tropical spastic paraparesis 
(HAM/TSP) [20]. The HTLV-1 genome harbours the typical retroviral genes gag, env and pol, 
but also encodes a unique oncoprotein, Tax. The oncogenic abilities of this protein were 
demonstrated in both cell culture and animal model systems, where Tax expression is sufficient 
to induce cell transformation and induce tumours [20]. The molecular mechanism by which 
HTLV-1 Tax causes T cell proliferation is by acting as a potent transcriptional regulator of both 
viral and cell genes, doing so through activation of other cell DNA-binding transcription factors 
and co-activators [10]. For example, Tax regulates transcription through chromating remodelling 
cell factors, such as HDAC-1 and SWI/SNF. Additionally, similarly to EBV LMP-1 (see section 
1.6.5), Tax powerfully activates NF-kB, AP-1 and CRE pathways which exert pro-proliferative 
effects in lymphocytes [18]. For example, via NF-kB, Tax activates viral transcription from the 
LTR and transcription of the cell genes IL-2/IL-2R which mediate T cell growth through an 
autocrine mechanism [10]. Additionally, Tax can bind to and inactivate the cell cycle checkpoint 
proteins p16 and MAD1 and can also inhibit DNA repair mechanisms, thus leading to genomic 
instability and ultimately contributing to cell transformation [18]. Even though Tax protein is 
required for HTLV-1 to initiate T cell transformation, tax transcripts are detected in only 
approximately 40% of all ATLs [21]. It is believed that ATL cells can silence Tax expression by 
three mechanisms: accumulation of mutations in the tax gene, deletion of the 5’ LTR containing 
the viral promoter or silencing of viral transcription by DNA methylation of the 5’ LTR [21]. 
The current view is therefore that Tax is required early after infection to initiate transformation, 
but not to maintain the transformed phenotype of ATL cells. Since Tax is the main target of 
cytotoxic T lymphocytes (CTL) responses, cells that shut down Tax expression have an 
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advantage in escaping immunosurveillance and are preferentially selected in vivo during disease 
progression. Maintenance of ATL transformation seems to require the function of a novel 
antisense protein and RNA, termed HTLV-1 bZIP factor (HBZ), that has been recently identified 
and is believed to play an important role in HTLV-1-mediated pathogenesis and oncogenesis. 
Expression of the HBZ antisense mRNA, from the minus strand of HTLV-1 genome in the 3’ 
LTR, was consistently detected in all ATL cells studied to date, in contrast to tax mRNA, which 
is present only in approximately 40% of ATL cases [22]. HBZ is also expressed in vivo in 
patients with HAM/TSP and in asymptomatic carriers, as demonstrated by detection of specific 
CD4+ and CD8+ T cell responses ex vivo [23]. HBZ protein was shown to suppress Tax-
mediated transactivation of the viral transcription from the 5’ LTR through interaction with Jun 
and ATF/CREB families. HBZ RNA was demonstrated to up-regulate transcription of the cell 
transcription factor E2F1, leading to induction of E2F1-responsive genes, and to promote ATL 
cell proliferation [22]. HBZ was shown to promote CD4+ T cell proliferation in transgenic mice 
and to enhance viral infectivity and persistence in rabbits [24]. Among the activities ascribed to 
HBZ protein, interaction and activation of the cell transcription factor JunD leads to up-
regulation of human telomerase reverse transcriptase gene (hTERT) [25]. Being a retrovirus, 
HTLV-1 can lead to development of leukaemia by integration into host chromosomes. Earlier 
reports indicated that the viral integration events are random [26], however, recent studies 
suggest that the viral genome preferentially integrates into transcriptional units in ATL cells, 
frequently near genes involved in growth-regulation, and deregulated expression of some of 
these genes has also been detected [27,28].  
 
1.2.2.3  Hepatitis Viruses  
Chronic infection with Hepatitis B (HBV) or C Viruses (HCV) is the predominant cause of liver 
cirrhosis and hepatocellular carcinoma (HCC), which accounts for around 4% of all cancers 
world-wide [10]. None of the virally encoded proteins have been directly linked to acute 
oncogenic activity, rather the current view is that the cancer is a result of chronic liver damage 
caused by the continuous inflammation induced by persistent viral infection [18]. HBV is a 
hepadnavirus with a small circular dsDNA genome. Only in a few cases has HBV DNA been 
found to integrate in the host cell chromosomes, similarly to retroviruses, in proximity to 
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oncogenes. One of the four viral major proteins of HBV, the X protein. is a transcriptional 
transactivator that can cause cell transformation in vitro, similarly to HTLV-1 Tax and HPV 
E6/E7, and may inhibit p53 function. The X protein has been proposed to activate several cell 
pathways involved in proliferation and inflammation (NF-kB, AP-1, PI3K), and has also been 
shown to bind to XAP-1, involved in DNA damage repair [18], thereby contributing to HCC 
progression. HCV is a small enveloped RNA virus of the flaviviridae family. HCV-associated 
HCC has a later onset compared to HBV-related cases and is more frequently associated with 
alcohol-induced cirrhosis. To date there is very little evidence of a direct oncogenic function for 
HCV and no viral oncogenes have been identified [10,18].  
 
1.2.2.4  Epstein-Barr Virus (EBV) 
EBV is a dsDNA virus belonging to the gamma subfamily of herpesviruses. EBV was the first 
candidate human tumour virus. The virus is involved in several types of cancer (see section 1.1). 
In tissue culture EBV is one of the most potent transforming viruses of B cells, since infection of 
resting naïve B cells in vitro results in establishment of immortalised B cell lines [6]. The general 
mechanism by which EBV causes lymphoproliferation consists of activating proliferation 
pathways normally used by B cells in response to foreign antigens. Several EBV-encoded 
proteins have the potential to contribute to transformation (see section 1.5.4.4.2), including 
LMP-1, EBNA-2 and EBNA-3A and -3C. These will be described more extensively in section 
1.6. Briefly LMP-1, similarly to the transforming proteins KSHV K1 and HVS Stp, is a 
transmembrane signalling protein and provides survival signals for the B cells by mimicking an 
activated CD40 and inducing anti-apoptotic genes; EBNA-2 is functionally equivalent to HTLV-
1 Tax in that acts as a promiscuous transcriptional activator of both viral and cell genes which 
cause cell proliferation; EBNA-3A and -3C can promote cell proliferation by overriding cell 
cycle check-points. Potential contribution of EBV to EBV-related cancers will be discussed in 
section 1.5.4.3. 
 
1.2.2.5  Kaposi’s Sarcoma-associated Virus (KSHV) 
KSHV is also a gamma-herpesvirus and establishes life-long latent infection in B cells, similarly 
to EBV. However, in contrast to EBV, KSHV is present only in about 5% of the human 
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population world-wide [10]. KSHV was discovered relatively recently. It was isolated in 1994 
from a Kaposi’s Sarcoma (KS) biopsy [29] and is now the recognised aetiological agent of KS 
(classic and AIDS-related) and of two rare B lymphoproliferative diseases occurring in AIDS-
patients (primary effusion lymphoma and multicentric Castleman’s Disease) [17]. The KSHV 
genome harbours numerous potential oncogenes, many of which represent pirated versions of 
cell genes. In the KSHV-tumours the virus is found mainly in a latent state. Potential latent 
oncogenes include LANA, v-cyclin and v-FLIP. LANA is the functional homologue of EBV 
EBNA-1 (see section 1.6.4), in that it plays a role in replication and ensures maintenance of the 
viral episome in latently-infected cells. Additionally, LANA deregulates various cell pathways 
such as pRB and p53, an oncogenic mechanism reminiscent of SV40, adenoviruses and HPV, 
and can cooperate with activated RAS oncogene to transform fibroblasts in culture [18]. v-cyclin 
is a virally encoded homologue of human cyclin D2 and is very effective at promoting G1/S cell 
cycle progression. Its oncogenic potential is exposed when p53 function is defective [18]. v-FLIP 
is a viral homologue of the human FLICE inhibitory protein that protects the cells from apoptosis 
by inhibiting signal transduction from Fas or TNF receptors [18]. Although latency is the most 
frequent viral state in the KSHV-infected tumours, 1-5% of the cells undergo lytic replication, 
and some of the viral lytic products may contribute to disease pathogenesis. For example, 
secreted v-IL-6, a homologue of the human IL-6 cytokine, acts as a growth factor for rat embryo 
fibroblasts, induces transforming phenotype when expressed in murine fibroblast and leads to 
expression of vascular endothelial growth factor (VEGF) [18]. The KSHV G-protein coupled 
receptor (v-GPCR) has potent transforming and pro-angiogenic functions. It induces a 
transforming phenotype when expressed in several cell types and can lead to development of KS-
lesions in multiple animal model systems. v-GPCR promotes angiogenesis and transformation by 
stimulating numerous cell pathways, including Akt-mTOR (via PI3 kinase) and the MAP kinases 
pathways JNK and p38. The latter converge to the nucleus to stimulate several transcription 
factors (NF-kB, AP-1 and hypoxia-inducible factor 1) which up-regulate expression of pro-
inflammatory cytokines (VEGF, IL-6, IL-8 and MIP-1) that can promote tumoural cell growth in 
a paracrine fashion [18]. In lytically infected cells, the virus also encodes an analogue of the cell 
BCL-2 inhibitor of apoptosis (v-bcl-2).  
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1.2.2.6  Human Polyomaviruses 
In addition to the animal polyomaviruses SV40 and MPyV (section 1.2.1.2), human viruses of 
the polyoma family with potential roles in cancer have also been identified. BK Virus (BKV) and 
JC Virus (JCV) are ubiquitous viruses widely spread in adult human populations and have been 
detected in a variety of human tumours [30]. BKV is able to immortalise rodent, monkey and 
human cells and inoculation of the virus in newborn animals causes several types of brain 
tumours [31]. JCV can immortalise rodent and human cells and induce tumours in hamsters and 
rats [31]. However, a direct causative role of BKV and JCV in cancer remains controversial. 
Recently a new human polyomavirus has been identified in Merkel Cell Carcinoma (MCC) 
samples, and was hence named Merkel Cell Polyoma Virus (MCPyV) [32]. Several 
epidemiological studies indicated that MCPyV is frequently present in MCC, which is a rare but 
aggressive human skin cancer of neuroendocrine origin, typically occurring in 
immunosuppressed patients [31,33]. The majority of the viral DNA was found to be integrated in 
the tumour cell genome in a clonal form and a single integration site was found for the viral 
DNA in each tumour analysed, within both primary tumours and metastatic deposits [32,34]. 
These observations suggest that the viral integration event takes place prior to tumour 
development and support a causal role of MCPyV in MCC. In one study, the viral integrated 
sequences commonly found in all tumours include the replication origin, the Small T antigen 
(ST) and the Large T antigen (LT) encoding genes [34]. In models of polyomavirus-induced 
oncogenesis, LT inactivates both pRB and p53, whereas ST may bind to cell protein phosphatase 
2A, leading to cell transformation (see section 1.2.1.2). Expression of MCPyV T antigens (TA), 
in particular LT and specifically its RB interaction domain, has been shown to be required for 
sustained growth of MCPyV-positive MCC cell lines and in vivo knock down of TA was 
demonstrated to lead to tumour regression [35,36]. MCV-positive MCC tumour cells have been 
shown to undergo selection for LT mutations that prevent viral replication but not pRB binding 
function [37]. Hence, in a model of MCPyV-induced oncogenesis lack of virus replication 
prevents autoactivation of integrated virus that could be detrimental to cell survival; at the same 
time, preservation of an intact pRB binding domain in the LT antigen allows inactivation of the 
pRB tumour-suppressor and facilitates cell transformation [37]. These observations strongly 
support a causative role for MCPyV in the oncogenesis of MCC. However, it is believed that 
there are additional cofactors (i.e. ultraviolet light and immunosuppression) as MCC tumours are 
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relatively rare, whereas the virus appears to be widespread in humans. In fact, even though 
MCPyV was found at high levels in MCC samples, the virus was detected also in normal human 
tissues and the seropositivity of MCPyV in the general population was found to be 
approximately 50-60% [33].  
 
1.2.2.7  Xenotropic Murine Leukaemia Virus-related Virus (XMRV) 
Recently, a gamma-retrovirus known as Xenotropic Murine Leukaemia Virus-related Virus 
(XMRV) has been associated with prostate cancer [38] as well as with chronic fatigue syndrome 
[39]. Linkage between XMRV and prostate cancer is however still controversial and a matter of 
intense debate. The presence of XMRV in prostate cancer patients was confirmed in several 
studies using a variety of methods, including PCR, fluorescence in situ hybridization (FISH), 
immunohistochemistry, serology assays and integration site mapping [38,40,41,42]. However, 
numerous studies provided negative results instead [43,44]. Differences between studies may be 
explained by either laboratory contamination, geographical differences in the distribution of 
XMRV or sequence variations in XMRV and XMRV-like viruses [45,46,47]. XMRV proteins 
have been found in malignant epithelial cells and in a prostate carcinoma cell line as well as in 
approximately 1% of prostate stromal cells in regions adjacent to the carcinoma [38,40]. XMRV 
lacks direct transforming activity, as measured by focus formation in fibroblasts and epithelial 
cell lines, but can induce low rates of transformation in cultured cells, suggesting an indirect 
transforming activity, through activation of endogenous oncogenes [48]. In fact, being a 
retrovirus, XMRV may potentially contribute to the oncogenic process by insertional 
mutagenesis. When XMRV infects epithelial cells, integration of viral promoters/enhancers near 
cell proto-oncogenes may lead to their activation and viral integration events may also disrupt a 
host tumour-suppressor gene, directly causing cell transformation [40,45]. Additionally, viral 
integration in stromal cells could cause release of cytokines, chemokines and growth factors that 
can promote tumorigenesis and proliferation of adjacent cells, contributing to chronic 
inflammation that precede and lead to prostate cancer [40,45]. In prostate cancer tissues, XMRV 
integration has been shown to occur preferentially at specific sites in the host chromosomes 
including sites associated with cancer breakpoints, common fragile sites, miRNA genes and 
cancer-related genes [49]. Interestingly, two of these (APPBP2 and PIK3C2B) affect androgen 
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signalling and the PI3K-Akt pathway, both of which are involved in prostate cancer 
development. Further epidemiologic evidence of an association of XMRV with prostate cancer 
in large-scale studies will be critical in determining whether the virus is an aetiological cause of 
prostate cancer or only a passenger virus. 
 
1.3  The Herpesviridae family 
EBV (also named HHV-4) belongs to the Herpesviridae family. Herpesviridae, of the recently 
established order Herpesvirales [50], is a broad family of large double stranded DNA viruses 
highly disseminated among animals, including mammals, birds and reptiles. More than 130 
different herpesviruses have been identified to date [51]. Eight herpesviruses have been 
identified in humans: Herpes Simplex Virus Type 1 (HSV-1) and Type 2 (HSV-2), Varicella-
Zoster Virus (VZV), Epstein-Barr virus (EBV), Human Cytomegalovirus (HCMV), Human 
Herpesviruses 6 (HHV-6) and 7 (HHV-7) and Kaposi Sarcoma-associated Virus (KSHV) (Figure 
1.1). The human herpesviruses cause a variety of diseases ranging from asymptomatic to life-
threatening infections and cancers. The majority of these viruses are acquired during childhood 
and persist for life. The Herpesviridae family is divided into three subfamilies, alpha-, beta- and 
gamma-herpesvirinae, based on biological properties and genome sequence and organization 
[50,51] (Figure 1.1). The alpha-herpesvirinae subfamily is defined by variable host range, short 
reproductive cycle and rapid spread in culture and includes HSV-1/2 and VZV. Features of the 
beta-herpesvirinae subfamily are the restricted host range to mammalian hosts, long reproductive 
cycle and slow infection in culture. HCMV, HHV-6 and HHV-7 belong to this subfamily. EBV 
belongs to the gamma-herpesvirinae subfamily, characterized by a host range limited to the 
family or order to which the natural host belongs. Viruses of this subfamily display a tropism for 
lymphoid cells and can replicate in vitro in lymphoblastoid cells, but also in epithelial and 
fibroblast cells. Most of these viruses establish lifelong infections in their hosts and a 
characteristic feature, but epidemiologically rare, is that they may have oncogenic effects, 
resulting in development of malignancies [52]. The gamma-herpesvirinae subfamily includes 
two genera: the gamma 1, or Lymphocryptovirus (LCV), to which EBV belongs, and the gamma 
2, or Rhadinovirus (RDV) genera, to which KSHV belongs. EBV is the only human LCV known 
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and KSHV is the only human RDV [52]. EBV strains can be further classified into two broad 
families known as type 1 or type 2 (see section 1.9).  
 
 
 
 
Figure 1.1. Herpesviridae taxonomy 
 
 
1.4  EBV viral particle and genome 
Like other herpesviruses, the EBV viral particle contains, from the inside outwards, a protein 
core surrounded by linear double stranded DNA, a nucleocapsid formed by 162 capsomeres, a 
protein tegument and an envelope displaying several viral glycoproteins on the outer surface 
[52]. 
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The EBV genome is about 172 kb long and expresses approximately 85 protein coding genes 
plus several non-coding functional RNAs (EBER RNAs, BART miRNAs and BHRF1 miRNAs). 
Like other LCVs, it has a single genome format and gene organization and contains several 
identical tandem direct repeats of 0.5 kb at both termini of the genome (TR). Additionally, 
similarly to the genome of other LCVs, EBV genome displays several internal direct repeats (IR) 
of 3 kb which consist of the Wp latency promoters and unique long and short sequences (UL and 
US respectively). UL and US contain almost the entire genome coding content [52]. In the viral 
particle, the EBV genome is present in a linear form but when the virus infects B cells the 
genome circularises via the TRs and becomes an episome [53]. EBV was the first herpesvirus to 
be completely sequenced. The complete genomic sequence of EBV strain B95-8, derived from a 
patient with infectious mononucleosis [54] was first published in 1984 by Baer et al. [55]. In 
1990 the region deleted in B95-8 was sequenced from Raji strain [56]. Additional minor 
corrections were reported in 2003 [57]. The sequence starts 1 nucleotide to the left of the EcoRI 
site separating EcoRI Dhet from EcoRI I (the first A of AGAATTC). The EBV genome was 
sequenced from an EcoRI and BamHI fragment library. The restriction fragments were named 
alphabetically by their size. EBV genes are designated according to position and orientation of 
the reading frame on the corresponding BamHI fragment (e.g. BZLF1 is the first leftward 
reading frame starting in the EBV BamHI-Z fragment). To date two additional EBV strains have 
been sequenced: AG876, derived from a case of Burkitt’s Lymphoma from Ghana [58,59] and 
GD1, derived from a patient with NPC in Guangdong, China [60].  
Several EBV genes show a high degree of conservation with other herpesviruses. These include 
genes coding for lytic cycle proteins involved in the replication of viral DNA, structure of the 
viral particle, and packaging of the viral DNA [52]. Some EBV genes are shared among gamma-
herpesviruses only, for example those encoding for BZLF1 and BRLF1, the immediate early 
regulators of lytic viral gene expression, and the latent proteins LMP-1 and LMP-2A [52]. A few 
genes show similarities to cell genes: BZLF1, BHRF1/BALF1 and BCRF1 are similar to c-FOS, 
BCL-2 and IL-10 respectively [61,62,63].  
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1.5  EBV life cycle  
 
1.5.1  Primary infection 
The general mode of transmission of the virus is through the saliva. Primary infection with EBV 
usually occurs early in childhood and afterwards, in the majority of the cases, the virus 
establishes a harmless and lifelong latent infection in the host memory B cell pool [7]. However, 
if primary infection is delayed until adolescence or adulthood, it may cause infectious 
mononucleosis (IM), a benign self-limiting lymphoproliferative disease [7]. Symptoms include 
fever, pharyngitis and lymphoadenopathy and are the result of a strong host T cell response to 
viral infection [8]. 
As for all herpesviruses, EBV has a lytic phase and a latent phase to its life cycle. During lytic 
infection the virus replicates and produces new infectious progeny, whereas during latent 
infection viral replication is suppressed and the virus is dormant. Epithelial cells and B cells are 
important targets in the life cycle of EBV. Primary infection occurs in the mucosal tissues of the 
oropharynx, where orally transmitted virus establishes foci of lytic replication in the epithelial 
cells. At the same time the virus starts to colonize the B cell compartment, by establishing a 
latent infection. The exact mechanism of primary infection at oropharyngeal sites is not clear, 
especially with respect of the initial target of infection: it is still matter of debate whether this is 
an epithelial cell or a naïve B cell of the Waldeyer’s ring in the tonsils. A dual tropism model for 
the mechanisms of primary infection by EBV at oropharyngeal sites has been proposed by 
Faulkner et al. [64]. According to this model, EBV initially infects resting naïve B cells in the 
Waldeyer’s ring structures in the tonsils. Here, B cells and squamous epithelial cells are in close 
proximity, since the lymphoepithelium forms crypts to penetrate into the lymphoid tissue 
beneath. This environment allows transfer of EBV from latently infected B lymphocytes to 
epithelial cells, which would then serve as a site of amplification of the virus. The new viral 
progeny could then either infect new naïve B cells in the same carrier or exit the body and infect 
new hosts. Alternatively, EBV could initially infect oropharyngeal epithelial cells, and from this 
first focus of infection the amplified viral population could then move on to establish persistent 
infection of the closely positioned naïve B cells [64]. In vitro studies supporting this dual tropism 
model of EBV infection showed that EBV particles released from infected epithelial cells 
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efficiently infect B cells but virus originating from B cells infects epithelial cells better [65]. 
Moreover, epithelial cells can be infected in vitro in the presence of virus-producing B cell lines 
with a higher efficiency compared to infection with cell-free viral particles [66]. A recent model 
suggests that infection of pharyngeal epithelium by orally transmitted EBV is not dependent 
upon initial viral replication in B cells, but is achieved by binding to the B cell surface and using 
this surface as a transfer vehicle [67]. The importance of the oropharyngeal epithelium during 
EBV infection is supported by the strong association between EBV and two malignancies of 
squamous epithelial cells, namely nasopharyngeal carcinoma and oral hairy leukoplakia in 
AIDS-patients, and by the detection of viral replication in oropharyngeal epithelial cells of both 
IM patients and healthy carriers [68,69,70].  
 
1.5.2  Attachment and cell entry 
Infection of B lymphocytes by EBV is initiated by the attachment of the major viral envelope 
glycoprotein gp350/220 to the surface receptor CD21, also known as complement receptor 2 
(CR2), which is the primary B cell receptor for EBV [71]. In B cells, CD21-gp350/220 binding 
is followed by aggregation of CD21 receptor in the plasma membrane and subsequent CD21-
mediated tyrosine kinase signal transduction and NF-kB activation, which leads to activation of 
the B cells and cell cycle entry [72,73]. Entry into B cells requires a complex of glycoproteins, 
including gH, gL and gp42 [74]. The EBV gH-gL complex is essential for penetration into B 
cells, since they mediate viral envelope fusion with the cell membranes, and gB glycoprotein has 
also been implicated in this process [74,75]. The entry process into B cells is triggered by 
binding of gp42 to the human leukocyte antigen (HLA) class II molecule, which acts as a co-
receptor for EBV [76]. Following entry into the cell, the viral capsids are released in the 
cytoplasm and transported on microtubules to nuclear pores [77]. Similarly, the viral genome, 
which is linear in the virion, is translocated to the nucleus, where it circularises to produce a 
covalently closed extrachromosomal episome [52]. EBV infection of epithelial cells, which do 
not express CR2 or HLA class II, is mediated by complexes lacking gp42 but the EBV receptor 
on these cells has not been identified [78]. gH is required for both attachment to and penetration 
into these cells [79]. This mechanism of viral entry into epithelial cells is supported by the 
observation that lack of gp350/220 enhances the efficiency of infection [67]. The virus contains 
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both three-part gH-gL-gp42 complexes and two-part gH-gL complexes, thereby endowing it with 
the ability to infect both B and epithelial cells [78]. Alternate replication of EBV into HLA class 
II-positive B cells and HLA class II-negative epithelial cells modifies the ratio of two-part and 
three-part complexes and therefore the tropism of the virus [65]. 
 
1.5.3  Lytic infection 
The lytic stage of the virus life cycle allows the virus to produce new viral progeny that can 
either infect novel naïve B cells in the same host or be shed through the saliva and infect new 
hosts, thereby ensuring viral spread and survival. EBV reactivation from latency is coupled to the 
B cell maturation pathway. In fact, it takes place in terminally differentiated plasma cells in the 
tonsil epithelium, a convenient location for shedding of the virions into the saliva. This was 
deduced from the observation that lytic viral replication is detected only in antibody-secreting 
plasma cells, among the various B cell populations present in the tonsils of healthy carriers 
[80,81].  
Lytic genes are classified as immediate early, early and late genes [52]. BZLF1 and BRLF1 are 
the major immediate early genes involved in the lytic cycle initiation. In in vitro model systems 
for EBV reactivation from latency, their expression is directly triggered by signal transduction 
through the B cell receptor (BCR) [82] and once expressed they function as transcription factors 
and induce immediate early and early lytic genes. BZLF1 gene, which is induced first in the 
BCR response, is the major mediator of the switch from latency to the lytic cycle. BZLF1 codes 
for a bZIP sequence specific transcription factor with sequence similarity to c-fos and C/EBP 
[61]. It transactivates both viral and cell genes and also autoactivates its own expression.  
In vivo, the physiological stimuli that induce EBV reactivation from latency in memory B cells 
are believed to originate from the signals that normally drive differentiation of memory cells into 
plasma cells, as occurs during immune responses upon recognition of specific antigen by the 
memory cells. In fact, the cell transcription factor XBP-1, which plays a key role in the 
differentiation of memory B cells into plasma cells [83], can contribute to regulation of the Zp 
promoter, from which BZLF1 is expressed [84]. 
The immediate early and early genes, triggered by BZLF1 and BRLF1, drive viral DNA 
replication, a phenomenon that requires the lytic origins of replication (OriLyt) and is mediated 
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also by BZLF1 [52]. Subsequent expression of the late genes leads to the synthesis of the viral 
structural proteins (glycoproteins, capsid and tegument). The replicated DNA is packaged into 
capsids in the cell nucleus and then budded through the nuclear membrane. Cytoplasmic 
vescicles containing enveloped virus are thereby formed and, by fusion with the cell plasma 
membrane, they release the newly formed viral particles via exocytosis [52].  
 
1.5.4  Latent infection 
 
1.5.4.1  EBV latent infection in vivo 
A hallmark of all herpesviruses is their ability to establish and maintain latent infection. In vivo, 
the B cell pool is the primary target for EBV latency and represents the long-term reservoir for 
the virus in the host. A model for the in vivo colonization of the B cell system by EBV was 
originally proposed by Thorley-Lawson and Gross and is now widely accepted [85]. This model 
suggests that EBV exploits the normal B cell differentiation pathway to gain access to and persist 
within the long-lived memory B cell compartment (Figure 1.2). EBV latently infects resting 
naïve B cells in the Waldeyer’s ring in the tonsils and drives these to proliferate as activated B 
blasts, which resemble antigen-activated B cells in terms of cell surface phenotype and 
morphology [85]. In these cells, all the latent genes of EBV are expressed (latency III infection, 
or growth-program, see section 1.5.4.2 and Table 1.1) causing activation and proliferation of the 
infected B cells [86,87] (Figure 1.2). During immune responses, efficient activation of B cells by 
antigens in vivo requires two signals: antigen binding to the B cell receptor (BCR) and CD40 
binding by CD40L displayed on the surface of antigen-specific T helper cells [88]. EBV mimics 
the same signals triggered by foreign antigens through expression of two latent membrane 
proteins (LMPs): LMP-1, which acts as functional homologue of CD40, and LMP-2A, which 
mimics a constitutively active BCR [89,90]. As part of normal immune responses, once activated 
by foreign antigens, B blasts make the transition into memory B cells in the germinal centre 
(GC) [88]. Similarly, virus-infected blasts differentiate into resting memory B cells through the 
process of the germinal centre reaction [85,91]. This transition is accompanied by establishment 
of a more restricted latent gene expression program (latency II, or the default program; see 
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section 1.5.4.2 and Table 1.1) whereby only the LMPs and the genome-maintenance protein 
EBNA-1 are expressed [92,93,94] (Figure 1.2). In the germinal centre, the EBV-infected B cells 
undergo clonal expansion, causing an increase in the size of the pool of infected cells, and 
rearrangements in their Ig genes, through somatic hypermutation and isotype switching. The 
LMPs, instead of foreign antigens, are thought to produce the signals in the germinal centre 
necessary for the latently infected B cell to make the transition into the memory compartment 
[89,90]. EBV infected memory B cells enter the peripheral circulation where they become the 
site of EBV persistence (Figure 1.2). In the memory compartment, viral expression is further 
shut-down, so that none of the latent proteins is expressed. This expression pattern is named 
latency program or latency 0 (see section 1.5.4.2 and Table 1.1) and is believed to be how 
infected cells remain undetected by the immune system, enabling the virus to persist for the 
lifetime of the host [85,95] (Figure 1.2). When the latently infected memory B cells occasionally 
divide, EBNA-1 is expressed in order to allow the viral DNA to replicate (latency I or EBNA-1-
only transcription program; see section 1.5.4.2 and Table 1.1) [95] (Figure 1.2). This cell 
division is not driven by the virus, but is part of the normal memory B cell homeostasis [85]. 
Memory B cells eventually return to the Waldeyer’s ring in the tonsils where they can 
occasionally differentiate into plasma cells: this is believed to be a signal for the latent virus to 
reactivate, initiate the lytic cycle and replicate [81]. New viral particles can either infect new 
naïve B cells for further rounds of infection or be shed into the saliva and transmitted to new 
hosts [81,85] (Figure 1.2).  
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Figure 1.2. EBV persistence in vivo 
After Thorley-Lawson and Allday, 2008 [91]. EBV has evolved to be an efficient and benign parasite of B 
lymphocytes. EBV is transmitted through the saliva and infects naïve B cells in the Waldeyer’s ring. It uses its 
growth program to activate the infected resting B cells and drive them to proliferate. The infected B blasts undergo 
the germinal centre reaction and then differentiate into resting memory B cells. The B cell differentiation process is 
coupled to a progressive shut-down of EBV-gene expression from the growth-promoting latency III program, 
displayed by activated B-blasts, to the latency II profile in germinal centre cells, ending with the latency 0 pattern in 
resting memory B cells. In memory B cells, the virus finds a perfect niche where it evades detection by the immune 
system and can therefore persist for a long time. Memory B cells eventually either divide (latency I program) or 
return to the Waldeyer’s ring and differentiate into plasma cells, which support the lytic cycle and produce new viral 
particles.  
 
 
 
 
Transcription 
program 
Latent proteins 
expressed 
Function of the 
program 
Type of infected B cell 
Type of EBV-
associated 
Lymphoma 
Growth 
(Latency III) 
EBNA-1 (Cp/Qp),  
EBNA-2, 
EBNA-3s, 
EBNA-LP, 
LMPs 
Activates B cells 
Newly infected naïve 
cell 
Immunoblastic 
Lymphoma 
Default 
(Latency II) 
EBNA-1 (Qp),  
LMPs 
Differentiates activated 
B cells into memory B 
cells 
Germinal centre B cell 
Hodgkin’s 
Lymphoma 
EBNA-1-only 
(Latency I) 
EBNA-1 (Qp) 
Allows replication and 
segregation of viral 
genome 
Dividing peripheral-
blood memory B cells 
Burkitt’s 
Lymphoma 
Latency 
program 
(Latency 0) 
None 
Allows lifetime 
persistence 
Peripheral-blood 
memory B cells  
 
Table.1.1. Transcription programs found during EBV persistence in vivo and in EBV-associated lymphomas 
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1.5.4.2  Patterns of latent gene expression in vivo and in vitro 
Alternative forms of latent infection may be established by EBV in B cells and these are named 
latency 0, I and II and III [96,97] (Table 1.1). Each type of latency is characterized by a specific 
pattern of gene expression and can be observed in different stages of EBV infection in vivo and 
in several EBV-associated malignancies, supporting the view that each EBV-linked malignancy 
is tightly related to a specific stage of the normal B cell differentiation pathway. Latency III, also 
referred to as the growth program, is characterized by expression of six nuclear antigens (EBNA-
1, -2, -3A, -3B, -3C and -LP) through usage of the EBV promoters W (Wp) and C (Cp), three 
latent membrane proteins (LMP-1, LMP-2A and LMP-2B), the BamHI A rightward transcripts 
(BARTs), which are a family of spliced polyadenylated transcripts, several miRNAs and high 
levels of two small non-polyadenylated and non-coding RNAs, termed EBERs (Table 1.1). 
Recently, a low level of expression of the BCL-2 homologue BHRF1 protein, previously 
regarded as being a lytic cycle gene product, has also been associated with latency III type 
infection [98]. Latency III is observed in vitro in EBV-transformed LCLs, in vivo in newly 
infected naïve B cells in the tonsils [86,87] and in some EBV-associated immunoblastic 
lymphomas arising in immunocompromised patients [85,99] (Table 1.1).  
More restricted forms of EBV latency have been detected in other EBV-associated malignancies. 
EBV-positive Burkitt’s Lymphoma most frequently displays a latency I infection, where latent 
EBV gene expression is reduced to the EBERs and BARTs transcripts and the genome 
maintenance protein EBNA-1 from an alternative promoter, Qp, since Cp and Wp promoters are 
silenced, abolishing expression of the other EBNAs [85,95,96,97,100,101,102]. This expression 
profile is also referred to as the EBNA-1-only transcription program and is also observed in 
dividing memory B cells in the healthy host [85,93,95] (Table 1.1). 
An intermediate pattern of gene expression (latency II or default program) is activated in 
Hodgkin’s Lymphoma (HL), undifferentiated nasopharyngeal carcinoma, T cell lymphomas and 
gastric carcinomas, and this consists of expression of the EBERs, BARTs, EBNA-1 (from the 
Qp) and the LMPs [85,97,103]. In vivo, this expression profile is also found in germinal centre B 
cells in the immunocompetent host [92,95,97] (Table 1.1).  
Any of these three types of latent infection may be established in B cells, whereas other cell 
types usually support only the more restricted patterns of latent gene expression latency I or 
latency II [97,103]. EBV limits the use of the full growth-transforming program to B 
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lymphocytes by exploiting the B cell specific transcription factor BSAP/Pax5 for activation of 
the Wp promoter, which is normally required to initiate a latency III expression profile [104]. 
More recently, an alternative form of restricted viral latency associated with BL (more than 15% 
of endemic cases) has been identified [105]. This is characterized by expression of all the 
EBNAs, exept for EBNA-2, and absence of the LMPs. Lack of expression of EBNA-2 is due to 
deletion of the EBNA-2 gene in the viral genome and expression of the other EBNAs is driven 
by Wp, rather than by Qp. Therefore this type of latency is called “Wp restricted”. Importantly, 
BHRF1, the viral homologue of cell BCL-2 protein, is also expressed and confers a survival 
advantage to this tumour cells [105].  
 
1.5.4.3 Role of EBV in cancers  
The model of EBV persistence in vivo proposed by Thorley-Lawson et al. is further supported by 
the relationship of EBV-associated malignancies to specific stages of the B cell differentiation 
pathway. Because EBV-positive lymphomas occurring in immunosuppressed patients after 
transplant are similar to in vitro EBV-LCLs, in that the virus expresses the growth program, 
these lymphomas are thought to arise when EBV infects a naïve B cell in the Waldeyer’s ring 
and causes it to proliferate under the influence of the growth program. The EBV-infected B cell 
is unable to exit the cell cycle and become a resting memory cell. In the presence of defective 
cytotoxic T cell responses, the EBV-infected lymphoblasts are not killed and can grow 
unchecked. However, additional mutations must be acquired by these lymphoma cells to make 
them more tumourigenic than simple EBV-LCLs if they are to give rise to a lymphoma [85]. 
The role of EBV in tumours arising in immunocompetent hosts, including Burkitt’s Lymphoma 
and Hodgkin’s Lymphoma, is less clear because many of the viral genes that are essential for 
proliferation of LCLs (see section 1.5.4.4.2) are not expressed in malignant cells. In fact, in 
EBV-positive Burkitt’s Lymphoma, EBNA-2 expression is selected against, since it is 
incompatible with high c-MYC expression levels. This is in striking contrast to LCLs, where 
EBNA-2 is instead required for continuous proliferation (see section 1.5.4.4.2). A constant future 
of BL, is the translocation of the c-MYC oncogene into the immunoglobulin (Ig) gene loci, 
leading to unusually high and deregulated expression of the c-MYC protein, which is very likely 
to contribute to the high level of proliferation seen in BL cells [106]. This translocation is 
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believed to occur as an accident of Ig gene rearrangement during class switching in the germinal 
centre B cell. Similarly to dividing peripheral-blood memory B cells, EBV-positive BL cells 
express the latency I pattern of viral gene expression. Moreover, they display the same 
arrangement of Ig gene hypermutations as germinal centre and memory B cells [107] and have a 
cell phenotype of a GC B cell [108]. Taken together these observations suggest that BL may 
arise if a translocation in the c-MYC gene occurs in an EBV-infected germinal centre B cell that 
is in the process of differentiating into a memory B cell: in this scenario the EBV-GC cell 
becomes stuck in proliferation due to activated c-MYC [85]. In addition to the translocation in 
the c-MYC locus, BL cells often display other genetic mutations, such as alterations in the p53 
and RB pathways [109,110], which may contribute to BL pathogenesis. The mechanism by 
which EBV may contribute to the development of BL is still a matter of debate. One view is that 
initially EBV, through the EBNAs and the LMPs, expands the population of EBV-infected 
lymphoblasts at risk for translocation and subsequently enhances survival and proliferation of 
translocation-positive clones. A second theory is that EBV protects BL cells from apoptosis 
induced by deregulated c-MYC, rather than promoting their proliferation. In fact, comparison of 
EBV-positive and EBV-negative BL clones revealed that restricted forms of EBV latent 
infection, such as latency I and Wp-restricted, provided the cells with a slight protection from 
apoptotic triggers [111,112]. However, the mechanism of this protection is not yet known. 
Candidate viral gene products involved include EBNA-1 and the EBERs, which have been 
shown to confer resistance to apoptosis when transfected into BL cell lines [113]. In Wp-
restricted BLs, the BCL-2 homologue BHRF1 and the EBNA-3 proteins have been shown to 
elicit anti-apoptotic effects [98,112,114].  
Based on the observation that EBV-positive HL displays the same pattern of gene expression as 
virus latently infected GC B cells [115] and the Ig genes in the Reed-Sternberg tumour cells are 
hypermutated to the same extent of germinal centre B cells, the current view is that EBV-positive 
HL arises from an EBV-infected GC B cell [116]. High expression of LMP-1 and LMP-2 is 
detected in the Reed-Sternberg tumour cells, suggesting a critical role for the viral membrane 
proteins in the survival of these cells. Additionally, it is believed that for an EBV-infected GC B 
cell to give rise to and HL tumour, a mutation must be acquired in order to prevent 
differentiation into memory cells [85]. Recently a specific genomic translocation involving the 
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major histocompatibility complex (MHC) class II transactivator CIITA (MHC2TA) was shown to 
occur with high frequency in Hodgkin’s Lymphoma [117].  
Both EBV-associated BL and NPC have endemic patterns of incidence (Central Africa and 
Southern China respectively). This strongly suggests that both environmental and genetic factors, 
in addition to viral infection, contribute to the neoplastic process. For example, factors like 
parasitic infections including malaria, nutrition, status of the immune system and translocation of 
c-MYC are believed to contribute to the development of endemic BL [17,118,119]. In the case of 
NPC, tumour-promoting chemicals have been found in food products in Southern China [17]. 
 
1.5.4.4  EBV latent infection in vitro 
 
1.5.4.4.1 Conversion of primary B lymphocytes into Lymphoblastoid Cell Lines (LCLs) 
EBV has the unique ability to infect primary B lymphocytes in vitro and transform them into 
latently infected lymphoblastoid cell lines (LCLs) which proliferate permanently [5]. LCLs are 
considered a good model of the lymphomagenic potential of the virus and represent the dominant 
in vitro model system used to study EBV infection and the roles of the different viral latent 
proteins. Upon EBV infection of primary B lymphocytes in vitro, 3-10% of the cells are 
transformed into LCLs [52]. Virus replication in LCLs is minimal or undetectable, however the 
virus maintains the ability to replicate upon reactivation [52]. In EBV-transformed LCLs every 
cell carries multiple episomal copies of the viral genome and display a latency III gene 
expression pattern [97] (Table 1.1) which is responsible for maintaining latent infection and 
inducing perpetual proliferation of the infected B cells [52]. After the initial events of viral 
infection, involving virus attachment, penetration, uncoating and delivery of the viral episome to 
the host nucleus (see section 1.5.2), at 12 to 16 hours post-infection viral transcription starts from 
the W promoter (Wp) in the large internal repeats (IR) of the viral genome (Figure 1.3), driven 
by the host cell RNA polymerase II, and generates EBNA-2 and EBNA-LP transcripts 
[120,121,122]. EBNA-2 and EBNA-LP proteins are detected within 12-24 hours and by 24-32 
hours post-infection they reach expression levels that are thereafter maintained in LCLs [121]. 
Once expressed, EBNA-2 acts as a potent transcriptional regulator to activate transcription from 
an upstream promoter, the C promoter (Cp) (Figure 1.3), which leads to expression of an 
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alternatively spliced transcript that can give rise to the mRNA for all the other EBNAs 
[52,123,124,125,126,127]. Cp transcription shuts down Wp and brings the viral genome under its 
own transcriptional control [128,129]. In addition, EBNA-2 activates expression of two other 
viral promoters, LMP-2A and the LMP-1/-2B divergent promoter (Figure 1.3), as well as of a 
plethora of cell genes crucial for B cell survival and proliferation 
[130,131,132,133,134,135,136,137]. Activation of some of these promoters by EBNA-2 is 
enhanced by cooperation with EBNA-LP [138,139,140,141,142,143,144]. Between 46 and 72 
hours post-infection, EBNA-1, -3A, -3B, -3C and the LMPs (LMP-1, -2A, -2B) reach steady-
state LCL levels of expression [121]. EBNA-1 ensures that the viral episome is transmitted to 
progeny cells by binding to OriP, the plasmid origin of replication, and to chromosomes. 
Moreover, EBNA-1 participates in activation of the Cp and LMP-1 promoters with EBNA-2 and 
EBNA-LP, by regulating enhancer elements within the OriP region (Figure 1.3), thereby 
increasing transcription of the latent antigens [128,145,146]. In contrast, the EBNA-3s limit 
EBNA-2-induced Cp transcription by competing with EBNA-2 for binding to RBP-Jk, the host 
tethering factor for EBNA-2 on the Cp enhancer [147,148]. The LMP-1/-2B bidirectional 
promoter responds to EBNA-2, EBNA-LP and EBNA-3A [131,132,139,140,149], whereas the 
LMP-2A promoter is stringently controlled by EBNA-2 [134,150]. 24 hours post-infection, two 
small non polyadenylated RNAs (EBERs) are expressed in the cell nucleus by cell RNA 
polymerase III and steady-state expression levels are reached 72 hours after infection. 
Expression of these viral proteins rapidly triggers the cells to enter the cell cycle and proliferate. 
EBNA-2, acting with EBNA-LP, induces the G0 to G1 cell cycle transition, marked by up-
regulation of cyclin D2 [138]. The first round of DNA synthesis starts around 48-72 hours after 
infection, followed by continuous proliferation, with a doubling time of 20-30 hours [52]. 
Following induction of proliferation, the telomeres shorten progressively at each cell division 
round until a critical length is reached. After 100-150 population doublings, the cells undergo a 
crisis and most of them die. Immortal cells grow out that have stabilized their telomeres and up-
regulated telomerase activity [151,152]. In vitro infection of resting primary B cells by EBV is 
associated with dramatic phenotypic changes. The cells lose their round small-size morphology, 
typical of resting B cells, become large, irregular in shape and activated and adhere one to 
another to form big clumps. Accordingly, established LCLs express high levels of the B cell 
activation markers CD23, CD30, CD39 and CD70 and of the cell-adhesion molecules LFA1, 
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LFA3 and ICAM1 [52,96,100,153]. The phenotypic alterations induced by EBV infection are 
similar to those observed in naïve B cells stimulated by IL-4, anti-CD40 or by antigen. [52].  
 
 
 
Figure 1.3. Diagram of the EBV genome 
Locations of the coding exons for the six nuclear antigens (EBNA-1, -2, -3A, -3B, -3C and -LP), the viral BCL-2 
homologue BHRF1 and the three latent membrane proteins (LMP-1, -2A and -2B) are shown. EBNA-LP repeated 
coding exons (W0, W1’, W1 and W2) are located within the BamHI W internal repeat region (IR1) marked by the 
grey box. The unique Y1 and Y2 EBNA-LP exons are downstream to the IR1. The latent origin of replication (OriP) 
and the joined terminal repeats (TR) are also displayed. Arrows indicate the promoters (Cp, Wp, LMP-2Ap and the 
bidirectional promoter LMP-1p/LMP-2Bp).  
 
 
1.5.4.4.2  Minimal set of EBV latent genes involved in in vitro B cell immortalisation  
The role of EBV latent genes in the in vitro transformation of B cells has been established by 
genetic studies using recombinant EBV viruses lacking individual latent genes. EBNA-2, LMP-1 
and EBNA-3C are absolutely required for the immortalisation process [89,154,155,156,157]. 
EBNA-3A was shown to be essential using recombinant EBVs with translation termination 
codon mutations inserted by second-site homologous recombination in the P3HR1 genetic 
background [158]. However a more recent report showed that deletion of EBNA-3A in the 
context of a Bacterial Artificial Chromosome (BAC)-derived EBV (B95-8 strain) results in 
viruses which are indeed able to transform B cells into LCLs in vitro, albeit with reduced 
efficiency compared to wild-type, since the knock out EBV-LCLs displayed reduced 
proliferation rates and increased levels of apoptosis [159]. EBNA-1 is required to maintain the 
viral genome as an episome in proliferating cells as it mediates the binding of EBV OriP to 
mitotic chromosomes [160,161]. EBNA-LP is not absolutely required but can greatly improve 
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the outgrowth of the virus-infected B cells [154,162]. EBV recombinant viruses lacking the 
LMP-2 genes have been shown to be as efficient as wild-type viruses in B cell transformation in 
vitro, indicating a non-essential role for LMP-2 [163,164,165,166,167]. Deletions of the LMP-2 
genes were generated by insertion of a marker gene in the EBV genome of the B95-8 cell line by 
homologous recombination. However, two studies have challenged these findings, suggesting 
that the LMP-2 genes might be important for optimal efficiency of the B cell immortalisation 
process in the context of either mini EBV plasmids [168], which are E. coli constructs containing 
the minimal EBV genomic sequences sufficient for induction of growth transformation of B cells 
[169], or BAC-derived EBV recombinant viruses [170]. EBER-2 has been reported to be 
required for efficient transformation of B cells and optimal growth of LCLs, using a recombinant 
Akata EBV genome background [171], however other studies have found the EBERs not to be 
essential for primary infection and LCLs growth in the context of either P3HR1 or B95-8 EBV 
genetic backgrounds [172,173]. In contrast to the other two members of the EBNA-3 family of 
proteins, EBNA-3B is completely dispensable for EBV-mediated B cell transformation 
[158,174,175]. Recently, the BHRF1 miRNA cluster has been shown to be important for EBV-
mediated B cell immortalisation process, since recombinant knock out viruses displayed up to 
20-fold reduction in B cell transformation ability compared to wild-type [176]. 
EBNA-2, LMP-1 EBNA-3A and EBNA-3C have been shown to be essential, not only for the 
initiation of the EBV-induced transformation process of primary B cells, but also for the 
maintenance of the continuous proliferation of the EBV-immortalised LCLs. This was shown 
using either B cell lines with mini-EBV plasmids with regulated EBNA-2 or LMP-1 genes, or 
primary B cell transformation assays with recombinant EBVs expressing conditionally active 
EBNA-3A or -3C proteins [89,157,177,178]. However, in the case of EBNA-3A, earlier studies 
using B cell immortalisation assays with mini-EBV plasmids showed that EBNA-3A is not 
required to maintain cell proliferation, but can provide a selective advantage to the proliferating 
cells [179].  
So far, the precise roles of some of the EBV latent genes in primary B cell transformation and 
maintanenance of cell proliferation remain to be determined (i.e. EBNA-3A, LMP-2s, EBERs). 
The discordant results reported for these EBV genes by different studies are likely to be due to 
the use of different systems for recombinant EBV genetic analysis. 
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1.6  Latent gene products 
 
1.6.1  EBNA-2 
EBNA-2 will be described extensively in section 1.7. 
 
1.6.2  EBNA-LP 
EBNA-LP is an unusual protein composed of multiple copies of an N-terminal 66-amino acid 
domain encoded by two exons (W1 and W2), located within each of the BamHI W repeats of the 
EBV genome, and a unique C-terminal 45-amino acid domain encoded by the Y1 and Y2 exons 
within the downstream BamHI Y fragment [124,125] (Figures 1.5 A).  
EBNA-LP protein is translated from a bicistronic transcript which can also code for EBNA-2, 
through alternative splicing [180,181] (Figure 1.4). EBNA-2 and EBNA-LP mRNAs are partially 
overlapping, since they both start with a short non-coding exon termed W0 which ends with the 
sequence AT. The EBNA-LP mRNA W0 exon is spliced to a W1’ exon which begins with a G 
providing and ATG for EBNA-LP translation. In contrast, the EBNA-2 mRNA W0 first exon is 
spliced to the W1 exon and this splicing event results in a transcript without an initiation codon 
for EBNA-LP. In both EBNA-LP and EBNA-2 mRNA, the second exon is followed by a W2 
exon, several pairs of W1W2 exons, two short unique exons Y1 and Y2, and C-terminal exons, 
containing the polyadenylation signal that is in common between the two mRNAs. The Y2 exon 
contains the EBNA-LP stop codon whereas the YH exon comprises the entire EBNA-2 ORF 
[124,125,181] (Figure 1.4). In the EBNA-LP mRNA, while the first W1 repeat (W1′) starts with 
the initiating methionine, generated through a W0/W1’ splicing event, subsequent downstream 
W1 exons use the W1 splice acceptor [124,125,180]. In some EBNA-LP mRNAs, there is a 
further splice removing most of the EBNA-2 coding region from YH [182]. (Figure 1.4). 
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Figure 1.4. Alternative splicing at the Wp promoter produces EBNA-LP or EBNA-2 mRNA 
 
 
Due to variations in the number of BamHI W repeats in different viruses and alternative splicing 
between the repeated W1W2 exons and the unique Y1Y2 exons, EBNA-LP proteins of different 
sizes can be expressed in different EBV-immortalised cell lines [183,184]. During the first stages 
of infection, multiple EBNA-LP isoforms can be detected, whereas most established LCLs 
ultimately express only one or a few isoforms [183,184]. Furthermore, a Y1Y2-truncated form of 
EBNA-LP also exists in cells (Daudi and P3HR1) infected with variant EBV strains with a 
genomic deletion in this region [185,186].  
EBNA-LP function has been investigated using genetic and cell-based assays and these analyses 
have focussed on the C-terminal Y1Y2 exons, because mutations in the repeating W1W2 exons 
are more difficult to construct. Recombinant viruses lacking the C-terminal 45-amino acids 
encoded by Y1 and Y2 display a markedly lower immortalisation efficiency compared to wild-
type viruses and require feeder cells [154,162]. Once established, however, these cell lines do not 
markedly differ from wild-type virus immortalised cells in phenotype and growth properties 
[187]. These observations suggest that EBNA-LP is important but not essential for EBV-induced 
immortalisation.  
Linkage between EBNA-LP and EBNA-2 expression in the same initial transcript during the 
initiation of EBV infection in primary B cells suggests that their functions need to be tightly 
coordinated. In fact, EBNA-LP has been shown to enhance EBNA-2-mediated transcriptional 
activation both of cell genes, such as cyclin D2 in resting B cells, and viral target promoters (i.e. 
LMP-1/LMP-2B, Cp) [121,138,139,140,141,142]. Co-activation has been observed either with 
endogenous LMP-1 expression in EBV-positive latency I BL cell lines or with transient reporter 
assays with synthetic promoters containing either LMP-1/LMP-2B regulatory elements or 
multimerized Cp sequences [139,140]. Co-activation with EBNA-2 has not been detected on 
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other EBNA-2 target genes, such as the CD21, LMP-2A, and HES-1 promoters, indicating that 
EBNA-LP cooperative function is promoter-specific [142]. Several non-human 
lymphocryptoviruses (LCVs) also encode EBNA-LP homologues and the ability to co-activate 
EBNA-2 is conserved [188]. Due to its ability to enhance EBNA-2-mediated viral and cell gene 
expression, EBNA-LP plays a key role during EBV conversion of primary B cells to LCLs.  
Most of the cooperative function of EBNA-LP maps to the W1W2 repeats, whereas the unique 
carboxyl-terminal Y1Y2 domains modulate EBNA-LP function [139,140] (Figure 1.5 A). Only 
proteins with two or more copies of the W1W2 repeat are capable of cooperating with EBNA-2 
and viruses with two BamHI W repeats are immortalisation competent [140,189,190,191]. 
EBNA-LP isoforms with only one W1W2 repeat localize to the cytoplasm and this may account 
for their inability to co-activate EBNA-2 [140,189,190]. 
The functional domains of EBNA-LP have been identified by sequence comparison of EBNA-
LP from type 1 and type 2 EBV strains and homologues from baboon and rhesus macaque LCVs 
[188]. Five evolutionary conserved regions (CRs) can be defined: CRs 1 to 3 map to each of the 
W1W2 domain and CRs 4 and 5 are located whithin the Y2 domain (Figure 1.5 B). CR1 and 
CR2 represent a bipartite nuclear localization signal, which together with CR3 are essential for 
the co-activation function of EBNA-LP [189,190]. Moreover phosphorylation of at least one 
serine residue within the W1W2 repeat (S35 and S101) is required for EBNA-2 coactivation 
function [189,190].  
The mechanism through which EBNA-LP potentiates EBNA-2-mediated transcription is not 
entirely clear but has been proposed to involve interaction with histone deacetylase 4 [192]. 
Wild-type EBNA-LP does not significantly associate with EBNA-2 in lymphoblasts, as 
demonstrated by coimmunoprecipitation and immunofluorescence assays [141,142]. However 
interaction between EBNA-LP and EBNA-2 is detected when the two full-lenght proteins are 
expressed and purified from E.coli and in human B lymphocytes when EBNA-LP is deleted for 
its C-terminal 11 amino acids [141]. In vitro binding studies with truncated portions of EBNA-2 
and EBNA-LP have demonstrated that EBNA-LP stably interacts whith the acidic transactivation 
domain of EBNA-2 and with an EBNA-2 N-terminal 58-amino acid domain, referred to as a 
second activation domain (AD2, see section 1.7.2) [141,193]. It has been suggested that these 
specific biochemical interactions between the EBNA-LP and EBNA-2 may be the basis for the 
EBNA-LP co-activation function only when the interaction is unstable; in fact, the high-level 
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stable association occurring between EBNA-2 and EBNA-LP lacking the C-terminal 10 amino 
acids was incompatible with EBNA-LP co-activation [141]. Alternatively EBNA-LP may 
stimulate EBNA-2-mediated gene activation through mechanisms that do not require direct or 
indirect interactions with EBNA-2 [142].  
Host cell proteins that interact with EBNA-LP include oncogenes and tumour suppressors (pRB, 
p53, p14ARF), heat shock proteins (hsp72/hsc73 and hsp27), molecules involved in cell cycle 
regulation (HA95 and DNA-Pkcs) and Hax-1, an anti-apoptotic protein. However, so far no 
correlation has been made between EBNA-LP association with these factors and its ability to 
coactivate EBNA-2 [52]. EBNA-LP has also been shown to associate with the promyelocytic 
leukaemia (PML) nuclear body-associated protein Sp100 and displace Sp100 along with 
heterocromatin protein 1 α (HP1-α) from PML nuclear bodies. This may represent a mechanism 
by which EBNA-LP coactivates with EBNA-2 [143].  
An additional function, distinct from cooperation with EBNA-2, has been ascribed to the Y1Y2-
truncated EBNA-LP isoform. This consists of mediating protection against caspase-dependent 
apoptosis, through inhibition of protein phosphatase 2 [194], a mechanism common to other viral 
oncoproteins, including SV40 small T antigen, small and middle T antigents of polyomavirus 
and adenoviral E4orf4 protein, all of which contribute to cell transformation [195].  
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Figure 1.5. EBNA-LP protein structure and sequence 
(A) Schematic diagram of the structure of EBNA-LP protein. The repeated (W1W2) and unique (Y1Y2) domains 
are shown. W1’: first W1 domain containing the initiating methionine, generated through a W0/W1’ splice (see text 
for details). EBNA-LP can comprise multiple (n) W1W2 domains. EBNA-2 cooperative function maps to the 
repeated W1W2 region of EBNA-LP, whereas the unique Y1Y2 domains have only a regulatory role. (B) 
Alignment of the amino acid sequences of EBNA-LP from type 1 and type 2 EBV, baboon LCV and rhesus LCV 
indicates the presence of conserved regions (CRs 1 to 5). CR2 and part of CR1 correspond to nuclear localization 
signals (NLS). Identical amino acid residues are indicated by asterisks, and similar nonidentical residues are 
indicated by a dotted line. Amino acid numbers are indicated at the beginning and end of each line. Exons W1, W2, 
Y1, and Y2 exons are shown above the sequences. Adapted from [143,188]. 
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1.6.3  EBNA-3A, -3B and -3C 
The EBNA-3 family of proteins comprises three related latent nuclear antigens (-3A, -3B and -
3C) which are expressed in EBV-immortalised latency III B cells and composed of 944, 937 and 
992 amino acids, respectively. The EBNA-3 proteins share limited amino acid sequence identity 
and are encoded by tandemly arranged genes located in the middle of the long unique region of 
the viral genome (Figure 1.3). While EBNA-3A and -3C are important for B cell transformation 
by EBV, EBNA-3B is completely dispensable [158,174,175] (section 1.5.4.4.2). Recently 
EBNA-3B has been proven to be a tumour suppressor gene in vivo, following the observation 
that infection of humanized Nod-scid γc-/- mice with EBNA-3B knock out EBV, but not with 
wild-type EBV, resulted in development of large tumour masses and splenomegaly [196].  
The EBNA-3 proteins have important functions in gene expression regulation and cell survival. 
Anti-apoptotic activity has been ascribed to the EBNA-3 proteins in Burkitt's Lymphoma cell 
lines and EBNA-3A and -3C have been shown to cooperate to repress the pro-apoptotic tumour 
suppressor BIM [114]. EBNA-3C is regarded as an oncogene since it is able to cooperate with 
oncogenic RAS in immortalising and transforming embryonic rat fibroblasts [197]. Moreover, 
EBNA-3C participates in the control of the cell cycle by overriding multiple cell cycle 
checkpoints and by counter acting the action of cyclin-dependent kinase inhibitor p16/INK4A, to 
functionally inactivate pRB, in a similar way to papillomavirus E7 and adenovirus E1A proteins 
[197,198].  
Importantly, EBNA-3A and -3C proteins function as strong transcriptional repressors when 
targeted directly to DNA [199,200,201]. Examples of mechanisms of transcriptional repression 
are interaction with the cell C-terminal binding protein (CtBP), involved in transcriptional 
silencing, [202,203] and interaction with histone deacetylases (HDACs) [204]. Furthermore, both 
EBNA-3A and -3C repress the pro-apoptotic protein BIM and the cell cycle inhibitor 
p16/INK4A via a common repressive epigenetic mechanism that involves trimethylation of 
lysine 27 on histone H3 (H3K27Me3) [205,206]. Transcriptional repression is achieved by all of 
the EBNA-3 proteins through binding to the cell DNA-bound factor RBP-Jk, which is also 
responsible for directing EBNA-2, the master transcriptional activator of latency III, to target 
promoters [207,208]. Interaction of the EBNA-3s and EBNA-2 with RBP-Jk is mutually 
exclusive, therefore the EBNA-3 proteins can inhibit RBP-Jk-dependent transcriptional 
activation of the EBNA-2-responsive promoters Cp and LMP-2A [147,148,209,210,211]. The 
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EBNA-3 proteins are believed to counterbalance and fine-tune the transcriptional function of 
EBNA-2 of not only viral but also cell promoters, including c-MYC, CD21 and CD23, through 
competition for interaction with RBP-Jk [212]. Uniquely, EBNA-3C, but not -3A or -3B, 
positively cooperates with EBNA-2 in the induction of LMP-1 promoter through PU.1 
[149,213,214]. The EBNA-3 proteins do not act as simple negative regulators of EBNA-2 but 
harbour also intrinsic transcriptional activation function [215]. Several microarray studies have 
been undertaken recently to identify host target genes both up- and down-regulated by the 
EBNA-3 proteins [159,216,217,218]. Targets include genes involved in apoptosis, cell cycle 
progression, cell migration and B cell activation and differentiation.  
 
1.6.4  EBNA-1 
Among the latency genes, EBNA-1 is the most consistently expressed in all forms of latency and 
viral-associated tumours (Table 1.1). EBNA-1 is required for the establishment of episomal 
latent infection and for the long-term survival of latently infected cells. In EBV-LCLs, EBNA-1 
expression can be driven by either Wp or Cp [219], while in latency I or II EBNA-1 transcription 
is initiated from Qp [101]. EBNA-1 is a functionally pleiotropic protein. Its major function is to 
ensure maintenance and replication of the episomal EBV genome and this is achieved through 
sequence-specific binding to the plasmid origin of viral replication, OriP [220]. EBNA-1 also has 
a role in transcriptional regulation. In fact, binding of EBNA-1 to the regulatory elements within 
the OriP region enables the protein to function as a transcriptional enhancer of the Cp promoter 
[161,221]. Another EBNA-1-binding site in the viral genome, in addition to OriP, is located in 
the Qp promoter. By binding to Qp, EBNA-1 negatively regulates its own promoter in latency I 
and II [222]. In addition to regulating viral transcription, EBNA-1 can bind to and regulate 
numerous cell gene promoters [223,224]. In a recent study a genome-wide analysis of the cell-
DNA sites associated with EBNA-1 protein was performed in latently infected BL cells, 
revealing that EBNA-1 binding sites are located not only whithin cell promoters, but also in 
other regions of the cell chromosomes not closely linked to a promoter start site, that may be 
important for regulation of chromatin structure [225].  
EBNA-1 functions in both replication and transcription regulation are mediated by its ability to 
bind directly to DNA, through a C-terminal DNA-binding and dimerization domain [226]. The 
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N-terminal part of EBNA-1 protein is responsible for tethering the EBV genome to metaphase 
chromosomes [227,228]. The amino- and carboxyl-terminal domains are separated by a 
characteristic Gly-Ala repeat sequence, which stabilizes the mature protein by preventing its 
proteasomal degradation [229].  
EBNA-1 is the only EBV latent protein to be consistently expressed in malignancies associated 
with EBV. As such, it is an obvious candidate viral protein to possibly have a role in tumour 
pathology. Although gene knock out experiments indicate that EBNA-1 contribution to virus-
induced B cell immortalisation in vitro seems to be limited to the maintenance of the viral 
genome [230,231], an oncogenic function for EBNA-1 is suggested by the ability of the protein 
to induce B cell lymphomas in transgenic mice when following in vivo targeted expression in the 
B cell compartment [232] and by its possible contribution to survival of Burkitt’s Lymphoma 
cell lines in vitro [233].  
 
1.6.5  LMP-1 
The latent membrane protein 1 (LMP-1) was the first EBV latent protein to be identified as an 
oncoprotein based on the observation that its ectopic expression in rodent fibroblasts induces a 
transformed phenotype, characterized by anchorage-independent growth, and tumour formation 
in nude mice. Furthermore, expression of LMP-1 in the B cell compartment of transgenic mice 
was found to induce lymphomagenesis [234,235]. LMP-1 expression has been detected in 
tumour cells from several EBV-associated malignancies, such as Hodgkin’s Lymphoma, 
immunoblastic lymphomas and nasopharyngeal carcinomas [8]. Strikingly, when expressed at 
high levels in EBV-negative BL cells, LMP-1 is cytostatic [236]. However, when expressed at 
physiological levels, it causes broad alterations in gene expression and induces many of the 
phenotypic changes observed during EBV infection, such as up-regulation of B cell activation 
markers (CD23 and CD40) and cell adhesion molecules (LFA1, LFA3 and ICAM) [237]. 
Furthermore, LMP-1 can induce expression of several anti-apoptotic proteins (BCL-2, Mcl-1, 
Bfl-1, A20 and cIAPs), thereby protecting the cells from apoptosis [237,238,239]. Additional 
mechanisms underlying LMP-1 oncogenic ability include induction of DNA synthesis following 
transient expression of the viral protein in primary resting B cells as well as upregulation of 
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cytokines (i.e. IL-6, IL-8, IL-10) and matrix metalloproteinases, the latter being suggestive of a 
role for LMP-1 in angiogenesis and metastasis in EBV-associated malignancies [237,239].  
Structurally, LMP-1 is a 63 kDa phosphoprotein with a short N-terminal cytoplasmic tail, six 
hydrophobic membrane-spanning domains and a long C-terminal cytosolic region [239]. Genetic 
analyses showed that both the transmembrane domains, which promote oligomerization at the 
plasma membrane, and the C-terminal tail are required for LMP-1-induced transduction of 
signals which drive B cell transformation. Two functional subdomains are contained in the C-
terminal region: the membrane proximal C-terminal activating region 1 (CTAR1) and the distal 
CTAR2 [240]. CTAR1 is essential for EBV-mediated B cell immortalisation and recruits 
members of the TNF receptor-associated factor (TRAF) family, thereby triggering activation of 
the transcription factor NF-kB [240,241,242,243]. CTAR2 is key for the long-term growth of 
EBV-transformed primary B cells and binds to the TNF receptor-associated death domain 
(TRADD) protein leading to NF-kB activation and to JNK/MAPK signal transduction, which 
culminates in induction of the AP-1 family of transcription factors [240,244,245,246]. NF-kB 
and AP-1 are both involved in prevention of apoptosis in B lymphocytes and mediate up-
regulation of many of the LMP-1-inducible genes, including B cell activation markers and 
adhesion molecules [237,238]. An additional pathway downstream from CTAR1 and CTAR2 is 
p38 MAPK [247], which leads to activation of c-Jun and ATF2 transcription factors, responsible 
for the LMP-1-mediated induction of cytokines IL-6 and IL-8 [237].  
The structural features and functions of LMP-1 are reminiscent of those of a constitutively active 
CD40 receptor, a member of the tumour necrosis factor receptor (TNF-R) superfamily which is 
critical for survival of antigen-activated B cells. In fact, LMP-1 usurps the anti-apoptotic 
component of the CD40 signalling pathway to promote survival and growth of B lymphocytes 
[248,249,250]. LMP-1 is functionally similar to two other gamma-herpesvirus oncoproteins, 
namely K1 protein of KSHV and Saimiri transformation protein (Stp) of HVS, to the extent that 
they all act as transforming and signalling proteins, even though they do not share much 
sequence identity [15]. They all share the ability to interact with host factors and activate cell 
signalling pathways that lead to lymphocyte transformation. For example, LMP-1 and Stp C can 
both activate the NF-kB pathway through binding to TRAF molecules. In addition, all three 
membrane proteins share the ability to self-oligomerize, a property that is important for their 
signalling activity [251].  
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LMP-1 is expressed in latency II and III type infection. LMP-1 transcription can be initiated 
from two promoters, a proximal (ED-L1p) and a distal (TR-L1p) promoter [252,253]. EBNA-2 is 
the most potent transactivator of LMP-1 through the ED-L1 promoter. In latency II, LMP-1 
expression is EBNA-2-independent, while in latency III LMP-1 expression is critically 
dependent on EBNA-2 [131,254]. Regulation of LMP-1 expression in LCLs by EBNA-2 is 
complex and involves many host factors, for example RBP-Jk, PU.1, AP-2, SWI/SNF, 
CBP/p300, ATF/CREB and the DP103/SMN complex (see also sections 1.7.4.1 and 1.7.4.3) 
[255,256,257,258,259,260,261].  
 
1.6.6  LMP-2A and -2B 
LMP-2A and LMP-2B are two related integral membrane proteins which share their 12 
transmembrane domains and the short C-terminal tail. LMP-2A carries an additional hydrophilic 
N-terminal domain of 119 amino acids with signalling properties. LMP-2A and LMP-2B are 
expressed from a common gene, LMP-2, but by different promoters. Circularization of the viral 
genome through the terminal repeats is required for the formation of the LMP-2A and -2B 
transcription units [262]. A 2.0 kb messenger RNA is produced to encode LMP-2A while a 
shorter message (1.8 kb) is initiated from a bidirectional promoter shared with LMP-1 to encode 
LMP-2B [262,263,264]. Both promoters of LMP-2A and LMP-2B respond to EBNA-2 [265]. 
LMP-2A promoter transactivation by EBNA-2 occurs through interaction with RBP-Jk [150].  
Consistent with the reports demonstrating that the LMP-2 genes are not required for EBV-B cell 
transformation in vitro [163,164,165,166,167], LMP-2 has been shown to be unessential for in 
vivo growth of EBV-LCLs in SCID mice. SCID mice injected with LMP-2+ or LMP-2– LCLs 
developed tumours in a similar fashion [266]. In vitro studies proved that LMP-2A inhibits the 
signalling activity from the endogenous B cell receptor (BCR), and therefore blocks B cell 
activation and development [267,268]. This is achieved by interaction of the Immunoreceptor 
Tyrosine-Based Activation Motif (ITAM)-containing N-terminal domain of LMP-2A with a src 
family tyrosine kinase, Lyn, which is expressed in B lymphocyte [269]. As a consequence, the 
high level of LMP-2A in LCLs blocks EBV lytic cycle reactivation, which occurs in response to 
BCR signalling [270]. This role for LMP-2A in maintenance of latency and prevention of entry 
into the lytic cycle might be important during in vivo infection: in fact, LMP-2A expression has 
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been detected in uncultured peripheral memory B cells in vivo [271]. On the other hand, in vivo 
studies using transgenic mice demonstrated that LMP-2A, when expressed in progenitor B 
lymphocytes, is also able to provide a positive signal by acting as a constitutively active 
surrogate BCR, providing a survival signal for EBV-infected B cells and allowing B lymphocyte 
development to proceed in the absence of a functional B cell receptor [90,272]. Interestingly, 
LMP-2A is required for growth transformation of B cells from germinal centres which do not 
express a bona fide BCR because of deleterious somatic hypermutations in their immunoglobulin 
genes [273]. Thus, LMP-2A could enable EBV-infected GC B cells with non-functional 
immunoglobulin genes to escape negative selection and contribute to the onset of BCR- B cell 
lymphomas of germinal centre origin, such as Hodgkin’s Lymphoma.  
At a position equivalent to that of the LMP-2A gene in the EBV genome, the rhadinoviruses 
KSHV and HVS contain distinct ORFs called K15 and tip respectively (section 1.2.1.4 and 
1.2.2.5). LMP-2A, K15 and tip proteins share a common function in the absence of any sequence 
identity. All three proteins have been shown to dampen lymphocyte receptor (BCR or TCR) 
signalling pathways. In fact LMP-2A, K15 and tip are all capable of interacting with the 
BCR/TCR-associated Syc and Src family kinases and down-regulate their signalling activities. 
By doing so, they all prevent the onset of aberrant viral reactivation from latently infected 
lymphocytes as a result of cell proliferation triggered by external signals. Therefore the common 
function of these gamma-herpesvirus proteins is to help maintain viral latency in the host.  
In contrast to LMP-2A, less is currently known about the function of LMP-2B in B cells. LMP-
2B has been suggested to act essentially as a modulator of LMP-2A function. Specifically, LMP-
2B is able to prevent the LMP-2A-mediated block of BCR signal transduction upon BCR-cross-
linking [274] and to counteract the function of LMP-2A in preventing the switch from latent to 
lytic EBV replication. In fact, overexpression of LMP-2B in EBV-positive Akata BL cells, leads 
to increased frequency of EBV reactivation following BCR cross-linking, as demonstrated by 
up-regulation of EBV lytic genes [275]. Consistent with a role for LMP-2B in the negative 
regulation of LMP-2A, the two proteins have been found to colocalize to intracellular perinuclear 
compartments and to co-immunoprecipitate in B cell lines [275,276]. 
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1.6.7  EBERs 
The EBV-encoded RNAs EBER-1 and EBER-2 are small non-translated, non-polyadenylated 
and highly structured RNAs of 167 and 172 nucleotides respectively [277,278]. The EBERs are 
transcribed by RNA Polymerase III and are by far the most abundant EBV transcripts detected in 
the nuclei of EBV-transformed cells and in all EBV-associated cancers [277,278]. EBER-1 has 
been shown to associate with ribosomal protein L22, a constituent of the large ribosomal subunit, 
and both EBERs associate with La, which is involved in biogenesis and maturation of 
polymerase III transcripts [279,280]. EBER-1/L22 interaction causes L22 to delocalize from 
nucleoli into the nucleoplasm [173,281] but the functional significance of this binding is still 
unclear.  
Although the precise role of the EBERs in EBV-induced B cell transformation in vitro remains 
to be determined (see section 1.5.4.4.2), an oncogenic role for the EBERs in Burkitt’s 
Lymphoma has been proposed following the observation that, upon expression in EBV-negative 
Akata BL cells, the EBERs promote resistance to apoptosis and up-regulate BCL-2 oncoprotein 
[282]. Moreover, the EBERs have been shown to interact with RIG-I protein and activate 
signalling to induce type I IFN in EBV-infected BL cells [283]. Furthermore, in BL cells, 
EBERs-induced RIG-I signalling leads to expression of IL-10, which acts as an autocrine growth 
factor for B cells [284,285]. Recently, EBERs-regulated target genes in EBV-LCLs have been 
identified by microarray expression profiling analysis [173] and these include genes that regulate 
host biosynthetic processes and antiviral responses (EBER-1) and genes involved in membrane 
signalling and apoptosis regulation (EBER-2).  
 
1.7  The Epstein-Barr Nuclear Antigen 2 (EBNA-2) 
 
1.7.1  Role of EBNA-2 in B cell transformation 
EBNA-2 is essential for primary B lymphocyte growth transformation in vitro. In fact, deletion 
of the EBNA-2 open reading frame, and part of the EBNA-LP gene, in the mutant EBV strain 
P3HR1 is associated with a loss of immortalising capacity of the virus [185,286,287,288,289]. 
Immortalisation-competent virus can be rescued if the deletion is complemented by 
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recombination either with wild-type virus or with cloned fragments harbouring the EBNA-2 gene 
[154,155]. The key role played by EBNA-2 during the B lymphocyte immortalisation process 
induced by EBV was further corroborated by the development of the EREB2.5 system by 
Kempkes et al. [157]. The EREB2.5 cell line is an LCL containing P3HR1 EBV and an OriP 
plasmid carrying the region deleted in the P3HR1 genome modified such that a conditional 
EBNA-2-oestrogen receptor fusion protein (ER-EBNA-2) is expressed from the EBV Wp 
promoter. A full-length EBNA-LP, which is missing in the P3HR1 genome, is also expressed 
from the OriP plasmid. When oestrogen is present in the cell culture medium, it binds to the 
oestrogen receptor and the conditional ER-EBNA-2 protein is localized to the nucleus where it 
can activate target genes which will drive cell proliferation. EBNA-2 is essential for the 
maintenance of the growth of the cells. In fact, when oestrogen is withdrawn, the oestrogen 
receptor binding domain is bound by heat-shock proteins, hence ER-EBNA-2 protein is 
sequestered in the cytoplasm and therefore inactive [290]. As a consequence, about half of the 
cells cease proliferation and enter a quiescent state while others die by apoptosis. Growth arrest 
occurs at both G1 and G2 stages of the cell cycle and it can be reversed by re-addition of 
oestrogen only for cells blocked in G0/G1, indicating that EBNA-2 is required to stimulate G1 cell 
cycle progression. This result is consistent with the ability of EBNA-2, in cooperation with 
EBNA-LP, to induce expression of a G1 cyclin, namely cyclin D2, during EBV infection of 
resting B cells in vitro [138]. The experiments in the EREB2.5 system suggested that EBNA-2 is 
required not only for initiation of transformation of primary B cells into LCLs by EBV but also 
for maintenance of the immortalised state of EBV-LCLs [157]. In summary, EBNA-2 functions 
as a transcriptional activator to regulate viral (latency III) and cell gene expression in B cells in 
order to drive cell cycle progression into G1 and maintain continuous proliferation of the cells. 
The EREB2.5 cell line has been widely used to identify and investigate EBNA-2 functions 
[291,292,293] and it was adapted into a functional assay used in this thesis.  
 
1.7.2  EBNA-2 structure and functional domains 
Numerous genetic and biochemical studies have been performed in the past to unravel the 
functions of the EBNA-2 protein. However, these investigations have almost exclusively 
focussed on type 1 EBNA-2, whereas little is known about the type 2 protein. The EBNA-2 gene 
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of the prototype type 1 B95-8 strain encodes a protein of 487 amino acids, whereas type 2 
prototype strain AG876 encodes an EBNA-2 protein of 455 amino acids. The two types of 
proteins share around 50% of sequence identity [294,295]. EBNA-2 protein does not display any 
substantial sequence similarity to any cell protein. This represented an obstacle in determining its 
function during the earlier studies. Sequence comparison analysis of the EBNA-2 allele isolated 
from different primate lymphocryptoviruses (LCVs), namely type 1 and type 2 EBV, the baboon 
Herpesvirus Papio (HVP) and the rhesus macaque LCV, led to the identification of nine 
evolutionary conserved regions (CR1 to CR9) (Figure 1.6), which represent much of the total 
sequence identity between type 1 and type 2 EBNA-2 proteins of EBV and define some 
functional domains and important structures [188,294]. The CRs form two clusters in the EBNA-
2 protein: one at the amino-terminus (CRs 1 to 4) and the other at the carboxyl-terminus (CRs 5 
to 9). The portion in between is referred to as the diversity region, as it varies in length and 
sequence between different EBNA-2 types and homologues [296]. An additional region of 
variability is the poly-proline region (PPR), a long stretch of prolines between CRs 2 and 3 that 
varies in length in different EBV isolates [294]. EBNA-2 can homotypically self-associate 
through two self-association domains (SAD1 and SAD2) which map to the 57 amino acids N-
terminal to the polyproline domain (which also coincide with CRs 1 and 2) and to the 120 amino 
acids C-terminal to the polypoline domain, respectively [297,298]. CR5 corresponds to a region 
involved in interaction with the cell DNA-binding protein RBP-Jk [299,300,301,302]. This 
interaction occurs through the conserved tryptophan residues at positions 323 and 324 [299,303]. 
CR6 mediates binding to the cell protein SKIP, which is a co-factor of RBP-Jk, and thereby 
facilitates EBNA-2/RBP-Jk complex formation [304]. CR8 is part of an acidic transactivation 
domain (TAD), which mediates gene transcriptional activation, whereas CR9 coincides with a 
nuclear localization signal (NLS) at the carboxyl-terminus of the protein [294,305]. An 
additional karyophilic signal is represented by the RG sequence, between CRs 6 and 7, which 
consists of an 18-amino acid stretch rich in arginines and glycines [294]. Four domains of 
EBNA-2 have been shown to be involved in cooperation with EBNA-LP in the context of Gal4 
DNA binding domain fusions and in Cp promoter-reporter assays: these are the transactivation 
domain TAD, the CR7, the RG motif and the self-association domain SAD1. The latter is also 
referred to as a second activation domain (AD2). Both TAD and AD2 are specifically bound by 
EBNA-LP [141,193]. A cartoon of the structure of EBNA-2 protein is represented in Figure 1.7.  
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EBNA-2 protein is very stable, with a half-life of at least 24 hours, it associates with 
nucleoplasm, chromatin, and nuclear matrix fractions and localizes to large nuclear granules 
[306,307]. EBNA-2 is phosphorylated on serine and threonine residues and may be subjected to 
additional post-translational modification, since the size of the nascent protein is 10 kDa smaller 
than stable intranuclear EBNA-2 [181,306]. 
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Figure 1.6. Alignment of EBNA-2 amino acid sequence from EBV type 1 (B95-8), EBV type 2 (AG876), 
baboon LCV and rhesus LCV 
From [188]. Asterisks indicate amino acid residues identical between sequences and dotted lines mark amino acid 
residues with overall similarity. Conserved regions (CRs from 1 to 9) are boxed. Amino acid numbers are indicated 
at the beginning and end of each line.  
74 
 
 
 
Figure 1.7. Structure of the EBNA-2 protein 
The B95-8 EBNA-2 (487 aa) and the AG876 EBNA-2 (455 aa) proteins share approximately 50% of sequence 
identity, which consists mainly of 9 conserved regions (CRs 1 to 9). Characteristic parts of the EBNA-2 protein are: 
two N-terminal self-association domains (SAD1 and SAD2); a poly-proline region (PPR); a diversity region, which 
is a sequence with low similarity between EBV types; a region interacting with the cell DNA-binding protein RBP-
Jk (RBP-Jk); a short sequence rich in arginine and glycine residues (RG); a transactivation domain (TAD); a 
carboxyl-terminal nuclear localization signal (NLS). EBNA-LP indicates regions involved in cooperation between 
EBNA-2 and EBNA-LP in transcriptional activation.  
 
 
1.7.3 EBNA-2 regions important for B cell transformation 
Regions essential for the transforming ability of EBNA-2 have been mapped by extensive 
mutational analysis using either recombinant viruses or the EREB2.5 trans-complementation 
system and are highlighted in Figure 1.7. An initial study identified four EBNA-2 domains 
essential for B cell transformation and LMP-1 promoter transactivation in transient assays, 
suggesting that transformation and transactivation functions of EBNA-2 are closely related 
[308]. Subsequently, numerous reports further defined the subdomains whithin these four regions 
of EBNA-2 important for LCL outhgrowth. In the N-terminal part of the protein the essential 
domains correspond to the two self-association domains (amino-acids 1 to 58 and 97 to 210) 
[297,298,308]. Moreover, residues 3 to 30 have been shown to be required for induction of 
LMP-1 expression and, consequently, for immortalisation maintenance, using the EREB2.5 
75 
 
trans-complementation system [292]. B cell infection experiments with recombinant EBV 
viruses suggested that at least seven prolines out of the poly-proline region are required for 
transformation, whereas in the EREB2.5 system, the whole poly-proline region has been shown 
to be dispensable for EBNA-2-mediated immortalisation maintenance [291,309]. The CR4 has 
been shown to contribute to EBNA-2-mediated immortalisation of B cells, as mutant viruses 
with a deleted CR4 are drastically impaired in B cell transformation [310]. In the carboxyl-
terminal half of the protein, the entire RBP-Jk binding domain (amino acids 280 to 337) and the 
transactivation domain are essential for B cell transformation and LMP-1 induction 
[305,308,311]. Viruses with a randomized core amino acid sequence within the TAD display a 
markedly reduced transcriptional activity and transformation efficiency, demonstrating that 
transcriptional activation by TAD is required for EBNA-2-induced B cell transformation [312]. 
The RG motif has been demonstrated to be important for optimal B lymphocyte transformation 
efficiency [313]. However, a deletion mutant EBNA-2 protein lacking the RG sequence displays 
a four-fold increase in the activation of the LMP-1 promoter in reporter assays, compared to 
wild-type EBNA-2, suggesting that the RG domain is a negative regulator of EBNA-2 
transactivation function on the LMP-1 promoter [313]. CR7 has been shown to be nonessential 
for B cell transformation [313] although it seems to be important to modulate EBNA-2 co-
activation by EBNA-LP [193]. Additionally, mutation of a CKII phosphorylation site (SS469) 
between CRs 8 and 9, has been shown to abolish EBNA-2 binding to hSNF5/Ini1, a component 
of the cell SWI/SNF chromatin remodelling complex, and severely impair EBNA-2 growth-
promoting effects [314,315]. 
 
1.7.4  Mechanisms of EBNA-2-mediated transactivation  
 
1.7.4.1  EBNA-2 responsive elements 
EBNA-2 lacks intrinsic DNA binding activity and is therefore tethered to EBNA-2 responsive 
viral and cell promoters through various host DNA-binding proteins. The most studied of these is 
the cell transcriptional repressor RBP-Jk or CBF1 [207,301,302,316]. EBNA-2 is at least 
partially dependent on RBP-Jk sites for transactivation of the LMP-1/LMP-2B, LMP-2A, Cp, 
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CD21 and CD23 promoters [150,256,257,303,317,318]. Other cell factors binding to promoter 
elements important for EBNA-2 responsiveness include PU.1/Spi-1, Spi-B, AP-2 and POU 
domain proteins, in the case of LMP-1 promoter [132,256,258]. Likewise, the hnRNP-protein 
AUF1 is important for regulation of the Cp and CD21 promoters [319,320].  
 
1.7.4.2  EBNA-2, RBP-Jk and Notch 
RBP-Jk is a ubiquitously expressed transcriptional factor highly conserved in evolution and is 
involved in the Notch signalling pathway. EBNA-2 is considered a viral functional homologue of 
a constitutively active Notch receptor, since both EBNA-2 and Notch receptor intracellular 
domain (Notch-IC) interact with RBP-Jk to modulate gene expression [321,322]. RBP-Jk acts as 
a transcriptional repressor, by recruiting a histone deacetylase complex (HDAC) to target 
promoters [323]. EBNA-2 and Notch-IC bind to the same minimal repression domain of RBP-Jk, 
thereby relieving repression by replacing the HDAC repressor complex with their own 
transactivation domains. The WWP sequence of EBNA-2 is similar to the WFP sequence in 
Notch -IC that mediates contacts with RBP-Jk [52]. Mutation of the WW residues of EBNA-2 to 
SS abolishes EBNA-2-mediated up-regulation of the Cp promoter, partially reduces LMP-1 
promoter activation and prevents EBV transformation of primary B lymphocytes [311]. The 
Notch signalling pathway regulates multiple developmental processes in vertebrates, including 
lineage commitment of lymphocytes. Deregulated expression of Notch is associated with several 
human malignancies and has been shown to be oncogenic in some animal model systems [296]. 
The oncogenic potential of deregulated Notch signalling suggests that EBNA-2 can contribute to 
B cell immortalisation by constitutively activating the Notch signalling pathway. In EBV-
immortalised LCLs, Notch is not able to completely replace EBNA-2 in its ability to maintain B 
cell proliferation [293,324]. Partial rescue of proliferation can only be achieved when LMP-1 is 
expressed independently of EBNA-2 or when Notch1-IC is expressed at very high levels 
[293,324]. These biological differences between EBNA-2 and Notch were recently traced back 
to profound differences in the regulation of target genes by EBNA-2 and Notch, as assessed by 
comparative genome-wide expression analysis. EBNA-2 is more effective at up-regulating genes 
involved in proliferation, survival and chemotaxis, whereas Notch is more potent in regulating 
genes associated with differentiation and development [325]. Furthermore, earlier studies 
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showed that, in B cells, Notch-IC was able to modulate expression of only some of the viral 
EBNA-2 target genes containing RBP-Jk binding sites (Cp, LMP-2A but not LMP-1) and 
induction of Cp and LMP-2A by Notch-IC was lower than that achieved with EBNA-2 
[322,326]. These observations suggest that the viral EBNA-2 has evolved the ability to usurp 
part of the cell Notch signalling pathway but also uses viral-specific mechanisms other than 
interaction with RBP-Jk to transactivate genes, thereby promoting B cell proliferation. This is 
consistent with the notion that the interaction of RBP-Jk with EBNA-2 is necessary but not 
sufficient to induce gene expression [327] and that in some promoters additional factors have to 
bind within the enhancer elements to confer EBNA-2-responsiveness (see section 1.7.4.1). For 
example, the dominant importance of the host PU.1 factor for the EBNA-2-mediated 
transactivation of the LMP-1 promoter, confirms that regulation of this promoter is more 
complex than simple RBP-Jk-tethering and this might explain why Notch-IC is unable to 
effectively up-regulate LMP-1 in EBV-LCLs.  
 
1.7.4.3  Co-activating proteins interacting with EBNA-2  
Once positioned at target promoters, EBNA-2-mediated gene transcription is activated by the 
acidic transactivation domain (TAD) which interacts with histone acetyltransferases (HAT) 
p300/CBP and PCAF [260] and with several components of the cell transcription machinery, 
including TFIIH [328], TAF40, TFIIB [329] and co-activator p100 that interacts with TFIIE 
[330]. The TAD from EBNA-2 is similar to Herpes Simplex VP16 acidic domain [294,312]. The 
two acidic domains share binding to the transcription factors TFIIH, TAF40 and TFIIB and to 
the histone acetyltransferases p300/CBP and PCAF [260]. Moreover the VP16 activation 
domain, or a core hydrophobic 14-amino acid sequence of it, can substitute for the homologous 
portion of the EBNA-2 TAD in transactivation assays [294,312]. Also, a chimaeric EBV virus 
containing the 14-amino acid sequence from VP16 was able to transform primary B lymphocytes 
as efficiently as wild-type viruses [312].  
EBNA-2-mediated transactivation is augmented by interaction with EBNA-LP [138,139,140], 
which occurs mainly via the TAD and the AD2 domains of EBNA-2 [141,193]. EBNA-2-
mediated transcriptional activation can be further modulated by EBNA-LP through interaction 
with two other domains of EBNA-2 protein, i.e. the RG sequence and CR7 [193].  
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Both EBNA-LP and the EBNA-3 family of viral proteins have been shown to modulate EBNA-2 
transcriptional activity at the level of RBP-Jk interaction. EBNA-LP has been proposed to 
displace the RBP-Jk repressive complex from cell promoters [331] thereby positively regulating 
EBNA-2 transactivation function. In contrast, EBNA-3 proteins negatively regulate EBNA-2 
transcriptional activation by competing with EBNA-2 for binding to RBP-Jk [147,209].  
Moreover, EBNA-2 can regulate transcription by interacting with hSNF5/Ini1, a component of 
the cell multiprotein chromatin remodelling complex SWI/SNF, which converts the chromatin 
structure to a form accessible for transcription [315,332]. This interaction involves two specific 
amino acid motifs of EBNA-2 protein: IIP (aa 286-288), upstream of CR5, and DQQ (aa 313-
315), within the RBP-Jk binding domain. A mutation at a CKII phosphorylation site (SS469) has 
been shown to be required for this interaction [314]. Additionally, the poly-proline region seems 
to be required for stabilization of the interaction [315].  
EBNA-2 has also been shown to bind to the DEAD-box protein DP103/Geminin3, which is 
considered to be a putative RNA helicase, and to the survival motor neuron (SMN) protein, 
which is involved in RNA metabolism and in transcriptional regulation, since it co-activates the 
RNA-polymerase II transcription complex [261,333,334]. Binding of EBNA-2 to 
DP103/Geminin3 occurs through the N-terminus of EBNA-2 (aa 121-216), whereas binding to 
SMN protein occurs via the RG sequence and requires methylation of this motif [333].  
Similarly to Notch-IC, EBNA-2 has been shown to interact with the cell protein Nur77, which is 
both a transcription factor and a mediator of apoptosis, thereby blocking Nur77-mediated 
apoptosis [335].  
 
1.7.5  EBNA-2 target genes 
Being such a potent transcriptional activator, EBNA-2 is able to regulate not only the viral 
promoters Cp and LMP but also an array of primary and secondary target genes in the human 
genome that ultimately govern B cell transformation. In earlier studies EBNA-2 cell target genes 
were identified and studied individually. These include mainly genes involved in control of cell 
growth and survival such as the proto-oncogenes c-FGR and c-MYC [336,337], the transcription 
factor RUNX3 (described later) [338], the cell cycle regulator cyclin D2 [138] and the Notch-
family member HES-1 [142]. Several genes among EBNA-2 targets code for cell surface and 
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soluble proteins that modulate the interactions between  the cell and the environment, such as the 
B cell activation markers CD21 and CD23 [339,340], the receptors IL-18R [341] and CCR7, the 
latter being involved in maturation of B cells [342], and the cytokines TNF-α, LT-α and IL-16 
[338,343]. In addition, EBNA-2 has been shown to down-regulate the germinal centre proteins 
TCL1 and BCL6, suggesting that EBNA-2 may interfere with the GC phenotype [344]. In 
contrast to other cell genes induced by EBNA-2, one gene, BATF, encodes a member of the AP-
1 family of transcription factors that functions as an antagonist of cell growth. BATF is 
seemingly involved in promoting viral latency and preventing lytic cycle entry [345]. EBNA-2 
has also been shown to induce FcRH5, a recently identified B cell membrane protein with 
unknown function, whose expression is deregulated in some Burkitt’s Lymphoma cell lines 
[346]. In contrast, EBNA-2 suppresses the transcription of the immunoglobulin (Ig) µ gene via 
RBP-Jk-independent mechanisms [347]. Among this preliminary small group of EBNA-2-
regulated genes, only a few were conclusively demonstrated to be direct targets of EBNA-2 (i.e. 
CD23, RUNX3, c-MYC and FcRH5) since no de novo protein synthesis was required for their 
induction. Regulation of some of the EBNA-2 targets (i.e. CD21, CCR7 and FcRH5) has been 
demonstrated to be strictly RBP-Jk-dependent [342,346]. RUNX3, c-MYC, BATF and HES-1 are 
all transcription factors, indicating that there are likely to be numerous indirect targets of EBNA-
2.  
Recently several independent studies have identified comprehensive lists of EBNA-2 targets in 
LCLs and BLs, using whole genome microarray analysis [135,136,137,348]. One of these 
studies, performed in this laboratory, used a protocol designed to identify direct target genes, 
whose induction by EBNA-2 did not depend on protein synthesis of intermediate genes 
[348,349]. In another study, an RBP-Jk-somatic knock out B cell line was used to define the 
contribution of RBP-Jk to the activation of the EBNA-2 target genes [136]. In addition to the 
previously known EBNA-2 targets, numerous novel genes were identified which code for 
proteins with diverse and heterogeneous functions [135,136,137,348]. These can be classified as: 
• members of the Notch signalling pathway (e.g. DTX1 and HEY1);  
• transcription factors involved in activation and differentiation of B cells (e.g. IRF4 
and ETS1) or specific to post-germinal or germinal centre; 
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• transcription factors and other proteins important for B cell proliferation and survival, 
such as regulation of cell cycle and apoptosis (e.g. STAT6, MAD1, GADD45β, JunD, 
PIK3R1); 
• various cytokines and chemokines (CCL3, CCL4), chemokine receptors (CXCR7, 
CCR7) involved in lymphocyte trafficking;  
• proteins important for cell adhesion and cytoskeleton remodelling, which usually 
occurs during B cell activation; 
• proteins involved in endocytosis and recycling; 
• proteins implicated in transcription and RNA processing. 
In one study a proteomic approach was used in EBV-LCLs and in primary B cells; EBNA-2 
target proteins were classified as c-MYC-dependent and c-MYC-independent. The proteins 
identified are mainly involved in cell growth (e.g. regulation of apoptosis) and cell metabolism, 
but also stress responses, signal transduction and protein synthesis and degradation [350].  
The roles of some of the EBNA-2 direct target genes have been investigated in depth in this 
laboratory, including RUNX3, PI3K and CXCR7 (the latter will be described in detail in the 
following paragraph) [135,338]. All three genes are absolutely required for proliferation and 
survival of EBV-infected LCLs, as proved by RNAi experiments [135,348,351].  
RUNX3 is a member of the Runt domain family of transcription factors involved in 
hematopoiesis and osteogenesis [338]. RUNX3 and RUNX1, another member of family, are 
expressed at many stages of B cell differentiation, suggesting a role in development of this cell 
lineage [352]. RUNX genes have been associated with B cell cancer: for example deregulated 
expression of RUNX1, due to the t(12;21) translocation, is found in acute lymphocytic 
leukaemia of B cell origin [353]. Cross-regulation of RUNX1 expression by RUNX3 is 
important for regulating proliferation of EBV-infected LCLs. In fact, upon EBV infection of 
resting B cells, EBNA-2 induces RUNX3 which in turn down-regulates RUNX1 [351]. Reduced 
levels of RUNX1 are required for optimal EBV-driven B cell proliferation since over-expression 
of RUNX1 into EBV-LCLs inhibits cell growth [354]. Therefore not only is RUNX3 required, 
but RUNX1 must also be removed to ensure normal proliferation of the B cells. 
The proto-oncogene c-MYC is one of the most prominent direct targets of EBNA-2 [336]. In its 
physiological role c-MYC protein regulates cell growth, proliferation, loss of differentiation and 
apoptosis, whereas activated oncogenic c-MYC, whose expression is deregulated, is involved in 
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pathogenesis of a variety of cancers [355,356]. In the EREB2.5 cell line, EBNA-2 was shown to 
induce expression of c-MYC to moderate levels, whereas enforced over-expression of c-MYC to 
much higher levels is sufficient to drive B cell proliferation independently of EBNA-2 and LMP-
1 [357]. The proliferation program imposed by over-expressed c-MYC is however different from 
that activated in EBV-immortalised cells: the typical lymphoblastoid morphology and phenotype 
of EBV-LCLs changes into that of BL cells. In fact EBV-LCL normally grow in large clumps, 
express activation markers and adhesion molecules, are highly immunogenic and are highly 
resistant to apoptosis, whereas c-MYC-driven cells, in the absence of EBNA-2 and LMP-1, grow 
mostly as single cells in suspension, do not express adhesion or activation molecules typical of 
EBV-LCLs, are markedly sensitive to apoptosis and are poorly immunogenic [357]. In contrast 
to EBV-LCLs, activation of EBNA-2 in latency I or EBV-negative BL cells causes growth arrest 
[347]. A constant feature of BL cells is deregulated expression of c-MYC due to chromosomal 
translocation. The most frequent t(8;14) translocation juxtaposes the c-MYC gene locus on 
chromosome 8 and the promoter of the µ immunoglobulin heavy chain gene locus on 
chromosome 14 [103,106]. Since the immunoglobulin µ gene is a negative target of EBNA-2, 
expression of EBNA-2 in BL cells results in suppression of the translocated allele of c-MYC and 
consequently in cell cycle arrest [347].  
The aforementioned studies of EBNA-2 target genes have used the type 1 protein. A few recent 
studies have investigated the ability of type 2 EBNA-2 to regulate gene expression and these will 
be reported in section 3.1. 
 
1.8  CXCR7 
 
1.8.1  CXCR7: a novel and atypical chemokine receptor 
CXCR7 (RDC1, CMKOR1) is a G-protein coupled receptor with seven trans-membrane 
domains. Originally, the CXCR7 gene was cloned from a dog cDNA library, therefore named 
Receptor Dog cDNA 1 (RDC1). Combined phylogenetic analysis revealed that this receptor 
belongs to the subfamily of rhodopsin-like receptors, in close proximity to the chemokine 
receptors subfamily [358,359]. A link between RDC1 and chemokine receptors was also 
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suggested on the basis of sequence similarity (43%) and identity (32%) with CXCR2 and its 
chromosomal location in close proximity to cxcr4, cxcr2 and cxcr1 genes on mouse chromosome 
1. A similar gene arrangement is found in human chromosome 2 [360,361]. CXCR7/RDC1 gene 
is highly conserved among mammalian species, including human, dog, mouse and rat [362]. 
RDC1 was considered for many years an orphan receptor, until Burns et al. demonstrated that it 
can bind with high affinity to the chemokines CXCL12/SDF-1 and CXCL11/I-TAC [363]. 
RDC1 was therefore officially “deorphanized” and renamed as CXC receptor 7 (CXCR7) 
[363,364]. Importantly, the inflammatory and homing chemokines CXCL12/SDF-1 and 
CXCL11/I-TAC are also ligands for CXCR4 and CXCR3 receptors respectively [363,364].  
Like CXCR4 and several other chemokine receptors, CXCR7 can serve as co-receptor for certain 
HIV and SIV strains which infect both T lymphocytes and brain-derived cells [365]. However, 
while the role of CXCR4 as a cofactor for HIV virus infection of T lymphocytes is well known, 
less is known about CXCR7 in relation to HIV transmission and pathogenesis.  
CXCR7 is believed to be an atypical chemokine receptor since coupling of the receptor to G-
proteins could not be demonstrated and controversy exists about CXCR7-mediated triggering of 
typical chemokine responses such as chemotaxis or receptor-induced calcium mobilization 
[363,364,366]. So far, the only response characteristic of chemokine receptors that has been 
ascribed to CXCR7 is ligand-induced internalization in several cell types [364,367,368]. 
In the absence of typical chemokine receptor functions, CXCR7 has been proposed to be mainly 
a modulator of CXCR4 and CXCR3 signalling. This is suggested by the observation that CXCR7 
expression on mature B cells inversely correlates with the activity of CXCR4 [369]. 
Furthermore, CXCR7 has been proven to be critical for CXCR4 to mediate CXCL12-induced 
integrin activation and adhesion of T lymphocytes to endothelial cells [366]. Additionally, 
CXCR7 has been implicated in CXCL12/CXCR4-mediated transendotelial migration of 
CXCR4+CXCR7+ human tumour cells, based on the observations that CXCL12 triggers adhesion 
of these cells to CXCR7+ endothelium and CXCL11 binding to CXCR7 interferes with this event 
[363,367]. One possible mechanism underlying the ability of CXCR7 to modulate CXCR4 
functions is heterodimerization of the two receptors, which enhances CXCL12-induced 
signalling [370,371]. Alternatively, CXCR7 may regulate CXCR4 and CXCR3 functions by 
acting as a specific scavenger receptor that sequesters CXCL12 and CXCL11, internalizes them 
and targets them for degradation, thereby limiting the amount of chemokines available in the 
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extracellular space to stimulate CXCR4/CXCR3 signalling. [372]. Studies in a zebrafish model 
support this mechanism [368,373]. For example, CXCR7 is able to guide cell migration during 
the development of the posterior lateral line primordium through ligand sequestration and the 
shaping of local CXCL12 gradients [373]. Moreover, CXCL12 binds with 10 times higher 
affinity to CXCR7, compared to CXCR4, and binding of both CXCL11 and CXCL12 to CXCR7 
was shown to result in ligand internalization in CHO-CXCR7 cells [367]. Consistently, CXCR7 
was also shown to be continuously cycling between the plasma membrane and the intracellular 
compartments in both mammalian cells and zebrafish [372].  
Recently, the idea that CXCR7 is a “silent” receptor because it is incapable of activating G-
proteins has been challenged. In fact, the receptor was shown to trigger intracellular signalling by 
engagement of β-arrestins in a ligand-dependent manner [367,374]. Therefore the possibility 
remains open that the receptor is not just a modulator of CXCR4/CXCR3-mediated effects, but 
could also differentially contribute to CXCL12/CXCL11-induced responses, providing 
additional effects which are independent from those of CXCR4 and CXCR3. For example, in the 
context of CXCL12-mediated homing of renal progenitor cells, CXCR7 was shown to be mainly 
involved in cell survival and cell adhesion to the endothelium, whereas CXCR4 mediates 
chemotaxis of these cells [375].  
 
1.8.2  CXCL12-CXCR4  
CXCL12/SDF-1, the ligand that CXCR7 shares with CXCR4, is a homing cytokine that 
regulates many biological processes, including cardiac and neuronal development, stem cell 
motility, trafficking of naïve lymphocytes, neovascularisation and tumorigenesis [376,377]. 
Before the recent evidence that CXCL12 binds not only to CXCR4 but also to CXCR7, CXCL12 
and CXCR4 were thought to be a “monogamous pair”, since targeted disruption of either gene 
resulted in remarkably similar phenotypes in mice, which include defects in hematopoiesis, 
vascularisation and heart development [378,379]. CXCR4 and CXCL12 are widely expressed in 
normal tissues. Importantly, CXCR4 mRNA and protein expression is detected in many immune 
cell types (including B cells) and in primitive hematopoietic CD34+ progenitor cells in the bone 
marrow [377]. CXCL12 is constitutively expressed by stromal cells in many tissues and in 
lymphoid tissue in the periphery and is considered to be a homeostatic chemokine. In normal 
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conditions in the bone marrow, the most important function for CXCL12-CXCR4 is to regulate 
proliferation, survival, homing and retention of CD34+ progenitor cells in the bone marrow for 
further maturation [380,381]. CXCR4 and CXCL12 play also important roles in the periphery, 
where they regulate trans-endothelial migration of leukocytes and their lymphoid and peripheral 
trafficking [377]. The involvement of the CXCL12-CXCR4 axis in tumorigenesis has been 
extensively studied and it has been shown to promote survival of cancer cells in sub-optimal 
conditions, angiogenesis and migration of tumour cells to the sites of metastasis in breast, lung, 
ovarian, renal and prostate cancer [377]. CXCR4 is the chemokine receptor most commonly 
found on cancer cells, in both human and murine models. CXCL12 expression has been detected 
both in primary tumour sites and at sites of metastasis and its secretion by stromal fibroblasts in 
primary breast tumours increases angiogenesis and the proliferation of tumour cells [382]. 
CXCL12-CXCR4 is believed to be important in lymphomagenesis, including pathogenesis of 
acute leukaemia, multiple myeloma and B cell chronic lymphocytic leukaemia 
[383,384,385,386]. 
 
1.8.3  CXCL11-CXCR3  
CXCL11 (I-TAC) is considered to be manly an inflammatory chemokine and it binds to CXCR3 
and CXCR7 [363]. CXCR3 is preferentially expressed on the surface of Th1 T lymphocytes and 
has been detected in a variety of human inflammatory conditions [387]. CXCL11 induces 
CXCR3-mediated migration of Th1 lymphocytes and is involved in epidermal maturation in 
wound healing [388]. CXCL11 has only recently been implicated in cancer, although its role in 
malignancy is poorly understood so far. CXCL11 was reported both to accelerate tumour 
progression (i.e. in ovarian cancer) and to limit tumour growth by inhibiting angiogenesis and 
cell proliferation [376]. 
 
1.8.4  Physiological functions of CXCR7 
CXCR7 expression patterns are more restricted than those of CXCR4, which, in contrast, is 
almost ubiquitous. CXCR7 is highly expressed on transformed cells and during embryonic 
development, both in human and mouse tissues, but it is poorly expressed on normal somatic 
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cells [362,363]. CXCR7, protein and mRNA, expression levels in the hematopoietic system have 
been analysed in several studies, but with inconsistent results. Infantino et al. reported that 
CXCR7 mRNA is broadly expressed in normal human leukocytes (B/NK cells, monocytes, 
basophils, CD4+ but not CD8+ T cells), whereas the protein is strictly expressed only at the 
plasma membrane of monocytes, basophils and mature B cells [369]. Another study reported the 
expression signature of CXCR7 in normal human PBMCs and revealed that the mRNA is 
expressed in various fractions of resting PBMCs (T and B cells and monocytes) and is 
consistently downregulated in activated cells, whereas surface CXCR7 can be detected only on 
monocytes, but not on B cells [389]. Balabanian et al. detected CXCR7 surface expression on T 
cells [364], whereas in a report by Berahovich et al., no CXCR7 protein or mRNA was detected 
on any human or mouse peripheral blood leukocyte type (T, B, NK cells, monocytes or 
neutrophils) [390].  
Valuable information about the role of CXCR7 in embryogenesis and development was obtained 
from CXCR7-deficient mice [371,391]. CXCR7-knock out animals die perinatally with severe 
heart defects, suggesting a role for CXCR7 restricted to cardiac development only. Surprisingly, 
hematopoiesis in these mice is normal, in contrast to CXCR4 and CXCL12 knock-down mice, 
which both show severe B cell lymphopoiesis defects [378,379]. No brain or bone phenotypes 
were observed in CXCR7-deficient mice, despite high expression levels of CXCR7 in brain cells 
and osteocytes in healthy adult mice [371,391].  
The physiological role of CXCR7 in adult tissues remains unclear. The best studied normal cell 
types so far are lymphocytes. However, the data reported is contradictory, especially with respect 
to T lymphocytes and whether CXCR7 mediates ligand-induced chemotaxis in these cells 
[364,366]. A role in B lymphopoiesis was postulated by Infantino et al., based on the observation 
that CXCR7 expression is tightly regulated during B cell development and differentiation. In 
peripheral blood switch memory B cells, the expression of the receptor at the plasma membrane 
correlates with the ability to differentiate into antibody-producing plasma cells, suggesting that 
CXCR7 is a marker for memory B cells, which are precursors of antibody-secreting cells [369]. 
However the absence of a hematopoietic phenotype of the knock out mice argues against a role 
for CXCR7 in B lymphopoiesis [371].  
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1.8.5  CXCR7 and tumorigenesis 
While there is no general consensus about the biological functions of CXCR7 in normal tissues, 
there is instead a large body of evidence pointing towards a clear role for CXCR7 in 
tumorigenesis. This is also an important function for CXCR4-CXCL12, and an emerging 
function mediated by CXCR3-CXCL11 interaction. CXCR7 protein is highly expressed on 
numerous human and mouse transformed cell lines and also in tumour biopsies 
[363,392,393,394,395,396]. Additionally, CXCR7 expression was detected on tumour-associated 
vasculature and endothelial cells activated with pro-inflammatory cytokines [363,392]. CXCR7 
was first implicated in tumorigenesis by Raggo and colleagues, who demonstrated that ectopic 
expression of the gene in fibroblasts increases cell proliferation and induces tumour formation in 
nude mice [397]. Furthermore, expression of CXCR7 on breast and lung cancer cells was found 
to induce tumour formation, vascularization and metastasis in immunodeficient and 
immunocompetent mouse models of cancer [394]. In human prostate cancer tissues, CXCR7 
protein levels were found to correlate with tumour aggressiveness and in vitro CXCR7 was 
shown to confer a pro-survival advantage to prostate cancer cell lines, possibly mediated by the 
Akt signalling pathway [392]. Dowstream targets of CXCR7 identified in prostate cancer cells 
have been suggested to mediate CXCR7-induced invasiveness of these cells (CD44 and 
cadherin-11) and pro-angiogenic activities of CXCR7 (IL-8 and VEGF) [392]. Moreover, 
administration of antagonists to CXCR7 results in hindrance of tumour growth in animal models, 
suggesting that the receptor could be a novel target for anti-cancer treatments [363].  
Further evidence that implicate CXCR7 as a key player in tumorigenesis came by the 
observation that the human tumour suppressor HIC1, is involved in the transcriptional regulation 
of the CXCR7 gene [398]. Moreover, recently CXCR7 has been shown to be a target gene of 
several different oncogenic viruses. CXCR7 RNA is strongly induced in hDMVECs transformed 
with KSHV and is essential for transformation and focus-formation of KSHV-infected 
hDMVECs [397,399,400]. Interestingly, ectopic expression of K13, one of the major latent 
proteins of KSHV, in human vascular endothelial cells is sufficient to mimic the effect of KSHV 
infection on spindle cell transformation and up-regulation of CXCR7 through strong induction of 
the NF-kB pathway [401]. The CXCR7 gene is also up-regulated by human T cell leukaemia 
virus type 1 (HTLV-1) transctiptional activator Tax, via the NF-kB pathway, and has a pro-
survival effect on HTLV-1-infected T cells [389]. In line with these observations, this laboratory 
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has previously published that CXCR7 is induced by EBV EBNA-2 (type 1) and is essential for 
survival and proliferation of EBV-infected LCLs [135,348].  
Although an important role for CXCR7 has been identified in many types of malignancies, its 
specific role in the pathogenesis of leukaemias and lymphomas still remains to be addressed. In 
contrast to CXCR4, which is highly expressed on early hematopoietic stem progenitor cells in 
the bone marrow, CXCR7 is expressed at very low levels on the surface of these cells and does 
not seem to induce their proliferation or migration in response to CXCL11 [402,403]. However, 
functional CXCR7 is highly expressed in several human myeloid malignant cell lines and 
mediates adhesion and mobilization of these cells upon CXCL11 stimulation, via 
phosphorylation of MAPKp42/44 and Akt [402].  
 
1.9  EBV types 
Genetic analysis of EBV isolates world-wide has identified two broad families of EBV, 
designated as type 1 and type 2, or A and B respectively. The most divergent locus between the 
two types is EBNA-2, with 46% difference in the predicted primary amino acid sequence, hence 
the EBNA-2 locus defines the types 1 and 2, although there are linked differences in EBNA-LP 
and EBNA-3 genes [188,189,295,404,405,406,407]. There is additional polymorphic variation in 
EBNA-1 [408,409], BZLF1 and LMP-1 [410,411] but is not linked to the type 1 / type 2 
variation. Additional divergence has been reported also in the EBER genes, but this is less 
consistent [412,413]. In contrast, in the rest of the EBV genome there is an extremely low degree 
of sequence variation. Sequencing of type 2 EBV in the AG876 cell line in 2006, allowed a 
comparison between type 1 and type 2 EBV genomes which revealed that the two types are co-
linear and very similar, with the exception of the known divergent alleles [58].  
The most important biological difference between the two viral types is that type 1 EBV 
efficiently immortalises B cells in vitro, whereas type 2 strains are far less effective [414]. Type 
1 EBV-transformed LCLs grow more quickly and to a higher saturation cell density than do type 
2-transformants [414]. This difference in in vitro transforming efficiency between the EBV types 
has been mapped to the EBNA-2 locus [155]. Experiments with a recombinant type 2 P3HR1 
EBV strain carrying a type 1 EBNA-2 sequence showed that this virus gained a type 1 
immortalisation phenotype [155]. In contrast, the type sequence of the the EBNA-3 genes does 
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not affect the immortalisation ability of the virus, since replacement of the EBNA-3A, -3B, and -
3C loci in the type 2 P3HR1 EBV genome, with the corresponding type 1 sequences produced no 
difference in primary B lymphocyte growth transformation [405,415]. The in vitro transforming 
activities of type 1 and type 2 EBV also correlate with the frequency of tumour formation in 
SCID mice inoculated intraperitoneally with type 1 or type 2 EBV in vitro transformed LCLs 
and the key factor of this correlation is the type of the EBNA-2 locus [416,417]. In fact, EBV-
LCLs generated in vitro with a wild-type type 1 strain or with a type 2 P3HR1 strain bearing a 
type 1 EBNA-2 induced the appearance of tumours with similar rates in the SCID mice model 
[417]. Type 1 and type 2 EBV strains have also been reported to differ in another biological 
property which is the ability to spontaneously enter the lytic cycle in the context of either LCLs 
or BL cell lines. Despite similar levels of growth rate, cell lines harbouring type 2 EBV appear to 
support spontaneous viral replication at a higher frequency than type 1 cell lines [418]. 
Several small epidemiological studies investigating the geographical distribution of the EBV 
types showed that type 1 strains of EBV are ubiquitous in the world and predominate in 
European, American and Chinese populations, whereas type 2 strains are rare in these 
populations (3-10%) [419,420,421,422]. Type 2 EBV strains are less rare in some areas of 
Central Africa and Papua New Guinea, which are endemic for Burkitt’s Lymphoma and malaria: 
in Kenya and New Guinea type 2 EBV was detected in 24% and 21% respectively of healthy 
carriers analysed [419]. Despite the clear difference in B cell transformation phenotype in vitro 
and in B cell tumour growth in the SCID mouse model between type 1 and type 2 EBV strains, 
no type specific disease associations have been demonstrated. Extensive literature exists on the 
frequencies at which type 1 and type 2 are found in EBV-associated tumours and it shows that 
this simply reflects the patterns of geographical distribution of these strains in the normal 
population [413,423,424]. For example, early work showed that both types of EBV are 
associated with endemic BL in Central Africa [419,420], whereas almost all the EBV-positive 
sporadic BL cases in the Western world contain type 1 EBV [420,425]. Moreover, several 
European studies showed that EBV-positive Hodgkin’s Lymphoma arising in immunocompetent 
individuals in these areas, most frequently carry type 1 EBV [426,427]. This early work was 
based on virus rescue from spontaneous in vitro transformed peripheral blood lymphocytes of 
healthy carriers, a method that favours the isolation of type 1 EBV, which is more efficient at 
transforming B cells in vitro [414]. Subsequent PCR analyses performed directly on peripheral 
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blood mononuclear cells (PBMC), without need for prior culture, cast doubt on the restricted 
geographical distribution of type 2 strains, showing that among a population of healthy 
Americans, 50% was carrying type 1 EBV, whereas 41% had type 2 EBV [428]. Furthermore, 
studies on EBV carriage in immunosuppressed individuals (HIV positive and cardiac transplant 
recipients) from Western communities showed as well high prevalence (from 20 to 30%) of type 
2 EBV [429,430]. The increased frequency of type 2 EBV in HIV-positive patients is also 
reflected in its association with EBV-related malignancies, such as non-Hodgkin’s Lymphomas 
and HL (25 to 50% type 2) [427,429,430,431,432,433,434,435]. These figures of type 2 EBV 
prevalence in HIV-patients from Western populations are substantially higher (>30%) compared 
to that of type 2 EBV carriage state (3-10%) in the general population from which they were 
drawn. One interpretation is that the EBV carrier state in HIV-positive patients [429,430] 
magnifies the picture existing in the immunocompetent population and that the entire range of 
viral resident strains is easier to detect in a situation of immunodeficiency because of the higher 
viral loads. In fact, patients with HIV or HIV-related disorders have been shown to have a 
defective EBV-specific T cell immunity and therefore have abnormally high numbers of EBV-
infected B cells in the circulation [436]. Type 2 strains might be the subdominant strain in vivo 
and therefore might be undetected in immunocompetent individuals, in which viral loads are 
low. Therefore type 2 EBV might have a wider geographical distribution than originally thought 
[419,420,421,422]. However, many of the studies on HIV-patients consistently involved one 
specific immunocompromised patient group that is male homosexuals. Therefore, an alternative 
scenario might be that high incidence of type 2 EBV in western communities is not consequence 
of immune impairment per se but is specific to one immunocompromised cohort. In fact, one 
study compared the incidence of type 2 EBV in two T cell immunocompromised cohorts, HIV-
positive male homosexuals and HIV-positive hemophilic patients, and found that in the latter the 
overall incidence of type 2 strains was very similar (10%) to that found in the normal population 
from the same geographical area. Those findings suggested that type 2 EBV is indeed rare in the 
general Caucasian population but has become endemic in the homosexual community [437]. 
Nevertheless, the question of the real prevalence of type 2 EBV strains in the western societies 
still remains to be resolved.  
Dual infections, normally rare in healthy carriers, are also frequent in immunocompromised 
populations in the Western world, not only in male homosexual AIDS-patients but also in a T 
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cell-immunocompromised hemophilic cohort, suggesting that T cell immunodeficiency per se 
does indeed favour super-infections [429,437,438].  
While the type 1 / type 2 variation has not been directly associated to EBV-related malignancies, 
one study reported that type 1 EBV strains are significantly more likely to result in infectious 
mononucleosis, compared to type 2 strains [439]. Although not clearly linked to tumorigenesis in 
vivo so far, some evidence seems to suggest the type 1 / type 2 the variation might be important 
for the immune detection of the virus. The EBNA-3 proteins, which may exist as type 1 or type 
2, are the major determinant of MHC class I cytotoxic T cell responses [440]. In individuals with 
the HLA A11 haplotype CTL responses are predominantly directed against two specific peptide 
sequences in EBNA-3B (epitopes 399-408 and 416-424, both of which vary between type 1 and 
type 2 sequences) [405,441,442]. In Caucasians and African populations the A11 haplotype is 
rare and the EBNA-3B epitopes are conserved in the viral strains circulating in those 
populations. In contrast, in two highly A11-positive populations (from Southern China and 
Papua New Guinea) the endemic EBV strains lack the immunodominant A11-restricted CTL 
epitopes [442]. One mutational hotspot in the 399-408 epitope that causes loss of the 
immunodominant epitope frequently involves a change from Ala (as seen in the type 1 B95-8 
EBV strain) to Ser (in type 2 AG876 strain), suggesting that viral strains with the type 2 
sequence in the EBNA-3B allele might become dominant within a specific population as a 
consequence of immune pressure [405,442]. EB virus-specific cytotoxic T cell responses can 
also be elicited by EBNA-2 [440,443]. It is not clear whether the type 1 / type 2 variation in this 
gene is related to EBV type specific T cell responses. In fact, one report showed that cytotoxic T 
cells prepared from donors carrying a type 1-virus are able to lyse type 1 EBV LCLs and type 2 
EBV-transformed target cells in vitro equally well, suggesting that those parts of the EBNA-2 
protein that differ between the type 1 and the type 2 variants, appear not to be a dominant antigen 
for induction of EBV-specific cytotoxic responses [443]. In contrast, another study, reported that 
EBV-specific T cell clones obtained from type 1 EBV-seropositive donors, are able to 
discriminate between autologous B lymphocytes transformed by type 1 EBV from those 
transformed with the type 2 strain: only type 1, but not type 2, autologous targets were efficiently 
killed in vitro [444].  
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1.10 Aims of the thesis 
 
The aim of this study is to understand why type 1 EBV strains are more effective at causing B 
cell transformation in vitro compared to type 2 EBV and to identify the molecular mechanisms 
underlying the superior in vitro transforming ability of type 1 EBV. Specifically, the objectives 
are:  
 
1. Investigation of the regulation of genes relevant for B cell proliferation by type 1 and type 2 
EBNA-2: 
• do type 1 and type 2 EBNA-2 differentially regulate viral and/or cell genes which are 
important for B cell proliferation? 
• does this differential gene regulation correlate with the difference in in vitro 
transforming ability of type 1 and type 2 EBV? 
 
2. Mapping of the domains of type 1 EBNA-2 which confer higher B cell immortalisation 
efficiency compared to the type 2: 
• which parts of the EBNA-2 protein are responsible for the superior ability of type 1 
EBNA-2 to sustain B cell growth compared to the type 2? 
• what are the EBNA-2-mediated mechanisms of transcriptional activation responsible 
for this?  
• is the type 1 / type 2 variation of EBNA-LP important for the weaker ability of type 1 
EBNA-2 to maintain B cell proliferation? 
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2  Materials and methods 
 
2.1  Solutions and chemicals 
All chemicals were supplied by BDH, unless otherwise stated.  
 
2.1.1  Cell culture protocols solutions 
• PBS: 137 mM NaCl, 2.7 mM KCl, 19 mM Na2HPO4, 1.7 mM KH2PO4, pH 7.0. 
• 0.8 % (w/v) ammonium chloride: 8 g of ammonium chloride (Sigma) was dissolved 
in cell culture grade water (Sigma) and made up to 1 litre. 
 
2.1.2  DNA protocols solutions 
• 1 M Tris-Cl pH 6.8, 7.6, 8.0, 8.5, 8.8: 121,1 g of Tris Base was dissolved in 900 ml of 
dH2O, the pH was adjusted with 1 M HCl and the volume adjusted to 1 litre. The 
solution was autoclaved and stored at RT. 
• 1 x TBS: 140 mM NaCl, 10 mM Tris-Cl pH 7.6. 
• 0.5 M EDTA pH 8.0: 186.1 g of EDTA was dissolved in 900 ml of dH2O, the pH was 
adjusted with NaOH and the solution was then diluted to a final volume of 1 litre, 
autoclaved and stored at RT. 
• NET buffer: 10 mM NaCl, 1 mM EDTA, 10 mM Tris-Cl. 
• TE buffer: 10 mM Tris-Cl pH 7.6 or 8.0 and 1 mM EDTA pH 8.0 in dH2O; 
autoclaved and stored at RT. 
• 3 M sodium acetate pH 5.2: 408.3 g of sodium acetate-3H2O were dissolved in 900 
ml of dH2O. The pH was adjusted with acetic acid to 5.2, the solution was topped up 
to 1 litre and autoclaved. 
• STET: 8% (w/v) sucrose (Sigma), 5% (v/v) Triton X-100 (Sigma), 50 mM EDTA, 50 
mM Tris-Cl pH 8.0. 
• Alkaline SDS: 1% (w/v) SDS, 0.2 M NaOH in dH2O. 
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• 10 x TBE: 108 g Tris Base, 55 g boric acid (Sigma) and 40 mM of EDTA pH 8.0 
were added to 800 ml of dH2O. The volume was then adjusted to 1 litre and 
autoclaved. 10 x TBE was diluted to 5 x, 1 x or 0.5 x in dH2O before use.  
• Agarose gel loading buffer: 10% (w/v) sucrose, 0.03% (w/v) bromophenol blue, 
0.03% (w/v) xylene cyanol FF, 60% (v/v) glycerol, 10 mM Tris-Cl pH 7.6, 60 mM 
EDTA in dH2O.  
• Luria Bertani medium (LB): 10 g tryptone, 5 g yeast extract and 10 g NaCl were 
dissolved in 1 litre of dH2O. The pH was adjusted to 7.0 with 0.5 M NaOH. The 
solution was then autoclaved and stored at RT. For LB agar plates, 15 g of bacto-agar 
was added per litre of medium before autoclaving.  
• For antibiotic selection, ampicillin and chloramphenicol were used at 50 µg/ml, 
kanamycin at 25 µg/ml and tetracycline at 10 µg/ml concentration. The 1000 x stock 
solutions were sterilized by filtering through 0.2 µm filters. 
• Buffer EB: 10 mM Tris-Cl, pH 8.5. 
• Buffer P1: 50 mM Tris-Cl pH 8.0, 10 mM EDTA, 100 µg/ml RNaseA. 
• Buffer P2: 200 mM NaOH, 1% SDS (w/v). 
• Buffers N3 and P3: 3 M potassium acetate pH 5.5. 
• Buffer QBT: 750 mM NaCl, 50 mM MOPS pH 7.0, 15% (v/v) isopropanol. 
• Buffer QC: 1.0 M NaCl, 50 mM MOPS pH 7.0, 15% isopropanol. 
• Buffer QF: 1.25 M NaCl, 50 mM Tris-Cl pH 8.5, 15% (v/v) isopropanol. 
 
2.1.3  RNA protocols solutions 
• Elution buffer (RPA kit, Ambion): 0.5 ammonium acetate, 1 mM EDTA, 0.2% SDS. 
• 6% acrylamide gel: 80 ml monomer solution, containing acrylamide/bis (19:1) and 6 
M urea, 20 ml buffer reagent (containing 5 x TBE), 100 µl 20% ammonium 
persulphate (APS, Sigma) and 10 µl tetramethyl ethylene diamine (TEMED).  
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2.1.4  Protein protocols solutions 
• RIPA lysis buffer: 0.15 M NaCl, 1% (v/v) Nonidet-P40, 0.5% (v/v) deoxycholic acid, 
0.1% (w/v) SDS, 50 mM Tris-Cl pH 8.0, 1 mM PMSF (Fluka) and Complete protease 
inhibitors (Roche). 
• 2 x SDS sample buffer: 250 mM Tris-Cl pH 6.8, 0.01% (w/v) bromophenol blue, 20 
mM β-mercaptoethanol, 2% (w/v) SDS, 10% (v/v) glycerol were prepared in dH2O 
and stored in aliquots at -20˚C. 
• 10 x SDS Running Buffer: 50 mM Tris-Cl, 400 mM glycine, 0.1% (w/v) SDS. 10 x 
SDS buffer was stored at RT and diluted to 1 x in dH2O prior to use. 
• Western blot transfer buffer: 25 mM Tris Base, 200 mM glycine, 0.05% (w/v) SDS, 
25% (v/v) ethanol. 
• Western blot washing buffer: 0.1 % (v/v) Tween-20 (Sigma) in PBS; stored at RT. 
• Western blot blocking solution: 10% (w/v) fat-free dried milk powder (Sigma) was 
reconstituted in western blot washing buffer and stored at 4˚C. 
• Western blot stripping buffer: 2 % (w/v) SDS, 62.5 mM Tris-Cl, pH 6.8 in dH2O. The 
solution was stored at RT and 100 mM β-mercaptoethanol was added prior to use. 
 
2.1.5  Flow cytometry solutions 
• Staining buffer for live cell staining: 1 x PBS, 1% (w/v) bovine serum albumin (BSA, 
Sigma), 0.1% (w/v) sodium azide. 
• Staining buffer for intracellular antigens staining procedure: 1 x PBS, 5% (w/v) BSA. 
 
2.1.6  Immunofluorescence solutions 
• Blocking buffer: 1% BSA in PBS. 
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2.2  Cell culture and virus protocols 
 
2.2.1  Cell lines and cell maintenance 
 
Suspension cell lines  
The B cell lines used in this study are listed in table 2.1. The B cells were grown in suspension in 
RPMI 1640 medium (Gibco-BRL) supplemented with 10% to 20% (v/v) heat inactivated (56˚C 
for 20 minutes) foetal bovine serum (FBS) from BioWhittaker. In LCL generation experiments, 
cells were maintained with 20% (v/v) FBS. All cell lines were grown in the presence of 200 
units/ml penicillin and 200 units/ml streptomycin (Gibco-BRL) with the appropriate antibiotic 
selection and maintained at 37˚C in a humidified incubator with 10% CO2. All the B cell lines 
were fed 2-3 times per week by dilution in an equal volume of pre-warmed new medium.  
 
Adherent cell lines 
293 is a transformed human embryonic kidney cell line [445] and HeLa is a human epithelial 
carcinoma cell line [446]. The 293-T1 EBV-BAC cell line was available in the laboratory [173] 
and was generated by stably transfecting 293 cells with a Bacterial Artificial Chromosome 
(BAC) carrying the EBV genome from B95-8 strain (B95-8 EBV-BAC, kind gift from W. 
Hammerschmidt [447]). All adherent cells were maintained at 37˚C in a humidified incubator 
with 10% carbon dioxide. The adherent cell lines were grown as monolayers in Dulbecco 
Modified Eagle Medium (DMEM, Gibco-BRL) supplemented with 10% (v/v) FBS and 
antibiotics. 293 cell lines stably transfected with EBV-BAC constructs were maintained in 
DMEM with 10% (v/v) FBS, antibiotics and 100 µg/ml Hygromycin B (Roche). When 
confluent, the cells were split by washing in 1 x PBS before detaching with Trypsin-EDTA 
(Gibco-BRL) and seeded at 1:20 (293 and Hela cells) or 1:2 (293 stable cell lines with EBV-
BAC) dilution in new 10 cm-Petri dishes.  
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Cell line Characteristics Plasmids 
Medium 
supplements 
Reference 
EREB2.5 
LCL with P3HR1 EBV genome and a 
conditional ER-EBNA-2 (type 1) 
p554-4 (section 
2.3.3.2.1 and 
[157,448]) 
10% (v/v) FBS, p/s, 
1 µM β-estradiol 
[157,448] 
AG876/ZHT BL, EBV positive 
puro-OriP-ZHT 
(section 2.3.3.2.3) 
10% (v/v) FBS, p/s, 
1 µg/ml puromycin 
This study 
(section 
3.2.3.1.1) 
AG876 BL, EBV positive  10% (v/v) FBS, p/s [58,59] 
Jijoye BL, EBV positive  10% (v/v) FBS, p/s [449] 
C2+BL16 LCL with IARC BL16 EBV  10% (v/v) FBS, p/s [406,414] 
BL41/B95-8 BL with B95-8 EBV  10% (v/v) FBS, p/s [450,451] 
Raji BL, EBV positive  10% (v/v) FBS, p/s [452] 
DG75 BL, EBV negative  10% (v/v) FBS, p/s [453] 
Daudi 
BL, EBV positive, ∆EBNA-2, 
∆Y1Y2 EBNA-LP, type 1 / type 2 
chimaeric genome  
 10% (v/v) FBS, p/s 
[186,454] 
and section 
3.3 
P3HR1 cl.16 
BL, EBV positive, ∆EBNA-2, 
∆Y1Y2 EBNA-LP 
 10% (v/v) FBS, p/s [455,456] 
Daudi:ER-
EBNA-2 T1 
BL, EBV positive with a conditional 
ER-EBNA-2 type 1 
p554-4 (section 
2.3.3.2.1 and 
[157,448]) 
10% (v/v) FBS, p/s, 
400 µg/ml G418 
[348] 
Daudi:ER-
EBNA-2 T2 
BL, EBV positive with a conditional 
ER-EBNA-2 type 2 
pERT2 (section 
2.3.3.2.1 and 
[348]) 
10% (v/v) FBS, p/s, 
400 µg/ml G418 
[348] 
P3HR1 cl.16: 
ER-EBNA-2 
T1 
BL, EBV positive with a conditional 
ER-EBNA-2 type 1 
p554-4 (section 
2.3.3.2.1 and 
[157,448]) 
10% (v/v) FBS, p/s, 
500 µg/ml G418 
This study 
(section 
3.2.1.2) 
P3HR1 cl.16: 
ER-EBNA-2 
T2 
BL, EBV positive with a conditional 
ER-EBNA-2 type 2 
pERT2 (section 
2.3.3.2.1 and 
[348]) 
10% (v/v) FBS, p/s, 
500 µg/ml G418 
This study 
(section 
3.2.1.2) 
 
Table 2.1. B Cell lines used in this study 
LCL: lymphoblastoid cell line; BL: Burkitt’s Lymphoma cell line; p/s: 100 units/ml penicillin and 100 units/ml 
streptomycin (Gibco-BRL); G418 (Calbiochem); β-estradiol (Sigma); puromycin (Sigma). T1: type 1; T2: type 2. 
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2.2.2  Viable cell counts 
Cells were stained with Trypan Blue solution (Sigma) at 1:1 dilution and the number of live cells 
was determined by counting, by light microscopy, cells that exclude Trypan Blue on a 
haemocytometer (Improved Neubauer). 
 
2.2.3  Freezing cells  
5 x 106 cells were centrifuged at 335 x g for 5 minutes at 4˚C, resuspended in 1 ml of cold 10% 
(v/v) DMSO in FBS solution and transferred into a cryovial. The vials were then kept in a 
Nalgene Cryo 1C freezing container overnight at -80˚C. The cryovials were subsequently 
transferred into liquid nitrogen. 
 
2.2.4  Removal of cells from liquid nitrogen 
Cells were thawed rapidly at room-temperature and 10 ml of complete medium was added 
slowly to dilute the DMSO. Cells were washed from the DMSO by centrifuging at 335 x g for 5 
minutes at 4˚C. The cell pellet was then resuspended in 10 ml of fresh medium and transferred 
into a tissue culture flask and incubated at 37˚C. When appropriate, the antibiotic selection was 
applied after 1-2 days.  
 
2.2.5  Cell harvesting 
The required number of cells was centrifuged at 335 x g for 5 minutes at 4˚C and subjected to 
one wash in ice-cold PBS. The supernatant was then removed, the cell pellet was snap-frozen in 
dry-ice and stored at -80 ˚C.  
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2.2.6  Transfections of eukaryotic cell lines 
 
2.2.6.1  Transfection of B cell lines by electroporation 
Cells were diluted 1:2 on 2 consecutive days before transfection. Aliquots of 8 x 106 of cells 
were harvested by centrifugation (335 x g for 5 minutes at 4˚C) and the conditioned medium was 
retained, while the cell pellet was resuspended in 150 µl of unsupplemented medium at a density 
of 3.2 x 107 cells/ml. The plasmid DNA was diluted in 50 µl of serum-free medium and placed in 
a Bio-Rad Gene Pulser Cuvette (0.4 mm electrode). The cells were then added to the cuvette and 
electroporated using a Bio-Rad Gene Pulser set at 960 µF capacitance and 250 V. The cells were 
left at 37˚C for 5 minutes before being transferred to tissue culture flasks containing 10 ml of the 
conditioned medium supplemented with serum. For transient transfections, cells were left at 
37˚C for 48 hours before being harvested and analysed for protein expression or luciferase 
activity.  
 
2.2.6.2  Transfection of B cell lines by Amaxa nucleofection 
LCL and BL cell lines were diluted 1:2 on 2 consecutive days prior to nucleofection. Aliquots of 
6 x 106 cells were washed twice with pre-warmed PBS, centrifuging at 335 x g for 5 minutes at 
4˚C. The cell pellet was resuspended in 100 µl of room-temperature Nucleofector solution T 
(Amaxa Biosystems). The cells were mixed with the plasmid DNA (1-10 µg in TE buffer) and 
transferred to an Amaxa cuvette. EREB2.5 and AG876 cells were nucleofected using the 
program A-23, whereas the program T01 was used to transfect DG75 cells. Immediately after 
nucleofection, 500 µl of pre-warmed complete medium supplemented with 20% (v/v) FBS and 
antibiotics (without any selection) was added to the transfected cells. The whole mix was 
transferred to 1 well of a 12-well plate containing 1.5 ml of supplemented medium (without 
selection) and incubated at 37˚C overnight. During transient transfection assays for detection of 
protein expression, cells were harvested at the desired time-points (either 24-48 hours or 4 days 
after transfection). For the EREB2.5 growth assay, β-oestradiol was withdrawn immediately after 
transfection in order to select for β-oestradiol-independent lymphoblastoid cell lines. During the 
nucleofection and for subsequent maintenance of the cell lines, medium supplemented with 20% 
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(v/v) FBS and antibiotics but without any β-oestradiol was used. The day after the transfection 
each transfected sample was diluted up to 10 ml of fresh supplemented medium without β-
oestradiol and aliquoted into 5 wells of a 24-well plate. Cell growth was monitored daily by 
microscopic observation and medium was refreshed every 2-3 days. At the desired time-points, 
cell samples were either counted or harvested for RNA and protein extraction. For generation of 
stable cell lines, 24 hours after transfection the selection was started by adding 1 µg/ml 
puromycin (Sigma) in a final volume of 12 ml of complete medium, to select successful 
transformants. The cells were plated into 6 wells of a 24-well plate. Every 2-3 days half the 
volume of the supernatant in each well was replaced by fresh medium supplemented with 
puromycin. 3-4 weeks later, cell culture wells containing viable cells were identified under the 
microscope and expanded.  
 
2.2.6.3  Transfection of B cell lines using the Neon system 
Aliquots of 2 x 106 cells were washed with pre-warmed PBS by centrifuging at 335 x g for 5 
minutes at 4˚C and the cell pellets were resuspended in 100 µl of room-temperature Neon 
solution R (Invitrogen). The cells were mixed with the plasmid DNA (2-6 µg in TE buffer) and 
transferred to a Neon 100 µl tip (Invitrogen). For luciferase reporter assays, 2 µg of each of the 
following plasmids were co-transfected: OriP-p294 E2 T1/T2 (section 2.3.3.2.2), pGL3b B95-
8/P3HR1 LRS (section 2.3.3.2.5) and pCMV19-βGal (section 2.3.3.2.6). The electroporation 
conditions used for Daudi, P3HR1 cl.16, DG75 and BJAB cell lines and the respective 
transfection efficiencies achieved are listed in Table 2.2. The best electroporation parameters for 
each cell line were determined by transfecting aliquots of 2 x 106 cells with 5 µg of a GFP-
expression plasmid (pMAX GFP from Amaxa) and testing a range of standard transfection 
protocols provided by the Neon transfection device. Optimization of the transfection conditions 
for each cell line used in this study is reported in the Appendix (Supplementary Figure 2). After 
electroporation, cells were transferred into 3 ml of pre-warmed supplemented medium without 
antibiotics in 6-well plates and incubated at 37˚C. For generation of stable cell lines, selection 
was started 24 hours after transfection by adding G418 (Calbiochem) at a concentration of 500 
µg/ml in a final volume of 12 ml. 2 ml aliquots were placed in each well of 24-well plates and 
the medium with selection was refreshed every 3 days. When clear outgrowth occurred 
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(approximately 3-4 weeks after transfection) cells were transferred to tissue culture flasks and 
expanded. For transient transfection assays, cells were harvested at the desired time-points (24 or 
48 hours after transfection) and processed for either protein extraction or luciferase assays. 
 
 
Cell line 
Neon transfection 
protocol no. 
Pulse voltage 
(V) 
Pulse 
width 
Pulse 
no. 
Transfection 
efficiency (%) 
Cell viability (%) 
Daudi 9 1400 30 1 40 80 
P3HR1 cl.16 8 1300 30 1 32 84 
DG75 11 1100 40 1 40 73 
BJAB 14 1200 20 2 82 98 
 
Table 2.2. Neon electroporation conditions used for B cell lines 
Transfection efficiency was assessed as GFP-positive cells, measured by flow cytometry, when transfecting 5 µg of 
a GFP-expressing plasmid. Cell viability was determined by the side versus forward scatter profile obtained by 
FACS analysis (for details see Appendix, Supplementary Figure 2).  
 
 
2.2.6.4  Lipofectamine™2000 mediated transfection of adherent cell lines  
5 x 105 cells were seeded on to each well of 6-well plates and incubated overnight in 2 ml of 
DMEM medium supplemented with 10% (v/v) FBS without antibiotics. For 
immunofluorescence experiments, cells were grown on coverslips (VWR). Cells were 
transfected with plasmid DNA using Lipofectamine™2000 (Invitrogen). For transient 
transfections, cells were used at 80% confluence. 1-4 µg of DNA was combined with 
Lipofectamine™2000 in 500 µl of Optimem I (Invitrogen) at a ratio of 2 µl 
Lipofectamine™2000 : 1 µg DNA. The mixture was incubated at room-temperature for 20 
minutes before being added to the cells and the cells were then incubated at 37˚C. For detection 
of protein expression, cells were harvested at 24 or 48 hours after transfection by scraping the 
plate and washing in 1 x PBS. The cell pellets were subsequently snap-frozen in dry ice and 
stored at -80˚C. For establishment of 293 stable cell lines containing EBV-BAC constructs, 1 µg 
of EBV-BAC DNA purified using EndoFree plasmid Maxi kit (Qiagen) was transfected into 293 
cells at 60% confluence. 4 hours after transfection fresh medium supplemented with 10% (v/v) 
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FBS but without antibiotics was added to the cells and the following day the cells were detached 
with trypsin-EDTA and seeded at 1:4, 1:8, 1:16 dilution in new 6-well dishes in 3 ml of the same 
medium. 2 days after transfection, the culture medium was replaced with DMEM supplemented 
with 10% (v/v) FBS, antibiotics and hygromycin selection was started (100 µg/ml). Cells 
reaching 100% confluence were split at 1:2 dilution in 6-well dishes and complete DMEM 
medium with selection was replaced every 2-3 days until hygromycin-resistant cells grew out. 
Clonal cell lines were isolated, expanded and subsequently screened for integrity of the EBV-
BAC DNA by episome rescue and restriction digestion or PCR analysis (see section 2.3.3.3.3).  
 
2.2.7  Oestrogen-activation of ER-EBNA-2 fusion proteins 
The conditional proteins ER-EBNA-2 type 1 or type 2, expressed in Daudi:ER-EBNA-2 T1/T2 
[348] and P3HR1 cl.16:ER-EBNA-2 T1/T2 cell lines (see Table 2.1 and section 3.2.1.2), were 
activated by adding β-oestradiol at a final concentration of 1 µM. Cells were split 1:2 the day 
before the induction. 
 
2.2.8  Small and large scale preparation of AG876 virus  
To activate the ZHT fusion protein (ER-BZLF1), exponentially growing AG876/ZHT cells (see 
Table 2.1 and section 3.2.3.1.1) were stimulated with 4-hydroxytamoxifen (4HT, Sigma) at a 
final concentration of 0.2 µM for the appropriate times. For small scale preparation of AG876 
virus, 2 x 106 AG876/ZHT cells were plated in each well of a 24-well plate in 2 ml of 
supplemented medium. After the appropriate incubation period, both the culture supernatant and 
the stimulated cells were harvested. The culture supernatant, containing the released virus, was 
centrifuged twice at 335 x g for 10 minutes at 4˚C, to completely remove any cells. The virus-
containing supernatant was then filtered using 0.45-µm Nalgene syringe filters and stored at 4˚C. 
For large-scale preparation of the virus, 200 x 106 AG876/ZHT cells in a T225 tissue culture 
flask were treated with 4HT for 7 days. After this time, the cells were pelleted at 335 x g for 10 
minutes at 4˚C and the culture supernatant was recovered. This was centrifuged again twice at 
the same conditions, to remove all the cells and then filtered as before. The supernatant 
containing virus was subsequently divided in 6 Beckman tubes (25 x 89 mm) and centrifuged in 
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the Sorvall Ultracentrifuge Discovery 100SE, using the SW28 rotor, at 25,000 rpm for 1 hour at 
4˚C, to pellet the virus. The supernatant was then removed from each tube and the pellet was 
resuspended in 400 µl each of RPMI 1640 without any supplements. The virus stocks were 
stored in 400 µl aliquots in liquid nitrogen. Aliquots from the same batch of concentrated virus 
were used in all the experiments reported in this study. 
 
2.2.9  EBV-BAC recombinant virus production 
Infectious virus was produced from the 293 stable cell lines containing EBV-BAC constructs by 
transient transfection of BZLF1 and BALF4 expression plasmids (0.5 µg) using 
Lipofectamine™2000 as described in section 2.2.6.4 [447,457,458]. Transfection of BALF is 
required to ensure optimal expression levels of the gp110 envelope glycoprotein, which is 
required for efficient infection, whereas BZLF1 induces the lytic reactivation of EBV. After 4 
days, the supernatants containing the virus were harvested, filtered (0.45 µm pore size) and titred 
by infecting Raji cells.  
 
2.2.10 UV-inactivation of EBV virus 
UV radiation inactivation of EBV preparations prior to infection was performed in a Stratalinker 
with 9 J of UV radiation.  
 
2.2.11 Raji cell infection 
A 10-fold serial dilution of each virus preparation made as described in sections 2.2.8 and 2.2.9 
was set up in 1 ml of supplemented RPMI medium in a 24-well plate. 105 Raji cells in 0.5 ml of 
supplemented RPMI medium were plated in each well containing a virus preparation dilution. 
The plates were incubated at 37˚C and, after 2 days, 0.5 ml of medium containing 5 nM TPA 
(Sigma) and 5mM sodium butyrate (Sigma) was added to each well. For titration of EBV-BAC 
viral preparations, GFP-positive cells (Green Raji Units, GRU) were counted the following day 
on an inverted fluorescent microscope. For detection of AG876 infectious virus in the 
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supernatants from AG876/ZHT cells (section 2.2.8), the cells were harvested 4 days after 
infection and proteins were extracted and analysed by western blotting.  
 
2.2.12 Purification of B cells 
Primary B cells were isolated from mixed-donors buffy coat residues by negative selection using 
the RosetteSEP Human B cell Enrichment cocktail (Stemcell Technologies). 50 µl of 
RosetteSEP cocktail was added for every 50 ml of blood, and the mixture was then incubated at 
RT for 20 minutes. After this incubation period, the mixture was diluted in 1 volume of 1 x Ca2+ 
Mg2+-free PBS (Gibco-BRL) supplemented with 2% (v/v) filtered (0.22 µm size pore) FBS and 
slowly overlaid on to FicollPaquePlus (StemCell Technologies) at a ratio of 1:1 in 50 ml Falcon 
tubes. The tubes were then centrifuged for 20 minutes at 1200 x g at room-temperature with the 
brake off. The B lymphocytes were removed from the dense medium : plasma interface and 
washed twice in 1 x Ca2+ Mg2+-free PBS supplemented with 2% (v/v) filtered FBS by 
centrifuging for 15 minutes at 311 x g at room-temperature. Residual red blood cells were lysed 
in 10 ml of 0.8% ammonium chloride for 10 minutes at room-temperature. After this incubation 
period, 10 ml of 1 x Ca2+ Mg2+-free PBS supplemented with 2% (v/v) filtered FBS was added to 
restore the isotonic balance and the cells were pelleted by centrifuging for 10 minutes at 311 x g 
at room-temperature. The enriched cells were then washed twice as above and resuspended in 5 
ml of RPMI medium supplemented with 20% (v/v) filtered (0.22 µm size pore) FBS and 
antibiotics. The isolated cells were analysed by flow cytometry for surface expression of CD20, a 
marker specific for B cells (section 2.6.1). Purity of isolated B cells was normally > 90%. An 
example of this analysis is reported in the Appendix (Supplementary Figure 5). Aliquots of 1-2 x 
106 of cells were plated in each well of a 24-well plate and incubated at 37˚C overnight prior to 
infection with EBV. 
 
2.2.13 Virus infections 
For analysis of regulation of EBNA-2 target gene expression, 2 x 106 primary B lymphocytes 
were infected with 5000 GRUs of EBV-BAC recombinant viruses and cultured in RPMI 1640 
medium supplemented with 20% (v/v) FBS and antibiotics. At the desired time-points cells were 
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harvested and processed for RNA or protein extraction. For LCL establishment, 106 primary B 
lymphocytes were infected with 5-fold serial dilutions of recombinant EBV starting with 8000 
GRUs. Cells were grown initially in RPMI 1640 medium with 20% (v/v) FBS and antibiotics 
and every 2-3 days half the medium was replaced. Once LCLs had grown out in large culture 
volumes, the FBS level in the medium was reduced to 10% (v/v) and cells were selected in 
hygromycin at a concentration of 150 µg/ml for 3 weeks. After this time, hygromycin selection 
was discontinued.  
 
2.3  Nucleic acid protocols 
 
2.3.1  Phenol/chloroform purification and ethanol precipitation of nucleic 
acids 
To purify nucleic acids from enzymatic reactions, the DNA/RNA solution was diluted to 100 µl 
and an equal volume of phenol:chloroform:isoamylalcohol (25:24:1) (Sigma) was added and 
mixed thoroughly by vortex mixing. After centrifugation at 16,000 x g for 5 minutes, the 
aqueous phase was transferred to a fresh tube. The nucleic acids were then precipitated by adding 
1:10 (v/v) of 3 M sodium acetate pH 5.2 and 2.5 volumes of 100% ethanol. The samples were 
mixed by inversion and incubated at -20˚C for 20 minutes. The nucleic acids were pelleted by 
centrifuging at 16,000 x g for 10 minutes. The pellet was then washed with 70% ethanol, dried 
for 2-5 minutes at room-temperature and finally resuspended in either TE buffer for DNA or 
DEPC-treated milliQ water (Ambion) for RNA. 
 
2.3.2  Quantification of nucleic acids 
Concentration and purity of nucleic acids was determined by measuring the absorbance at 
wavelengths 260 nm and 280 nm using a spectrophotometer (Unicam Heλiosβ). The 
concentration was calculated from the 260 nm reading assuming an absorbance of 1.0 at this 
wavelength corresponds to 50 µg/ml for double stranded DNA and 40 µg/ml for RNA. The 
105 
 
purity was calculated from the A260/A280 ratio. Pure DNA has a ratio of 1.8 in sterile water and 
pure RNA has a ratio of approximately 2.0 in 10 mM Tris-Cl pH 7.6. 
 
 
2.3.3  DNA protocols, plasmid vectors and cloning strategies 
 
2.3.3.1  DNA protocols 
 
2.3.3.1.1  Genomic DNA extraction 
5 x 106 LCL or BL cells were harvested and pelleted by centrifugation at 335 x g for 5 minutes at 
4˚C then washed twice in 50 ml TBS. Cells were resuspended in 20 ml NET buffer. SDS was 
added to 1% (w/v) prior to overnight incubation at room-temperature with 0.3 mg/ml of 
proteinase K. The cleared lysate was extracted twice with phenol/chloroform and then with 
chloroform. The DNA was precipitated with 2.5 volumes of 100% ethanol and then washed with 
70% ethanol. The DNA pellet was resuspended in an appropriate volume of TE to have a final 
concentration of 1 µg/µl.  
 
2.3.3.1.2  Low molecular weight DNA extraction 
For suspension cells, 5-10 x 106 cells were harvested and washed in 1.5 ml 1 x PBS by 
centrifugation (335 x g, 5 minutes, 4˚C). Adherent cells were grown to confluency in a 10 cm-
Petri dish and detached by scraping, followed by a wash in 1.5 ml of 1 x PBS as before. The cell 
pellet was then resuspended in 60 µl of STET. The cells were lysed by adding 130 µl of alkaline 
SDS, followed by neutralization with 110 µl of 7.5 M ammonium acetate (Sigma). The mixture 
was incubated on ice for 5 minutes and subsequently centrifuged at 13,000 x g for 30 minutes at 
4˚C. The supernatant was then transferred to a new 1.5 ml eppendorf tube and extracted with 
phenol/chloroform and then with chloroform (twice). To precipitate the DNA, 670 µl of 100% 
ethanol was added and the DNA was pelleted by centrifugation at 13,000 x g for 10 minutes. The 
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DNA pellet was washed with 70% ethanol and then resuspended in 50 µl TE buffer 
supplemented with 5 µg/ml RNase A (Novagen).  
 
2.3.3.1.3  Digestion of DNA with restriction enzymes 
Digestions were performed with NEB restriction enzymes (stocks were 10-20 U/µl), buffers and 
BSA, when required. The volume was adjusted according to the amount of DNA to digest (50 µl 
for 2-3 µg of DNA, then 5 µl more for every 1 µg of additional template). In double digestions 
the volume of the enzymes did not exceed 5% of the total reaction volume. Digestions were 
performed at the recommended temperature. Analytical restriction digests were carried out for 1-
2 hours. To prepare DNA vectors and inserts for cloning, reactions were performed on a large 
scale and were were incubated overnight, to allow efficient digestion. The digested DNA was 
then purified with 2 phenol/chloroform extractions and the fragments were separated by agarose 
gel electrophoresis and extracted from the gel as required.  
 
2.3.3.1.4  Removal of 5’ phosphate groups from DNA fragments 
The 5’ phosphate group was removed from the linearised vector before ligation in order to 
diminish self-ligation and re-circularization. 1.5 µl of Calf Intestinal Phosphatase (CIP) (10 U/µl) 
from NEB was added to the restriction digestion and incubated at 37˚C for 30 minutes. The DNA 
was then purified with 2 phenol/chloroform extractions. The DNA fragments were separated by 
agarose gel electrophoresis and extracted from the gel. 
 
2.3.3.1.5  Agarose gel electrophoresis 
0.8 to 2 g of agarose (Invitrogen) per 100 ml of 1 x TBE buffer was dissolved by heating and 
poured into a gel casting tray after addition of 0.5 µg/µl ethidium-bromide. DNA samples were 
mixed with gel loading buffer and loaded on the gel together with 1 µg of 1 kb or 100 bp ladder 
(NEB) in order to determine the size of the DNA fragments. Electrophoresis was performed in 1 
x TBE buffer at 10 V/cm. The nucleic acids fragments were visualized using a Syngene 
transilluminator ultraviolet (UV) light source and Gene-Snap software.  
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2.3.3.1.6  Pulsed field gel electrophoresis (PFGE) 
Analytical restriction digests of BAC DNA were mixed with gel loading buffer and resolved by 
pulsed field gel electrophoresis (PFGE) using a BioRad CHEF DR II apparatus on 1% agarose 
gels in 0.5 x TBE at 14˚C. To determine the size of the DNA fragments, 1.5 µg of lambda DNA-
monoCut Mix (NEB) was also loaded on to the gel. The electrophoresis was carried out for 14 
hours at 6 V/cm with a start switch of 1 and an end switch of 10. The DNA fragments were 
visualised as described in section 2.3.3.1.5.  
2.3.3.1.7  Extraction of DNA from agarose gels 
The slice of gel containing the DNA fragment of interest was excised using a scalpel under UV 
light and the DNA was extracted from the gel using a Qiagen QIAquick gel extraction kit. The 
agarose gel was dissolved in 3 volumes of Buffer QG (Qiagen) at 50˚C for 10 minutes. The 
solution was then loaded on to a QIAquick spin column and centrifuged at 16,000 x g for 1 
minute to bind the DNA. The column was washed with 750 µl of Buffer PE (Qiagen) and the 
DNA was eluted with 40 µl of Buffer EB.  
 
2.3.3.1.8  Ligations with T4 DNA Ligase 
Ligations were performed with vector and insert in a molar ratio of 1:3. The amount of insert was 
calculated using the following formula: 
 
ng insert = 3 x [size of insert (kb) x ng of vector / size of vector (kb)] 
 
Ligations were performed in a final volume of 15 µl, with 1.2 µl of T4 DNA ligase (400 U/ µl, 
NEB), and incubated at 16˚C overnight. A control reaction was set up using the vector alone.  
 
2.3.3.1.9  Preparation of chemically competent bacteria 
A single colony of E.coli XL1 Blue cells from a Luria Bertani (LB)-agar plate was picked and 
inoculated in 2 ml of LB medium and the culture was incubated at 37˚C overnight with shaking. 
The culture was then diluted 1:100 in fresh LB medium and grown at 37˚C with shaking until an 
absorbance at 600 nm of 0.3 to 0.5 was reached. The bacterial cells were then pelleted by 
centrifugation (3750 rpm, 4˚C, 15 minutes) in a Beckman-Coulter Allegra 6R centrifuge, 
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resuspended in half the original volume of ice-cold 50 mM CaCl2 and subsequently incubated on 
ice for 10 minutes. After centrifuging as above, the bacterial pellet was resuspended in 1/10 the 
original volume of ice-cold 50 mM CaCl2, 15% glycerol. Aliquots of the cells were snap-frozen 
on dry ice and stored at -80˚C.  
 
2.3.3.1.10    Transformation of chemically competent bacteria 
Frozen competent E.coli XL1 Blue cells were thawed on ice. 100 µl of bacteria and 5 µl of 
ligation reaction were mixed and incubated on ice for 30 minutes. The bacteria were then heat-
shocked for 45 seconds at 42˚C and, immediately after, incubated on ice for 2 minutes. 200 µl of 
pre-warmed LB medium was added and the samples were incubated at 37˚C with shaking for 1 
hour. Bacteria were then plated on to LB-agar plates containing the appropriate antibiotic 
selection and incubated overnight at 37˚C.  
 
2.3.3.1.11    Episome rescue 
To assess the integrity of episomes in cell lines, DNA was transfected into bacteria. 2 µl of either 
low molecular weight DNA preparations (section 2.3.3.1.2) or genomic DNA extracts (section 
2.3.3.1.1) were added to 20 µl of ElectroMAX™ DH10B™ cells (Invitrogen) and electroporated 
using a Bio-Rad GenePulser® II electroporator set at 2.0 kV, 200 Ω, 25 µF. 1 ml of S.O.C. 
medium (Invitrogen) was added immediately after and the bacterial cells were incubated at 37˚C 
for 1 hour with shaking. 100-200 µl of the bacterial culture was then plated on to LB-agar plates 
containing the appropriate antibiotic selection and incubated overnight at 37˚C.  
 
2.3.3.1.12    Small scale preparation of plasmid DNA from bacterial cultures 
Small scale plasmid DNA preparations were performed using the QIAprep Spin Miniprep Kit 
(Qiagen). Individual colonies were picked from a selective LB agar plate and inoculated into 3 
ml of LB medium containing the appropriate antibiotic selection. The cultures were incubated 
overnight at 37˚C while shaking. 1.5 ml of overnight culture was centrifuged (2400 x g, 4˚C, 10 
minutes). The cell pellet was resuspended in 250 µl of Buffer P1. 250 µl of Buffer P2 was added 
and mixed and the cells were lysed at room-temperature for 5 minutes. 350 µl of Buffer N3 was 
added for neutralization and precipitation. The sample was centrifuged at 16,000 x g for 10 
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minutes at room-temperature and the supernatant was recovered and applied on to a QIAprep 
column. The column was centrifuged for 1 minute as before and washed with 750 µl of Buffer 
PE (Qiagen). The DNA was eluted with 40 µl of Buffer EB.  
 
2.3.3.1.13    Small scale preparation of BAC DNA from bacterial cultures 
A freshly grown bacterial colony was picked and inoculated into 1.5 ml of Terrific Broth (TB, 
Sigma) containing the appropriate selective antibiotics and grown overnight at 37˚C with 
shaking. The bacterial cells were pelleted by centrifugation (800 x g, 10 minutes, RT) and 
resuspended in 70 µl of STET. 200 µl of alkaline SDS was added to lyse the cells and the 
mixture was subsequently neutralized by addition of 150 µl of 7.5 M ammonium acetate. The 
samples were mixed thoroughly and incubated on ice for 5 minutes prior to centrifugation at 
16,000 x g for 20 minutes at 4˚C. The cleared lysate was then recovered and transferred to a 
fresh 1.5 ml eppendorf tube. The DNA was precipitated by addition of 240 µl of isopropanol and 
centrifugation at 5000 x g for 5 minutes. The DNA pellet was then washed in 200 µl of 70% 
ethanol and centrifuged as before. The supernatant was aspirated and the DNA was dried for 
approximately 10 minutes at room-temperature, followed by resuspension in 50 µl of TE buffer 
with 5 µg/ml of RNaseA.  
 
2.3.3.1.14    Large scale preparation of plasmid and BAC DNA from bacterial cultures 
Large scale preparations of plasmid or BAC DNA were performed using either the QIAprep 
Plasmid Maxi Kit (Qiagen) or EndoFree plasmid Maxi kit (Qiagen). 250 ml of LB medium 
containing the appropriate antibiotic selection was inoculated with 250 µl of overnight culture 
and grown for approximately 16 hours at 37˚C with shaking. The bacteria were harvested by 
centrifugation (3750 rpm, 4˚C, 15 minutes) in a Beckman-Coulter Allegra 6R centrifuge. All 
subsequent centrifugation steps were preformed in the same centrifuge. The bacterial pellet was 
resuspended in 10 ml of Buffer P1. 10 ml of Buffer P2 was added and the solution was mixed 
thoroughly. The cells were lysed for 5 minutes at room-temperature. 10 ml of ice-cold Buffer P3 
was then added and the solution was mixed prior to incubation on ice for 20 minutes to allow 
neutralization and precipitation to occur. The sample was centrifuged (3750 rpm, 4˚C, 30 
minutes) and the supernatant was filtered through muslin and applied to a QIagen-tip 500 column 
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from the kit, which had been pre-equilibrated in 10 ml of Buffer QBT. The DNA bound on the 
column was washed twice with Buffer QC and then eluted in 15 ml of Buffer QF. 10.5 ml of 
isopropanol was added to precipitate the DNA and the sample was centrifuged (3750 rpm, 4˚C, 1 
hour). The DNA pellet was washed with 5 ml 70% (v/v) ethanol and centrifuged again for 30 
minutes. The pellet was air dried and dissolved in an appropriate volume of TE buffer to have a 
final concentration of 1 µg/µl.  
 
2.3.3.1.15    Caesium chloride purification of DNA 
To obtain a high level of purity, the plasmid DNA preparations obtained by the Qiagen column 
method described in section 2.3.3.1.14 were further purified by caesium chloride (CsCl) 
gradients centrifugation. For this 12.5 g of caesium chloride and 0.4 ml of ethidium-bromide (10 
mg/ml) were added to each DNA preparation in 10 ml of TE buffer. The solutions were mixed 
thoroughly and the refractive index was adjusted to 1.395. The solutions were then transferred 
into 60 Ti tubes (Beckman centrifuge tubes 16 x 76 mm), the tubes were heat-sealed and then 
spun in a Sorvall Ultracentrifuge Discovery 100SE using rotor 70 Ti at 42,000 rpm for 40 hours 
at 4˚C. After centrifugation, different forms of DNA (relaxed or covalently closed circular), were 
found at specific levels in the gradient of CsCl, according to their density: relaxed DNA was 
towards the top of the sealed tubes, while covalently closed circular DNA was normally found as 
a compact band approximately in the middle of the gradient. The DNA could be visualised under 
UV light due to incorporation of the ethidium-bromide, but there was sufficient DNA to also see 
the red band in visible light. The band of supercoiled plasmid DNA was collected using a syringe 
and the DNA was extracted 5 times with CsCl-saturated isopropanol, to remove the ethidium-
bromide. The DNA was then dialysed against TE overnight, to purify it from the isopropanol and 
the CsCl. After ethanol precipitation, the DNA pellet was resuspended in an appropriate volume 
of sterile TE buffer to have a final concentration of 1 µg/µl.  
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2.3.3.1.16    Amplification of DNA by polymerase chain reaction (PCR) 
DNA was synthesised by polymerase chain reaction (PCR) using Taq or Pfu DNA polymerase 
(Promega). One of the following reactions was used.  
For Taq PCR: 
 
Template 5 ng plasmid, 1 µg genomic DNA 
5 x PCR Green/colorless GoTaq® Flexi Buffer  10 µl 
MgCl2 (25 mM) 3 µl (1.5 mM) 
dNTPs mix (10 mM each) 1 µl (0.2 mM each) 
Forward primer 5 µM 10 µl (50 pmol) 
Reverse primer  5 µM 10 µl (50 pmol) 
GoTaq® DNA polymerase (5 U/µl) 0.25 µl (1.25 U) 
Sterile water to 50 µl final volume 
 
For Pfu PCR: 
 
Template 5 ng plasmid, 1 µg genomic DNA 
Pfu DNA polymerase 10 x Buffer  5 µl 
dNTPs (10 mM each) 1 µl (0.2 mM each) 
Forward primer 5 µM 10 µl (50 pmol) 
Reverse primer  5 µM 10 µl (50 pmol) 
Pfu DNA polymerase (3U/µl) 0.2 µl (1U) 
Sterile water to 50 µl 
 
The PCR was performed on the Gene Amp System 9700 (Applied Biosystems). Cycling 
parameters for Taq PCR were adjusted according to the purpose of the experiment but would 
typically be: 
 
Segment Temperature Time Cycles 
Initial denaturation 95˚C 3 min  1 
Denaturation 95˚C 0.5-1 min 
25-30 Annealing 50-60˚C 0.5-1 min 
Extension 72˚C 1 min/kb  
Final extension 72˚C 7 min 1 
112 
 
For Pfu PCR the cycling parameters used were: 
 
Segment Temperature Time Cycles 
Initial denaturation 95˚C 2 min 1 
Denaturation 95˚C 0.5 min 
25-30 Annealing 50-60˚C 0.5 min 
Extension 72˚C 2 min/kb  
Final extension 72˚C 5 min 1 
 
The annealing temperature used was the melting temperature of the primers minus 4 or 5˚C. The 
melting temperature was calculated using the formula: 
 
Tm = 81.5 + 0.41 (% GC) – 675/bp primer length 
 
2.3.3.1.17    Site-directed mutagenesis 
DNA mutations were introduced using the QuickChange Site-Directed Mutagenesis Kit 
(Stratagene) and performed on the Gene Amp System 9700 (Applied Biosystems). Sets of 
complementary primers were designed with the required mutation, flanked by unmodified 
nucleotide sequence. The primers were 25 to 45 bases in length (n) and had a melting 
temperature (TM) greater than or equal to 78˚C, which was calculated using the formula below: 
 
TM  = 81.5 + 0.41 (% GC) – 675/n - % mismatch 
 
The reaction was set up as follows: 
 
10 x reaction buffer 5 µl 
Template DNA (10 ng/µl) 2 µl 
Forward primer (50 ng/µl) 2.2 µl 
Reverse primer (50 ng/µl) 2.2 µl 
Nucleotide mix 1 µl 
Pfu Turbo DNA polymerase (2.5 U/µl) 1 µl 
Nuclease-free water 36.6 µl 
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The PCR was performed according to the following thermal cycling conditions: 
 
Segment Temperature Time Cycles 
Initial denaturation 95˚C 30 sec 1 
Denaturation 95˚C 30 sec 
12 Annealing 55˚C 1 min 
Extension 68˚C 1 min/kb 
 
Following cycling, the PCR reaction was cooled on ice. Parental methylated plasmid DNA was 
digested by adding 1 µl of DpnI (10 U/µl) restriction enzyme (Stratagene) to the reaction and 
incubating for 1 hour at 37˚C. 1 µl of DpnI-digested DNA was transformed into 50 µl of 
supercompetent E.coli XL1 Blue cells (Stratagene). Mutations were screened by restriction 
mapping of plasmid DNA and sequencing. 
 
2.3.3.1.18    TA cloning 
To clone PCR products into a plasmid vector, the TA® cloning kit (Invitrogen) was used 
according to the manufacturer instructions. Briefly, the PCR product to be cloned was amplified 
with Taq polymerase as described in section 2.3.3.1.16. Taq polymerase has a non-template 
dependent activity that adds a single deoxyadenosine (A) to the 3’ ends of PCR products. The 
PCR insert can then be ligated efficiently to a linearized vector (pCR2.1) which has single 3’ 
deoxythymidine (T) residue overhangs. The PCR insert was ligated to the vector in a molar ratio 
of 3:1. The amount of PCR product needed to ligate with 50 ng of pCR2.1 vector was calculated 
with the following formula: 
 
ng PCR product = (bp PCR product) x 50 ng pCR2.1 / size in bp of pCR2.1 (~3900) 
 
The ligation reaction was performed in a final volume of 10 µl, with 1 µl of T4 DNA ligase (400 
U/µl, NEB), and incubated at 16˚C overnight. A control reaction was set up using the vector 
alone. 5 µl of the ligation reaction was used to transform 100 µl of competent E.coli XL1 Blue 
cells (section 2.3.3.1.10). Positive transformants grown on selective LB-agar plates (with 50 
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µg/ml ampicillin) were screened by restriction digestion with the appropriate enzymes or by 
sequencing for the desired orientation of the insert. 
 
2.3.3.2  Plasmid vectors 
 
2.3.3.2.1  p554-4, pERT2, p554 and pAG1 vectors 
p554-4 is an OriP plasmid of 28,428 bp bearing 2 EBV BamHI W repeats and the coding 
sequence for a type 1 chimaeric EBNA-2 protein fused to the hormone-binding domain of the 
oestrogen receptor (ER-EBNA-2) [157,448]. The methionine of the ER domain coincides with 
an EcoRI restriction site and a unique NotI restriction site defines the end of the 3’ UTR of 
EBNA-2 sequence (Figure 2.1). 
pERT2 vector is an analogous of p554-4, but carries the sequence coding for a type 2 ER-
EBNA-2 protein, derived from the AG876 EBV strain (GenBank Accession number: 
NC009334). This vector was generated previously in the laboratory [348] (Figure 2.1).  
p554 is a 27,467 bp vector analogous to p554-4 carrying the coding sequence for a constitutive 
type 1 EBNA-2 protein [157,448]. The pAG1 vector is 27,410 bp in length and was derived from 
the p554 plasmid by substituting the type 1 EBNA-2 ORF with type 2 sequences derived from 
AG876 EBV strain [348]. The EBNA-2 type 2 in pAG1 spans between EcoRI and NotI 
restriction sites. The EcoRI site coincides with the methionine of the EBNA-2 proteins and the 
NotI restriction site corresponds to end of the 3’ UTR. The type 1 EBNA-2 sequence in the p554 
vector lacks the EcoRI site in front of the starting ATG but retains the NotI site at the end of the 
3’ UTR (Figure 2.1). 
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Figure 2.1. p554-4, pERT2, p554 and pAG1 vectors 
 
 
2.3.3.2.2  OriP-p294 plasmids 
The OriP-p294 MCS plasmid used in this study was available in the laboratory and was derived 
from the CMVpEBNA-1 plasmid described in [459]. The vector includes OriP, which allows the 
vector to replicate as a plasmid in EBV-transformed cells, the hph gene (an E.coli gene encoding 
a Hygromycin B phosphotransferase), the CMV promoter, the ampicillin-resistance gene and a 
multicloning site (MCS), which includes HindIII, BamHI and NotI sites. In the OriP-p294 MCS 
plasmid used in this study, the MCS was inserted as a HindIII- BamHI fragment in the original 
CMVpEBNA-1 plasmid in place of the EBNA-1 gene (Figure 2.2).  
Two additional plasmids were already available in the laboratory: OriP p294 E2T1 and OriP 
p294 E2T2, bearing wild-type type 1 or type 2 EBNA-2 respectively. The former was generated 
by cloning as a BglII – NotI insert the region comprising 1 BamHI W repeat and the type 1 
EBNA-2 coding sequence from the p554 plasmid (section 2.3.3.2.1) into OriP-p294 MCS, 
between the BamHI and NotI sites. The latter was created by inserting the BglII – NotI fragment 
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of the pAG1 vector (section 2.3.3.2.1), encompassing 1 BamHI W repeat and the type 2 EBNA-2 
ORF, between the BamHI and NotI sites in the OriP-p294 MCS vector. The expression of the 
EBNA-2 proteins from these plasmids is driven by the EBV Wp promoter (Figure 2.2).  
 
 
Figure 2.2. OriP-p294 plasmids 
(A) Diagram of the p294-OriP plasmids. (B) Diagnostic restriction digestion of p294- OriP plasmids. The identity of 
the OriP-p294 vectors carrying either type 1 (E2T1) or type 2 (E2T1) EBNA-2 sequences was determined by single 
digestion with BamHI (type 1 specific) and PstI (type 2 specific). The expected unique pattern of bands was 
obtained for both constructs. M: 1 kb and 100 bp markers (NEB); nd: non-digested plasmids.  
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2.3.3.2.3  puro-OriP-ZHT 
The puro-OriP-ZHT plasmid used in this study was available in the laboratory. The plasmid is 
based on a pCDNA3-ZHT plasmid carrying the sequence of a mutant murine oestrogen receptor 
hormone binding domain cloned in frame with the 3’ codon of the BZLF1 open reading frame 
from B95-8 EBV genome (ZHT) [460]. The mutant oestrogen receptor is unable to bind to 
oestrogen, but shows affinity for 4-hydroxytamoxifen (4HT), a synthetic ligand [461]. The ZHT 
coding sequence was cloned from the pCDNA3-ZHT plasmid into a puro-OriP plasmid carrying 
the EBV origin of replication (OriP) and the puromycin and ampicillin resistance genes. 
 
 
 
Figure 2.3. puro-OriP-ZHT plasmid 
 
 
2.3.3.2.4  pSNOC vectors for EBNA-LP expression  
A pSNOC vector expressing a type 1 3-repeat EBNA-LP coding sequence was available in the 
laboratory [187]. This consists of an OriP expression plasmid containing the G418-resistance 
locus and the cytomegalovirus immediate early (CMV-IE) promoter expressing the EBNA-LP 
coding sequence with SV40 poly A sequences. An analogous pSNOC vector bearing the coding 
sequence of a type 1 7-repeat EBNA-LP and the empty vector were also available.  
 
 
 
Figure 2.4. pSNOC vectors for EBNA-LP expression 
118 
 
2.3.3.2.5  pGL3 Basic vectors containing the LMP-1 and CXCR7 promoters  
pGL3b B95-8 LRS and pGL3b P3HR1 LRS vectors comprise the LMP-1 regulatory sequence 
(LRS) from B95-8 or P3HR1 EBV genomes respectively, cloned upstream of the luc gene in a 
pGL3 Basic vector backbone (Promega). These constructs were a kind gift from Dr. L. Rymo 
(Goteborg University, Gothenburg, Sweden) [462]. The LRS is defined as nt 16,9019-16,9692 of 
the B95-8 EBV sequence (Genbank accession number AJ507799), which corresponds to 
positions -634 to +40 relative to the transcription initiation site (Figure 2.5).  
The pGL3b CXCR7 -1144/-36 reporter construct was generated by PCR-amplyfing the region of 
the CXCR7 promoter spanning between positions -1144 and -36 relative to the transcriptional 
start site mapped in [389] at 10,641 bases upstream from the translation start codon. The PCR 
amplicon was then cloned into a pGL3 Basic luciferase reporter plasmid (Figure 2.5). This 
cloning was carried out by Claudio Elgueta.  
The LMP-1 and CXCR7 promoter-reporter vectors and the empty pGL3b vector were used for 
luciferase reporter assays (section 2.5.1). 
 
 
 
 
Figure 2.5. pGL3 Basic vectors containing the LMP-1 and CXCR7 promoters 
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2.3.3.2.6  pCMV19-βGal 
pCMV19-βGal plasmid was available in the laboratory [201] and was used for normalization of 
transfection efficiency during luciferase assays (section 2.5.1). It contains the β-galactosidase 
gene under the control of the cytomegalovirus (CMV) immediate-early promoter.  
 
 
 
 
Figure 2.6. pCMV19-βGal plasmid 
 
 
2.3.3.2.7  HTLV-1 Tax-expressing vector 
The pJFE14 vector expressing the HTLV-1 Tax protein was a kind gift from Prof. Charles 
Bangham (Imperial College London). This contains a pBR322 origin of replication, an ampicillin 
resistance gene and the HTLV-1 LTR promoter, which drives expression of the Tax gene. This 
construct was used as a positive control in CXCR7 promoter-reporter assays (section 3.2.2.2). 
 
 
 
 
Figure 2.7. pJFE14 vector 
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2.3.3.3  Cloning strategies 
 
2.3.3.3.1  Cloning of OriP-p294 plasmids with chimaeric type 1 / type 2 EBNA-2 sequences 
 
To generate the EBNA-2 chimaeric sequences, two pBluescript plasmids were used (Figure 2.8). 
These carry type 1 (pBS E2T1) or type 2 (pBS E2T2) EBNA-2 coding sequences between EcoRI 
and NotI sites, extracted from the p554 and pAG1 plasmids respectively (section 2.3.3.2.1 ). 
 
 
 
 
Figure 2.8. Cloning of EBNA-2 type 1 and type 2 from p554 and pAG1 vectors into pBluescript plasmid 
(A) Schematic of the cloning strategy. (B) Diagnostic restriction digestion of pBS E2T1 and pBS E2T2 constructs 
with EcoRI and NotI. As expected, both constructs gave 2 fragments: a ~3 kb band, which corresponds to the vector 
backbone, and a band of either 2138 bp or 2081 bp, corresponding to EBNA-2 sequence, type 1 and type 2 
respectively. M: 1 kb marker (NEB); nd: non-digested plasmid. 
 
 
 
121 
 
In order to swap sequences between the type 1 and type 2 EBNA-2 ORFs in the pBS 
background, artificial SacII, EcoRV or BstBI restriction sites were individually inserted in the 
type 2 EBNA-2 sequence of the pBS E2T2 plasmid by site-directed mutagenesis (section 
2.3.3.1.17) using the oligonucleotides reported in section 2.8.1. To engineer the SacII restriction 
site the nucleotide sequence CCACGG, corresponding to type 2 EBNA-2 codons 337-338 
(Appendix, Supplementary Figure 1), between the RG sequence and the CR7, was changed to 
CCGCGG, generating the SacII restriction site but without altering the amino acid sequence. To 
insert the EcoRV restriction site, a modified version of the pBS E2T2 plasmid, lacking the 
EcoRV restriction site in the multi-cloning site (MCS) of the vector, was used. The sequence 
GACATT, corresponding to type 2 EBNA-2 codons 388-389 (see Supplementary Figure 1, 
Appendix) between domains CR7 and TAD, was changed to the EcoRV restriction site 
GATATC, maintaining the original amino acid sequence. For insertion of a BstBI restriction site, 
a modified pBS E2T2 plasmid, lacking the BstXI restriction site in the MCS of the vector, was 
used. Mutagenic primers targeting the sequence TTTGAA, corresponding to codons 429-430 of 
the type 2 EBNA-2 protein (Appendix, Supplementary Figure 1) at the end of the TAD domain, 
were used to generate the BstBI sequence TTCGAA with no alteration of the amino acid 
sequence. Sequencing these positions confirmed that the correct nucleotide changes were 
introduced and that none of the engineered sequences caused a change in the amino acid 
sequence. The entire EBNA-2 ORF was sequenced as well to ensure that no second-site 
mutations had occurred during the mutagenesis process.  
 
To generate chimaeras 1 and 2, a fragment spanning between two BstXI sites, one in the EBNA-
2 ORF, mapping to the WWPP amino acid motif within the RBP-Jk domain (type 1 EBNA-2 
codons 324-327; see Appendix, Supplementary Figure 1), and one in the vector backbone, 
downstream of the NotI site, was swapped between the type 1 and the type 2 EBNA-2 constructs. 
To generate chimaera 3, the region comprising the domains CR7, TAD and NLS from type 1 
EBNA-2 was Pfu-PCR amplified using a primer with an overhanging SacII (5’) restriction site 
and the universal T3 primer (section 2.8.2). The type 1 PCR amplicon was then digested with 
SacII restriction enzyme and inserted at homologous positions in the pBS E2T2 vector with the 
engineered SacII restriction site inserted between the RG sequence and the CR7. A similar 
strategy was used to generate chimaera 4. Briefly, a PCR amplicon, consisting of the TAD and 
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the NLS sequences of type 1 EBNA-2, was generated by Pfu DNA polymerase PCR of pBS 
E2T1 vector using an oligonucleotide carrying an overhanging EcoRV (5’) sequence and the 
universal primer T3 (section 2.8.2). The PCR amplicon was then digested with EcoRV/NotI 
restriction enzymes and was subsequently inserted at the same positions into the pBluescript 
plasmid carrying type 2 EBNA-2 ORF, in which a silent EcoRV site had been previously 
introduced by in vitro mutagenesis at type 1 EBNA-2 codons 388-389 (see Appendix, 
Supplementary Figure 1), between domains CR7 and TAD. To produce chimaera 5, the RG 
sequence from type 1 EBNA-2 (pBS E2T1 vector) was amplified by PCR with Pfu DNA 
polymerase using oligonucleotides with overhanging BstXI (5’) and SacII (3’) sites (section 
2.8.2) and cloned between the same restriction sites into a modified pBS E2T2 plasmid, bearing 
the artificial SacII site within the type 2 EBNA-2 ORF, but lacking the SacII and BstXI sites in 
the MCS of the vector. Likewise, to make the chimaera 6 construct, the type 1 sequences 
encompassing the RG and the CR7 domains were Pfu-PCR amplified with primers bearing 
overhanging BstXI (5’) and EcoRV (3’) restriction sites (section 2.8.2). The PCR product was 
then digested with BstXI and EcoRV restriction enzymes and cloned between the same positions 
into the pBS E2T2 vector with the engineered EcoRV sequence within the EBNA-2 ORF, but 
lacking the BstXI and EcoRV restriction sites in the vector backbone. For construction of 
chimaera 7, the RG, CR7 and TAD sequences were amplified by Pfu-PCR from the type 1 
EBNA-2 vector (pBS E2T1), using primers with overhanging BstXI (5’) and BstBI (3’) sites 
(section 2.8.2). The PCR product was then cloned between the same restriction sites into the pBS 
E2T2 plasmid bearing the engineered BstBI site at codons 429-430 of type 1 EBNA-2 (see 
Appendix, Supplementary Figure 1), at the end of the TAD, but lacking the BstXI site in the 
MCS in the vector backbone. At this stage, the identity of all the chimaeric EBNA-2 sequences 
was screened by restriction mapping, PCR and by sequencing, to ensure that there were no 
unwanted alterations in the EBNA-2 open reading frame and that no extraneous amino acids 
were inserted at the fusion points. For this, restriction digestions and PCR reactions would be 
typically performed with the same restriction enzymes or oligonucleotides used to generate the 
chimaeric EBNA-2 ORFs. For example, the integrity of the pBS constructs carrying EBNA-2 
chimaera 4 and chimaera 5 sequences were screened by restriction digestion, with the enzymes 
EcoRV and NotI, and by PCR, with the same primers used for cloning (section 2.8.2), 
respectively (Figure 2.9). 
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Figure 2.9. Confirmation of generation of chimaeric EBNA-2 sequences in pBluescript background 
(A) Chimaera 4 comprises type 1 TAD and NLS sequences, spanning between EcoRV and NotI restriction sites, 
inserted in a type 2 EBNA-2 protein. Several clones of pBS constructs carrying chimaera 4 EBNA-2 sequences were 
screened by restriction digestion with EcoRV and NotI enzymes. A band of 860 bp, representing the type 1 insert, 
and one of approximately 4.2 kb, corresponding to the pBs vector plus the type 2 EBNA-2 sequences, were 
obtained. M: 1 kb marker (NEB). (B) Chimaera 5 consists in a type 2 EBNA-2 protein with a type 1 RG element, 
cloned between BstXI and SacII sites. Several clones of chimaera 5 EBNA-2 sequences in the pBs vector were 
screened by PCR with the same primers used for cloning (section 2.8.2). A 158 bp amplicon, corresponding to type 
1 RG sequence, was amplified from all 4 clones screened. “-“: negative control (pBS E2T2 vector); “+”: positive 
control (pBS E2T1 vector); M: 100 bp marker (NEB).  
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In order to express the chimaeric type 1 / type 2 EBNA-2 sequences in B cells, they were cloned 
into the expression vector Orip-p294 MCS (section 2.3.3.2.2). Because there are several EcoRI 
sites in the OriP-p294 MCS plasmid, it was not possible to clone the chimaeric EBNA-2 
sequences, spanning from EcoRI to NotI sites, directly into this expression vector, so several 
intermediate steps were needed. An intermediate vector, pSuperInt1, was generated by extracting 
a BglII – NotI fragment from the pAG1 vector (section 2.3.3.2.1), which consists of 1 BamHI W 
repeat and the EcoRI – NotI EBNA-2 coding sequence, and inserting it at the same restriction 
sites in the commercially available pSuper vector (OligoEngine) (Figure 2.10).  
 
 
` 
Figure 2.10. Generation of the intermediate construct pSuperInt1 
(A) Cloning of BglII/NotI fragment, bearing the E2T2 sequence and the EBV Wp promoter (~ 6 kb), from pAG1 
vector into pSuper vector (~ 3 kb), generating the intermediate construct pSuperInt1 of ~ 9 kb. (B) Diagnostic 
restriction digestion with BglII and NotI of the pSuperInt1 vector. 1 kb M: DNA size marker (NEB). n.d.: non-
digested plasmid. 
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The chimaeric type 1 / type 2 sequences were subcloned as EcoRI – NotI DNA fragments from 
the pBluescript background into the intermediate vector pSuperInt1 thereby generating the 
intermediate plasmids pSuperInt2 (Figure 2.11). 
 
 
 
 
Figure 2.11. Subcloning of the chimaeric EBNA-2 sequences from the pBluescript background into the 
intermediate plasmid pSuperInt1 
(A) Schematics of the cloning strategy. The chimaeric EBNA-2 sequences spanning between EcoRI and NotI 
restriction sites were subcloned from the pBS E2 T1/T2 vectors into the intermediate plasmid pSuperInt1, 
generating the intermediate plasmids pSuperInt2 E2 T1/T2 (B) Example of an EcoRI/NotI diagnostic restriction 
digestion analysis normally carried out to screen for the integrity of pSuperInt2 E2 T1/T2 constructs. Positive clones 
would typically produce a ~ 7 kb band, representing the pSuper vector backbone and the EBV BamHI W fragment, 
and a ~ 2 kb band corresponding to the chimaeric EBNA-2 ORF. 1 kb M: DNA size marker (NEB). n.d.: non-
digested plasmid. 
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The sequences of the pSuperInt2 vectors spanning from BglII to NotI and encompassing 1 EBV 
BamHI W repeat and the chimaeric type 1 / type 2 EBNA-2 sequences, were excised and ligated 
to OriP-p294 MCS vector digested with BamHI/NotI, thereby generating the final expression 
plasmids (Figure 2.12). Transcription of the chimaeric EBNA-2 ORFs in these plasmids is driven 
by the EBV Wp promoter, similarly to the type 1 and type 2 EBNA-2 constructs (section 
2.3.3.2.2). 
 
 
 
 
Figure 2.12. Generation of the OriP-p294 expression vectors with the chimaeric type 1 / type 2 EBNA-2 
sequences 
The BglII/NotI fragment, bearing the chimaeric EBNA-2 sequences (E2 T1/T2) and the EBV BamHI W promoter, 
was extracted from the pSuperInt2 vector and cloned into the empty vector OriP-p294 MCS, generating the final 
expression plasmids OriP-p294 E2 T1/T2. In these plasmids expression of the chimaeric EBNA-2 sequences is 
driven by the EBV W promoter. Note: BamHI and BglII have compatible ends. Hyg: hygromycin. MCS: multiple 
cloning site. 
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The final OriP-p294 constructs carrying the chimaeric EBNA-2 sequences were screened using 
several diagnostic restriction digestions. These would typically include: double digestion with 
EcoRI and NotI, to screen for the presence of the EBNA-2 ORF and EcoRI digestion in 
combination with either BstXI, SacII, EcoRV or BstBI, according to the relevant restriction site 
that defines the boundaries between type 1 and type 2 sequences. In addition, digestions with 
BamHI and PstI enzymes, which are type 1 and type 2-only cutters respectively, were also 
performed to discriminate between type 1 and type 2 EBNA-2 sequences. Examples are shown 
in Figure 2.13 (EBNA-2 chimaeras 3, 4 and 5). 
 
 
 
Figure 2.13. Representative diagnostic restriction digestion of OriP-p294 constructs carrying the chimaeric 
EBNA-2 sequences 
(A) OriP-p294 vectors carrying EBNA-2 chimaera 3 (type 2 EBNA-2 with type 1 CR7, TAD and NLS) and 
chimaera 4 (type 2 EBNA-2 with type 1 TAD and NLS) were doubly digested with EcoRI/NotI (both), 
EcoRI/EcoRV (chimaera 4) and EcoRI/SacII (chimaera 3). The empty vector OriP-p294 (e.v.) was included in the 
analysis. The expected pattern of fragments was obtained and confirmed that the restriction sites EcoRV (chimaera 
4) and SacII (chimaera 3) were reconstituted after ligation. M: 1 kb marker (NEB). (B) PstI digestion of the OriP-
p294 vector carrying EBNA-2 chimaera 5 (type 2 EBNA-2 with type 1 RG sequence). 2 individual clones were 
screened and compared to an OriP-p294 plasmid with wild-type type 2 EBNA-2 sequence (E2 T2). Identical 
patterns of restriction fragments were obtained from the chimaeric and the wild-type type 2 vectors. n.d.: non-
digested. M: 1 kb and 100 bp markers (NEB). 
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2.3.3.3.2  Cloning of LMP-1 and LMP-2A probes for ribonuclease protection assay  
To generate LMP-1 and LMP-2A specific probes for use in ribonuclease protection assay (RPA), 
described in section 2.3.4.2, genomic DNA was extracted from exponentially-growing Daudi 
cells. This was used as template for Pfu-PCR amplification using the primer pairs described in 
section 2.8.5, designed based on the EBV wild-type genome sequence (accession number 
NC007605). The PCR products of 241 bp (LMP-1) and 141 bp (LMP-2A) obtained (Figure 2.14) 
were cloned into the pCR2.1 plasmid by the TA cloning procedure (section 2.3.3.1.18) and 
clones carrying the insert in the correct orientation were selected by PCR-screening. The 
resulting plasmids were named pCR2.1 LMP-1 probe or pCR2.1 LMP-2 probe. The plasmids 
were linearized with BamHI and in vitro transcribed with T7 enzyme (Ambion) for production of 
antisense probe, as described in section 2.3.4.2. The probes were designed in order to generate, 
in RPA analysis, protected fragments of 175 nt (LMP-1) and 92 nt (LMP-2A) (Figure 2.15). 
 
 
 
 
Figure 2.14. Pfu-PCR amplification of LMP-2A and LMP-1 sequences to use as probes in ribonuclease 
protection assays 
1 µg of EBV genomic DNA extracted from the Daudi cell line was amplified by PCR with Pfu DNA polymerase 
using primer pairs listed in section 2.8.5. ntc: no template control; M: 100 bp DNA size marker (NEB). 
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Figure 2.15. EBV sequences used to generate the LMP-1 and LMP-2A probes for ribonuclease protection 
assay 
The exon structure and the TATA boxes for LMP-1 (A) and LMP-2A (B) genes are shown. Coordinates of the EBV 
wild-type sequence (accession number NC007605) are indicated. Fw and rev represent positions of the primers used 
listed in section 2.8.5. Primer pairs coordinates are: nt 168,881-169,121 for LMP-1 and nt 195,993-166,131 for 
LMP-2A (based on EBV wild-type sequence, accession number NC007605). 
 
 
2.3.3.3.3  Construction and characterisation of EBNA-2 EBV-BAC mutants  
EBNA-2 in the type 1 B95-8 EBV-BAC [447] was substituted with the type 2 EBNA-2 gene or 
the chimera 2 EBNA-2 gene by RecA-mediated homologous recombination. The final targeting 
constructs used for this were cloned between the BamHI and Psp0MI sites of pKov-Kan-∆Cm 
p4487.1 [463] and were called p121 for introduction of type 2 EBNA-2 and p1211 for 
introduction of chimaera 2 (Figure 2.16). Starting from the type 2 EBNA-2 pBluescript plasmid 
(section 2.3.3.3.1), type 1 upstream flanking sequences were added by cloning a HindIII – EcoRI 
fragment from p554 vector (section 2.3.3.2.1) using a HindIII site in the pBluescript polylinker. 
Type 1 downstream flanking sequence was then added by substituting in a PmeI to NotI 
fragment from p554. An XhoI site in the pBluescript polylinker upstream of the HindIII site was 
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converted into a BglII site using an oligonucleotide adaptor and then the whole assembly was 
cloned as a BglII – NotI fragment between the BamHI and Psp0MI sites of p4487.1. The 
resulting type 2 EBNA-2 with type 1 flanking sequences contained type 2 EBV from 36,201 – 
38,008 of the AG876 sequence (GenBank accession number NC009334). The chimera 2 
targeting plasmid (p1211) was similar except that the C-terminal EBNA-2 sequence was made 
type 1 from the BstXI site in the EBNA-2 open reading frame (37,063 of the AG876 sequence) 
by exchanging a BstXI – BssHII fragment from type 1 EBV (using a BssHII site in the p121 
polylinker). B95-8 EBV-BAC (p2089, chloramphenicol resistant) in E. Coli strain DH10B (HB9 
bacteria) was kindly provided by W. Hammerschmidt [447]. For clarity, the name T1 E2 EBV-
BAC is used for this plasmid in this study. For production of the EBNA-2 mutants, targeting 
p121 (type 2 EBNA-2) and p1211 (chimaera 2) plasmids were transformed into HB9 bacteria 
with pDF2.5-tet (expressing RecA, tetracycline resistant, temperature-sensitives replication 
origin, only grows at 30˚C). Transformed cells were selected on chloramphenicol, kanamycin, 
tetracycline at 30˚C overnight and small pools of colonies were then cured of RecA by growth on 
chloramphenicol and kanamycin at 42˚C overnight. Correct co-integrants were identified by PCR 
and restriction digestion. Competent bacteria from these co-integrants were then resolved by 
transforming pDF2.5, selecting on chloramphenicol and tetracycline at 30˚C overnight and 
curing small pools of colonies of p121 and p1211 targeting vectors by liquid growth in sucrose 
(5% w/v), chloramphenicol and tetracycline at 30˚C followed by plating on sucrose and 
chloramphenicol and growth at 42 ˚C overnight to remove the RecA plasmid. Correctly resolved 
EBNA-2 mutants (which were now sensitive to kanamycin on replica plating) were identified by 
PCR and restriction digestion followed by PFGE analysis. Cloning of the EBNA-2 EBV-BAC 
mutants was carried out by Prof. Paul Farrell, Rachel Bosshard and Claudio Elgueta.  
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Figure 2.16. Schematic of the EBV sequences used to generate EBNA-2 EBV-BAC mutants 
The boxed region shows the part of the EBV genome cloned into the targeting vectors p121 (type 2 EBNA-2 EBV 
BAC) and p1211 (chimaera 2 EBNA-2 EBV-BAC) with the EBV type sequence indicated below by the open 
arrows. The filled box marks the EBNA-2 coding region. Closed arrows indicate annealing positions of the forward 
and reverse primers (section 2.8.6) used to screen positive clones for chimaera 2 EBNA-2 EBV BAC (see Figure 
2.18). 
 
 
BACs were screened at each stage of recombination by miniprep DNA isolation, restriction 
digest and pulsed field gel electrophoresis (PFGE) in order to control for any second-site 
mutations that may have occurred. Substitution of the type 1 EBNA-2 ORF with either type 2 or 
chimaera 2 EBNA-2 sequence introduced an additional EcoRI restriction site into the EBV-
BAC, in front of the starting ATG of the EBNA-2 open reading frame. Digestion of the final 
construct with EcoRI and PFGE analysis were therefore performed to diagnose correct insertion 
of the type 2 and chimaeric EBNA-2 sequences (Figure 2.18 A). A 46,444 bp band, 
corresponding to the EBV fragment comprising the BamHI W repeat region and the EBNA-2 
ORF, was detected in the parental type 1 EBNA-2 BAC but not in the type 2 EBNA-2 construct. 
This band was expected to be substituted by 2 smaller bands of 25,829 and 20,621 bp in the latter 
construct. However, the EcoRI digest of the type 2 EBNA-2 BAC produced 2 bands of 
approximately 20 kb, indicating loss of approximately 6 kb of genetic material, which 
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corresponds to the size of 2 BamHI W repeats (~ 3 kb for each BamHI W repeat). Hence, the 
analysis suggested that the type 2 EBNA-2 EBV-BAC had lost 2 copies (out of 6) of the BamHI 
W repeat compared to the parental type 1 construct. This was confirmed by digestion with 
another restriction enzyme, EcoRV (Figure 2.17 B). The band of approximately 34 kb detected 
in the type 1 BAC, which corresponds to a DNA fragment comprising the EBV BamHI W repeat 
region, was approximately 6 kb smaller in the type 2 EBNA-2 DNA (~ 28 kb band), consistent 
with the loss of 2 BamHI W repeats (Figure 2.17 B). This was the only major change that had 
occurred, as the pattern of the remaining bands was identical in the type 1 and the type 2 BAC 
constructs in both EcoRI and EcoRV digests (Figure 2.17 A and B). Because the number of 
BamHI W repeats varies considerably in different EBV strains, from 3 to 12 [464] and because 
the repeat number found in the type 2 BAC is within this range, this deletion was not considered 
to be undesirable.  
Chimaera 2 EBV-BAC construct was checked by PCR for the insertion of the correct hybrid 
EBNA-2 sequence (Figure 2.18) and diagnostic restriction digestion (EcoRI and EcoRV) 
analysis of pulsed field gels were also performed to show that there were no unwanted mutations 
other then the insertion of the chimaeric ORF (Figure 2.17 A and B). Similarly to the type 2 
EBNA-2 construct, the chimaera 2 EBNA-2 EBV BAC has an additional EcoRI site, compared 
to the parental BAC carrying the type 1 EBNA-2 sequence. As expected, the EcoRI digestion 
revealed that the 46,444 bp band, detected in the type 1 digested sample, was split into 2 bands 
of the correct size (25,829 and 20,621 bp) in the chimaeric EBV-BAC (Figure 2.17 A). EcoRV 
digestion of type 1 and chimaera 2 EBNA-2 EBV-BACs produced identical patterns of bands, 
confirming that the two constructs are otherwise isogenic, differing only at the EBNA-2 locus 
(Figure 2.17 B).  
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Figure 2.17. Diagnostic restriction digestions of type 1, type 2 and chimaera 2 EBNA-2 EBV-BAC constructs 
1 µg of EBV-BAC DNA purified using EndoFree plasmid Maxi kit (Qiagen) (section 2.3.3.1.14) was digested with 
the restriction enzymes EcoRI (A) and EcoRV (B) and analysed by PFGE. (A) After EcoRI digestion the ~ 46.4 kb 
band detected in the type 1 EBNA-2 EBV-BAC (T1 E2) and corresponding to a DNA fragment that includes the 
BamHI W repeat region and the EBNA-2 ORF, was split into a doublet of ~ 20 kb size in the type 2 EBNA-2 EBV-
BAC (T2 E2) and in 2 bands of ~ 25.8 and 20.6 kb in the chimaera 2 EBNA-2 EBV-BAC (C2 E2), due to the 
presence of an extra EcoRI site upstream the ATG in the mutant EBNA-2 ORFs. The size of the ~20 kb doublet 
produced in the T2 E2 construct suggests that 2 BamHI W repeats (~ 6 kb) have been lost. (B) The ~ 34 kb band 
produced by EcoRV digestion of the T1 E2 EBV-BAC was substituted by a ~ 28 kb fragment in T2 E2 EBV-BAC, 
consistent with loss 2 BamHI W repeats of ~ 6 kb. The EcoRV digestion pattern of the chimaera 2 EBNA-2 
construct is identical to that of the type 1 EBNA-2 BAC. Either 1 or 2 DNA preparations of the same clone for each 
BAC construct were analysed. M: size marker lambda DNA-monoCut Mix (NEB). The sizes of the marker DNA 
fragments are indicated. 
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Figure 2.18. PCR analysis of chimaera 2 EBNA-2 EBV-BACs 
The sequence of the primers used is shown in section 2.8.6. The forward primer anneals to type 2 EBNA-2-specific 
sequences, whereas the sequence of the reverse primer is type 1 (see Figure 2.16). A 170 bp amplicon was 
successfully amplified from the EBNA-2 chimaera 2 (C2 E2) EBV-BAC, but not from the type 1 EBNA-2 (T1 E2) 
EBV-BAC, demonstrating that the chimaeric EBNA-2 sequence has been cloned correctly in the EBV-BAC 
backbone. 2 different DNA preparations of the same clone of C2 E2 EBV-BAC were analysed. pBS E2 C2: positive 
control, EBNA-2 chimaera 2 sequence in pBluescript vector background. ntc: no template control. M: 100 bp size 
marker (NEB). 
 
 
2.3.4  RNA protocols 
 
2.3.4.1  Total RNA extraction from LCLs using Trizol reagent 
Total RNA was extracted from LCLs using Trizol reagent (Invitrogen). The cells were harvested 
and lysed in Trizol reagent (1 ml for 5 x 106 cells). 0.2 volume of chloroform was added to each 
sample and, after vortexing for 15 seconds, the samples were incubated on ice for 15 minutes. 
After centrifuging at 16,000 x g for 15 minutes at 4˚C, the aqueous phase, containing the RNA, 
135 
 
was transferred to a fresh 1.5 ml eppendorf tube. The RNA was then precipitated by adding 1 
volume of ice-cold isopropanol. The samples were mixed by inversion and incubated at -20˚C 
for 45 minutes. The RNA was then pelleted by centrifuging at 16,000 x g for 30 minutes at 4˚C. 
The pellet was washed twice with 70% (v/v) ethanol in RNase-free water by centrifuging at 
16,000 x g for 5 minutes at 4˚C and then air-dried for 2-5 minutes at room-temperature. The 
RNA pellet was then resuspended in DEPC-treated milliQ water.  
 
2.3.4.2  Ribonuclease protection assay (RPA)  
 
Synthesis of anti-sense RNA probes and production of size markers by in vitro transcription for 
use in RPAs 
Antisense RNA probes and RNA size markers were synthesised using the MAXIscript SP6/T7 in 
vitro transcription kit (Ambion). The templates for transcription were plasmids pCR2.1 LMP-1 
probe and pCR2.1 LMP-2A probe (section 2.3.3.3.2), digested with BamHI. The reaction mix 
contained: 
 
10 x transcription buffer 1.0 µl 
10 mM ATP 0.5 µl 
10 mM CTP 0.5 µl 
10 mM GTP 0.5 µl 
0.06 mM UTP 0.75 µl 
Sterile dH2O 1.25 µl 
α-
32P UTP (800 µCi/mmol) 2.5 µl (0.06 mM) 
T7 RNA polymerase (20 U/µl) 1.0 µl 
DNA template  2 µl (1 µg) 
Total volume 10 µl 
 
 
Production of markers for use in RPAs 
To prepare the size markers, 5 µg of plasmid pCR2.1 LMP-1 probe or pCR2.1 LMP-2A probe 
(section 2.3.3.3.2), was digested with EcoRI/BglI/HindIII or with HindIII/PstI restriction 
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enzymes respectively. A mixture of the two digested plasmids was then used as template for in 
vitro transcription with the following reaction:  
 
10 x transcription buffer 1.0 µl 
10 mM ATP 0.5 µl 
10 mM CTP 0.5 µl 
10 mM GTP 0.5 µl 
1 mM UTP 0.5 µl 
Sterile dH2O 3 µl 
α-
32P UTP (800 µCi/mmol) 1 µl (0.024 mM) 
T7 enzyme (20 U/µl) 1.0 µl 
DNA template  2 µl (1 µg) 
Total volume 10 µl 
 
The reaction mixture was incubated at 37˚C for 45 minutes. 1 volume of gel loading dye 
(Ambion) was added to the size markers mixture prior to purification of the markers using a 
Micro Bio-spin P-30 Tris Chromatography column (Bio-Rad). 1 µl of RQ1 RNase-free DNase (2 
U/µl; Promega) was added to the probe mixture to remove template DNA and the reaction was 
further incubated at 37˚C for 15 minutes. An equal volume of gel loading dye was added, the 
probe was denatured at 95˚C for 5 minutes and then electrophoresed on a 6% polyacrylamide gel 
(with 6 M urea) in TBE for 45 minutes at 20 W to purify the probe. The gel was exposed to an 
autoradiography film (Hyperfilm, Amersham) for 1 minute, which was then developed using a 
Fuji Xray film processor RGII. This allowed identification of the location of the probe band, 
which was then excised from the gel, eluted in 400 µl of elution buffer (RPA kit, Ambion) at 
65˚C for 1 hour and then counted using a scintillation counter (Beckman LS6500).  
 
Ribonuclease protection assay (RPA)  
The RPA was carried out using the RPAIII kit (Ambion). 50,000 counts of probe were added to 
20 µg of each RNA sample or to an equivalent amount of yeast RNA, as control. The RNA and 
probe mix was dried in a Speed-Vac (Savant DNA100), then resuspended in 10 µl of 
hybridisation buffer (Ambion), denatured at 95˚C for 5 minutes and hybridised overnight at 
42˚C. RNA was digested with 150 µl of RNase digestion buffer and 1.5 µl of RNase A/T1 
(RNase A 0.25 U/µl, RNase T1 10 U/µl) at 37˚C for 20 minutes. The RNA was precipitated by 
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adding 225 µl of RNase inactivation/precipitation solution and 75 µl of 100% ethanol, followed 
by incubation at -20˚C for 20 minutes. The sample was pelleted (16,000 x g, 15 minutes, 4˚C) 
and resuspended in 3 µl of gel loading dye, denatured at 95˚C for 5 minutes and loaded on to a 
6% polyacrylamide gel (with 6 M urea) with 500 counts of undigested probe and 8,000 counts of 
markers. Electrophoresis was carried out for 90 minutes at 45 W in TBE and the gel was then 
vacuum dried on 3MM chromatography paper (Whatman) for 2 hours at 80˚C (Bio-Rad Gel 
Dryer Model 583). Radioactive products were visualized using a phosphor-imager screen 
(Molecular Dynamics) applied for 1 to 3 days, which was then scanned using a Molecular 
Dynamics scanner (STPRM 860) and analysed on ImageQuant 5.0 software.   
 
2.3.4.3  RT-PCR and qRT-PCR 
Total cell RNA was extracted from growing cells using Trizol reagent and then quantified by 
measuring its absorbance at 260 nm. RNA samples were digested with RQ1 RNase-free DNase 
(Promega) to remove DNA prior to RT-PCR. 30 µl was digested with 5 µl of DNaseI (1 U/µl) in 
a final volume of 50 µl at 37˚C for 30 minutes. The RNA was then extracted with 
phenol/chloroform. cDNA was prepared using Protoscript M-Mulv First strand cDNA Synthesis 
kit (NEB) using random primer as recommended by the manufacturer’s instructions. To detect 
the expression of the EBNA-2-regulated genes, semi-quantitative RT-PCR or quantitative RT-
PCR (qRT-PCR) was used with the primer pairs listed in section 2.8.7.  
For RT-PCR, the GoTaq PCR system (Promega) was used. qRT-PCR was performed on an ABI 
7900HT real-time PCR machine using ABsoluteTM QPCR SYBR® Green ROX Mix (Thermo 
Scientific). The cycling conditions were 95°C for 15 min, followed by 40 cycles of 15 sec at 
95°C, 30 sec at 60°C and 40 sec at 72°C on a fast block. Dissociation curve analysis was 
performed at the end of each run to ensure absence of non-specific products. Quantification of 
mRNA levels was carried out using the Delta-Delta Ct method. Results were analysed with 
SDS2.3 software (Applied Biosystems). mRNA levels for each target gene analysed were 
normalised on the housekeeping gene GAPDH used as a loading control. 
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2.4  Protein protocols 
 
2.4.1  Extraction of cell proteins in RIPA lysis buffer  
Cell pellets were resuspended in 2 volumes of RIPA lysis buffer and lysed by pipetting up and 
down. The solution was incubated on ice for 15 minutes and then centrifuged at 16,000 x g for 
10 minutes at 4˚C to pellet cell debris. The supernatant was recovered and transferred to new 1.5 
ml eppendorf tubes and stored at -20˚C.  
 
2.4.2  Measurement of protein concentration 
The protein concentration of lysates was determined to allow loading of equal amounts of protein 
for western blotting. The Biorad DC Protein Assay (Bio-Rad) was used. 5 µl of protein sample 
was diluted with 15 µl of RIPA lysis buffer. 100 µl of Reagent A (Alkaline copper tartarate 
solution) and 2 µl of reagent S were added to each sample, followed by 800 µl of reagent B 
(Folin reagent). Samples were mixed by inversion and incubated at room-temperature for 15 
minutes. Different amounts of bovine serum albumin (0, 0.78, 1.56, 3.12, 6.25, 12.5, 25 and 50 
µg) were processed similarly to produce a standard curve. The sample concentrations were 
measured by reading the absorbance at 750 nm using a spectrophotometer (Unicam Heλiosβ) and 
comparing it with the standard curve samples.  
 
2.4.3  SDS-Polyacrylamide gels 
Protein separation was performed by sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) using the Bio-Rad Mini Protean II system. The gel was composed 
of a 10% or 7.5% resolving gel (10% or 7.5% acrylamide, 375 mM Tris-Cl pH 8.8, 0.1% SDS) 
and a 5% stacking gel (5% acrylamide, 125 mM Tris-Cl pH 6.8, 0.1% SDS). Gels were 
polymerised with 10 µl NNN’N’-tetramethylethylenediamine (TEMED) and 50 µl 10% w/v 
ammonium persulphate (APS), per 10 ml gel volume. 20 µg protein samples were mixed with 2 
x SDS sample buffer, boiled for 5 minutes and loaded on the stacking gel. Samples were run 
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along with the Full Range Rainbow Molecular Weight Marker (Amersham). The gel was run at 
150 V for 1 hour in 1 x SDS running buffer.  
 
2.4.4  Western Blotting  
Proteins separated on SDS-PAGE were electrotransferred on to a nitrocellulose membrane 
(Schleicher & Schuell) at 100 V for 1 hour in transfer buffer. The nitrocellulose membrane was 
placed on top of the gel. Both the membrane and the gel were then sandwiched between three 
layers of 3 mm Whatman paper with a sponge at each side and placed in a Bio-Rad transfer 
cassette. After the transfer, the membrane was saturated in blocking solution for 1 hour at room-
temperature on a shaker. The membranes were incubated with the primary antibody diluted in 
blocking solution at 4˚C overnight. The following day, the membrane was washed 3 times for 15 
minutes in washing buffer. The appropriate secondary antibody conjugated to horseradish 
peroxidase (HRP) diluted 1:2000 in blocking solution was added to the membrane and incubated 
for 1 hour at room-temperature. The membrane was washed again 3 times for 15 minutes in 
washing buffer and proteins were visualised using the ECL chemiluminescence detection kit 
(Amersham), exposing on autoradiography film (Hyperfilm, Amersham). A list of the primary 
and secondary antibodies used in this study is reported in Table 2.3. 
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Antigen Primary antibody Source Dilution 
EBNA-2 
PE2 clone, mouse monoclonal (recognises type 1 and 
type 2 with equal efficiency on a western blot [348])1 
Tissue culture 
supernatant from 
hybridoma cell line 
1/100* 
EBNA-LP 
JF186, mouse monoclonal, (recognises only type 1) 
[183] 
Tissue culture 
supernatant from 
hybridoma cell line 
1/500* 
 
4D3 clone, mouse monoclonal, (recognises both types)  [465] 1/100,0002 
EBNA-1 human  human serum 1/1000* 
EBNA-3A sheep polyclonal 
ExAlpha, USA  
(# F115P) 
1/1000 
EBNA-3B sheep polyclonal 
ExAlpha, USA  
(# F120P) 
1/350 
EBNA-3C A-10 clone, mouse monoclonal2 
Tissue culture 
supernatant from 
hybridoma cell line 
1/10* 
LMP-1 CS 1-4 clone, mouse monoclonal Dako (#M0897) 1/500 
BZLF1 BZ1, mouse monoclonal 
Tissue culture 
supernatant from 
hybridoma cell line 
1/500* 
CXCR7 rabbit polyclonal 
ProteinTech, IL, USA 
(#51024-1-AP) 
1/1200 
β-actin AC-15 clone, mouse monoclonal Sigma (#A5441) 1/2500 
GAPDH 6C5 clone, mouse monoclonal Ambion (#AM4300) 1/500 
 Secondary antibody Source Dilution 
mouse IgG sheep polyclonal, HRP cojugated GE Healthcare (#NA9310) 1/2000 
rabbit IgG goat polyclonal, HRP cojugated Dako (#P0448) 1/2000 
sheep IgG rabbit polyclonal, HRP conjugated Dako (#P0163) 1/2000 
human IgG rabbit polyclonal, HRP conjugated Dako (#P0214) 1/2000 
 
Table 2.3. Primary and secondary antibodies for immunoblotting 
1
 kind gift from Prof. M. Rowe, University of Birmingham, UK 
2 The batch used in this study was kindly provided by Dr. Kawaguchi (University of Tokyo, Japan) and was used at 
the recommended dilution 
* the antibody preparations used in this study were made previously in this laboratory and the dilution was 
determined by titration experiments 
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2.5  Quantitative assays 
 
2.5.1  Luciferase reporter assay 
Cells were harvested 24 and 48 hours after transfection by centrifugation at 335 x g for 5 
minutes, washed with ice-cold PBS and lysed in 60 µl of 1 x reporter lysis buffer (Promega) for 
10 minutes at room-temperature. Cell debris was removed by centrifugation (16,000 x g, RT, 10 
minutes) and a 20 µl sample of the supernatant was assayed for 10 seconds on a Berthold 
Autolumat luminometer with 100 µl of luciferase assay substrate (Promega).  
 
2.5.2  β-Galactosidase assay 
To correct for differences in transfection efficiency during transient transfections, cells were co-
transfected with 0.5-1 µg of pCMV19-β-galactosidase plasmid (section 2.3.3.2.6). Cell extracts 
were prepared as described in section 2.5.1 and 20 µl of each sample was added to each well of a 
96-well plate and analysed for β-galactosidase activity. 20 µl of 1 x reporter lysis buffer were 
used as a control. 150 µl of chlorophenolred-β-D-galactopyranoside (CPRG) (Roche) was added 
to each sample. After a colour change was detected the absorbance was measured at 570 nm 
using an ELISA plate reader (Antos Labtec Instruments). Luciferase values were divided by the 
β-galactosidase values to control for transfection efficiency.  
 
2.6  Flow cytometry 
 
2.6.1  Live cell staining of cell surface markers 
1 x 106 cells were harvested and washed with live cell staining buffer (1 x PBS, 1% w/v BSA, 
0.1% w/v sodium azide). The cell pellet was then resuspended in 100 µl of staining buffer 
containing the appropriate antibody (when required) and incubated on ice for 1 hour in the dark. 
To determine purity of human primary B cells after preparation from buffy coat residues  a 
fluorescein-isothiocyanate (FITC)-conjugated anti-CD20 antibody (Dako) was used (Appendix, 
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Supplementary Figure 5). For detection of CXCR7 surface expression an allophycocyanin 
(APC)-conjugated anti-human CXCR7 antibody (R&D systems) was used. Prior to staining for 
CXCR7, the cells were Fc-blocked by treatment with 1 µg of human IgG (Sigma)/105 cells for 
15 minutes at room-temperature. For each marker stained, an aliquot of 1 x 106 cells was stained 
with an appropriate isotype specific control antibody. After incubation with the primary 
antibody, the cells were then washed as before, resuspended in 400 µl of staining buffer and 
analysed by flow cytometry using a Beckman Coulter CyAn™ ADP Analyzer. At least 100,000 
events were collected. Data was analysed using the software Summit v4.3 (Dako).  
 
2.6.2  Staining of intracellular antigens  
For staining of intracellular antigens (i.e. EBNA-2), 1 x 106 cells were harvested, washed with 
staining buffer by centrifugation at 335 x g, for 5 minutes at room-temperature and then fixed by 
resuspension in 100 µl of Fixation Medium (Reagent A, Fix&Perm Cell Pemeabilization 
Reagents, Invitrogen). After 15 minutes of incubation at RT, the cells were washed in staining 
buffer and centrifuged as before. The cell pellet was then resuspended in 100 µl of 
Permeabilization Medium (Reagent B, Fix&Perm Cell Pemeabilization Reagents, Invitrogen) 
supplemented with 1 µg of human IgG (Sigma)/105 cells stained, to saturate non-specific binding 
sites. The cells were left for 15 minutes at RT and then the mouse monoclonal PE2 antibody (or 
matching isotype control antibody) was added at 1:50 dilution and the cells were incubated on 
ice for 30 minutes. After washing as before, the cells were incubated with the secondary 
antibody (goat anti-mouse IgG FITC-cross-linked, Sigma) following the same procedure 
described for incubation with the primary antibody. The cells were then washed, resuspended in 
500 µl of staining buffer and analysed immediately by flow cytometry as described above.  
 
2.7  Indirect immunofluorescence 
24 hours after Lipofectamine2000-mediated transfection (section 2.2.6.4), adherent cells were 
fixed using 4% paraformaldehyde (Electron Microscopy Sciences) and permeabilized with 
0.25% Triton-X 100 (Sigma) in PBS. Primary mouse monoclonal anti-EBNA-2 antibody (PE2 
clone) was diluted 1/100 in blocking buffer and cells were incubated for 45 minutes at room-
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temperature. The coverslips were washed 3 times with PBS and TRITC-conjugated anti-mouse 
secondary antibody (Sigma) was applied at a dilution of 1/5000 in blocking buffer for 45 minutes 
at room-temperature. After 3 washes in PBS, the coverslips were mounted in Mowiol and 
visualized using a Zeiss 510 Meta laser confocal microscope.  
 
2.8  Primers 
 
2.8.1  Primers for insertion of artificial restriction sites in the type 2 EBNA-2 
ORF  
 
Complementary oligonucleotides were used in site-directed mutagenesis experiments. The sense 
strands of these oligonucleotides are as follows: 
 
SacII 
5’-GGCCCTGGTCTCCGCGGTTCAGGAAGTTTG-3’ 
 
EcoRV 
5’-GGTTCATGTATTGGTGAGATATCAGGGGTTGCTGAAGG-3’ 
 
BstBI 
5’-CTATGAGATTCTGTTGTTTCGAAAATGCCCTCCCAACTT-3’  
 
2.8.2  Primers for cloning of EBNA-2 type 1 / type 2 chimaeras 
 
The sequences of the SacII, EcoRV, BstXI and BstBI restriction sites are underlined. 
 
Chimaera 3 
Forward: 5’-CAGCCGCGGAGACCAGAGCCAAACACCTC-3’ 
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Reverse (universal T3 primer): 5’-ATTAACCCTCACTAAAGG-3’ 
 
Chimaera 4 
Forward: 5’-CTAGATATCTCACCAATACATGAACCGGAG-3’ 
Reverse (universal T3 primer): 5’-ATTAACCCTCACTAAAGG-3’ 
 
Chimaera 5 
Forward: 5’-CAGCCACCATGGTGGCCACCCATCTGCGACCCCCC-3’ 
Reverse: 5’-CAGCCGCGGTCCACCGGGCTTGCGTTGCT-3’  
 
Chimaera 6 
Forward: 5’-CTGCAGAACCACCATGGTGGCCACCCAT-3’ 
Reverse: 5’-CTAGATATCAGGGGTTGCCGTGTGTGAAT-3’ 
 
Chimaera 7 
Forward: 5’-CTGCAGAACCACCATGGTGGCCACCCAT-3’ 
Reverse: 5’-CAGCAGTTCGAAAATGTAATCCCAACTTTCGTC-3’ 
 
2.8.3  Primers for cloning of type 2 EBNA-LP cDNA 
 
Forward: 5’-ATGCGGCCATGTAGGCCCACTT-3’ 
Reverse: 5’-TGCCCAACCACAGGTTCAGGCA-3’ 
 
2.8.4  Primers for restoration of the starting ATG in the type 2 EBNA-LP 
cDNA clone 
 
Complementary oligonucleotides were used in site-directed mutagenesis experiments. The sense 
strand is: 
5’-CAGCCTCCTGCACGTGAGCATGGGAGACCGAAGTGAAGTCCC-3’ 
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2.8.5  Primers for cloning of LMP-1 and LMP-2A probes for RPA 
 
LMP-1 
Forward: 5’-CACTCATAACGATGTACAGC-3’ 
Reverse: 5’-CAAGAAACACGCGTTACTC-3’ 
 
LMP-2A 
Forward: 5’-CGGTTTCAGCATCACAGGTT-3’ 
Reverse: 5’-CGGTTTCAGCATCACAGGTT-3’ 
 
2.8.6  Primers for screening of chimaera 2 EBNA-2 EBV-BAC 
 
Forward: 5’-CCTTCCAGGTGTCATTTATG-3’ 
Reverse: 5’-GGGCTTGCGTTGCTTGT-3’ 
 
2.8.7  RT-PCR and qRT-PCR primers  
 
LMP-1 
Forward: 5’-CTAGGAAGAAGGCTAGGAAG-3’ 
Reverse: 5’-CTAGGAAGAAGGCTAGGAAG-3’ 
 
CXCR7 
Forward: 5’-CAGCTTCAGATCTGGGTATTTATCC-3’ 
Reverse: 5’-TGGGCATGTTGGGACACATCACC-3’ 
 
CXCR4 
Forward: 5’-ATCTTCCTGCCCACCATCTACTCCATCATC-3’ 
Reverse: 5’-ATCCAGACGCCAACATAGACCACCTTTTCA-3’ 
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c-MYC 
Forward: 5’-TCATCCAGGACTGTATGTGG-3’ 
Reverse: 5’-CAGAAGGTGATCCAGACTCT-3’ 
 
Cyclin D2 
Forward: 5’-TTCAAGTGCGTGCAGAAGGAC-3’ 
Reverse: 5’-AGTTGCAGATGGGACTTCGGAG-3’ 
 
GAPDH 
Forward: 5’-TGCCTCCTGCACCACCAACT-3’ 
Reverse: 5’-CGCCTGCTTCACCACCTTC-3’ 
 
2.8.8  EBNA-2 type specific primers 
 
Forward (both type 1 and type 2): 5’-AGGGATGCCTGGACACAAGA-3’ 
Reverse: 
• type 1 specific primer: 5’-TTGTGACAGAGGTGACAAAA-3’ 
• type 2 specific primer: 5’-TGGAAGAGTATGTCCTAAGG-3’ 
 
2.8.9  Primers for sequencing the C-terminal region of EBNA-2 
 
Forward: 5’-CCACCAGCAGCACCAGCACA-3’ 
Reverse: 5’-CTGGCAAAGTGCTGAGAGCA-3’ 
 
2.8.10 Primers for sequencing the LRS from Daudi EBV genome 
 
Forward: 5’-CACTCATAACGATGTACAGC-3’ 
Reverse: 5’-TGTCATTCTACCCTCCAACG-3’ 
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2.8.11 EBNA-3 type specific primers 
 
EBNA-3A 
Forward: 5’-GAAACCAAGACCAGAGGTCC-3’ 
Reverse: 5’-TCCCAGGGCCGGACAATAGG-3’ 
 
EBNA-3B 
Forward: 5’-CCCTTGCGGATGCAGCCAAT-3’ 
Reverse: 5’- GGCTGATATGGAATGTGCCC-3’ 
 
EBNA-3C 
Forward: 5’-AGAAGGGGAGCGTGTGTTGT-3’ 
Reverse: 5’-GGCTCGTTTTTGACGTCGGC-3’ 
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3  Regulation of viral and host genes relevant for B cell 
proliferation by type 1 and type 2 EBNA-2 
 
The aim of this chapter is to investigate the differing effects of type 1 and type 2 EBNA-2 on 
host and viral gene regulation, with focus on genes important for B cell survival and 
proliferation.  
 
3.1  Introduction 
 
The most prominent functional difference between type 1 and type 2 strains of EBV lies in their 
ability to growth-transform primary B cells in vitro. Studies by Rickinson et al. demonstrated 
that the transforming ability of type 1 EBV is greater than that of type 2 strains [414]. 
Subsequently, sequence variation in the EBNA-2 locus was found to be the molecular 
determinant of this phenotype [155] and is now therefore considered to be the basis of the 
classification of EBV viral strains as type 1 or type 2. Although this biological difference 
between the EBV viral types has been known for many years now, the molecular mechanism 
underlying this phenotype has not yet been identified and little is known to date about the in vitro 
physiology of type 2 EBV, whereas there is extensive literature on the functions of type 1 
EBNA-2 (reviewed in section 1.7). 
Following EBV infection of naïve B cells in vitro, EBNA-2 drives B cell transformation into 
LCLs by acting as a potent and promiscuous transcriptional activator that activates both viral and 
cell genes which in turn cause survival and proliferation of the infected cells 
[52,135,136,137,348]. Therefore the ability of EBNA-2 to up-regulate the transcription of viral 
and host genes is important for the transforming mechanism of EBV. Among the viral genes 
induced by EBNA-2, LMP-1 is the major EBV oncogene as it elicits potent oncogenic effects in 
EBV-infected LCLs by activating several signaling pathways in the cell [131,254]. Furthermore 
LMP-1 is required for not only initiation of primary B cell transformation in vitro [156] but also 
maintenance of continuous proliferation of EBV-LCLs [89]. The host genes induced by EBNA-
2, which have been recently identified by whole genome expression profiling analysis, are 
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mainly involved in activation and differentiation of B cells, control of cell growth and survival, 
regulation of the cell cycle and apoptosis (reviewed in section 1.7.5). Most previous studies on 
EBNA-2 direct target genes focussed on the type 1 protein and until recently little was known 
about the ability of type 2 EBNA-2 to regulate gene expression. In earlier reports type 1 and type 
2 EBNA-2 were compared for their ability to regulate the promoters of the viral gene LMP-1 and 
the cell gene CD23 [131,466]. In transient transfection assays in the BL30/P3HR1 and Daudi 
Burkitt’s Lymphoma cell lines, LMP-1 induction was higher in the presence of type 1 EBNA-2 
in some experiments, but was equal in others [131]. In another study, both LMP-1 and CD23 
promoters were more strongly induced by type 1 EBNA-2 in CAT assays in an EBV-negative 
cell line [466], suggesting that a higher transactivation ability of type 1 EBNA-2 might be a 
molecular mechanism underlying the superior ability of type 1 EBV strains to immortalise B 
cells. Recently, whole genome microarray analysis of EBNA-2 direct target genes was carried 
out in this laboratory in order to compare genes induced by type 1 EBNA-2 with genes induced 
by the type 2 protein. Only a few targets were found to be differentially regulated by the two 
types (CXCR7, ADAMDEC, IL-1β and MARCKS), with a higher induction by type 1 EBNA-2 
[348]. Among these, CXCR7 was the most differentially regulated gene, being more strongly 
induced by type 1 EBNA-2, whereas expression of MARCKS, IL1β and ADAMDEC was very 
low [348]. RNAi experiments demonstrated that CXCR7 is required for proliferation of EBV-
infected LCLs [348]. Furthermore, previous studies in this laboratory showed that in a Burkitt’s 
Lymphoma cell line, engineered to stably express oestrogen-regulated EBNA-2 proteins, the 
type 1 EBNA-2 is able to induce the viral oncoprotein LMP-1 more rapidly and to a higher 
extent compared to the type 2 [348]. Collectively, those results suggested that the higher 
induction of some genes by the type 1 EBNA-2 may account for the enhanced transforming 
ability of type 1 EBV strains compared to type 2. In the present study I therefore decided to 
investigate in more detail differences and similarities in gene regulation induced by type 1 and 
type 2 EBNA-2 using both cell line-based systems (sections 3.2.1 and 3.2.2) and primary 
infection assays (section 3.2.3), with focus on two candidate genes: the viral oncogene LMP-1 
and the cell gene CXCR7.  
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3.2  Results 
 
3.2.1  Differential regulation of LMP-1 and CXCR7 mRNA by ER-EBNA-2 
in BL cell lines 
 
3.2.1.1  Transcriptional regulation of LMP-1 and CXCR7 in a Daudi BL assay with 
oestrogen-regulated type 1 and type 2 EBNA-2 proteins 
To investigate whether there is a differential effect on regulation of the LMP-1 gene by type 1 
and type 2 EBNA-2 at the transcriptional level, the system engineered previously in this 
laboratory [348] was here developed further. This consists of Daudi cells (which lack the EBNA-
2 locus [186] and therefore do not express LMP-1) engineered to stably express type 1 or type 2 
chimaeric EBNA-2 proteins fused to the hormone-binding domain of the oestrogen receptor (ER-
EBNA-2) [348]. In the absence of oestrogen, the ER-tagged EBNA-2 proteins are localized to 
the cytoplasm and are therefore inactive [290]. Addition of oestrogen results in normal 
localization of the EBNA-2 fusion proteins to the nucleus, hence activation of EBNA-2 target 
genes from the resident EBV genome can be monitored over time.  
To ensure that the fusion proteins were expressed and to test their function in the Daudi:ER-
EBNA-2 T1/T2 stable cell lines, a western blot analysis was performed on protein extracts, using 
the PE2 antibody. Both type 1 and type 2 EBNA-2 conditional proteins were detected at the 
expected position on SDS-PAGE, according to their molecular weight (Figure 3.5, upper panel). 
Treatment with oestrogen produced an increased level of the fusion proteins and a shift in the 
electrophoretic mobility (Figure 3.5, lanes 5 to 8), which is due to phosphorylation [448]. The 
anti-EBNA-2 PE2 antibody was previously shown to recognise the two types of EBNA-2 
proteins with equal efficiency on a western blot [348].  
In a time-course experiment of oestrogen stimulation over 48 hours, total cell RNA from the 
Daudi cell lines containing type 1 or type 2 ER-EBNA-2 was extracted with Trizol (section 
2.3.4.1), and analysed by ribonuclease protection assay (RPA), as described in section 2.3.4.2. 
An LMP-1 specific probe (section 2.3.3.3.2) was synthesised in vitro using T7 RNA polymerase 
and radiolabelled with 32P (section 2.3.4.2). The LMP-1 specific RPA identified a protected 
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fragment of the expected size (175 nt), as estimated by comparison with the marker (Figure 3.1 
A). An additional slightly smaller protected fragment was also observed - it is known that 
transcription of LMP-1 gene may occur from 2 start sites. The intensity of the bands visualised 
by phosphor-imager screen was quantified using ImageQuant 5.0 software (Figure 3.1 C). When 
type 1 EBNA-2 function was activated, LMP-1 mRNA levels were strongly induced as soon as 8 
hours after the stimulation and were maintained thereafter throughout the time-course (Figure 3.1 
A and C). In contrast, after induction of type 2 EBNA-2 function, markedly lower levels of 
LMP-1 transcripts were detected (Figure 3.1 A and C). At 20 hours post-induction, the intensity 
of the band representing the protected fragment seems slightly higher than at the other time-
points, however this sample has been slightly overloaded due to underestimation of RNA 
concentration, as proven by the agarose-gel electrophoresis analysis (Figure 3.1 B). Agarose-gel 
electrophoresis analysis of total cell RNA used for the RPA analysis confirmed no degradation of 
the samples (Figure 3.1 B). In conclusion, at each time-point analysed type 1 EBNA-2 induces 
higher levels of LMP-1 mRNA than the type 2 EBNA-2.  
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Figure 3.1. LMP-1 mRNA levels are differentially induced by type 1 and type 2 EBNA-2 in Daudi:ER-EBNA-
2 T1/T2 stable cell lines 
20 x 106 Daudi cells stably expressing type 1 (T1) or type 2 (T2) ER-EBNA-2 were induced with 1 µM oestrogen 
(+) or ethanol (-) as a solvent control, for 8, 20 or 48 hours. Untreated samples harvested at the 0 hour time-point (t0) 
were included in the analysis. (A) RPA for LMP-1 mRNA. 20 µg of total cell RNA were used. The doublet 
protected fragment of around 175 nt, is marked by arrows. M: size marker, the 179 nt band is shown; P: undigested 
probe; Y: yeast RNA (RPAIIIkit, Ambion). (B) Agarose-gel electrophoresis analysis of total RNA (10 µg each 
lane). 18S and 28S rRNA bands are visualised. (C) Quantification of the intensity of the bands visualized by RPA 
using ImageQuant 5.0 software. Values were normalised to untreated cells stably expressing type 1 ER-EBNA-2 (T1 
t0). A.U.: arbitrary units. 1 representative experiment of 3 is shown. 
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In contrast to LMP-1, LMP-2A, which is another EBNA-2 viral target, is not absolutely required 
for primary B cell transformation but can contribute to optimal efficiency of the process 
[163,164,165,166,167,168]. To test whether type 1 and type 2 EBNA-2 differentially regulate 
LMP-2A, the Daudi:ER-EBNA-2 T1/T2 system was further exploited to compare levels of 
transcriptional activation of LMP-2A in an RPA assay. The RPA analysis showed that the 
kinetics of RNA induction of this gene (Figure 3.2) are different from those of LMP-1 (Figure 
3.1). In fact, type 1 and type 2 ER-EBNA-2 proteins induced LMP-2A mRNA more similarly: 
LMP-2A transcripts levels increased to the same level by 48 hours with either type 1 or type 2 
EBNA-2, although type 2 induced LMP-2A less at the early time-points (Figure 3.2 A and C). 
The very similar kineticts of LMP-2A mRNA induction by the two types of EBNA-2 is 
consistent with the notion that regulation of LMP-2A by EBNA-2 occurs mainly via the host 
factor RBP-Jk [150] and the EBNA-2 region involved in interaction with this cell protein is 
highly conserved between type 1 and type 2. Furthermore, the differing kinetics of induction of 
LMP-1 and LMP-2A genes by type 1 and type 2 EBNA-2 is also consistent with the fact that the 
promoters of these two genes seem to use different combinations of transcription factors. In fact, 
while RBP-Jk/EBNA-2 interaction is key at the LMP-2A promoter, transcriptional regulation of 
LMP-1 in LCLs by EBNA-2 is thought to involve numerous host transcriptional activators, in 
addition to RBP-Jk, including PU.1, AP-2, SWI/SNF, CBP/p300, ATF/CREB and DP103/SMN 
complex (see also sections 1.6.5, 1.7.4.1 and 1.7.4.3) [255,256,257,258]. The lack of differential 
regulation of LMP-2A by type 1 and type 2 EBNA-2 suggests that this EBNA-2 target gene does 
not account for the differing transforming ability of type 1 and type 2 EBV viruses. 
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Figure 3.2. LMP-2A mRNA levels are similarly induced by type 1 and type 2 EBNA-2 in Daudi:ER-EBNA-2 
T1/T2 stable cell lines 
(A) 20 x 106 Daudi cells stably expressing type 1 (T1) or type 2 (T2) ER-EBNA-2 were induced with 1 µM 
oestrogen (+) or ethanol (-) as a solvent control, for 8, 20 or 48 hours, or left untreated (t0). (A) 20 µg of total cell 
RNA was analysed using LMP-2A RPA. The predicted protected fragment of around 92 nt, is marked by the arrow. 
P: undigested probe; Y: yeast RNA (RPAIIIkit, Ambion). (B) Agarose-gel electrophoresis analysis of total RNA (10 
µg each lane). 18S and 28S rRNA bands are visualised. (C) Quantification of the intensity of the bands visualised by 
RPA using ImageQuant 5.0 software. Values were normalised to untreated cells stably expressing type 1 ER-EBNA-
2 (T1 t0). A.U.: arbitrary units. 1 representative experiment of 2 is shown. 
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Differential regulation of LMP-1 mRNA by type 1 and type 2 EBNA-2 observed by RPA 
analysis in the Daudi:ER-EBNA-2 T1/T2 stable cell lines (Figure 3.1) was further corroborated 
by qRT-PCR analysis (Figure 3.3 A). Upon oestrogen administration, type 1 EBNA-2 was found 
to readily induce markedly higher levels of LMP-1 mRNA, compared to type 2 EBNA-2 or to 
unstimulated cells (Figure 3.3 A). Taken together these results suggest that the greater induction 
of LMP-1 by type 1 EBNA-2 occurs not only at the protein level, as shown previously in this 
laboratory [348], but also at the RNA level.  
qRT-PCR analysis was also performed to detect CXCR7 transcripts levels in the same 
experiment (Figure 3.3 B). These were found to be significantly higher in type 1 EBNA-2 cell 
lines, stimulated with oestrogen, than in type 2 cells that had undergone the same treatment. This 
observation further strengthens the notion that type 1 and type 2 EBNA-2 differentially regulate 
CXCR7, as previously demonstrated in this laboratory [348]. 
 
 
 
 
Figure 3.3. qRT-PCR analysis of LMP-1 and CXCR7 mRNA levels induced by type 1 and type 2 EBNA-2 in 
Daudi:ER-EBNA-2 T1/T2 cell lines 
20 x 106 Daudi cells stably expressing type 1 (T1) or type 2 (T2) ER-EBNA-2 were induced with 1 µM oestrogen 
(+) or ethanol (-) as a solvent control, for 8, 20 or 48 hours. Untreated samples harvested at the 0 hour time-point 
were included in the analysis. 1 µg of total cell RNA was used to synthesise cDNA and qPCR was performed to 
quantify LMP-1 (A) and CXCR7 (B) transcripts. For LMP-1 qRT-PCR (A) values for each sample are expressed as 
the ratio LMP-1/GAPDH mRNA relative to the sample T1 stimulated with oestrogen for 20 hours, whereas for 
CXCR7 qRT-PCR (B) values shown represent the ratio between CXCR7 and GAPDH mRNA levels, relative to the 
sample T1 stimulated with oestrogen for 48 hours. Each time-point corresponds to the average from 2 independent 
experiments both performed in duplicate. Error bars represent standard errors. A.U.: arbitrary units. Data shown in 
this figure and results presented in Figure 3.1 are from different experiments.  
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3.2.1.2  Differential regulation of LMP-1 protein by type 1 and type 2 ER-EBNA-2 
in the P3HR1 cl.16 BL cell line 
To avoid biases due to the genetic background of a single B cell line and to confirm the previous 
observation made in this laboratory, that type 1 EBNA-2 induces LMP-1 protein better than the 
type 2 in Daudi cells [348], a different cell line was used. This was the P3HR1 cl.16 cell line, 
which contains a resident EBV genome lacking the EBNA-2 locus and the Y1Y2-coding region 
of EBNA-LP, having a deletion similar but not identical to that present in Daudi cells [186,456]. 
In order to establish an analogous system to Daudi:ER-EBNA-2 T1/T2, in which regulation of 
the LMP-1 gene can be analysed in the context of the whole EBV genome, plasmids expressing 
type 1 or type 2 ER-EBNA-2 (p554-4 and its type 2 derivative, described in section 2.3.3.2.1) 
were transfected into P3HR1 cl.16 cells and stable cell lines were selected with G418, as 
described in section 2.2.6.3. Selected cell lines were grown out and tested for expression of ER-
EBNA-2 by western blotting with the PE2 antibody (Figure 3.6, upper panel). Both type 1 and 
type 2 fusion proteins were expressed at physiological levels, presented the expected size on the 
SDS-PAGE and responded to oestrogen treatment with an increase in abundance and size 
(Figure 3.6, lanes 5 to 8).  
In P3HR1 cl.16 cells, despite the absence of EBNA-2, basal expression of LMP-1 can still be 
detected, albeit at very low levels (Figure 3.4). Nevertheless, when a time-course experiment of 
oestrogen stimulation was performed, a clear increase of LMP-1 expression levels above 
background was detected by western blotting when type 1 EBNA-2 function was induced 
(Figure 3.4). LMP-1 induction was detected as soon as 4 hours after oestrogen stimulation; after 
8 hours LMP-1 expression level reached its maximum and was thereafter maintained throughout 
the time-course. Conversely, when type 2 EBNA-2 function was activated by oestrogen, LMP-1 
levels were induced only moderately above the background, with a modest peak at 20 hours 
followed by a slight decrease (Figure 3.4). Therefore, differential regulation of LMP-1 protein by 
type 1 and type 2, previously observed in the Daudi BL cell background [348], occurs also in the 
P3HR1 cl.16 cell line.  
Collectively the results, presented in this and in the previous section, demonstrate that type 1 and 
type 2 EBNA-2 differentially regulate endogenous levels of LMP-1, mRNA and protein, and 
CXCR7 mRNA in BL cell line systems. 
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Figure 3.4. LMP-1 protein is induced to a higher extent by type 1 EBNA-2, compared to the type 2, in P3HR1 
cl.16:ER-EBNA-2 T1/T2 stable cell lines 
P3HR1 cl.16 cells stably expressing type 1 (T1) or type 2 (T2) ER-EBNA-2 were induced with 1 µM oestrogen for 
4, 8, 12, 20, 24 or 48 hours or left untreated (0 hour time-point). At these time-points proteins were extracted and 
analysed by western blotting for EBNA-2 (PE2 antibody), LMP-1 (CS 1-4 antibody) and β-actin, as a loading 
control. h p.i.: hours post-induction; est: oestrogen. 1 representative experiment of 2 is shown.  
 
 
3.2.1.3  Cooperation between type 1 / type 2 EBNA-2 and EBNA-LP in induction of 
LMP-1 in the Daudi and P3HR1 cl.16:ER-EBNA-2 assays 
 
3.2.1.3.1  Expression of EBNA-LP species in Daudi and P3HR1 cl.16:ER-EBNA-2 assays 
As EBNA-LP is important in cooperation with EBNA-2 for induction of LMP-1 (see section 
1.6.2 and [139,140]), it was important to determine which isoforms of EBNA-LP are expressed 
in normal Daudi and P3HR1 cl.16 cells and in the derivative stable cell lines bearing the 
oestrogen-inducible EBNA-2 proteins (Figures 3.5 and 3.6). In several previous reports, 
depending on the antibodies used, 1 or 2 species of EBNA-LP (around 31 and 37 kDa) have been 
detected in Daudi cells, both lacking the Y1Y2 domain [181,194,465,467]. In this study the 4D3 
antibody was used and the 37 kDa isoform was detected (Figure 3.5, lane 4), which corresponds 
to a 4-repeat species, as determined by comparison with the EBNA-LP proteins expressed in 
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B95-8 and in 293 cells transiently transfected with plasmids coding for 3- or 7-repeat EBNA-LP 
(section 2.3.3.2.4) as standards (Figure 3.5, lanes 1, 2 and 3). P3HR1 cl.16 cells have been 
reported to express Y1Y2-deleted EBNA-LP species migrating as a major band of around 28-30 
kDa and a minor band of about 48-50 kDa on a SDS-PAGE [468] and this was confirmed by 
western blot analysis with the 4D3 antibody (Figure 3.6, lane 4). These species contain 3 and 6 
W repeats, respectively (judged by comparison with B95-8). In both cell lines these truncated 
EBNA-LP proteins are type 2, since they were detected with the 4D3 antibody, which recognises 
both type 1 and type 2 EBNA-LP [465], but not with the JF186 antibody, which is type 1-
specific [465]. In the stable cell lines expressing ER-EBNA-2 proteins, several EBNA-LP 
isoforms were detected, with 2 to 4 repeats in Daudi:ER-EBNA-2 T1/T2 (Figure 3.5, lanes 5 to 
8) and with 2 to 7 repeats in P3HR1 cl.16:ER-EBNA-2 T1/T2 (Figure 3.6, lanes 5 to 8). These 
species are type 1, since they can be detected with the JF186 antibody, and are expressed from 
the plasmids that code for the ER-EBNA-2 proteins (p554-4 and its type 2 derivative section 
2.3.3.2.1). These vectors contain not only the ER-EBNA-2 open reading frame, but also 2 W 
repeats and the Y fragment, both of type 1 sequence. The expression of EBNA-LP species that 
are larger in size than that predicted simply from the number of W fragments has been already 
reported by others [183,464,469] and may indicate splicing of RNA transcribed more than once 
around the plasmid.  
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Figure 3.5. Analysis of EBNA-2 and EBNA-LP species expressed in Daudi cells and Daudi:ER-EBNA-2 T1/T2 
cell lines 
Protein extracts were prepared from Daudi:ER-EBNA-2 T1/T2 stable cell lines treated with oestrogen (est) for 4 
hours (+) or left untreated (-) and from Daudi cells. Western blot analysis was performed using anti-EBNA-2 (PE2) 
and anti-EBNA-LP (JF186 and 4D3) antibodies. In Daudi cells no EBNA-2 was detected, because of the deletion 
that encompasses the EBNA-2 locus and the Y1Y2 exons of EBNA-LP. No EBNA-LP was detected with the type 1-
specific JF186 antibody, confirming that EBNA-LP in these cells is type 2. The 4D3 antibody recognised the 37 kDa 
EBNA-LP species, corresponding to a 4-repeat isoform and lacking the Y1 and Y2 domains (arrow). Full-length 
type 1 EBNA-LP species with 2, 3 and 4 repeats (2R, 3R and 4R) were detected with both JF186 and 4D3 
antibodies, indicating that they are expressed from the p554-4 plasmid. Lysates from B95-8 cells and 293 expressing 
3 or 7-repeat EBNA-LP type 1 (T1 ELP 3R and 7R) were used as size markers to determine the number of repeats in 
EBNA-LP proteins. β-actin immunoblotting was performed to ensure equal loading of the proteins. Numbers on the 
left hand-side of the EBNA-LP immunoblots represent molecular weight (in kDa). 1 representative experiment of 2 
is shown. 
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Figure 3.6. Analysis of EBNA-LP species expressed in P3HR1 cl.16 cells and P3HR1 cl.16:ER-EBNA-2 T1/T2 
cell lines 
P3HR1 cl.16:ER-EBNA-2 T1/T2 stable cell lines were treated with oestrogen (est) for 4 hours (+) or left untreated 
(-) and proteins were extracted and analysed by western blotting. Protein samples from untreated P3HR1 cl.16 cells 
were also included in the analysis. EBNA-2 was detected with the PE2 antibody and EBNA-LP with the JF186 and 
4D3 antibodies. Similarly to Daudi cells, no EBNA-2 was detected in P3HR1 cl.16 cells, because of the deletion, 
and no EBNA-LP was detected with type 1 specific JF186 antibody, confirming that EBNA-LP in these cells is type 
2. A major ~30 kDa EBNA-LP species and a minor ~50 kDa isoform were detected with the 4D3 antibody: they 
both lack the carboxyl-terminal Y1Y2 region and comprise 3 and 6 repeats (arrows). In the stable cell lines bearing 
the ER-EBNA-2 proteins, both JF186 and 4D3 antibodies detected full-length type 1 EBNA-LP species with 2, 3, 4, 
5, 6 and 7 repeats (2R-7R) expressed from the p554-4 plasmid. Protein samples from B95-8 cells and 293 
expressing 3 or 7-repeat EBNA-LP type 1 (T1 ELP 3R and 7R) were used as size markers for EBNA-LP repeats 
number. β-actin immunoblotting was used as protein loading control. Numbers on the left hand-side of the EBNA-
LP blots represent protein molecular weight (in kDa). 1 representative experiment of 2 is shown. 
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In both systems (Daudi and P3HR1 cl.16:ER-EBNA-2 T1/T2) several isoforms of full-length 
type 1 EBNA-LP are present but no full-length type 2 EBNA-LP is available. Therefore, one 
might speculate that type 1 EBNA-LP proteins are able to enhance the ability of type 1 ER-
EBNA-2 to induce LMP-1 but not that of the type 2 ER-EBNA-2. To test whether this is the 
case, I performed an assay for EBNA-LP function, similar to that used in earlier studies by 
Nitsche et al. and by McCann et al., whereby the effect of EBNA-LP on EBNA-2-induced 
expression of LMP-1 from the resident EBV genome was examined in an Akata BL cell line 
[140,189]. In the present study, that assay was adapted to compare the cooperative effect of type 
1 and type 2 EBNA-LP on type 1 and type 2 EBNA-2-induced expression of LMP-1 in the 
Daudi cell line. For this some preliminary experiments were carried out to optimise the assay 
(section 3.2.1.3.2) and to generate a type 2 EBNA-LP-expression plasmid (section 3.2.1.3.3).  
 
3.2.1.3.2  Setting up of a functional assay for cooperation between EBNA-2 and EBNA-LP 
In order to set up an assay which allows comparison of the abilities of type 1 and type 2 EBNA-
LP to co-activate type 1 and type 2 EBNA-2-mediated up-regulation of LMP-1, a set of pilot 
experiments was carried out. The OriP-p294 (section 2.3.3.2.2) and pSNOC (section 2.3.3.2.4) 
plasmids, expressing type 1 EBNA-2 and EBNA-LP respectively, were transfected into the 
EBV-positive BL cell lines Daudi and P3HR1 cl.16 (which do not express EBNA-2, and 
therefore LMP-1 [186,456]). The pSNOC vector used here codes for an EBNA-LP protein 
comprising 3 repeats of the W1W2 domain, which is above the minimum required for optimal 
EBNA-LP cooperative function [140,189,190]. First, preliminary titration experiments of the 2 
plasmids were performed in the EBV-negative DG75 cell line to determine the amount of 
plasmids which gives appropriate expression levels of both EBNA-2 and EBNA-LP in transient 
transfection (see Supplementary Figure 3 in the Appendix). For this, the Neon transfection 
method was used and this gives similar transfection efficiencies in the Daudi, P3HR1 cl.16 and 
DG75 cell lines (see section 2.2.6.3). Good expression levels of EBNA-2 and EBNA-LP were 
obtained by western blot with 220 and 440 nmol of plasmids (see Supplementary Figure 3 in the 
Appendix). Therefore these vector doses were tested in the Daudi and P3HR1 cell lines. For this, 
2 or 4 µg of type 1 EBNA-2-expressing vector either alone or in combination with 1.2 and 2.4 µg 
of pSNOC vector coding for type 1 EBNA-LP were Neon-transfected into Daudi and P3HR1 cl. 
16 cells. Protein extracts were made 24 hours after transfection by RIPA extraction (section 
162 
 
2.4.1) and subjected to western blot analysis to detect EBNA-2, EBNA-LP and LMP-1 
expression levels (Figure 3.7). In the Daudi cell line, transfection of the the EBNA-2-vector 
alone, produced detectable amounts of EBNA-2 protein but led to a weak up-regulation of LMP-
1 expression above background levels, as seen in non transfected cells (Figure 3.7 A). In 
contrast, no LMP-1 protein was detected by western blot when either amount of EBNA-LP-
expressing vector was transfected alone, despite strong expression of the 3-repeat EBNA-LP 
species detected with the 4D3 antibody (Figure 3.7 A). When EBNA-2 and EBNA-LP encoding 
vectors were co-transfected, LMP-1 was clearly up-regulated, above levels observed in cells 
expressing EBNA-2 alone and this up-regulation occurred in a dose-dependent fashion (Figure 
3.7 A).  
A similar experiment was performed in the P3HR1 cl.16 cell line (Figure 3.7 B). Co-transfection 
of EBNA-2 and EBNA-LP expressing plasmids did produce an up-regulation of LMP-1 
expression levels, compared to non-transfected cells. However, non transfected cells, as well as 
cells expressing either EBNA-2 only or EBNA-LP only, also expressed LMP-1 to some extent 
(Figure 3.7 B). Because of this high background level of LMP-1 expression, the P3HR1 cl. 16 
cell line was not used for further studies and only the Daudi cell line was chosen for the 
subsequent experiments. Based on the results obtained in the Daudi cell line (Figure 3.7 A) 4 µg 
of EBNA-2-encoding vector and 2.4 µg of EBNA-LP-expressing vector were the doses of 
plasmids chosen for the next experiments because they produced the strongest effect on LMP-1 
induction.  
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Figure 3.7. Setting up a transient transfection assay to analyse the effect of EBNA-LP on EBNA-2-mediated 
induction of LMP-1 
2 x 106 Daudi (A) or P3HR1 cl. 16 (B) cells were transiently transfected with an OriP-p294 plasmid expressing type 
1 (T1) EBNA-2 either alone or together with a pSNOC plasmid expressing a type 1 EBNA-LP. A titration of the 
plasmids was carried out. The Neon transfection system was used. 24 hours after transfection, cells were lysed in 
RIPA lysis buffer and analysed by SDS-PAGE followed by immunoblotting for LMP-1 (CS 1-4 antibody), EBNA-2 
(PE2 antibody), EBNA-LP (4D3 antibody) and β-actin (to ensure equal loading of the proteins). The pSNOC 
plasmids express EBNA-LP proteins with 3 W repeats (3R). (A) Daudi cells already express an endogenous species 
of EBNA-LP which comprises 4 repeats and lacks the Y1Y2 domains (4R ∆Y1Y2). (B) In P3HR1 cl. 16 cells the 
endogenous Y1Y2-truncated EBNA-LP species comprise 3 and 6 repeats (3R ∆Y1Y2 and 6R ∆Y1Y2 respectively). 
Protein molecular weight (in kDa) are indicated. 
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3.2.1.3.3  Generation of a pSNOC vector expressing a type 2 3-repeat EBNA-LP  
To generate a pSNOC vector expressing a type 2 EBNA-LP protein comprising 3 W1W2 
repeats, homologous to the type 1 construct (pSNOC T1 EBNA-LP 3R) already available in the 
laboratory (section 2.3.3.2.4), cDNA clones from the type 2 cell lines C2+BL16 and Jijoye 
[406,449] were obtained by Pfu-PCR using oligonucleotides complementary to sequences within 
the C1 and YH exons (section 2.8.3). A PCR amplicon of the size of the coding sequence of an 
EBNA-LP comprising 3 W1W2 exons was obtained from both cell lines even though this was 
much more abundant in Jijoye cells (Figure 3.8). In order to obtain sufficient amounts of PCR 
product from the C2+BL16 cDNA sample, two consecutive PCRs were performed. The 918 bp-
PCR products were gel-purified and subcloned in a pCR2.1 vector via TA cloning strategy 
(section 2.3.3.1.18), and sequenced to verify their identity to the published AG876 EBNA-LP 
sequence (GenBank accession number NC009334). Interestingly, the sequence analysis of 
several cDNA clones obtained from the Jijoye cell line revealed that while the sequence of the 
W1W2 exons is type 2, the sequence of the unique Y1Y2 exons is type 1 (Appendix, 
Supplementary Figure 4). On the other hand, the sequence of the C2+BL16 cDNA clone 
analysed was identical to that of the AG876 EBNA-LP (GenBank accession number NC009334) 
and this was therefore selected for the subsequent experiments.  
The initiating methionine of the first EBNA-LP W1 repeat (W1′) is normally generated through a 
W0/W1’ splicing event that gives rise to an ATG initiation codon, while subsequent downstream 
W1 exons use a different splice acceptor that adds a proline and arginine residue to each repeat 
[124,125,180]. Since the cDNA C2+BL16 clone obtained lacked the ATG initiation codon that is 
normally generated in the first W1 repeat (W1’) this was generated artifically by site-directed 
mutagenesis (section 2.3.3.1.17) using the mutagenic primers reported in section 2.8.4. The 
whole EBNA-LP coding sequence, with the repaired initiating ATG, was then cloned in the 
expression vector pSNOC (section 2.3.3.2.4) as an EcoRI BamHI fragment, generating the final 
construct pSNOC T2 EBNA-LP 3R.  
Expression of the type 1 and type 2 3-repeat EBNA-LP proteins from the pSNOC vectors was 
tested by transient transfection of 293 cells. Western blot analysis performed on protein extracts 
prepared at 24 and 48 hours after transfection using the 4D3 antibody, which detects both types 
of EBNA-LP [465], revealed that both plasmids expressed EBNA-LP proteins of the expect size 
(approximately 31 kDa) (Figure 3.9). Slightly higher amounts of type 1 EBNA-LP were 
165 
 
expressed, compared to the type 2 at both time-points analysed. An additional minor band, 
smaller than 31 kDa, was detected in type 2 vector-transfected cells, which might represent a 
degradation product of the 3-repeat isoform. Nevertheless the major product expressed in these 
cells was the full-length protein.  
 
 
 
 
Figure 3.8. PCR amplification of the sequence coding for a type 2 3-repeat EBNA-LP from C2+BL16 and 
Jijoye cDNA 
Total RNA was extracted from C2+BL16 and Jijoye cells and retrotranscribed into cDNA. Oligonucleotides listed in 
section 2.8.3 were used to PCR amplify the EBNLP-coding exon sequence from 2 cDNA samples from each cell 
line. The 918-bp band corresponds to an EBNA-LP cosing sequence comprising 3 W1W2 repeated exons. PCR with 
GAPDH specific primers was performed to determine total amount of cDNA. 1 kb and 100 bp M: nucleic acids size 
markers (NEB); ntc: no template control. 
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Figure 3.9. Expression of type 1 and type 2 3-repeat EBNA-LP proteins from pSNOC vectors transiently 
transfected into 293 cells 
5 x 105 293 cells were transfected with either 2 or 4 µg of pSNOC T1 and T2 EBNA-LP 3R plasmids using 
Lipofectamine™2000. 24 and 48 hours after transfection cells were harvested and protein extract were prepared and 
analysed by western blotting using the 4D3 antibody which recognises both type 1 and type 2 EBNA-LP. β-actin 
immunoblot served as loading control. ELP 3R (+): positive control for EBNA-LP expression; 293 n.t.: non-
transfected cells; h post T: hours post-transfection. Protein molecular weight (kDa) are indicated. 
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3.2.1.3.4  Functional assay for cooperation between type 1 / type 2 EBNA-2 and EBNA-LP 
Having generated an expression vector expressing a type 2 3-repeat EBNA-LP protein (section 
3.2.1.3.3) and having established an assay that allows investigation of the cooperative effect of 
EBNA-LP and EBNA-2 on the resident expression levels of LMP-1 (section 3.2.1.3.2), I next 
aimed to compare the abilities of the type 1 and type 2 EBNA-LP to modulate type 1 and type 2 
EBNA-2-mediated induction of LMP-1. For this, Daudi cells were transiently transfected with 
combinations of OriP-p294 vectors expressing type 1 or type 2 EBNA-2 (4 µg) and/or pSNOC 
plasmids coding for type 1 or type 2 EBNA-LP (2.4 µg). Equimolar amounts of the 2 plasmids 
were transfected. Transfection of vectors expressing type 1 or type 2 EBNA-2 alone did not 
produce any significant induction of LMP-1, despite the strong expression of both types of 
EBNA-2 proteins, as assessed by immunoblotting (Figure 3.10). Likewise, no LMP-1 was 
detected when plasmids coding for either type 1 or type 2 EBNA-LP bearing 3 repeats were 
transfected, even though both EBNA-LP species were clearly detected on a western blot as an 
approximately 30 kDa band (Figure 3.10). Co-transfection of type 1 EBNA-2 and type 1 EBNA-
LP plasmids produced a clear induction of LMP-1 protein. A similar, but slightly lower level of 
induction was observed when the type 2 EBNA-LP was co-expressed with type 1 EBNA-2. In 
contrast, up-regulation of LMP-1 induced by the type 2 EBNA-2, in the presence of either type 
of EBNA-LP, was very modest and equal with either type 1 or type 2 EBNA-LP (Figure 3.10). 
These results indicate that the weaker up-regulation of LMP-1 induced by type 2 EBNA-2, 
compared to type 1 EBNA-2, can be ascribed to the EBNA-2 type and is not affected by the type 
of EBNA-LP present. Type 1 EBNA-2 up-regulates LMP-1 better than type 2 EBNA-2, in the 
presence of either type 1 or type 2 EBNA-LP. These observations support the conclusion that, in 
the Daudi and P3HR1 cl.16:ER-EBNA-2 T1/T2 cell lines, the impaired ability of type 2 EBNA-2 
to induce LMP-1 ([348] and Figure 3.4) is not due to sub-optimal cooperation with the full-
length type 1 EBNA-LP isoforms present in the systems, but is rather due to the type 2 EBNA-2 
protein.  
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Figure 3.10. In a transient transfection assay in Daudi cells, the weaker induction of LMP-1 by type 2 EBNA-
2, compared to the type 1 EBNA-2, is not affected by the EBNA-LP type 
2 x 106 Daudi cells were transiently transfected with an array of combinations of EBNA-2-expressing plasmids 
(OriP-p294, 4 µg) and EBNA-LP-expressing plasmids (pSNOC, 2.4 µg) of type 1 (T1) and type 2 (T2). Equimolar 
amounts of the 2 plasmids were used. The Neon transfection system  was used. 24 hours after transfection, cells 
were lysed in RIPA lysis buffer and analysed by SDS-PAGE followed by immunoblotting for LMP-1 (CS 1-4 
antibody), EBNA-2 (PE2 antibody), EBNA-LP (4D3 antibody) and β-actin (to ensure equal loading of the proteins). 
The pSNOC plasmids express EBNA-LP proteins with 3 W repeats (3R). Daudi cells already express an endogenous 
species of EBNA-LP which bears 4 repeats and lacks the Y1Y2 domains (4R ∆Y1Y2). Numbers alongside the 
EBNA-LP blot indicate protein molecular weight in kDa. 1 representative experiment of 2 is shown. 
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3.2.2  Transcriptional regulation of LMP-1 and CXCR7 promoters by type 1 
and type 2 EBNA-2 in promoter-reporter gene assays  
 
Having showed that type 1 and type 2 EBNA-2 differentially regulate endogenous levels of 
LMP-1 and CXCR7 in EBV-infected BL cell line assays (Daudi and P3HR1 cl.16:ER-EBNA-2, 
sections 3.2.1.1 and 3.2.1.2), I next decided to investigate whether differential regulation of those 
EBNA-2 targets may be recapitulated also in transient transfection assays using promoter-gene 
reporter constructs.  
 
3.2.2.1  Regulation of LMP-1 regulatory sequence (LRS) from the B95-8 and 
P3HR1 EBV genomes by type 1 and type 2 EBNA-2 
 
3.2.2.1.1  Transcriptional regulation of B95-8 and P3HR1 LRS by type 1 and type 2 
EBNA-2 in EBV-negative DG75 cells 
Several regulatory elements in the proximal LMP-1 ED-L1p promoter (or LMP-1 regulatory 
sequence, LRS) have been identified that mediate both transcriptional repression and activation 
and include multiple RBP-Jk sites, a PU-box, an AP-2 consensus site, an Sp factor-binding site, a 
cyclic AMP response element (CRE), an E-box element, an octamer-binding site and an 
interferon stimulated response element (ISRE) [462]. Their involvement in LMP-1 regulation by 
EBNA-2 has been described extensively for the type 1, but not the type 2 EBNA-2.  
Although sequence variations in the LMP-1 gene were reported for different EBV strains, both in 
the coding sequence and in the promoter region, these are not linked to the type 1 / type 2 EBV 
variation. However, a recent sequencing analysis of the LMP-1 regulatory sequence (LRS region 
-634/+40) in the P3HR1 (type 2) EBV strain revealed that there are several nucleotide variations 
compared to the B95-8 (type 1) EBV sequence. One of these substitutions, a C to an A at 
position (-43) occurs within the CRE element and similar sequence variations in this CRE site 
have also been found in other EBV strains [462]. These CRE sequence variation has been shown 
to have functional consequences for the regulation of the LMP-1 promoter. In fact, in promoter- 
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reporter assays, transactivation of the P3HR1 LRS by type 1 EBNA-2 was reduced compared to 
that of the B95-8 LRS. This diminished responsiveness was shown to be due to the CRE site, 
since reporter plasmids carrying the P3HR1 CRE sequence in a B95-8 LRS context displayed as 
well 50% lower activity in response to EBNA-2 (type 1) [462]. In light of these observations, I 
decided to compare the effects of type 1 and type 2 EBNA-2 on transcriptional activation of the 
LRS from B95-8 and P3HR1. For this, a transient transfection assay was developed whereby the 
LMP-1 promoter sequence from either B95-8 or P3HR1 EBV could be regulated by EBNA-2 in 
the EBV-negative DG75 cell line, used in the studies by Jansson and colleagues [462].  
 
DG75 cells were co-transfected with plasmids expressing either type 1 or type 2 EBNA-2 (OriP 
p294 E2 T1/T2, section 2.3.3.2.2), a luciferase reporter plasmid carrying the LRS from either 
B95-8 or P3HR1 EBV strain (pGL3b B95-8/P3HR1 LRS, section 2.3.3.2.5) and a β-
galactosidase expression plasmid (pCMV19-βGal, section 2.3.3.2.6) using the Neon system. The 
total amount of plasmid DNA used did not exeed the total dose of DNA used in the experiments 
aimed to optimise the Neon transfection method in the Daudi cell line (see section 2.2.6.3 and 
Supplementary Figure 2 in the Appendix). 24 and 48 hours after transfection, cell extracts were 
analysed for luciferase activity and results were adjusted for transfection efficiency based on the 
β-galactosidase reference values (Figure 3.11). An approximately 2-fold increase in luciferase 
activity was detected in DG75 cells transfected with the B95-8 LRS reporter construct compared 
to cells transfected with the P3HR1 LMP-1 promoter-reporter vector, in the presence of either 
type of EBNA-2 protein at 48 hours post-transfection, consistent with the previous report by 
Jannsson et al. [462]. However, no statistically significant differences between type 1 and type 2 
EBNA-2-induced activation of either the B95-8 or the P3HR1 LRS were observed at any time-
point analysed (Figure 3.11 A and B). Equal expression levels on a western blot were achieved 
when transfecting vectors expressing either type 1 or type 2 EBNA-2 (Figure 3.11 C).  
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Figure 3.11. Transcriptional regulation of B95-8 and P3HR1 LRS by type 1 and type 2 EBNA-2 in DG75 cells 
2 x 106 DG75 cells were co-transfected with 2 µg of each of the following plasmids: p294 E2 T1/T2, expressing 
either type 1 or type 2 EBNA-2, pGL3b B95-8/P3HR1 LRS reporter plasmids and pCMV19-βGal (β-galactosidase 
reference vector) using the Neon electroporation method. Equivalent amounts of empty vectors p294 (p294 e.v.) and 
pGL3b (pGL3b e.v.) were transfected as negative controls. At 24 (A) and 48 (B) hours post-transfection cells were 
harvested and analysed for luciferase and β-galactosidase activity. For each sample, luciferase values were corrected 
for transfection efficiency based on β-galactosidase reference values. Results are presented as luciferase activity 
relative to the LRS B95-8 reporter plasmid with type 1 EBNA-2. Transfections were performed in triplicate. Error 
bars represent standard deviations. Results were analysed by Student’s paired t-Test with 2-tailed distribution. n.s.: 
non significant. 1 representative experiment of 3 is shown. (C) Expression levels of type 1 (E2T1) and type 2 
(E2T2) EBNA-2 were compared by immunoblot analysis with the PE2 specific anti-EBNA-2 antibody at 24 hours 
after transfection. Immunoblotting for β-actin was performed as protein loading control. e.v.: OriP-p294 empty 
vector-transfected cells; n.t.: non-transfected DG75 cells; B95-8 and AG876: positive controls for type 1 and type 2 
EBNA-2 expression respectively.  
 
 
The results suggest that this transient LMP-1 promoter-reporter assay in the DG75 cell 
background does not reproduce the marked differential regulation of LMP-1 by type 1 and type 2 
EBNA-2 observed in the previous Daudi and P3HR1:ER-EBNA-2 T1/T2 cell line systems 
(sections sections 3.2.1.1 and 3.2.1.2). Because DG75 is an EBV-negative cell line, it might be 
the case that the presence of other EBV proteins, expressed in the EBV-positive Daudi and 
P3HR1:ER-EBNA-2 T1/T2 cell lines, may be important for differential regulation of the LMP-1 
promoter by type 1 and type 2 EBNA-2. Therefore, to investigate whether the presence of other 
viral latent proteins might affect the abilities of type 1 and type 2 EBNA-2 to transactivate B95-8 
and P3HR1 LRS sequences, LMP-1-promoter-reporter assays were performed in the Daudi and 
P3HR1 cl.16 cell lines. These provide an intracellular background similar to that used in the 
experiments with the oestrogen-inducible ER-EBNA-2 proteins.  
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3.2.2.1.2  Transcriptional regulation of B95-8 and P3HR1 LRS by type 1 and type 2 
EBNA-2 in EBV-positive Daudi cells 
To test whether the differential regulation of LMP-1 observed in the Daudi BL system in the 
presence of the oestrogen-regulated type 1 or type 2 EBNA-2 proteins (section 3.2.1.1) could be 
recapitulated by transient promoter-reporter assays, a transient transfection assay similar to that 
performed in DG75 cells (3.2.2.1.1) was carried out in Daudi cells (Figure 3.12). In the presence 
of either type 1 or type 2 EBNA-2, the P3HR1 LRS reporter construct displayed approximately 
50% less activity than the B95-8 LRS. This trend was detected both at 24 and at 48 hours after 
transfection, even though the effect with type 2 EBNA-2 at 48 hours was modest (Figure 3.12 A 
and B). Nevertheless, the results with type 1 EBNA-2 are consistent with the previous 
experiment in DG75 cells (Figure 3.11) and with observations reported by Jansson and 
colleagues [462]. Importantly, type 1 EBNA-2 activated the B95-8 LRS approximately 2-fold 
more than type 2 EBNA-2, at both time-points analysed. On the other hand, in the case of the 
P3HR1 LRS promoter, a similar 2-fold increase was observed in the presence of type 1 EBNA-2, 
compared to type 2 EBNA-2, at 24 but not at 48 hours after transfection (Figure 3.12 A and B). 
Similar levels of expression of type 1 and type 2 EBNA-2 were achieved at both time-points 
analysed, as indicated by western blot analysis with the PE2 antibody (Figure 3.12 C). Therefore, 
in contrast to the EBV-negative DG75 cell line, in EBV-positive Daudi cells type 1 and type 2 
EBNA-2 do differentially activate LRS reporter constructs, but this difference is only modest 
(~2-fold) when compared to the marked differential effect induced by type 1 and type 2 
oestrogen-inducible EBNA-2 proteins in the Daudi:ER-EBNA-2 T1/T2 system (section 3.2.1.1).  
Sequencing analysis of the endogenous LRS in the Daudi cell line and comparison to the B95-8 
and P3HR1 sequences revealed that the Daudi CRE site is identical to that of the P3HR1 LRS 
(Table 3.1). Therefore the results obtained for the regulation of the endogenous LMP-1 promoter 
in the Daudi:ER-EBNA-2 T1/T2 system (section 3.2.1.1) should be directly compared to those 
obtained with the P3HR1 LRS reporter construct in the luciferase assay in Daudi cells. The latter 
indicate that there is only a rather weak difference between type 1 and type 2 EBNA-2 (Figure 
3.12). Hence it appears evident that the strong differential regulation seen in the presence of type 
1 and type 2 ER-EBNA-2 in the former system (section 3.2.1.1) is only partially recapitulated 
using the P3HR1 LRS construct transiently transfected in the luciferase assay in the same cell 
background (Figure 3.12).  
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 Figure 3.12. Transcriptional regulation of B95
2 x 106 Daudi cells were co-transfected with 2 µg of either type 1 or type 2 EBNA
T1/T2), 2 µg of the pGL3b B95-8 LRS or pGL3b P3HR1 LRS reporter plasmids and 2 µg of a 
reference vector (pCMV19-βGal) with the Neon sys
pGL3b (pGL3b e.v.) were transfected as negative controls. At 24 
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bars represent standard deviations. Results were analysed by Student’s paired t
non significant. 1 representative experiment of 
(E2T2) EBNA-2 were compared by immunoblot analysis with the PE2 anti
hours. Immunoblotting for β-actin was performed as protein loading control. e.v.: empty p294 vector
cells; n.t.: non-transfected Daudi cells; B95
expression respectively.  
 
 
 
 
 
Table 3.1. Sequence of the LMP-1 CRE site in B95
Daudi LRS was PCR-amplified from genomic DNA using primers 
was sequenced using the same primers. The sequence of the CRE site of Daudi genome was compared to that of the 
B95-8 and P3HR1 reported in [462]
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3.2.2.1.3  Transcriptional regulation of B95-8 and P3HR1 LRS by type 1 and type 2 
EBNA-2 in EBV-positive P3HR1 cl.16 cells 
In order to determine whether the differential regulation of the LMP-1 promoter by type 1 and 
type 2 EBNA-2 seen in the P3HR1 cl.16:ER-EBNA-2 T1/T2 system (section 3.2.1.2, Figure 3.4) 
could be recreated using LMP-1 promoter-reporter constructs, a transient transfection assay 
similar to that performed in DG75 (Section 3.2.2.1.1) and Daudi (section 3.2.2.1.2) cells was 
carried out in the P3HR1 cl. 16 cell line (Figure 3.13). Consistent with previously reported data 
[462] and with the results obtained in DG75 and Daudi cells (Figures 3.11 and 3.12), in P3HR1 
cl.16 cells the B95-8 LRS construct displayed a stronger activation in the presence of both types 
of EBNA-2 proteins compared to the P3HR1 LRS reporter vector (Figure 3.13). This effect was 
detected at 24 hours after transfection (Figure 3.13 A), but was less evident at the 48 hours time-
point (Figure 3.13 B). In contrast to Daudi cells (Figure 3.12), in the P3HR1 cl.16 background no 
major differences in transcriptional activation of the B95-8 LRS were observed in the presence 
of either type 1 or type 2 EBNA-2, at either time-point considered (Figure 3.13 A and B). 
Differential regulation of the P3HR1 LRS by type 1 and type 2 EBNA-2 was detected at 24 
hours post-transfection but was modest (Figure 3.13 A). Western blot analysis with the PE2 
antibody ensured that equal levels of expression of both types of EBNA-2 proteins were 
achieved upon transfection of the OriP-p294 plasmids in P3HR1 cl.16 cells (Figure 3.13 C). 
Therefore, the differential effect on regulation of the endogenous LMP-1 gene in the P3HR1cl.16 
background observed using oestrogen-inducible EBNA-2 proteins (section 3.2.1.2, Figure 3.4) is 
not fully reproduced when using LMP-1 promoter-reporter plasmids in the same cell line (Figure 
3.13). 
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Figure 3.13. Transcriptional regulation of B95-8 and P3HR1 LRS by type 1 and type 2 EBNA-2 in P3HR1 
cl.16 cells 
2 x 106 P3HR1 cl.16 cells were co-transfected with 2 µg of either type 1 or type 2 EBNA-2-expressing vectors 
(p294 E2 T1/T2), 2 µg of the pGL3b B95-8 LRS or pGL3b P3HR1 LRS reporter plasmids and 2 µg of a β-
galactosidase reference vector (pCMV19-βGal) using the Neon system. Equivalent amounts of empty vectors p294 
(p294 e.v.) and pGL3b (pGL3b e.v.) were transfected as negative controls. At the 24 (A) and 48 (B) time-points cell 
lysates were analysed for luciferase and β-galactosidase activity. For each sample, luciferase values were corrected 
for transfection activity on the basis of β-galactosidase reference values. Results are given as luciferase activity 
relative to the LRS B95-8 reporter plasmid with type 1 EBNA-2. Transfections were performed in triplicate. Error 
bars represent standard deviations. Results were analysed by Student’s paired t-Test with 2-tailed distribution. n.s.: 
non significant. 1 representative experiment of 3 is shown. (C) Expression levels of type 1 (E2T1) and type 2 
(E2T2) EBNA-2 were compared by immunoblot analysis with the PE2 anti-EBNA-2 antibody at 24 and 48 hours. β-
actin immunoblot analysis ensured that equal amounts of proteins were loaded on the gel. e.v.: empty p294 vector-
transfected cells; n.t.: non-transfected P3HR1 cl.16 cells; B95-8 and AG876: positive controls for type 1 and type 2 
EBNA-2 expression respectively.  
 
 
Collectively the results presented in this and in the previous section suggest that the striking 
differential regulation of resident LMP-1 expression levels observed in the BL cell line systems 
with oestrogen-regulated EBNA-2 proteins (sections 3.2.1.1 and 3.2.1.2) are not entirely 
replicated in transient promoter-reporter assays (Figures 3.12 and 3.13) performed in similar cell 
backgrounds. While in Daudi and P3HR1 cell lines some, albeit modest, differential effect of 
type 1 and type 2 EBNA-2 could be observed on the LRS reporter constructs (Figures 3.12 and 
3.13), no effect at all was detected in the EBV-negative cell line DG75 (Figure 3.11), suggesting 
that the presence of other EBV proteins might account for this. Since the major viral latent 
protein that cooperates with EBNA-2 in activation of LMP-1 is EBNA-LP [139,140], subsequent 
experiments were devoted to test whether expression of EBNA-LP in an EBV-negative context 
could restore differential regulation of the LMP-1 promoters in reporter constructs by type 1 and 
type 2 EBNA-2, to the levels observed in Daudi and P3HR1 cl.16 cell lines (Figures 3.12 and 
3.13).  
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3.2.2.1.4  Attempt to study the cooperative effect of type 1 and type 2 EBNA-2 and EBNA-
LP on transcriptional activation of LRS promoter-reporter constructs in EBV-
negative BJAB cells 
In order to determine whether the lack of differential transcriptional regulation observed in the 
EBV-negative DG75 cell line, with type 1 and type 2 EBNA-2, is due to absence of EBNA-LP 
expression, LRS promoter-reporter assays were performed in an EBV-negative cell context by 
co-transfecting EBNA-2 and EBNA-LP-expressing plasmids. Previous reports have shown that 
EBNA-LP (type 1) enhances substantially the ability of EBNA-2 (type 1) to transactivate the 
LMP-1 promoter in CAT and luciferase reporter experiments [139,141]. In this study, the idea 
was to explore the cooperative effect of both type 1 and type 2 EBNA-LP on transcriptional 
activation of B95-8 and P3HR1 LRS mediated by both types of EBNA-2. For this the strategy 
devised was to co-transfect EBV-negative cells with combinations of plasmids expressing type 1 
or type 2 EBNA-2 (OriP-p294, section 2.3.3.2.2), type 1 or type 2 EBNA-LP (pSNOC, sections 
2.3.3.2.4 and 3.2.1.3.3) and B95-8/P3HR1 LRS reporter constructs (section 2.3.3.2.5). The BJAB 
cell line, instead of the DG75, was used because allowed higher transfection efficiencies and cell 
viability values with the Neon method (see section 2.2.6.3 and Supplementary Figure 2 in the 
Appendix). Preliminary experiments were required to determine the optimal amount of EBNA-2 
and EBNA-LP-expressing plasmids (OriP-p294 and pSNOC respectively) to use. Only the B95-8 
LRS sequence and the type 1 EBNA-2 and EBNA-LP vectors were tested for these titration 
experiments. A range of DNA doses of OriP-p294 EBNA-2-expressing plasmid (0.1, 0.2, 0.5 and 
1 µg) and equimolar amounts of EBNA-LP pSNOC expressing vector (0.07, 0.15, 0.3 and 0.6 
µg) were Neon-transfected into BJAB cells and luciferase and galactosidase activity were 
assayed after 24 hours (Figure 3.14). Substantial luciferase activity from the B95-8 LRS reporter 
vector was detected with the 0.5 µg dose of OriP-p294 EBNA-2 plasmid, but less with lower 
amounts. Using 0.5 µg of EBNA-2 plasmid, a dose-response relationship was detected when 
increasing amounts of EBNA-LP were expressed. However the overall levels of luciferase 
activity detected when both EBNA-2 and EBNA-LP were expressed were only moderately 
higher than those obtained with EBNA-2 alone (Figure 3.14).  
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Figure 3.14. Effect of EBNA-LP (type 1) on EBNA-2 (type 1)-mediated transcriptional activation of B95-8 
LRS (-634/+40) reporter construct in BJAB cells 
2 x 106 BJAB cells were co-transfected with the pGL3b B95-8 LRS reporter plasmid (2 µg), the β-galactosidase 
reference vector pCMV19-βGal (2 µg) and different combinations of the OriP-p294 E2 T1 plasmid expressing type 
1 EBNA-2 (T1 E2) and the pSNOC T1 ELP 3R vector expressing a 3-repeat type 1 EBNA-LP (T1 ELP). The OriP-
p294 E2 T1 and the pSNOC T1 ELP 3R vectors were titrated out by testing 13.75, 27.5, 55 and 110 fmol, which 
correspond to 0.1, 0.2, 0.5 and 1 µg of OriP-p294 vector (~14 kb) and to 0.07, 0.15, 0.3 and 0.6 µg of pSNOC vector 
(8420 bp) respectively. The Neon electroporation method was used. The total amount of DNA transfected was 
normalised each time by adding the empty vectors OriP-p294 and pSNOC. At 24 hours post-transfection cells were 
harvested and analysed for luciferase and β-galactosidase activity. Luciferase values were corrected for transfection 
efficiency based on β-galactosidase reference values (RLU/β-gal). Transfections were performed in triplicate. Error 
bars represent standard deviations. 1 representative experiment of 3 is reported. 
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In an attempt to optimise the assay, a second titration experiment (Figure 3.15) was carried out 
using 0.5 µg of EBNA-2-expressing vector and 2 intermediate doses of EBNA-LP plasmid (0.15 
and 0.3 µg), among the range tested in the previous experiment. Both type 1 and type 2 EBNA-
LP were tested in this experiment. No significant synergistic effect on LMP-1 promoter 
transactivation was detected when EBNA-2 and EBNA-LP (either type 1 or type 2) were co-
expressed, relative to when only EBNA-2 was expressed (Figure 3.15). Similar results were 
consistently obtained in 5 independent experiments. The results suggest that the luciferase 
reporter assays with the LMP-1 promoter region -634/+40, with the specific experimental 
conditions used in this study, are not able to reproduce a well documented function of EBNA-
LP, namely its ability to enhance EBNA-2-mediated transactivation of the LMP-1 promoter 
[139,140,141]. This is in contrast with the assays previously used in this study, which include 
EBV-positive B cell lines in which the endogenous LMP-1 protein can be regulated by either 
stable oestrogen-inducible EBNA-2 proteins (sections 3.2.1.1 and 3.2.1.2) or by constitutive 
EBNA-2 and EBNA-LP proteins expressed in a transient fashion (section 3.2.1.3.4). Therefore, 
the general conclusion from the body of experiments with LMP-1 promoter-reporter assays 
presented in section 3.2.2.1 is that they do not allow proper detection of regulation of the LMP-1 
promoter by type 1 and type 2 EBNA-2 and EBNA-LP/EBNA-2 cooperative transactivation 
function, perhaps due to the specific LRS sequence -634/+40 used or the specific experimental 
conditions used in this study. For this reason, these reporter assays were not developed further to 
explore differential activation of the LMP-1 promoter by type 1 and type 2 EBNA-2. 
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Figure 3.15. Effect of type 1 and type 2 EBNA-LP on EBNA-2 (type 1)-mediated transcriptional activation of 
B95-8 LRS (-634/+40) reporter construct in BJAB cells 
2 x 106 BJAB cells were co-transfected with 2 µg of the pGL3b B95-8 LRS (-634/+40) reporter plasmid, 2 µg of the 
β-galactosidase reference vector pCMV19-βGal and 1 or more of the following plasmids: OriP-p294 E2 T1 plasmid 
expressing type 1 EBNA-2 (0.5 µg) and pSNOC vectors expressing a 3-repeat EBNA-LP either type 1 (T1) or type 
2 (T2). 2 doses of the pSNOC vectors were titrated (0.15 and 0.3 µg). The Neon transfection system was used. The 
total amount of plasmid DNA tranfected was normalised each time with pSNOC empty vector. After 24 hours the 
cells were harvested and analysed for luciferase and β-galactosidase activity. Results are presented as the ratio 
between luciferase and β-galactosidase values (RLU/β-gal), in order to corrected for transfection efficiency. 
Transfections were performed in triplicate. Error bars represent standard deviations. 1 representative experiment of 3 
is shown. 
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3.2.2.2  Regulation of the CXCR7 promoter by type 1 and type 2 EBNA-2 
The RefSeq human CXCR7 gene encodes 2 exons only (accession number NM020311) although 
the UCSC consensus shows the presence of additional exons (accession number BC036661) and 
alterative splicing of the 5’ end has been reported [348,470]. The translated coding region is 
encoded only by the last exon. The 5’ flanking sequence for the first 2 exons (untranslated and 
translated) contains elements characteristic of promoter sequences (i.e TATA-box and CpG 
islands). The first study on CXCR7 promoter was reported by Jin et al. The major transcriptional 
start site (+1) of the CXCR7 gene was mapped at 10,641 bases upstream in the genomic DNA 
from the translation start codon [389]. The region from -1144 to -36 bp, relative to the 
transcriptional start site, was used in promoter-reporter assays in T cells to demonstrate that 
HTLV-1 Tax activates of the CXCR7 promoter [389]. In the present study, in order to measure 
transcriptional regulation by type 1 and type 2 EBNA-2 of the CXCR7 promoter, the promoter 
region -1144/-36 of this gene, used in the study by Jin et al. [389], was cloned in a pGL3basic 
luciferase gene reporter plasmid (section 2.3.3.2.5) and co-transfected with either type 1 or type 
2 EBNA-2 expressing vectors (Orip-p294, section 2.3.3.2.2) into B cells. A β-galactosidase 
reference vector was also transfected. The EBV-negative DG75 cell line was used and plasmid 
DNA was transfected by electroporation, as described in section 2.2.6.1. A titration of the 
EBNA-2-expressing plasmids was performed and, as a positive control for CXCR7 promoter 
activation, a Tax-expressing vector (section 2.3.3.2.7) was also included in the analysis. Even 
though a strong activation was detected in the presence of Tax-expressing plasmid, only a 
modest luciferase signal was obtained with either type 1 or type 2 EBNA-2 at any dose of 
plasmid DNA used (Figure 3.16). The results suggest that the CXCR7 promoter region used in 
this study (-1144/-36) is not sufficient to confer EBNA-2 responsiveness, even though it can be 
transactivated by HTLV-1 Tax protein in B cells.  
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Figure 3.16. Transcriptional regulation of CXCR7 by type 1 and type 2 EBNA-2 in DG75 cells 
5 x 106 DG75 cells were co-transfected with the pGL3b reporter plasmid, carrying the -1144/-36 promoter region of 
CXCR7 (10 µg), type 1 or type 2 EBNA-2-expressing vectors (OriP-p294) and the β-galactosidase reference vector 
(pCMV19-βGal, 2 µg) by electroporation. The EBNA-2 expressing vectors were titrated out by testing 5, 15 and 25 
µg of plasmid DNA. Tax-expressing vector (pJFE14) was used as positive control for CXCR7 promoter activation. 
Total amounts of plasmid DNA were normalised with empty vector. At 48 hours cells were harvested and analysed 
for luciferase and β-galactosidase activity. For each sample, luciferase values were corrected for transfection 
efficiency based on β-galactosidase reference values (RLU/β-Gal). Transfections were performed in triplicate. Error 
bars represent standard deviations. 1 representative experiment of 2 is shown.  
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Expression of EBNA-2 proteins, either type 1 or type 2, could not be detected on a western blot 
when 5 µg of plasmids were electroporated into DG75 cells, due to low transfection efficiency of 
this method. However, transfection by electroporation of the same amount (5 µg) of EBNA-2-
expressing plasmids in the same cell line was able to strongly activate an LMP-1 promoter-
reporter plasmid. Thus, to ensure that the lack of responsiveness displayed by the CXCR7 
promoter in the DG75 cell line in the presence of either type of EBNA-2 is a true phenomenon 
(Figure 3.16), a similar CXCR7 promoter-reporter assay was performed in a different cell line 
(Daudi) using a more efficient transfection method, the Neon system. The CXCR7 promoter-
reporter construct and the EBNA-2-expressing plasmids were co-trasfected into Daudi cells 
using the same transfection conditions (plasmid DNA doses and electroporation parameters) 
used to perform the LMP-1 promoter-reporter assays described in section 3.2.2.1.2. No 
significant differences were observed in luciferase activity from the pGL3b vector carrying the 
CXCR7 -1144/-36 promoter region, relative to the empty luciferase reporter plasmid, in the 
presence or absence of any type of EBNA-2 protein (Figure 3.17). HTLV-1 Tax protein induced 
a 3-fold increase in luciferase activity from the CXCR7 promoter-reporter construct compared to 
empy vector (Figure 3.17). The lack of transactivation of the CXCR7 promoter region -1144/-36 
by EBNA-2 seen in Daudi cells is consistent with the observations reported in the DG75 cell line 
(Figure 3.16) and similar results were also obtained in 2 non B cell lines (293 and HeLa 
epithelial cell lines). In summary, the data suggests that the -1144/-36 sequence of the CXCR7 
promoter can be transactivated by Tax but not by EBNA-2, either type 1 or type 2, in B cells and 
epithelial cells, suggesting that perhaps additional regulatory elements of the CXCR7 promoter 
will be required to confer EBNA-2 responsiveness.  
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Figure 3.17. Transcriptional regulation of CXCR7 by type 1 and type 2 EBNA-2 in Daudi cells 
2 x 106 Daudi cells were co-transfected with 2 µg of each of of the following plasmids: the luciferase reporter vector 
either with (pGL3b CXCR7 -1144/-36) or without (pGL3b e.v.) the CXCR7 promoter sequence, type 1 (T1 E2) or 
type 2 T2 E2) EBNA-2-expressing vectors (OriP-p294) and the β-galactosidase reference vector (pCMV19-βGal, 2 
µg) by Neon transfection. 2 µg of Tax-expressing vector (pJFE14) were transfected as positive control for CXCR7 
promoter activation. 24 hours after transfection cells were analysed for luciferase and β-galactosidase activity. 
Results are presented as luciferase values relative to β-galactosidase reference values, in order to correct for 
transfection efficiency (RLU/β-Gal). Transfections were performed in triplicate. Error bars represent standard 
deviations. 1 representative experiment of 3 is shown.  
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3.2.3  Differential regulation of LMP-1 and CXCR7 genes by type 1 and type 
2 EBNA-2 during infection of primary B cells 
The BL cell line-based assays used in this work (sections 3.2.1.1 and 3.2.1.2) and in previous 
studies from this laboratory [348], to demonstrate that type 1 and type 2 EBNA-2 differentially 
regulate LMP-1 and CXCR7, allow comparison of the kinetics of gene expression in response to 
EBNA-2 type 1 and type 2, in isolation from changes in the function of other EBV genes and 
from variables related to the process of infection or to B cell metabolism (e.g. virus entry and B 
cell activation). However, Daudi and P3HR1 cl. 16 cell lines, being BL tumour-derived cell 
lines, are likely to harbour many genetic mutations and therefore alterations in cell physiology or 
in cell signal pathways, such as the p53 and RB pathways [109,110]. Another approach that can 
be undertaken to investigate LMP-1 expression kinetics induced by type 1 and type 2 EBNA-2 is 
infection of human primary B lymphocytes, which represents a more physiological cell 
background, compared to Burkitt’s Lymphoma cell lines. Previous reports have analysed 
expression of LMP-1 and other EBV genes following infection of resting B cells with type 1 
virus [121,122], but a comparison with type 2 virus has not been reported up to date, and 
induction of CXCR7 upon EBV infection has not been previously analysed. Two infection 
assays have been developed in this study. Human primary B cells were infected with either the 
natural strains of EBV, B95-8 (type 1 prototype) and AG876 (type 2 prototype) (section 3.2.3.1), 
or with bacterial artificial chromosome (BAC)–derived B95-8 EBV containing either type 1 or 
type 2 EBNA-2 (section 3.2.3.2).  
 
3.2.3.1  Differential regulation of LMP-1 and CXCR7 genes by type 1 B95-8 virus 
and type 2 AG876 virus 
 
3.2.3.1.1  Generation of AG876 virus 
B95-8 viral preparations were already available in the laboratory but the AG876 virus was 
prepared in this study. The AG876 cell line is a BL cell line carrying the AG876 EBV genome 
[59]. In order to induce the EBV lytic cycle and subsequent virus release, the cells were 
transfected with caesium chloride-purified puro-OriP-ZHT plasmid (section 2.3.3.2.3) with the 
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Amaxa method, as described in section 2.2.6.2. Puromycin selection was applied 24 hours after 
transfection. After 3 weeks of selection, with re-feeding every 3 days, cells started to grow out. 
puro-OriP-ZHT plasmid codes for a chimaeric BZLF1 protein bearing at the C-terminus a 
modified oestrogen receptor domain (ZHT), which responds to 4-hydroxytamoxifen (4HT), a 
synthetic derivative of oestrogen, but not to oestrogen. Upon administration of 4HT, the ZHT 
fusion protein is translocated to the nucleus where it is stabilised and becomes functionally 
active. As BZLF1 function is switched on, the lytic cycle of EBV is therefore induced leading to 
release of viral particles from the cells. To test if the cell line obtained (AG876/ZHT) was able to 
produce virus, a pilot experiment was performed: 4HT was administered to the cells for 1, 3 or 7 
days, in order to identify the time-point at which there is the maximum viral release. At these 
time-points, both the culture supernatant and cell samples were collected. To test if lytic EBV 
replication had occurred in the stimulated cells, proteins were extracted with RIPA lysis buffer 
from cell samples and expression of BZLF1 was assessed by western blot (Figure 3.18). The 
analysis showed that ZHT was correctly expressed in AG876/ZHT cells at each time-point 
analysed, but not in non transfected AG876 cells. Moreover, stimulation of AG876/ZHT cells 
with 4HT, produced an increased expression and stabilization of the fusion protein and the 
highest level of expression of ZHT was obtained at 7 days after induction. The analysis 
confirmed that the AG876/ZHT cell line was stably expressing the ZHT protein and that BZLF1 
function was successfully induced by treatment with 4HT (Figure 3.18). To test if any virus was 
present in the supernatants collected from the stimulated AG876/ZHT cells at the same time-
points, 10-fold serial dilutions of each sample were used to infect Raji cells (section 2.2.11), 
which are highly susceptible to EBV super-infection. After 4 days, infected Raji cells were 
collected and protein extracts were analysed by western blot for EBNA-2 (Figure 3.19). As Raji 
cells express a type 1 EBNA-2, if any AG876 virus was present in the supernatants tested, the 
immunoblot analysis would show the appearance of the type 2 EBNA-2 band in addition to the 
endogenous type 1. This strategy showed that virus was released from AG876/ZHT cells after 7 
days of treatment with 4HT (Figure 3.19).  
The next step was therefore to produce the AG876 virus on a large scale by stimulating 
AG876/ZHT cells with 4HT for 7 days. At this time, the culture supernatant was harvested, the 
virus was concentrated by ultracentrifugation and aliquoted to be stored at -80 ºC, as described in 
section 2.2.8.  
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Figure 3.18. BZLF1 western blot analysis of protein extracts from AG876/ZHT cells 
AG876/ZHT cells were cultured with (+) or without (-) 4HT for 1, 3 or 7 days. At these time-points cells were 
harvested and proteins were extracted with RIPA lysis buffer and subjected to a western blot analysis for BZLF1 
using BZ1 mouse monoclonal antibody. β-actin immunoblot was used as a gel-loading control. A band between 46 
and 58 kDa, corresponding to the ZHT fusion protein, was detected in all samples from the AG876/ZHT cell line. 
The ZHT chimaeric protein is stabilized by treatment with 4HT. Proteins from AG876 cells treated with 4HT (+) or 
untreated (-) served as negative control. p.i.: post-induction. 
 
 
 
Figure 3.19. AG876 virus is released from AG876/ZHT cells after 7 days of treatment with 4HT 
Raji cells were infected with 4 10-fold serial dilutions (dil) of culture supernatants from AG876/ZHT cells cultured 
with (+ 4HT) or without (- 4HT) 4-hydroxytamoxifen for 1, 3 or 7 days. 4 days post-infection proteins were 
extracted and subjected to a western blot analysis for EBNA-2, with the PE2 antibody. The type 2 EBNA-2 band 
was detected in addition to the Raji endogenous type 1 band in cells infected with a 1:10 dilution of culture 
supernatant from AG876/ZHT cells treated with 4HT for 7 days (black oval). Jijoye: positive control for type 2 
EBNA-2; Raji: non-infected cells, positive control for type 1 EBNA-2. β-actin immunoblot was performed as 
loading control.   
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3.2.3.1.2  Titration of AG876 and B95-8 viral preparations 
 
To titrate the AG876 and B95-8 viral preparations several strategies were tested and will be 
described briefly in this section. Among these, western blot analysis of EBNA-1 expression 
levels induced by the two viruses upon infection of primary B cells eventually proved to be the 
most effective titration method and was used for the experments described in section 3.2.3.1.3.  
 
Titration of B95-8 virus is typically performed in this laboratory by using a semi-quantitative 
method that consists of infection of Raji cells with a range of viral doses and detection by 
western blot of expression of EBNA-LP, the first and most abundant latent protein expressed 
upon EBV infection. However this method was not useful for comparison of type 1 and type 2 
EBV since type 2 EBNA-LP lacks the JF186 antibody epitope. At the time the titration 
experiments were carried out, the anti-EBNA-LP 4D3 antibody (which detects both type 1 and 
type 2 EBNA-LP [465]) was not available in this laboratory. Hence, as an alternative strategy, 
the B95-8 and AG876 viruses were titrated by infecting primary B cells purified from buffy 
coats (section 2.2.12) with a range of viral doses and quantifying expression of EBNA-2 by 
intracellular staining and flow cytometry analysis (section 2.6.2). The percentage of infected 
cells expressing EBNA-2 was assessed as the fraction of FITC-positive cells (Figure 3.20 A). 
Good infectivity values were obtained when cells were exposed to B95-8 EBV (up to ~78 %) but 
less than 5% of the cells infected with any dose of AG876 virus expressed EBNA-2 (Figure 3.20 
A), revealing that this preparation had very low titres of infectious virus. Therefore it appears 
that the efficiency of virus production from the AG876/ZHT cell line, upon activation of the 
BZLF1 chimaeric protein with 4HT, is rather low. This was surprising as previous reports 
showed that virus release from a B95-8/ZHT stable cell line occurs with high efficiency [460]. 
Being able to produce only modest amounts of AG876 virus, the subsequent infection 
experiments could be performed only on a small scale.  
In the following titration experiment, a less quantitative approach was adopted, which involved 
detection of EBNA-2 expression levels by western blot analysis over a short time-course (Figure 
3.21). The viral doses used were determined on the basis of the previous titration experiment 
(Figure 3.20 B). Markedly lower expression levels of EBNA-2 were detected in AG876-infected 
cells, compared to cells exposed to B95-8 virus (Figure 3.21), suggesting that even lower 
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amounts B95-8 virus were needed in future experiments to obtain approximately equal type 1 
and type 2 EBNA-2 expression levels. LMP-1 could be detected by western blot in cells infected 
with the B95-8 virus, showing kinetics similar to those reported in previous studies [121,122], 
but not in AG876-infected cells (Figure 3.21). In summary, due to the small amount of virus 
available, this infection assay proved not to be sufficiently sensitive to detect LMP-1 at the 
protein level. I therefore decided to investigate LMP-1 kinetics of induction in type 1 and type 2 
EBV-infected cells at the transcriptional level, by RT-PCR.  
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Figure 3.20. Titration of AG876 and B95-8 viral preparations by infection of human primary B cells and 
quantification of EBNA-2 expression by intracellular staining and flow cytometry analysis 
2 x 10 6 human primary B cells were infected with 2-fold serial dilutions of B95-8 and AG876 viral preparations 
(200, 100, 50, 25 and 12.5 µl). 48 hours after infection, cells were fixed, permeabilized and stained for EBNA-2 
using the mouse PE2 antibody (at 1:50 dilution) and subsequently a FITC-labelled anti-mouse secondary antibody 
(section 2.6.2). Stained cells were analysed by flow cytometry in order to measure the fraction of FITC-positive 
cells, representing the population of infected cells expressing EBNA-2. Histograms obtained by flow cytometry 
analysis are reported in the Appendix (Supplementary Figure 6). (A) Values of EBNA-2-positive cells and mean 
fluorescence intensity (MFI) for each dose of either B95-8 or AG876 viral preparation used are shown. (B) Line 
chart showing values of the fraction of infected cells (FITC-positive) plotted against the doses of B95-8 viral 
preparation used (in µl). A polynomial trend-line represents the best fit of the data. The equation and the R-squared 
value of the trend-line are shown. The plot was used to extrapolate the dose of B95-8 preparation (1-6 µl) to use in 
future experiments in order to achieve an infectivity value of 5, as obtained with the highest dose of AG876 viral 
preparation (200 µl).  
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Figure 3.21. Titration of AG876 and B95-8 viral preparations by infection of primary B cells and detection of 
EBNA-2 on a western blot 
2 x 106 primary B cells were infected with either B95-8 (1 and 6 µl) or AG876 (200 µl) virus. Doses of viruses were 
determined based on the experiment illustrated in Figure 3.20. At 1, 2, 4 and 6 days after infection, cells were 
harvested, proteins were RIPA-extracted and analysed by western blot in order to detect EBNA-2 (PE2 antibody) 
and LMP-1 (CS 1-4 antibody). A short (1’) and a long (15’) exposition of the EBNA-2 immunoblot were performed 
in order to detect the AG876 EBNA-2. Mock-infected cells harvested ad the day 0 time-point were included in the 
analysis. Protein samples from the cell lines B95-8 and AG876 were used as positive control (+). The β-actin 
immunoblot ensured that the total levels of proteins did not alter throughout the experiment. The analysis indicates 
that amounts of B95-8 virus lower than 1 µl are required to give EBNA-2 expression levels similar to those obtained 
with the highest dose (200 µl) of AG876 virus. 
 
 
3.2.3.1.3  Infection of primary B cells with type 1 B95-8 EBV and type 2 AG876 EBV 
In order to compare LMP-1 and CXCR7 regulation in primary B cells infected with type 1 and 
type 2 EBV, aliquots of 2 x 106 primary B lymphocytes were infected with either AG876 viral 
preparation (200 µl) or with 2-fold serial dilutions of B95-8 EBV preparation (1.2, 0.6 and 0.3 
µl). The amounts of virus used were determined on the basis of the titration experiments 
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described in figures 3.20 and 3.21. Because only moderate amounts of AG876 virus were 
available, due to the low efficiency of viral release from the AG876/ZHT producer cell line 
(described in section 3.2.3.1.2), the infection experiment was carried out on a small scale and 
EBNA-2 target gene expression was analysed at a single time-point post-infection at the RNA 
level by RT-PCR analysis. A 6 day time-point was chosen, in order to allow enough time for 
viral gene expression, as suggested by preliminary experiments (Figure 3.21) and previous 
reports [121,122]. The titres of the 2 viral preparations were compared based on expression 
levels of EBNA-1 on a western blot, a titration method already used in previous studies [414]. 
The analysis revealed that, among the type 1 EBV dilutions tested, the 0.3 µl dose produced 
EBNA-1 expression levels approximately equal to those detected in AG876-infected cells 
(Figure 3.22 A). However, despite equal expression of EBNA-1, in AG876-infected cells EBNA-
2 was less expressed than in cells infected with B95-8 (0.3 µl), as assessed by immunoblotting 
with the PE2 antibody (Figure 3.22 A). This might indicate weaker transcriptional activity of the 
AG876 Wp promoter, compared to that of the B95-8 Wp, during the early stages of infection. 
Nevertheless, RT-PCR analysis was carried out on the RNA samples, and this showed that the 
mRNA levels for LMP-1 and CXCR7 were markedly lower in AG876-infected cells compared 
to cells infected with B95-8 (Figure 3.22 B) and this difference was much stronger than the 
difference in type 1 and type 2 EBNA-2 expression levels (Figure 3.22 A). Even though these 
results are not quantitative, they are consistent with the data obtained using the Daudi and 
P3HR1 cl.16:ER-EBNA-2 cell line systems (sections 3.2.1.1 and 3.2.1.2) showing that the 
EBNA-2 target genes LMP-1 and CXCR7 are less potently activated by the type 2 EBNA-2 
protein, compared to the type 1. The data therefore suggest that differential regulation of those 
genes by type 1 and type 2 EBNA-2 does occur also during primary infection. Because the 
infection system described in this section was not sensitive enough, a more quantitative infection 
assay was devised in order to detect and compare type 1 and type 2 EBNA-2 specific patterns of 
gene regulation. This was infection of primary B cells with BAC-derived EBV recombinant 
viruses. 
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Figure 3.22. Infection of primary B cells with AG876 and B95-8 EBV 
106 primary B cells were infected with either a range of 2-fold serial dilutions of B95-8 EBV preparation (1.2, 0.6 
and 0.3 µl) or a single dose of AG876 virus (200 µl). 6 days after infection, cells were harvested, proteins and total 
RNA were extracted and analysed by western blot (A) and RT-PCR (B) respectively. Mock-infected cells harvested 
ad the day 6 time-point were also analysed. (A) Protein samples were analysed for expression of EBNA-2 (PE2) and 
EBNA-1. Cell lysates from B95-8 and AG876 cell lines served as positive control (+). The β-actin immunoblot 
served as loading control. (B) Total cell RNA was retrotranscribed into cDNA and this was then analysed by PCR 
with LMP-1, CXCR7 and GAPDH specific primers. B95-8 (+): positive control; ntc: no template control. 1 
representative experiment of 2 is shown. 
196 
 
3.2.3.2  Differential regulation of LMP-1 and CXCR7 genes by BAC-derived EBV 
expressing type 1 or type 2 EBNA-2 
 
3.2.3.2.1  Generation of a type 2 EBNA-2 EBV-BAC recombinant virus 
In order to examine viral and host gene regulation by type 1 and type 2 EBNA-2 in EBV-
infected primary B cells, an infection assay with BAC-derived EBV recombinant viruses was 
devised. A type 1 B95-8 EBV-BAC [447] was available in the laboratory and will be called T1 
E2 EBV-BAC in this study. The type 1 EBNA-2 ORF in this construct was substituted with a 
type 2 EBNA-2 sequence by RecA-based homologous recombination in E. coli, as described in 
section 2.3.3.3.3, generating the T2 E2 EBV-BAC construct. The integrity of this EBNA-2 BAC 
mutant was screened by PCR and restriction digestion analysis on pulsed field gels, as reported 
in section 2.3.3.3.3. The type 2 EBNA-2 EBV-BAC, which contains a hygromycin-resistance 
gene, was then transfected into 293 cells and clonal cell lines resistant to hygromycin were 
selected (section 2.2.6.4). Generation of 293-T2 E2 EBV-BAC cell lines and screening of 
positive clones was carried out by Rachel Bosshard. One clonal cell line carrying a correct T2 E2 
EBV-BAC construct was used for all the experiments described below. A 293 clonal cell line 
with the T1 E2 EBV-BAC construct was already available in the laboratory [173,447]. As the 
BAC vector contains a GFP-cassette, to ensure that the 293 cell lines stably carry the EBV-BAC 
constructs, the cells were analysed by flow cytometry and green fluorescence was measured at 
the cell population level. 100% of the type 2 EBNA-2 EBV-BAC-transfected 293 cells analysed 
were GFP-positive (Supplementary Figure 7 in the Appendix). To further screen the integrity of 
the type 1 and type 2 EBNA-2 recombinant EBVs in the 293 producer cells, episomal BAC 
DNA was rescued from the clonal cell lines by preparation of low molecular weight DNA 
(section 2.3.3.1.2) and amplification in E. Coli (section 2.3.3.1.11). Individual colonies were 
selected and small scale preparations of the BAC DNA (section 2.3.3.1.13) were analysed by 
restriction digest and pulsed field gel analysis. Examples are reported in the Appendix 
(Supplementary Figure 8). The analysis revealed that the type 2 EBV BAC recovered from the 
293 cell lines had not suffered any alterations or rearrangements compared to the construct 
originally used to establish the 293 stable clones (see section 2.3.3.3.3).  
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In order to check that the type 2 EBNA-2 was expressed correctly from the EBV-BAC construct 
in the 293 stable cell line, protein extracts were prepared by RIPA extraction and analysed by 
western blotting using the PE2 antibody. Protein samples from the 293-T1 E2 EBV-BAC cell 
line were also analysed. No EBNA-2 expression could be detected from the type 1 or the type 2 
cell line (Figure 3.23) However, immunoblot analysis for LMP-1 revealed that the latent 
membrane protein is expressed in both cell lines, suggesting that perhaps the epithelial cell line 
293 does not support a latency III type of infection, but rather a latency II pattern of gene 
expression (see Table 1.1). However, this would need to be confirmed by testing expression of 
other EBV latent gene products in the 293 producer cell lines. Thus, to ensure that the type 2 
EBNA-2 protein was appropriately expressed from the T2 E2 EBV-BAC construct, infectious 
virus was obtained from the 293 producer cell lines and tested in primary B cells (see later).  
 
 
 
 
Figure 3.23. Western blot analysis for EBNA-2 and LMP-1 expression in the 293-T1 and T2 EBV-BAC cell 
lines 
Protein samples were prepared by extraction with RIPA lysis buffer from 293 T1 and T2 E2 EBV-BAC cell lines 
and 30 µg of proteins were analysed by SDS-PAGE followed by immunoblot analysis for EBNA-2 (PE2 clone) and 
LMP-1 (CS 1-4). 2 clonal 293-T2 EBV-BAC cell lines were analysed. Non-transfected (n.t.) 293 cells were included 
in the analysis. B95-8 and AG876: positive controls for type 1 and type 2 EBNA-2 expression respectively. 
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Infectious virus was generated from 293 producer cells by transient transfection of BZLF1 and 
BALF4 expression plasmids [457,458], as described in section 2.2.9. Expression of BZLF1 in 
the transfected cells causes the induction of EBV lytic reactivation and subsequent release of 
viral particles containing the recombinant EBV genomes. The infectivity of the 293 cell culture 
supernatants was measured by infecting Raji cells and quantifying GFP-positive cells as 
described in section 2.2.11. An example of typical titres normally obtained for the type 1 and 
type 2 EBNA-2-expressing EBV-BAC recombinant viruses is reported in figure 3.24. The viral 
preparations were then used to infect human primary B cells and analyse expression of EBNA-2 
and of its target genes. 
 
 
 
 
Figure 3.24. Titration of T1 and T2 E2 EBV-BAC viral preparations by super-infection of Raji cells 
10-fold serial dilutions of the cell culture supernatants from 293-T1 E2 EBV BAC and 293-T2 E2 EBV-BAC stable 
cell lines transfected with BZLF1 and BALF4-expressing plasmids were titred by infecting Raji cells. Infectivity is 
expressed as the number of GFP-expressing cells (GRU), counted on an inverted fluorescent microscope, for each µl 
of viral preparation (GRU/µl). Duplicate viral preparations for each recombinant type were titrated and titrations 
were performed in duplicate. Error bars represent standard errors. 
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3.2.3.2.2  Comparison of LMP-1 and CXCR7 expression levels induced by type 1 and type 
2 EBNA-2 EBV-BAC viruses during infection 
In order to compare regulation of both host and viral genes by type 1 and type 2 EBNA-2 during 
infection of primary B cells with BAC-derived EBV recombinant viruses, expressing either type 
1 or type 2 EBNA-2, normalised amounts (5000 GRUs) of the EB viruses were used to infect 
aliquots of 2 x 106 human primary B cells, purified from peripheral blood. Early stages of 
infection were studied since the differences in kinetics of gene regulation induced by the two 
types of EBNA-2 appeared rapidly in the cell line-based systems (sections 3.2.1.1 and 3.2.1.2). 
Hence, cells were harvested at 1, 2, 4 and 8 days post-infection and proteins and total RNA were 
extracted and analysed by western blotting and RT-PCR, respectively (Figure 3.25). 
Approximately similar amounts of type 1 and type 2 EBNA-2 proteins were expressed, as 
determined by the EBNA-2 immunoblot (Figure 3.25 A). Detection of the type 2 EBNA-2 
protein by western blot confirmed that the type 2 EBNA-2 ORF was cloned in frame in the T2 
E2 EBV-BAC construct. GAPDH levels at 4 and 8 days post-infection were somewhat lower in 
type 2-infected cells compared to type 1-infected cells, due to faster proliferation of the latter 
(Figure 3.25 A).  
RT-PCR analysis for EBNA-2 target gene expression revealed that in type 1 EBV-infected cells, 
LMP-1 transcripts were detected as soon as 2 days post-infection and gradually increased 
thereafter, reaching typical LCL levels of expression by day 8. In contrast, in type 2-infected 
cells LMP-1 induction was delayed and the mRNA could be detected only at day 8 post-
infection, with overall lower levels than those observed in type 1 infection (Figure 3.25 B). This 
kinetics of LMP-1 mRNA induction was observed consistently in 4 independent infection 
experiments, although the overall level of expression and precise timing varied slightly in 
different experiments, this variability perhaps being due to different B cell donors being used 
each time. As these experiments could be performed only on a small scale, LMP-1 protein could 
not be detected by western blotting at these early times after infection.  
Induction of cyclin D2 expression is an early event following EBV infection of B lymphocytes 
and depends on EBNA-2 and EBNA-LP expression [138]. In contrast to LMP-1, cyclin D2 
mRNA levels were up-regulated as soon as day 1 post-infection and were thereafter maintained 
at equal levels in both type 1 and type 2 EBNA-2-infected cells, suggesting that the initial G0/G1 
transition after EBV infection may occur in similar fashion in type 1 and type 2-infected B cells 
200 
 
(Figure 3.25 B). Likewise, no significant differences were observed with the two types of 
recombinant viruses in transcript levels of the proto-oncogene c-MYC, a well-established target 
of EBNA-2 [336] (Figure 3.25 B).  
RT-PCR analysis for CXCR7 mRNA revealed that uninfected resting B cells, harvested at day 0, 
already expressed substantial basal amounts of mRNA (Figure 3.25 B), an observation consistent 
with other reports [369,389]. Following viral infection, CXCR7 mRNA was present in type 1-
infected cells at each point in the time-course (Figure 3.25 B). On the other hand, in type 2 
infection the mRNA for CXCR7 was transiently down-regulated at day 2, but not completely 
eliminated, and then re-induced at day 4 and maintained thereafter, albeit at lower levels than 
those detected in type 1 virus-infected cells (Figure 3.25 B). This trend in CXCR7 mRNA levels 
was observed consistently in 3 independent experiments, with minor differences in the overall 
levels of expression. Further studies (Figure 3.26) suggest that CXCR7 mRNA is down-regulated 
immediately after EBV infection but is re-induced much more rapidly by type 1 EBNA-2 than 
type 2 EBNA-2, giving the appearance of continuous expression in the type 1 EBNA-2 time 
course reported in Figure 3.25 B. The down-regulation of CXCR7 upon EBV infection probably 
results from signal transduction during the infection process since it also occurs with UV-
inactivated EBV (Figure 3.26 B) and even treatment with TPA is sufficient to cause the rapid 
down regulation of CXCR7 mRNA in primary human B cells (Figure 3.26 B). Removing the 
EBV from the virus preparation by ultracentrifugation abolished the down regulation of CXCR7 
mRNA, confirming that this was not caused by a low molecular weight contaminant of the virus 
preparation (Figure 3.26 B). 
Expression of the chemokine receptor CXCR4, which shares the ligand CXCL12/SDF-1 with 
CXCR7, has been shown to be down-regulated in primary B cells upon infection by EBV 
[471,472,473]. Uninfected primary B cells were found to express high levels of CXCR4 mRNA 
(Figure 3.25 B), in agreement with other reports [474]. Upon viral infection, CXCR4 transcript 
levels were effectively repressed in cells infected with both type 1 and type 2 EBNA-2 
recombinant EB viruses, although the kinetics of down-regulation were slightly faster in type 1-
infected cells (Figure 3.25 B). 
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Figure 3.25. Differential regulation of LMP-1 and CXCR7 genes during infection of primary B cells with 
BAC-derived EBV expressing type 1 or type 2 EBNA-2 
2 x 106 primary B cells isolated from peripheral blood by negative selection were infected with 5000 GRUs of either 
T1 E2 EBV-BAC (expressing type 1 EBNA-2) or T2 E2 EBV-BAC (type 2 EBNA-2) recombinant viruses. Cells 
were harvested at 1, 2, 4 and 8 days post-infection and processed for protein and total RNA extraction. Uninfected 
cells, harvested at day 0, were included in the analysis. (A) Whole protein extracts from each well of infected cells 
were loaded on an SDS-PAGE gel and subjected to western blot analysis using the anti-EBNA-2 antibody (PE2 
clone) and the anti-CXCR7 antibody. Numbers alongside the CXCR7 immunoblot panel represent protein apparent 
molecular weight (kDa). The blots were re-probed for GAPDH to show the total amount of protein recovered from 
each sample. (B) RT-PCR analysis of total cell RNA using LMP-1, CXCR7, CXCR4, cyclin D2, c-MYC and 
GAPDH specific primers. RNAs from LCLs established with T1 and T2 EBNA-2 EBV-BAC were included in the 
analysis. p.i.: post-infection; ntc: no template control. 1 representative experiment of 4 is shown. 
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Figure 3.26. Early regulation of CXCR7 in primary B cells following either TPA treatment or infection with 
type 1 EBV recombinant virus (UV-treated or untreated) 
2 x 106 primary B cells negatively selected from peripheral blood were either infected with 5000 GRUs of type 1 
EBNA-2 EBV-BAC virus (untreated or UV-inactivated), treated with TPA (30 ng/ml), stimulated with the 
supernatant obtained by ultracentrifugation of the viral preparation or left uninfected (mock). Cells were harvested at 
1 and 3 days post-infection and processed for protein and total RNA extraction. Uninfected cells, harvested at day 0, 
were included in the analysis. (A) Whole protein extracts from each well of infected cells were analysed by western 
blot analysis using the anti-EBNA-2 antibody (PE2) and the blots were re-probed for β-actin to ensure that the total 
amount of protein in each sample is identical. (B) Total cell RNA was subjected to RT-PCR analysis for CXCR7 
and GAPDH. RNA from LCLs established with type 1 EBNA-2 (T1) EBV-BAC was included as a positive control. 
p.i.: post-infection; ntc: no template control. 1 representative experiment of 2 is shown. 
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3.2.3.2.3  Detection of CXCR7 protein in type 1 and type 2 EBNA-2 EBV-BAC-infected 
primary B cells 
To detect CXCR7 protein during infection with type 1 and type 2 EBNA-2 BAC viruses, protein 
samples were analysed by western blotting with an antibody specific for CXCR7. The antibody 
used (Table 2.3) detects: a ~50 kDa band, which is believed to be the unmodified protein, and 
also protein species of 76-102 kDa and of >150 kDa of molecular weight. These are likely to be 
CXCR7 isoforms with modest (76-102 kDa) and high (>150 kDa) levels of glycosylation, as 
suggested by experiments with an inhibitor of protein glycosylation (see Supplementary Figure 
10 in the Appendix). Low levels of total CXCR7 were detected in uninfected B cells, with no 
unmodified protein (50 kDa) and very modest amounts of >150 kDa highly-glycosylated species 
detected (Figure 3.25 A). Clear up-regulation of the protein was observed following infection 
with the type 1 recombinant virus, with all 3 species of CXCR7 being detected (Figure 3.25 A). 
In type 2-infected cells, after an initial induction at day 1, the protein levels subsequently 
decreased, with a complete disappearance of the smaller isoform. However, the GAPDH signal 
in type 2-infected cells also decreases throughout the time-course presumably due to slower 
proliferation and increased cell death compared to type 1-infected lymphocytes. Collectively, the 
data suggests that there are no major differences in CXCR7 protein expression levels in type 1 
and type 2 EBV-BAC-infected cells. 
 
In order to detect surface expression of CXCR7 protein during infection with type 1 and type 2 
EBNA-2-expressing recombinant EB viruses, infected cells were live stained with an APC cross-
linked anti-human CXCR7 antibody (section 2.6.1) and analysed by flow cytometry. Cells were 
analysed 2 days after infection, since previous RT-PCR analysis of CXCR7 mRNA expression 
levels (Figure 3.25 B) indicated that at this time-point there is the largest difference between type 
1 and type 2-infected cells. Expression levels of EBNA-2, type 1 and type 2, at this time-point 
were found to be approximately similar, as assessed by western blot (Figure 3.26 C). The flow 
cytometry analysis showed that CXCR7 is expressed on the surface of a small fraction (5.5%) of 
uninfected cells and is up-regulated (approximately 20% of CXCR7-positive cells) following 
infection with both types of recombinant viruses (Figure 3.27 A and B). In this experiment there 
were no major differences between type 1 and type 2 EBNA-2-infected cells (21.4% and 19.8 % 
of CXCR7-positive cells respectively). However this was not consistently observed in 
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independent experiments: in two other experiments differences up to approximately 2-fold were 
observed, with higher amounts of surface CXCR7 detected in type 1 infection (an example is 
shown in figure 3.28). Hence, based on the experiments performed so far, it is not possible to 
conclude whether there are differences in CXCR7 surface protein abundance in type 1 and type 2 
EBNA-2 infected cells.  
The scatterplots obtained by flow cytometry analysis (Figure 3.27) indicated that in mock-
infected samples there is one homogeneous population, which displays the typical profile of 
resting B lymphocytes (gate R3, Figure 3.27). In contrast, following EBV infection a second 
population is detected in addition to that observed in mock cells. This is likely to represent 
activated B lymphocytes and therefore the fraction of cells that has been efficiently infected by 
the virus. Further analysis will be required to ensure this is the case. In order to identify the 
population of infected cells, staining for a marker of activated B lymphocytes (i.e. CD21) could 
be included in the analysis. Unfortunately, GFP expression levels cannot be used as a marker of 
infection efficiency in these cells as in multiple experiments expression of this fluorochrome 
from the EBV-BAC construct in B cells could not be detected consistently.  
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Figure 3.27. Detection of CXCR7 surface expression by flow cytometry in type 1 and type 2 EBNA-2 EBV-
BAC-infected primary B cells 
1 x 106 primary B cells were either infected with 2500 GRU of the EBV-BAC recombinant viruses (expressing type 
1 or type 2 EBNA-2) (B) or left uninfected (mock) (A). After 2 days, cells were harvested and stained with an APC-
conjugated anti-human CXCR7 antibody (CXCR7-APC), or with an APC-crosslinked isotype control antibody (iso-
APC). Mock-infected cells were stained at the day 0 time-point. Cells were analysed by flow cytometry. The left-
hand side panels represent dot plot of the forward and side scatter profile of the mock (A) and virus (B) -infected 
cells. The gated population is marked by the oval (R3). The right-hand side panels represent histogram plots 
showing the fluorescence profile of stained cells detected in the APC channel for either mock-infected (A) or virus-
infected (B) cells. R8 shows the percentage of fluorescent cells and is set in order to have < 1 % of fluorescent 
mock-infected cells stained with the isotype antibody. In each histogram plot the percentage of APC (CXCR7)-
positive cells is shown. (C) Western blot analysis of protein extracts prepared at either the day 0 time-point (mock) 
or at 2 days post-infection (T1 and T2 EBNA-2 EBV-BAC-infected cells). Samples were tested for EBNA-2 
expression with the PE2 antibody. β-actin immmunoblot served as loading control.  
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Figure 3.28. CXCR7 surface expression measured by flow cytometry in type 1 and type 2 EBNA-2 EBV-BAC-
infected primary B cells 
The experiment was performed in the same way as for that described in figure 3.27. (A) Uninfected (mock) primary 
B cells were stained with APC-crosslinked isotype control antibody (iso-APC), immediately after isolation from 
buffy coat. R4 represents the percentage of fluorescent cells and is set at 1%. (B) B cells infected with EBV-BAC 
recombinant viruses expressing either type 1 (T1 E2 EBV-BAC) or type 2 (T2 E2 EBV-BAC) EBNA-2 were stained 
with the APC-conjugated anti-CXCR7 antibody (CXCR7-APC) 2 days after infection. The percentage of APC 
(CXCR7)-positive cells, is shown.  
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3.2.3.2.4  Establishment and characterization of type 1 and type 2 EBNA-2 EBV-BAC 
LCLs  
In order to establish LCLs, serial dilutions of preparations of EBVs expressing type 1 or type 2 
EBNA-2 were used to infect primary B lymphocytes (106 cells) and their outgrowth was 
monitored over time (described in section 2.2.13). Transformed foci appeared within a few 
weeks after infection with both type 1 and type 2 virus. As expected, type 1 EBV-BAC-infected 
cells grew very rapidly, and could be transferred from 24-well plates into tissue culture flasks 
within approximately 1 month from when the first foci appeared. In contrast, type 2 
transformants were much more difficult to expand, especially at the early stages, and culture 
volumes larger than the 24-well format were obtained only approximately 4 months after initial 
infection. The growth phenotype observed with the EBV-BAC recombinant viruses expressing 
either type 1 or type 2 EBNA-2 is consistent with the growth behaviour originally reported for 
the natural strains of EBV B95-8 (type 1 prototype) and AG876 (type 2 prototype) [414]. These 
differences in growth kinetics, which were revealed by microscopic observation of the cells in 
culture, were mirrored by the counts of proliferating cells assessed at a single time-point after 
infection, for each of the cell lines originally infected with serial dilutions of virus (Figure 3.29). 
For example, the amount of live cells counted in type 1 LCLs originally infected with either 
1600 or 320 GRUs of viral preparation was increased compared to the corresponding type 2 
transformants by 53 and 22-fold, respectively (Figure 3.29).  
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Figure 3.29. Live cell counts of type 1 and type 2 EBNA-2 EBV-BAC transformants 
106 primary B cells were either left uninfected (mock) or infected with 5-fold serial dilutions of recombinant EBVs 
starting with 8000 GRUs of T1 or T2 E2 EBV-BAC recombinant viruses, which express either type 1 or type 2 
EBNA-2 respectively. Infected cells were maintained in culture over time in order to establish LCLs and 1 month 
after infection differences in cell proliferation levels were assessed by counting the number of live cells on a 
haemocytometer. Error bars represent standard deviations. Data from 1 representative experiment of 2 is shown.  
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Once LCLs were established and large culture volumes were available, hygromycin selection 
was applied to ensure the cells contained the BAC-EBV constructs, which bear the hygromycin-
resistance gene, and not an EBV genome that might potentially have been endogenous at a low 
level in the donor B cells. Because type 1 LCLs were established much earlier than the type 2 
cell lines, the former were frozen and stored in liquid nitrogen after hygromycin selection and 
resuscitated when the type 2 LCLs were available for analysis. The fully established type 1 and 
type 2 EBNA-2 LCLs, growing in hygromycin-free medium, were then further checked by 
examining the pattern of expression of all the EBV latent antigens, using western blotting 
(Figure 3.30). The EBV latent antigens examined were expressed at similar levels in type 1 and 
type 2 LCLs and displayed the expected size. An exception was represented by EBNA-LP, as a 
3-repeat isoform was detected in the type 2 LCL, whereas type 1 transformants expressed 
EBNA-LP species with 5 and 4 repeats and in 1 of the type 1 clones also a 3-repeat isoform was 
detected (Figure 3.30). In both viruses the EBNA-LP is type 1 (detected by the JF186 antibody). 
This is consistent with the loss of 2 BamHI W repeats, relative to the parental type 1 EBV-BAC 
construct (described in section 2.3.3.3.3). This variation is not likely to affect transformation 
efficiency of the two types of recombinant viruses, since EBNA-LP proteins with a number of 
repeats above 2 have been shown to be functionally equivalent at enhancing EBNA-2-mediated 
activation of LMP-1 and viruses with 2 BamHI W repeats are immortalisation competent 
[140,189,190,191]. Additional minor variations in expression levels were detected in EBNA-3A, 
-3B and CXCR7 but these do not seem to be consistently linked to 1 specific type of LCL 
(Figure 3.30).  
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Figure 3.30. Validation of type 1 and type 2 EBNA-2 EBV-BAC LCLs 
Western blot analysis of latency-associated EBV proteins in LCLs established with type 1 (T1) and type 2 (T2) 
EBNA-2 (E2) EBV-BAC viruses. 4 clones of type 1 LCLs and one type 2 LCL were analysed. Proteins were 
extracted with RIPA buffer and subjected to SDS-PAGE analysis followed by immunoblotting with antibodies 
specific for the human CXCR7 protein and the EBV latent proteins EBNA-2 (PE2), EBNA-LP (JF186), EBNA-1, 
EBNA-3A, -3B, -3C and LMP-1 (CS 1-4). High (150 kDa) and low (76-102 kDa) glycosylated CXCR7 species, but 
no unmodified CXCR7 protein (~50 kDa) were detected with the anti-CXCR7 antibody. Re-probing with anti-β-
actin antibody ensured that equal amounts of proteins were loaded on the gel. 
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3.3  Discussion  
The most striking biological difference between type 1 and type 2 EBV is that type 1 strains are 
far better than type 2 at inducing primary B lymphocyte transformation in vitro. The EBNA-2 
gene is the key determinant of this difference and therefore defines the EBV viral types 
[155,414]. The results reported in this chapter demonstrate a mechanism that accounts for the 
superior B cell growth-transforming ability of type 1 EBV. Primary B cell infection experiments 
using BAC-derived recombinant EB viruses showed that higher and more rapid induction of 
some EBNA-2 target genes (which are required for continuous proliferation of EBV-infected 
LCLs) by type 1 EBNA-2-expressing virus correlates with the enhanced B cell transforming 
capability of this virus (Figures 3.25 and 3.29). In this study the focus was on two genes among 
all the direct target genes of EBNA-2, based on their crucial importance in B cell proliferation in 
the context of EBV infection: these are the viral oncogene LMP-1 and the cell gene CXCR7. 
Among the viral EBNA-2 targets, LMP-1 is the most important EBV oncogene and is required 
not only for initiation of primary B cell transformation in vitro [156] but also for maintenance of 
continuous proliferation of EBV-infected LCLs [89] (reviewed in section 1.6.5). Among the cell 
genes, CXCR7 was previously identified in this laboratory by whole host genome microarray 
screening as the most differentially regulated gene by the two types of EBNA-2 transcription 
factors, being more strongly induced by the type 1 [348]. Furthermore, CXCR7 was shown to be 
required for proliferation and survival of EBV-LCLs [348]. The time-course analysis of 
induction of LMP-1 and CXCR7 mRNAs during the initial stages of primary B cell infection 
with type 1 or type 2 EBNA-2 BAC-EBV, revealed that with type 2 EBNA-2 LMP-1 induction 
is delayed and weaker compared to type 1 EBV-infected cells, and CXCR7 expression levels are 
not maintained consistently throughout the time-points analysed (Figure 3.25 B). However, once 
a type 2 LCL is eventually established (up to 4 months after infection, with a delay of 
approximately 3 months compared to type 1 LCLs), LMP-1 and CXCR7 expression levels are 
similar to those detected in type 1 LCLs (Figure 3.25 B), confirming that those genes are 
essential for long-term proliferation of EBV-LCLs. The results therefore indicate that the key 
difference in transformation efficiency between type 1 and type 2 EBV is determined by 
differences in induction of the pro-survival genes LMP-1 and CXCR7 occurring during the early 
stages of infection.  
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Differential regulation of LMP-1 and CXCR7 by the two types of EBNA-2-expressing viruses 
during infection is consistent with the results obtained in cell line based assays. In fact, in Daudi 
and P3HR1 cl.16 cell line backgrounds, using oestrogen-regulated EBNA-2 proteins, LMP-1 
(mRNA and protein) and CXCR7 mRNA were shown to be more potently and rapidly induced 
by the type 1 EBNA-2 (sections 3.2.1.1 and 3.2.1.2).  
Regulation of LMP-2A, another EBNA-2 viral target gene, was not analysed in the infection 
assay as it is not an essential gene for EBV-mediated immortalisation of B lymphocytes in vitro 
[163,164,166,167]. Furthermore, RPA analysis of the LMP-2A gene in the Daudi:ER-EBNA-2 
T1/T2 system showed that type 1 and type 2 ER-EBNA-2 proteins induce LMP-2A mRNA fairly 
similarly (Figure 3.2). Therefore, the lack of differential regulation of LMP-2A by type 1 and 
type 2 EBNA-2 suggests that this EBNA-2 target gene does not account for the differing 
transforming ability of type 1 and type 2 EBV viruses. 
The proto-oncogene c-MYC was one of the first host genes identified as targets of EBNA-2 
transcriptional regulation. Although involved in control of cell growth and survival, in the 
infection assays no clear differences in c-MYC RNA levels induced in type 1 and type 2 EBV-
BAC-infected B cells were detected (Figure 3.25 B). These observations suggest that regulation 
of c-MYC in EBV-LCLs by the two types of EBNA-2 occurs in a similar fashion and does not 
account for the superior transforming ability of type 1 EBV.  
 
The finding that the CXCR7 gene, together with LMP-1, accounts for the greater transforming 
potential of type 1 EBV, compared to type 2, is particularly relevant in light of the fact that two 
other oncogenic viruses, HTLV-1 and KSHV, have been shown to induce this gene during 
infection. CXCR7 induction by HTLV-1 Tax protein has been reported to have a pro-survival 
effect on HTLV-1-infected T cells and in KSHV-infected hDMVECs induction of CXCR7 is 
essential for spindle cell transformation, much as occurs with EBV-mediated B cell 
transformation [389,397,399,400,401]. Targeting of CXCR7 may therefore represent a common 
mechanism exploited by oncogenic viruses to induce cell transformation. Extensive literature 
exists on the biological effects of CXCR7 in cancer cells (see section 1.8), however less is 
known about the underlying mechanism. Indeed the mechanism by which CXCR7 contributes to 
type 1 and type 2 EBV EBNA-2-induced cell transformation will merit further investigation. 
CXCR7 binds to the same ligand as CXCR4 (CXCL12/SDF-1), and has been proposed to 
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function as a modulator of CXCR4-mediated signalling, either by acting as a decoy receptor, to 
sequester CXCL12, or by heterodimerizing with CXCR4 [370,371,372]. Several reports indicate 
that CXCR4 is down-regulated in primary B cells upon infection by EBV [471,472,473] and this 
was confirmed in the RT-PCR time-course analysis during infection with type 1 and type 2 
EBNA-2 recombinant viruses (Figure 3.25 B). Nakayama et al. reported that while high levels of 
CXCR4 are detected in resting primary B cells, the receptor is expressed only at low levels in 
EBV-immortalised LCLs [472]. Ehlin-Nilsson and colleagues also reported down-regulation of 
CXCR4 on the plasma membrane of EBV-infected LCLs and the subsequent impairment of 
CXCL12/SDF-1-induced migration of tonsillar B cells infected with EBV in vitro [473]. It has 
been suggested that, since CXCL12/SDF-1 production has been detected in the crypts and the 
outer epithelium of the tonsils, which is the site of virus entry, a change in the response of EBV-
infected B cells to CXCL12/SDF-1 may serve as a viral strategy to direct the infected cells to the 
extrafollicular areas, rather than retaining them into the lymphoid epithelium through the 
CXCL12/SDF-1 axis [473].  
At least 5 EBV latent proteins have been found potentially to be involved in modulation of 
CXCR4 expression in EBV-LCLs. Stable expression of EBNA-2 and LMP-1 in the EBV-
negative BJAB cell line was shown to induce down-regulation of CXCR4 [472]. Moreover, 
whole genome microarray studies indicated that CXCR4 expression is down-regulated by 
EBNA-3A and EBNA-3B in EBNA-3A and -3B knock out LCLs, but up-regulated by EBNA-3C 
in LCLs with conditional EBNA-3C protein [159,216,217,218]. In the infection experiments 
performed in this study, CXCR4 was effectively repressed in both type 1 and type 2 EBNA-2-
virus infected cells by the day 8 time-point (Figure 3.25 B), although in the latter the time-course 
of this down-regulation seemed delayed compared to type 1 EBNA-2. Furthermore, in both type 
1 and type 2 infections, the kinetics of CXCR4 regulation were almost complementary to that of 
LMP-1 (Figure 3.25 B), consistent with the notion that both EBNA-2 and LMP-1 contribute to 
but are not the only determinants of CXCR4 regulation.  
Regulation of CXCR4 expression is also a common feature of some herpesviruses. Human 
herpesviruses 6 and 7 down-regulate CXCR4 at the transcriptional level during infection of 
human T cells [475] and KSHV infection of primary human dermal endothelial cells, in addition 
to ectopic expression of the KSHV gene K13 alone, has been shown to down-regulate CXCR4 
expression [476]. The mechanism by which KSHV represses CXCR4 expression involves K13-
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induced up-regulation of the cell microRNA miR-146a, which binds to the 3’UTR of CXCR4 
mRNA [476,477]. Interestingly, miR-146a expression is also up-regulated by LMP-1 in EBV-
infected cells, therefore raising the possibility that the same mechanism could be used by EBV 
LMP-1 to modulate CXCR4 [476,478,479].  
Importantly, the CXCR4/CXCL12 interaction has been recently implicated in EBV-associated 
lymphomagenesis in the immunocompromised host. Although low levels of CXCR4 were 
detected in EBV-LCLs in vitro, high levels of expression of the receptor and its ligand CXCL12 
were found in EBV-positive B cell lymphomas (hu/SCID tumours) arising in immunodeficient 
(SCID) mice injected intraperitoneally with PBMCs from EBV-positive donors [471]. 
Interference with the CXCR4/CXCL12 response, through neutralizing anti-CXCL12 antibodies 
or CXCR4 antagonist, inhibited tumour growth in vivo. Moreover, CXCL12 was highly 
expressed not only in the hu/SCID tumours but also in EBV-transformed LCLs in vitro, but not 
in resting or activated primary B cells, suggesting that CXCL12 expression may be related to the 
EBV-mediated process of immortalisation of B cells. Further studies will be required to elucidate 
the functional relationship between CXCR4 and CXCR7 and the role of their common ligand 
CXCL12 during EBV infection and the contribution of this interplay to type 1 and type 2 EBV-
mediated cell transformation. 
 
Western blot analysis for CXCR7 in type 1 and type 2 EBNA-2 EBV-BAC-infected cells (Figure 
3.25 A) showed that total levels of CXCR7 protein were up-regulated in primary B cells upon 
viral infection, but no major differences could be detected between type 1 and type 2-infected 
cells. This is in contrast to the RT-PCR analysis of CXCR7 mRNA expression levels, showing 
differential regulation by type 1 and type 2 EBNA-2 (Figure 3.25 B). Attempts to detect CXCR7 
surface expression by FACS did not produce consistent results, since a 2-fold increase in signal 
was detected in type 1 EBV-BAC-infected cells in one experiment (Figure 3.28), while no 
differences were detected in another (Figure 3.27). The regulation of CXCR7 protein expression 
is likely to be quite complex in the cell, as endocytosis, recycling and degradation of the surface 
receptor may be involved [363,366]. In fact, it has been reported that many non-transformed 
adult tissues express only low levels of CXCR7 on the plasma membrane, whereas high levels of 
mRNA are detected [360,403]. This observation, together with the finding that in T cells CXCR7 
protein is found mostly underneath the plasma membrane with partial colocalization with the 
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early endosomes, suggests that CXCR7 surface expression can be regulated by post-
transcriptional mechanisms, at the translational level or at the post-translational level, by 
modulating its intracellular trafficking and targeting to the plasma membrane [363,366]. It is 
important to highlight that the functional significance of the differential regulation of CXCR7 by 
type 1 and type 2 EBNA-2 in this study has been demonstrated only at the transcriptional level 
but no conclusive data has been obtained regarding regulation of CXCR7 protein and it might be 
possible that there are further protein products or post-translational modification in B cells. 
Antibody specificities and recognition of CXCR7 protein is also a complex and controversial 
topic (section 1.8.4 and [390,480]). 
 
Bearing in mind the importance of EBNA-LP for enhancement of the ability of EBNA-2 to 
activate genes essential for proliferation, such as LMP-1 [139,140], it appeared critical to 
determine which EBNA-LP species are expressed in the Daudi and P3HR1 cl.16 systems with 
oestrogen-inducible EBNA-2 proteins used to analyse the time-course induction of LMP-1 and 
CXCR7 by type 1 and type 2 EBNA-2 (sections 3.2.1.1 and 3.2.1.2). Several full-length type 1 
EBNA-LP isoforms are expressed from the ER-EBNA-2-coding vectors, in addition to the type 2 
Y1Y2-truncated species, encoded by the endogenous EBV genomes (Figures 3.5 and 3.6). Even 
though most of the EBNA-LP cooperative function has been mapped to the W1W2 repeat 
domains, whereas the unique C-terminal Y1Y2 region has been shown to have only a 
modulatory effect on EBNA-LP cooperative function [139,140], one could speculate that the 
type 1 full-length EBNA-LP might cooperate more efficiently with the type 1 EBNA-2 than with 
the type 2 EBNA-2 and that the absence of a full-length type 2 EBNA-LP could account for the 
weaker induction of LMP-1/CXCR7 by type 2 EBNA-2. A functional assay for EBNA-LP 
cooperative function [140,189] based on the Daudi cell line, was therefore used to demonstrate 
that this is not the case (Section 3.2.1.3.4). Co-expression of type 2 EBNA-2 with either type 1 or 
type 2 full-length EBNA-LP in the Daudi cell line induced only a weak up-regulation of the 
endogenous LMP-1 gene, which was markedly lower than that observed when type 1 EBNA-2 
was co-expressed with either type 1 or type 2 EBNA-LP (Figure 3.10). Therefore the weaker 
induction of LMP-1 by type 2 EBNA-2 is not affected by the EBNA-LP type. In all the assays 
for EBNA-LP cooperative function reported in this study, an EBNA-LP construct with 3 repeat 
W1W2 domains was used, which is above the minimum (2 repeats) required for optimal EBNA-
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LP function [140,189,190]. A role in protection from caspase-induced apoptosis has been 
recently proposed for the Y1Y2-truncated type 2 EBNA-LP species in BL cell lines [194], 
however the possible contributions of this additional function of the EBNA-LP mutant to both 
Daudi and P3HR1 cl.16:ER-EBNA-2 T1/T2 systems have not been explored in this study.  
 
The infection assays with the EBV-BAC recombinant viruses are similar to the Daudi/P3HR1 
cl.16:ER-EBNA-2 systems in that both the type 1 and the type 2 EBNA-2 EBV BAC viruses 
express full-length type 1 EBNA-LP species (Figure 3.30), containing at least 3 W1W2 repeats. 
Based on the results discussed before, showing that the weaker induction of LMP-1 in Daudi by 
type 2 EBNA-2 is not affected by the type of EBNA-LP present (Figure 3.10), it is possible to 
infer that the gene-expression pattern (Figure 3.25 B) and therefore the growth phenotype 
(Figure 3.29) induced by type 2 EBNA-2-expressing BAC virus in the infection experiments is 
not affected by the absence of a type 2 EBNA-LP. Moreover, the low-efficiency transformation 
phenotype produced by the type 2 EBNA-2 BAC recombinant EBV is similar to that reported for 
the wild-type type 2 AG876 EBV strain virus [414].  
 
The T2 E2 EBV-BAC used in this study for the infection experiments contains 4 BamHI W 
repeats, whereas the parental type 1 BAC construct has 6 repeats (see section 2.3.3.3.3). This 
difference is not likely to substantially affect the transformation phenotype of the type 2 virus 
because the total number of BamHI W repeats is well within the range (3-12) normally detected 
in EBV strains [464]. A recent report at the European EBV conference 2009 suggested that EBV 
recombinant viruses with different BamHI W repeat copy number display some differences in 
transformation efficiency [481]. However, the differences in transformation efficiency detected 
between viruses with 6 or 4 BamHI W repeats reported were modest (only a few fold) and much 
smaller that the differences in outgrowth observed in the present study between type 1 and type 2 
EBNA-2 EBV-BAC transformed B cells (Figure 3.29).  
 
The Daudi and P3HR1 cl.16:ER-EBNA-2 T1/T2 systems used in this study (sections 3.2.1.1 and 
3.2.1.2) provide a useful model to investigate regulation of endogenous EBNA-2 target 
promoters in the presence of properly chromatinized promoter regulatory elements and of 
physiological levels of expression of the two types of EBNA-2 proteins (from the EBV Wp 
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promoter). Using these assays, type 1 EBNA-2 was found to induce LMP-1, protein and RNA, 
more rapidly and to a higher level than type 2 EBNA-2 (Figures 3.1, 3.3 and 3.4). Type 1 
EBNA-2 has been shown to regulate LMP-1 expression in LCLs by interacting with many host 
factors proteins, including RBP-Jk, PU.1, AP-2, SWI/SNF, CBP/p300, ATF/CREB and 
DP103/SMN complex [255,256,257,258,259,260,261]. It is likely that the different outcome on 
LMP-1 expression levels induced by type 1 and type 2 EBNA-2 is due to recruitment of different 
groups of cell transcription factors at the LMP-1 promoter. The strong differential transcriptional 
regulation of LMP-1 by type 1 and type 2 EBNA-2 seen in the Daudi and P3HR1 cl.16:ER-
EBNA-2 T1/T2 systems was only partially recreated in promoter-reporter assays performed in 
the EBV-positive cell lines Daudi and P3HR1 cl.16 (Sections 3.2.2.1.2 and 3.2.2.1.3). One 
difference between the reporter assays and the cell lines with oestrogen-regulated EBNA-2 
proteins is that the latter express several type 1 EBNA-LP isoforms (encoded by the p554-
5/pERT2 plasmids, figures 3.5 and 3.6). One could speculate that type 1 EBNA-LP species 
account for the higher induction of LMP-1 promoter by type 1 EBNA-2 compared to type 2 
EBNA-2. However, the experiments performed using the functional assay for EBNA-2 and 
EBNA-LP cooperation in Daudi (Figure 3.10) demonstrate that this is not the case, since in the 
presence of either type 1 or type 2 EBNA-LP, the type 2 EBNA-2 protein activates LMP-1 to 
lower levels than does the type 1 EBNA-2. Therefore it is likely that the lack of differential 
regulation of the LMP-1 promoters seen in the luciferase assays is due to either lack of proper 
chromatinization of the LMP-1 regulatory sequences in the reporter plasmids or non-
physiological levels of expression of the EBNA-2 proteins achieved by transient transfection. 
Additionally, it might be the case that a promoter sequence larger than that used in the LRS 
reporter constructs, spanning between positions -634 and +40 relative to the transcription 
initiation site [462], is required to allow differential regulation by type 1 and type 2 EBNA-2.  
Substantial discrepancies in LMP-1 promoter regulation (i.e. on the B95-8 LRS) were detected 
between Daudi (Figure 3.12) and P3HR1 cl.16 (Figure 3.13) cell lines. These discrepancies 
might be due to differences in the intracellular conditions present in the different B cell lines. 
Consistent with this idea, Jansson and colleagues reported that LMP-1 promoter activity can be 
differentially modulated when the LRS reporter constructs are transfected into different EBV-
positive cell lines [462], suggesting that the intracellular environment and the cell phenotype of 
different B cell lines may have an effect on the regulation of either B95-8 or P3HR1 LMP-1 
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promoter. Strong differences were also observed between the two EBV-positive cell lines 
(Figures 3.12 and 3.13) and the EBV-negative DG75 cell background (Figure 3.11). In fact, 
while in the EBV-positive cell lines a partial differential regulation, albeit moderate, could be 
detected at certain time-points (Figures 3.12 and 3.13), no differences at all in LRS activation 
levels, in the presence of either type of EBNA-2 proteins, were observed in DG75 cells (Figure 
3.11). The presence or absence of other EBV proteins (i.e EBNA-LP) may modulate the abilities 
of type 1 and type 2 EBNA-2 to regulate the LMP-1 promoter on luciferase gene-reporter 
constructs. However, when LRS reporter assays were performed in an EBV-negative cell 
background by transfecting EBNA-2 and EBNA-LP, to test whether the cooperative effect of 
EBNA-LP can restore differential regulation of the LRS by type 1 and type 2 EBNA-2 as seen in 
Daudi and P3HR1 cell backgrounds (Figures 3.12 and 3.13), no significant synergistic effect on 
LRS transactivation was detected when both EBNA-2 and EBNA-LP were expressed (Figures 
3.14 and 3.15). This was observed repeatedly, even when a wide range of plasmid doses was 
tested and different time-points were included in the analysis. This result was in contrast to 
previous reports where a substantial increase in either CAT signal from CAT reporter plasmids 
with the LMP-1 promoter region -512/+40, or in luciferase activity from luciferase reporter 
vectors carrying the LMP-1 promoter sequence -512/+72, was observed when EBNA-2 (type 1) 
and EBNA-LP (type 1) were co-expressed, relative to EBNA-2 alone [139,141]. This 
discrepancy might be due to either the specific conditions used in this study to perform the 
reporter assays (e.g. transfection method) or to the specific LMP-1 promoter region used (-
634/+40), which may not be sufficient to confer physiological levels of responsiveness by 
EBNA-2 and EBNA-LP proteins as seen in previous reports [140,189]. In contrast to these 
reporter assays, the cooperative effect of EBNA-LP (type 1 and type 2) on the type 1 and type 2 
EBNA-2-mediated activation of LMP-1 could be successfully detected in this study when 
looking at endogenous levels of LMP-1 in an EBV-infected BL cell line (section 3.2.1.3.4 and 
Figure 3.10), further strengthening the conclusion that proper chromatinization of the LMP-1 
promoter sequences, displayed by the LMP-1 gene in the EBV genome but not on promoter-
reporter constructs, are important to allow regulation by EBNA-2 and EBNA-LP. The overall 
conclusion from the LRS reporter assays performed in this study (section 3.2.2.1), is that they are 
not suitable to investigate EBNA-LP/EBNA-2 cooperative transactivation function and 
differential regulation of the promoter by type 1 and type 2 EBNA-2, most likely due to either 
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the specific experimental conditions, the promoter region used, lack of physiological expression 
levels of EBNA-2/EBNA-LP or lack of proper chromatinization of the promoter region.  
In addition to EBNA-LP, another viral latent protein has been shown to co-operate with EBNA-2 
to induce LMP-1 and this is EBNA-3C [149,213,482,483]. However, the cooperation between 
EBNA-3C and EBNA-2 in the regulation of LMP-1 has not been explored in this thesis.  
 
The sequence analysis of the entire LRS from P3HR1 and B95-8 reported by Jansson et al. 
revealed the existence of considerable nucleotide variations, in addition to that in the CRE site, 
and significant variations were also found in the Daudi LRS, sequenced in the present study. 
However, while the CRE allelic variation has been shown to be functional for the LMP-1 
promoter regulation by EBNA-2 [462], the functional significance of the remaining variation in 
LRS is not known. Sequence analysis of the Daudi LMP-1 CRE revealed that this is identical to 
that of the P3HR1 EBV strain (Table 3.1). This may account for the similar regulation pattern of 
endogenous LMP-1 observed in response to the oestrogen-inducible EBNA-2 proteins in both 
Daudi and P3HR1 cl. 16 cell line backgrounds (Sections 3.2.1.1 and 3.2.1.2 and [348]).  
 
In an attempt to demonstrate direct transcriptional activation of the CXCR7 promoter region by 
EBNA-2 and compare the effects of the type 1 and the type 2 proteins, promoter-reporter assays 
were performed using the CXCR7 promoter sequence -1144/-36, relative to the transcription 
initiation site mapped in the study by Jin et al. [389]. This promoter region was shown to be 
regulated by HTLV-1 Tax in T cell lines [389]. No significant activation of this promoter region 
could be detected in the presence of either type of EBNA-2 in B cell lines (Figures 3.16 and 
3.17), even though significant transactivation was exerted by HTLV-1 Tax. It is likely that the 
promoter region used in these assays is sufficient to display responsiveness to Tax, whereas 
additional regulatory sequences (possibly both downstream and upstream the boundaries -1144 
and -36) are required to allow EBNA-2 mediated transactivation. In fact, in the CXCR7 promoter 
region there are several known EBNA-2-responsive elements, including 3 RBP-Jk binding sites 
and 5 PU-box regulatory elements, within a region of approximately 3.6 kb downstream to 
position -36. Moreover the promoter region -1144/-36 does not include the TATA box and this 
may also account for the lack of regulation by EBNA-2. It is important to highlight the fact that 
to date the exact structure of the CXCR7 promoter is not clearly defined and in particular there is 
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no consensus about the position of the transcription start site (TSS). In fact, the transcription 
initiation site mapped by Jin et al. [389], presumably in T cell lines, differs from that reported in 
GenBank under the accession number NM020311. During the course of this thesis work another 
study reported that the CXCR7 promoter can be directly activated by the human tumour-
suppressor gene HIC-1, using promoter-reporter assays in a human bone osteosarcoma epithelial 
cell line [398]. The promoter region spanning between positions -813 and +168, relative to the 
TSS defined in GenBank NM020311 was used [398]. Moreover, in another recent study by 
Twarnoski et al., the putative CXCR7 promoter region from -2,409 to +89 was shown to be 
regulated in promoter-reporter assays in rhabdomyosarcoma (RMS) cell lines by the oncogenic 
fusion protein PAX3-Forkhead Homologue in RMS (FKHR), which is expressed following a 
translocation frequently associated in alveolar RMS and has been shown to increase PAX3 
transcriptional activity [402]. The exact position of the transcription start site was not reported in 
that study. Several regulatory elements were identified in this region including five canonical 
NF-kB sites and two of these (proximal sites) were shown to be required for expression of 
CXCR7 in RMS cell lines [402]. The same two proximal NF-kB sites are included in the 
CXCR7 -1144/-36 promoter region used in the present study and were shown, by mutational 
analysis, to be required for transactivation of the CXCR7 promoter by HTLV-1 Tax [389]. It is 
likely that EBNA-2 may also rely on these NF-kB sites for activation of the CXCR7 promoter, 
however the experiments presented in the present thesis study (section 3.2.2.2) imply that more 
than the two proximal sites might be required. Given the fact that to date the exact structure of 
the CXCR7 promoter and in particular the TSS are not clearly defined, especially in B cell lines, 
future studies will be devoted to precisely map the TSS of this promoter in B cells, by 5’-rapid 
amplification of cDNA ends. A larger promoter region, including the EBNA-2 responsive 
elements present up to 3.6 kb downstream the TATA box, might be then used in promoter-
reporter assays to investigate direct regulation by EBNA-2, type 1 and type 2.  
Previously in this laboratory several attempts were made to demonstrate direct activation by 
EBNA-2 of two well-established target promoters, namely c-MYC and RUNX3, using promoter-
reporter assays, however no regulation could be detected. Nevertheless, EBNA-2-mediated 
regulation of both c-MYC and RUNX3 can be detected in cell line systems when looking at 
endogenous levels of these genes [336,338]. These observations reinforce the idea that proper 
chromatinization of promoter sequences, that does not take place on promoter-reporter 
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constructs, is important to allow EBNA-2-mediated transcriptional activation and highlights the 
value of the cell line-based assays created in this work and in previous studies from this 
laboratory (i.e. the Daudi/P3HR1 cl.16:ER-EBNA-2 assays, sections 3.2.1.1 and 3.2.1.2 and 
[348]).  
 
The major obstacle in the infection experiments with the wild-type AG876 and B95-8 viruses 
(section 3.2.3.1) lay in the fact that virus production from the AG876/ZHT stable cell line was 
not as efficient as from the B95-8/ZHT cell line [460] and therefore only moderate amounts of 
type 2 virus were obtained. Therefore, infection experiments could be carried out only on a small 
scale and hindered the sensitivity of detection of EBNA-2 target genes. To circumvent this 
problem and improve the assay, future experiments might involve stimulation of the 
AG876/ZHT cells with TPA, in addition to treatment with 4HT, in order to increase the yeld of 
AG876 virus released from the cells. Nevertheless, the infection assays with the AG876 and 
B95-8 viruses might not represent the best system to compare type 1 and type 2 EBNA-2 effects 
on host gene expression since the AG876 and B95-8 viral particles are produced from two very 
different cell lines (B95-8 is a marmoset cell line infected with type 1 EBV from an IM patient 
[451] whereas AG876 is a BL cell line [59]). Hence, B95-8 and AG876 virions are likely to 
present qualitatively very different envelopes and glycoproteins. This could cause major 
differences during the early stages of infection, specifically regarding virus attachment and virus 
entry into the cells. In fact, these early events taking place during EBV infection have been 
shown to activate several cell signalling pathways, including PI3 kinases, NF-kB and E2F-4 
protein, and lead to entry of the cell into the cell cycle [72,73]. In this respect, the infection assay 
with the BAC-derived recombinant EBV viruses represents a much more controlled system as 
both type 1 and type 2 EBNA-2 EBV-BAC virions are generated from the same cell line (293) 
and are therefore identical in terms of envelope composition and array of glycoproteins displayed 
on their surface. Moreover, the EBV-BAC viruses allow a much more quantitative infection 
assay as they can be easily and accurately titred because of the presence of a GFP-cassette in the 
BAC vector backbone.  
 
During the efforts to clone a type 2 EBNA-LP cDNA (section 3.2.1.3.3), a cDNA clone was 
obtained from the Jijoye cell line, which was hitherto believed to be type 2, based on allelic 
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variation of the EBNA-2 gene [449]. Sequencing analysis revealed that this was a mixture of 
type 2 (exons W1W2) and type 1 (exons Y1Y2) sequences (Supplementary Figure 4, Appendix). 
So far numerous examples of EBV intertypic recombinants, in which a type 1 EBNA-2 allele is 
paired with type 2 EBNA-3A, -3B and/or -3C, have been found in both inmmunocompromised 
and immunocompetent populations from different geographic regions [484,485,486,487,488]. 
Intertypic recombinants, generated by homologous recombination between type 1 and type 2 co-
resident viruses, are relatively frequent in immunocompromised hosts [484] and are likely to 
arise as consequence of their increased frequency of mixed-type infection. During the present 
study, the EBV genome from the laboratory cell line Daudi was found to be of mixed-type 
sequence. This strain lacks the EBNA-2 locus, expresses a type 2 truncated EBNA-LP (Figure 
3.5, lane 4 and [181,194,465,467]), and displays type 1 alleles in the EBNA-3 loci, as determined 
by PCR-amplification with type specific primes (Supplementary Figure 11, Appendix), 
confirming the intertypic recombination. However, the mixed allelic polymorphism detected in 
the Jijoye EBNA-LP gene appears to be the first example of chimaeric sequences whithin one 
specific locus. Collectively these observations suggest that accurate type determination requires 
simultaneous analysis of EBNA-2 (if present), EBNA-LP and EBNA-3 genes together. A higher 
resolution of EBV strain classification based on sequence variation in multiple genes might 
potentially reveal the true degree of natural variation of EBV strains in the wild. Neveretheless, 
despite the relatively high frequency of genetic mosaics in the EBV strains found in nature, the 
EBNA-2 gene is still the major determinant of the in vitro phenotype of the EBV types, because 
intertypic recombinant viruses with type 1 EBNA-2 allele and type 2 EBNA-3 alleles, displayed 
in vitro transforming capacity at least equal to that of type 1 EBV [484].  
 
In summary, in this chapter, a molecular mechanism underlying the differences in transforming 
abilities of type 1 and type 2 was identified. In BL cell lines, type 1 EBNA-2 was shown to be a 
more potent activator of the viral oncogene LMP-1 and the cell gene CXCR7, which are both 
required for proliferation of EBV-LCLs. Furthermore, during infection of primary B cells with 
EBV-BAC recombinant viruses, the superior immortalising ability of the type 1 EBNA-2 virus 
was found to correlate with a stronger and more rapid induction of LMP-1 and CXCR7 gene 
expression. 
 
224 
 
4  Mapping regions of the EBNA-2 protein responsible for 
the superior ability of type 1 EBNA-2 to sustain B cell 
proliferation compared to type 2 EBNA-2 
 
The aim of this chapter is to identify the domains of the EBNA-2 protein which account for the 
enhanced ability of type 1 EBNA-2 to promote growth of B cells relative to type 2 EBNA-2. 
 
4.1  Introduction 
Numerous studies performed in the past have led to identification of characteristic structures and 
functional domains of the EBNA-2 protein and have almost entirely focussed on the type 1 
(reviewed in section 1.7). Several regions of the protein have been identified to be important for 
EBNA-2-mediated B cell immortalisation, using either primary B cell transformation 
experiments with recombinant EBV viruses [305,308,309,310,311,313] or the EREB2.5 assay 
[157,291,292,293] (see sections 1.7.1 and 1.7.3). The former system involved reconstituting the 
EBNA-2/EBNA-LP deletion of the P3HR1 EBV strain with DNA fragments containing 
specifically mutated EBNA-2 genes. The resultant recombinant EBV viruses were then tested for 
their ability to growth-transform primary B cells. In this system EBNA-2 functions were studied 
in the context of EBV infection, so several variables related to the virus-B cell interaction 
process, including expression of other EBV genes, sequence variations in the EBV strains used, 
B cell activation or cell cycle induction, may play a role. On the other hand, the EREB2.5 cell 
line, developed by Kempkes et al. [157], allows investigation of the functions of EBNA-2 in 
isolation from other variables related to the virus-B cell interactions that typically take place 
during primary infection. EREB2.5 cells contain a P3HR1 EBV genome lacking the EBNA-2 
locus and the last two exons of EBNA-LP. An ER-EBNA-2 fusion protein is expressed from a 
separate plasmid (p554-4). Hence, EBNA-2 activity and therefore survival and proliferation of 
the cells are dependent on oestrogen. In the absence of oestrogen, ER-EBNA-2 function is 
inactivated and the cells undergo growth arrest and apoptosis, eventually dying out [157,254]. 
Stable expression in trans of a wild-type EBNA-2 can rescue growth of oestrogen-depleted cells 
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[135,291,292,293]. Hence, expression in trans of mutant EBNA-2 proteins allows determination 
of their effect on B cell growth and identification of domains of the protein that are important for 
maintenance of B cell proliferation [157,291,292,293]. Moreover, the EREB2.5 cell line has 
been exploited in the past by this laboratory and by others to measure the effects of EBNA-2 on 
gene expression: in fact, by removal and subsequent readdition of oestrogen to the cells, EBNA-
2 function can be switched on and off respectively and modulation of EBNA-2 targets can be 
monitored [135,338,343]. 
In this laboratory the trans-complementation approach in the EREB2.5 cell line was adapted into 
an assay that functionally distinguishes between type 1 and type 2 EBNA-2-induced B cell 
proliferation [348]. Following removal of oestrogen, cell proliferation can be rescued if an OriP 
plasmid expressing constitutive type 1, but not type 2, EBNA-2 protein is transfected into the 
cells. In this situation the wild-type type 1, but not the type 2, EBNA-2 can functionally replace 
the endogenous ER-EBNA-2 fusion protein and provide essential EBNA-2 functions in trans. 
This functional assay was used in the present study to identify the regions of the EBNA-2 protein 
which are responsible for the superior ability of the type 1 EBNA-2 to sustain B cell growth, 
compared to the type 2. 
 
4.2  Results 
 
4.2.1  Testing the EREB2.5 growth assay 
As an introductory experiment, the EREB2.5 growth assay was tested to determine conditions 
suitable for comparing the two alleles of EBNA-2. For this, caesium chloride purified DNA 
preparations of two OriP-p294 plasmids carrying the wild-type EBNA-2 sequences, type 1 and 
type 2 (section 2.3.3.2.2), were transfected separately into EREB2.5 cells using the Amaxa 
system, as described in section 2.2.6.2. As control, cells were transfected with an empty vector. 
A titration of the plasmids was performed to determine which concentration of DNA allows the 
clearest result. Oestrogen was removed from the culture medium immediately after transfection. 
Consistent with previous work from this laboratory, EBNA-2 type 1 OriP vector was the only 
one able to sustain indefinite proliferation of the cells and lead to LCL establishment. 1 week 
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after transfection, control cells lost clusters of growing cells and only dying cells were observed 
at the microscope. 3 weeks after transfection, cells transfected with type 1 EBNA-2-expressing 
vector formed big clumps and clusters that are characteristic of B cell growth (Figure 4.1 A). In 
the case of OriP-p294 carrying the type 2 EBNA-2 sequence, initial small clusters of cells 
formed but they soon lost growth; 1 month after transfection only single and dying cells, were 
observed, confirming that EBNA-2 type 2 is not able to produce stable growth and give rise to 
LCLs. Accumulation of proliferating cells was assessed by counting cells that exclude Trypan 
Blue on a haemocytometer, 3 weeks after transfection (Figure 4.1 B). Total numbers of live cells 
expressing type 1 EBNA-2 were markedly higher than those of type 2 EBNA-2-transfected cells 
(>3-fold). (Figure 4.1 B). The live cell counts were consistent with the differences in cell growth 
phenotype revealed by microscopic observation of the cells in culture and confirmed that only 
EBNA-2 type 1 can replace ER-EBNA-2 in EREB2.5 cells and is able to promote continuous 
cell growth. For each vector, transfection with 15 µg of DNA preparations appeared to be toxic 
for the cells, as live cell counts were considerably lower when compared to 5 or 10 µg (Figure 
4.1 B). Only minor differences in live cell counts were observed between 5 and 10 µg of plasmid 
DNA, and at both DNA doses used, cells appeared viable upon microscopic observation at the 
early time-points after transfection. Thus, 5 µg was chosen as the amount of DNA to use in all 
the subsequent transfection experiments. Cells transfected with type 1 EBNA-2 OriP plasmid 
were maintained in culture in the absence of oestrogen for 2 months. At this time, a western blot 
analysis was performed to assess the expression of the constitutive EBNA-2 protein (Figure 4.1 
C). For this, several cell clones were collected and proteins were extracted with RIPA lysis 
buffer. Protein samples were analysed by SDS-PAGE and immunoblots were probed with the 
PE2 antibody. Transfected clones had only a very low level of the ER-EBNA-2 fusion protein 
(120 kDa) and expressed mainly the constitutive type 1 EBNA-2 (85 kDa) (Figure 4.1 C). 
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Figure 4.1. Testing the EREB2.5 cell growth assay. 
6 x 106 EREB2.5 cells, which had been growing normally in oestrogen, were transfected with OriP-p294 plasmids 
carrying type 1 (E2 T1) or type 2 (E2 T1) EBNA-2 sequences or with an empty vector (e.v.) as control. The Amaxa 
transfection system was used and a vector titration was performed testing 5, 10 and 15 µg of caesium chloride 
purified DNA preparations for each construct. Following transfection, cells were grown in the absence of oestrogen. 
(A) Phase-contrast images of EREB2.5 cells transfected with 5 µg of EBNA-2 expressing plasmids, or empty vector 
control, showing proliferating cells only with type 1 EBNA-2 but not with type 2. Pictures were taken 3 weeks after 
oestrogen withdrawn. (B) Accumulation of proliferating cells was assessed 3 weeks after transfection by counting 
cells that exclude Trypan Blue on a haemocytometer. Duplicate wells of cells were counted. Error bars represent 
standard errors. (C) Western blot analysis for EBNA-2 of 5 oestrogen-independent LCL established after 
transfection of type 1 EBNA-2 OriP-p294 plasmid. The analysis was performed after 2 months of outgrowth. The 
PE2 antibody was used, which detects both the conjugated ER-EBNA-2 (ER-E2) and the wild-type type 1 EBNA-2 
(T1 E2). B95-8 (+): positive control for constitutive type 1 EBNA-2 expression; E2.5+est: non transfected cells 
normally grown in oestrogen, expressing the conditional ER-EBNA-2. E2T1 LCLs cl. 1 to 5: 5 different stable 
clones of EREB2.5 transfected with type 1 EBNA-2. Immunoblotting for β-actin was performed as a loading 
control.  
 
 
4.2.2  Mapping the regions of type 1 EBNA-2 which confer higher B cell 
immortalisation efficiency compared to type 2 EBNA-2 
The objective is to identify the regions of the type 1 EBNA-2 that can complement the deficiency 
of the type 2 protein to maintain LCL growth using the EREB2.5 trans-complementation assay. 
The strategy was to swap pieces between the type 1 and type 2 EBNA 2 proteins and 
subsequently test the ability of the resultant chimaeras to rescue growth of EREB2.5 cells in the 
absence of oestrogen. For this, several type 1 / type 2 EBNA-2 chimaeric sequences were 
generated as described in section 2.3.3.3.1 and cloned in the Orip-p294 expression vector where 
transcription of the EBNA-2 coding sequences is driven by the EBV Wp promoter. All the 
chimaeras were precise swaps of EBNA-2 sequence without extraneous amino acids at the point 
of fusion (characterisation of the plasmids is shown in section 2.3.3.3.1). The complete set of 
chimaeras tested and the respective growth phenotype observed in the trans-complementation 
assay are shown in Figure 4.2 B. Caesium chloride DNA preparations of OriP-p294 plasmids 
expressing the chimaeric or wild-type type 1 or type 2 EBNA-2 proteins were Amaxa-transfected 
into EREB2.5 cells that had been growing normally in the presence of oestrogen. Immediately 
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after transfection, oestrogen was withdrawn from the culture medium and cell proliferation was 
monitored over time by counting numbers of live cells (Figure 4.2 C). When the C-terminal 
region of type 1 EBNA-2 protein spanning from the WWPP motif (codons 323-326, see 
Supplementary Figure 1 in the Appendix), within the RBP-Jk binding domain, to the end of the 
protein was swapped at homologous amino acid positions into the type 2 EBNA-2 protein 
(chimaera 2), live cell counts were similar to those obtained with wild-type type 1 in the 
EREB2.5 growth assay (Figure 4.2 C). However, no growth, similar to wild-type type 2 or empty 
vector control, was observed with the converse chimaera (chimaera 1), generated by joining 
together the type 1 sequence from codon 1 to the WWPP motif with type 2 sequences spanning 
from the WWPP motif to the last codon of the protein (Figure 4.2 C). Therefore, the C-terminal 
third of type 1 EBNA-2 is able to confer a type 1 growth phenotype to type 2 EBNA-2 in the 
EREB2.5 trans-complementation assay. This region of the EBNA-2 protein includes the RG 
motif, the conserved region 7 (CR7), the transactivation domain (TAD), which maps to the 
conserved region 8 (CR8), and the nuclear localization signal (NLS), which maps to CR9 (Figure 
4.2 A). To further map the minimum type 1 sequences within the C-terminal region of EBNA-2 
responsible for the higher B cell immortalisation efficiency, additional chimaeras were 
constructed by swapping different combinations of the RG, CR7, TAD and NLS regions from 
the type 1 into the type 2 protein (chimaeras 3 to 7). Only when the type 2 RG, CR7 and TAD 
regions were together replaced with homologous type 1 sequences (chimaera 7), accumulation of 
proliferating cells was restored to almost wild-type type 1 levels (Figure 4.2 C). In contrast, 
chimaeras from 3 to 6 behaved like wild-type type 2 EBNA-2, as they were unable to sustain 
proliferation (Figure 4.2 C). Substitution of the type 1 RG region or RG+CR7 sequences of 
chimaera 2 with homologous type 2 sequences (chimaeras 3 and 4 respectively) produced 
complete loss of cell growth, down to wild-type type 2 or control levels, indicating that within 
the C-terminal region, the type 1 RG, either alone or together with CR7, is required for optimal B 
cell proliferation (Figure 4.2 C). However, the type 1 RG is not sufficient for this as a type 2 
EBNA-2 bearing the RG element from the type 1 protein (chimaera 5) was unable to rescue cell 
growth in the trans-complementation system. Substitution of the type 1 NLS in chimaera 2 with 
the corresponding type 2 sequence (chimaera 7) did not abolish wild-type type 1 cell 
proliferation levels indicating that type 1 and type 2 NLS are functionally equivalent in terms of 
growth-promoting ability. When type 2 sequences of the C-terminus of chimaera 7 were 
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extended in order to include the TAD (chimaera 6), growth-promoting effects of chimaera 7 
were completely lost, indicating that type 1 TAD is important for type 1 levels of cell 
proliferation (Figure 4.2 C).  
 
Long-term culture of oestrogen-independent EREB2.5 cells expressing the different EBNA-2 
chimaeras and wild-type proteins resulted in establishment of continuously proliferating LCLs 
only in the case of chimaeras 2 and 7 and wild-type type 1 EBNA-2. These results demonstrate 
that, within the C-terminal region of the type 1 EBNA-2, the RG, CR7 and TAD are the 
minimum type 1 sequences required to complement the lack of ability of type 2 EBNA-2 to 
rescue growth of oestrogen-depleted EREB2.5 cells. Introduction of any other combination of 
these domains from the type 1 protein (TAD+NLS, CR7+TAD+NLS, RG+CR7 or RG alone) 
into a type 2 background was not sufficient for restoration of type 1 function.  
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Figure 4.2. Type 1 / type 2 EBNA-2 chimaeras tested in the EREB2.5 growth assay. The carboxyl-terminal 
region of type 1 EBNA-2 complements the deficiency of type 2 EBNA-2 in the EREB2.5 growth assay. RG, 
CR7 and TAD domains are the minimum type 1 sequences required 
(A) Structure of EBNA-2 protein. CRs 1 to 9: conserved regions. SAD1 and SAD2: self-association domains; PPR: 
poly-proline region; diversity: sequence with low similarity between EBV types; RBP-Jk: RBP-Jk-interacting 
domain; RG: arginine-glycine rich region; TAD: transactivation domain; NLS: nuclear localization signal. EBNA-
LP: regions involved in EBNA-2/EBNA-LP transcriptional cooperation. (B) Panel of chimaeric proteins (Chim 1 - 
Chim 7) tested for their ability to rescue proliferation of oestrogen-starved EREB2.5 cells. The growth phenotype 
was scored as “++” (type 1 and chimaera 2) and “+” (chimaera 7), when cell proliferation was maintained over time 
after transfection and oestrogen withdrawal and LCLs were successfully established, or as “–” (type 2, chimaeras 1, 
3, 4, 5 and 6), when proliferation ceased after transfection. (C) Live cell counts of EREB2.5 cells expressing wild-
type type 1 / type 2 or chimaeric EBNA-2 proteins. EREB2.5 cells were transfected with OriP-p294 plasmids 
expressing wild-type type 1 (T1), type 2 (T2) EBNA-2, chimaeras 1 to 7 or with empty vector (e.v.). Oestrogen was 
removed from the culture medium and accumulation of proliferating cells was assessed at 1, 2, 3 and 4 weeks after 
transfection by counting cells that exclude Trypan Blue on a haemocytometer. Data from 1 representative 
experiment of at least 4 is shown. Transfections were performed in duplicate and for each replica, triplicate wells of 
cells were counted. Error bars indicate standard deviations. (D) Western blot analysis of protein extracts from 
EREB2.5 cells transfected with wild-type type 1 (E2T1) and type 2 (E2T2) and chimaeric (C1-C7) EBNA-2 
proteins. Cells were harvested 4 days after transfection. EBNA-2 was detected using the PE2 antibody, which 
recognises both types. Triplicate samples were analysed for each transfection. B95-8 and AG876: positive controls 
for expression of EBNA-2 type 1 (85 kDa) and type 2 (75 kDa), respectively; E2.5 + est: non-transfected EREB2.5 
cells normally grown in medium supplemented with oestrogen. Immunoblotting for β-actin served as a loading 
control. E2: EBNA-2; ER-E2: ER-EBNA-2.  
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4.2.2.1  Expression levels and subcellular localization of type 1, type 2 and 
chimaeric EBNA-2 proteins 
To ensure that the lack of growth of oestrogen-depleted EREB2.5 cells was not due to either lack 
of expression or inappropriate localization of the chimaeric proteins, western blot and 
immunofluorescence experiments were performed. Western blot analysis for EBNA-2 with the 
PE2 antibody on extracts from transfected EREB2.5 cells revealed that all the chimaeric EBNA-
2 proteins were expressed at levels comparable to wild-type type 1 and type 2 and displayed the 
expected size, which corresponds to 85 kDa (similar to type 1) for chimaera 1 and to 75 kDa 
(similar to type 2) for all the other chimaeras. The ER-EBNA-2 fusion protein (120 kDa) was 
also detected in every transfection (Figure 4.2 D).  
To determine the subcellular localization of the EBNA-2 proteins, Hela cells were transiently 
transfected with OriP-p294 plasmids carrying the wild-type or chimaeric EBNA-2 sequences and 
after 24 hours the cells were subjected to immunofluorescence analysis as described in section 
2.7. The analysis confirmed that all the chimaeras are appropriately localized to the nucleus of 
the cells with exclusion from nucleoli (Figure 4.3 A), with a pattern similar to that of wild-type 
type 1 and type 2 EBNA-2 (Figure 4.3 B and [307]). Variable staining patterns were observed in 
different transfections: either discrete nuclear speckles or diffuse staining of the whole nucleus. 
However, there did not seem to be correlation between one staining pattern and a specific 
EBNA-2 type or chimaera. A similar variability has been reported previously [142,489] and is 
possibly due to variations in transfection efficiencies.  
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Figure 4.3. Nuclear localization of the chimaeric EBNA-2 proteins and wild-type type 1 and type 2 in HeLa 
cells 
OriP-p294 plasmids carrying either chimaeric EBNA-2 sequences (chimaera 1 to 7) (A) or wild-type type 1 (E2T1) 
and type 2 (E2T2) EBNA-2 ORF (B) were transiently transfected into HeLa cells. After 24 hours, cells were fixed, 
permeabilized and probed with the anti-EBNA-2 antibody (PE2 clone) followed by TRITC-conjugated anti-mouse 
secondary antibody. The location of the EBNA-2 proteins was assessed by confocal microscopy. e.v.: empty vector-
transfected cells; n.t.: non-transfected cells; E2T1 + II Ab: cells transfected with type 1 EBNA-2-expressing plasmid 
and stained with the secondary antibody only.  
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4.2.3  The growth phenotype induced by wild-type and chimaeric EBNA-2 
proteins in the EREB2.5 assay correlates with LMP-1 and CXCR7 
expression levels 
Expression of the EBNA-2 direct viral target and major EBV oncogene LMP-1 was assessed in 
the EREB2.5 growth assay. Western blot analysis revealed that at 3 and 5 days after transfection, 
in oestrogen-starved cells expressing type 1 EBNA-2 and chimaeras 2 and 7, LMP-1 protein 
expression was maintained at levels similar to those detected in EREB2.5 cells normally grown 
in the presence of oestrogen (Figure 4.4 A). In contrast, LMP-1 expression was lost in type 2 
EBNA-2 or empty vector-transfected cells (Figure 4.4 A). Likewise, qRT-PCR analysis, 
performed on RNA samples from a similar experiment, conducted over a time-course of 7 days, 
showed a rapid increase in LMP-1 transcripts levels (up to approximately 12-fold at day 7) 
relative to EREB2.5 cells cultured in oestrogen-conditioned medium, when wild-type type 1 
EBNA-2 was expressed (Figure 4.4 B). In type 2 EBNA-2-transfected cells, LMP-1 mRNA was 
down-regulated by 5 days after transfection (fold increase <1, relative to EREB2.5 cells grown 
with oestrogen) (Figure 4.4 B). In these cells, LMP-1 mRNA levels could not be assessed at the 
day 7 time-point, since many of the cells were dying by then. In this particular experiment, less 
than 30% of type 2 EBNA-2-transfected cells were viable at this time-point, relative to type 1 
EBNA-2-expressing cells. When chimaeras 2 and 7 were expressed, LMP-1 mRNA levels were 
up-regulated compared to oestrogen-treated non-transfected EREB2.5 cells, although to a lesser 
degree than with type 1 EBNA-2 (Figure 4.4 B). qRT-PCR analysis for the mRNA of the cell 
gene CXCR7, which is essential for proliferation of EBV-LCLs, including the EREB2.5 cell line 
[348], was performed on the RNA samples from the same transfections. The transcripts for this 
gene were gradually up-regulated following expression of either type 1 EBNA-2 or chimaeras 2 
and 7, with a 14 (type 1 EBNA-2) or approximately 7-fold increase (chimaeras 2 and 7), 
compared to non-transfected cells, at 1 week after transfection (Figure 4.4 C). In contrast, when 
type 2 EBNA-2-expressing vector was transfected, CXCR7 mRNA was maintained at the same 
levels normally observed in non-transfected cells (fold increase of 1) up to 5 days after 
transfection but after this time-point it was not further induced and the cells died (Figure 4.4 C). 
These results demonstrate that LMP-1, protein and mRNA, and CXCR7 mRNA expression 
levels, induced by type 1 and type 2 EBNA-2 and chimaeras 2 and 7, correlate with the growth 
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phenotype in the EREB2.5 trans-complementation system. Loss of LMP-1 and CXCR7 
expression in type 2 EBNA-2-expressing cells is rapidly followed by growth arrest of the cells, 
whereas in cells expressing type 1 EBNA-2 and chimaeras 2 or 7, maintenance of LMP-1 and 
CXCR7 expression is accompanied by sustained proliferation of the cells. Therefore the C-
terminal sequences of type 1 EBNA-2 in chimaeras 2 and 7 are sufficient to confer induction of 
type 1 growth phenotype and approximately type 1 expression levels of LMP-1 and CXCR7. 
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Figure 4.4. LMP-1 and CXCR7 expression induced by type 1 and type 2 EBNA-2 and chimaeras 2 and 7 
correlates with the growth phenotype in the EREB2.5 growth assay 
EREB2.5 cells were transfected with OriP-p294 plasmids expressing type 1 EBNA-2 (E2T1), type 2 EBNA-2 
(E2T1), chimaera 2 (C2) and chimaera 7 (C7) or with an empty vector (e.v.) and grown without oestrogen. At 3, 5 
(A) and 7 (B) and (C) days after transfection (T), cells were lysed in either RIPA lysis buffer to extract proteins (A) 
or in Trizol, to extract total RNA (B) and (C). (A) Protein samples were subjected to western blot analysis, probing 
for EBNA-2 (PE2), LMP-1 (CS 1-4) and β-actin, as loading control. Constitutive EBNA-2 proteins, wild-type type 1 
(85 kDa), type 2 and chimaeric (75 kDa), as well as the conditional ER-EBNA-2 (120 kDa) are detected. Numbers 
alongside the EBNA-2 immunoblot panel represent the apparent molecular weight (in kDa). (B) and (C) Total RNA 
samples were retro-transcribed into cDNA and analysed by qPCR to quantify the levels of LMP-1 (B) and CXCR7 
(C) transcripts. No RNA could be extracted from type 2 EBNA-2-transfected cells at the day 7 time-point, since the 
majority of the cells were dead. The histograms show, for each transfection, the ratio LMP-1/GAPDH mRNA (B) or 
CXCR7/GAPDH mRNA (C) relative to non-transfected EREB2.5 cells grown in the presence of oestrogen. 
Experiments were performed in duplicate. Error bars represent standard errors. Data from 1 representative 
experiment of 2 is shown. 
 
 
4.2.4  Functional differences between EBNA-2 types, mapped to the C-
terminus, are typical of type sequence 
In the mapping analysis performed to identify the type 1 regions of EBNA-2 important for B cell 
growth (section 4.2.2), EBNA-2 sequences from the EBV strains B95-8 (type 1 prototype) and 
AG876 (type 2 prototype) were used. To ensure that the functional differences being mapped are 
typical of EBV type sequences, the C-terminal region of the EBNA-2 gene from additional type 
1 and type 2 isolates was sequenced and compared to the prototypes B95-8 and AG876. The 
EBV strains chosen for the analysis were derived from either laboratory LCL, BL and NPC cell 
lines or from BL biopsies obtained from patients from Malawi, Africa (kind gift from Prof. 
Beverly Griffin, Imperial College London). Genomic DNA samples from the laboratory cell 
lines were prepared by Prof. Paul Farrell and Claudio Elgueta. Among these EBV isolates, 8 
were type 1 and 6 were type 2, in addition to B95-8 and AG876, as determined by PCR with 
oligonucleotides annealing to type specific sequences in the EBNA-2 locus (Figure 4.5 A). The 
primers used are listed in section 2.8.8. Among the African BL samples tested (13), 7 were type 
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1 and 6 were type 2 (Figure 4.5 B). Even though the sample size is small, the frequencies of type 
1 and type 2 strains are similar to those previously reported in the African continent [419].  
 
 
 
 
Figure 4.5. Typing of EBV strains from laboratory cell lines and from BL biopsy samples  
(A) The laboratory cell lines analysed include: LCLs (B95-8, JAC-B2, C2+Obaji, MABA, AF-B1, WEI-B1, Alueck, 
C2+BL16), one NPC (C666.1) and BLs (Akata, Raji, Mak 1, SI-B1, AG876, Jijoye, Wewak). EBNA-2 type specific 
primer pairs used are reported in section 2.8.8. (B) EBV DNA samples extracted from BL biopsies from Malawi 
(Africa). 7 isolates were type 1 and 6 were type 2. B95-8 and AG876 genomic DNA samples served as type 1 and 
type 2 positive controls respectively (+). ntc: no template control. M: 100 bp size marker (NEB).  
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To sequence the C-terminal section of the EBNA-2 ORF of the EBV strains from the laboratory 
cell lines and the African BL biopsy samples, PCR fragments encompassing the region of 
interest were generated using specific primers (section 2.8.9), which anneal to sequences 
identical in type 1 and type 2 EBNA-2 (B95-8 coordinates 37,104 – 37,859, Genbank accession 
no. AJ507799) (Figure 4.6). The PCR products were sequenced using the same primers. 
 
 
 
Figure 4.6. PCR amplification of the C-terminal third of the EBNA-2 ORF from laboratory cell lines and BL 
biopsy samples 
Oligonucleotides described in section 2.8.9 were used to amplify by PCR the EBNA-2 sequences coding for the C-
terminal third of the EBNA-2 protein. PCR products of different size are obtained from type 1 (755 bp) and type 2 
(866 bp) isolates. (A) Representative PCRs performed on EBV strains from laboratory cell lines are shown. (B) 5 
BL samples of each type were selected for sequencing analysis. Raji and AG876: positive controls for type 1 and 
type 2 sequences respectively. T1: type 1 isolates; T2: type 2 isolates. ntc: no template control. 
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Sequence comparison of type 1 isolates to the type 1 strain of reference B95-8 showed that, in 
the region examined, which spans from the BstXI site (codons 323-326 of type 1 EBNA-2, see 
Supplementary Figure 1 in the Appendix) to the end of the EBNA-2 ORF, there is a very high 
percentage of identity (> 98%) with only a few nucleotide variations detected (Tables 4.1 and 
4.2). Most of the changes are silent but a few produce a change in the amino acid coded. 
Changes in the amino acid sequence were almost always located outside the known EBNA-2 
functional domains; only in two laboratory strains (Mak 1 and MABA, Table 4.1) were there 
changes within a functional domain (TAD and NLS respectively). Similarly, alignment of the 
sequence coding for the C-terminus of EBNA-2 from several type 2 isolates against the 
prototype strain AG876, indicated that the sequence identity is almost 100%, with only 2 
laboratory strains (Alueck and Wewak, Table 4.1) displaying nucleotide variations (two silent 
and one non-silent, but localized outside functional domains). These results indicate that the 
functional differences between type 1 and type 2 EBNA-2, which have been mapped to this 
region, are representative of viral type sequence.  
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Table 4.1. Sequence analysis of the C-terminus of EBNA-2 from type 1 and type 2 EBV isolates obtained from 
laboratory LCL, NPC and BL cell lines 
1Genbank accession number AJ507799; 2Genbank accession number NC009334; 3TAD: transactivation domain; 
4NLS: nuclear localization signal. 
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Table 4.2. Sequence analysis of the C-terminus of EBNA-2 from type 1 and type 2 EBV isolates obtained from 
BL patients from Malawi (Africa) 
1GenBank accession number: AJ507799; 2GenBank accession number: NC009334. pt.: patient. The samples were a 
kind gift from Prof. Beverly Griffin (Imperial College London). 
 
 
4.2.5  Cooperation between type 1 or type 2 EBNA-2 and EBNA-LP in the 
EREB2.5 assay 
 
EBNA-2-mediated activation of both cell (cyclin D2) and viral promoters (LMP-1/LMP-2B and 
Cp) can be greatly augmented by cooperation with the EBV latent protein EBNA-LP, which has 
been shown to be required for optimal virus-induced B cell transformation [138,139,140,162]. 
Several EBNA-LP proteins, of different type and size, are believed to be present in the EREB2.5 
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trans-complementation system. To address whether these EBNA-LP species may influence the 
growth phenotype induced by the wild-type (type 1 and type 2) and chimaeric EBNA-2 proteins 
in oestrogen-starved EREB2.5 cells it was essential to first determine which specific EBNA-LP 
isoforms are expressed in the EREB2.5 cell line and in the derivative oestrogen-independent 
LCLs established with type 1 EBNA-2 and chimaeras 2 and 7 (Figure 4.7). For this, western blot 
analysis was performed comparing two anti-EBNA-LP antibodies: JF186 (type 1 specific) and 
4D3, which recognises both types of EBNA-LP [183,465]. Using the 4D3 antibody, a type 2 
EBNA-LP species of around 52 kDa was detected in non-transfected EREB2.5 cells, normally 
grown in oestrogen-supplemented medium (Figure 4.7 A, lane EREB2.5 + est), and in all the 
oestrogen-autonomous LCLs (Figure 4.7 A and B). This isoform is encoded by the resident 
P3HR1 genome and is known to lack the Y1 and Y2 domains [185]. Both antibodies detected a 
type 1 EBNA-LP isoform containing 3 W repeats, as determined by comparison with lysates 
from 293 cells transiently transfected with a plasmid expressing a 3-repeat EBNA-LP (Figure 4.7 
A, lane T1ELP3R). This EBNA-LP species is expressed by the endogenous plasmid p554-4, 
whose sequence comprises only 2 BamHI W repeat fragments, perhaps following splicing of 
RNA transcribed more than once around the plasmid (discussed before, section 3.2.1.3.1). This 
type 1 3-repeat isoform of EBNA-LP was detected in non-transfected oestrogen-dependent 
EREB2.5 cells (Figure 4.7 A, lane EREB2.5 + est) and in all the oestrogen-independent LCLs 
established by transfecting chimaeras 2 and 7 or type 1 EBNA-2, analysed over a period of 6 and 
3 months (Figure 4.7 A and B, respectively). This observation suggests that in these experiments 
the p554-4 plasmid is not completely lost from the oestrogen-free LCLs. This was corroborated 
by the EBNA-2 immunoblot that showed continuous expression of ER-EBNA-2 over time, 
although at variable levels. It is likely that some of the p554-4 plasmid has become integrated in 
these cells since, after extraction of low molecular weight DNA from the oestrogen-independent 
LCLs, only the OriP-p294 plasmid (expressing constitutive type 1 EBNA-2) but not the p554-4 
vector was rescued (see Supplementary Figure 12, Appendix). No EBNA-LP proteins were 
expressed from the transfected OriP-p294 plasmids, even though these contain 1 BamHI W 
repeat sequence. Lack of expression of EBNA-LP isoforms from these plasmids was confirmed 
by western blot analysis of protein extracts from both EREB2.5 and DG75 (EBV-negative) cells 
transiently transfected with the OriP-p294 vectors (Supplementary Figure 13, Appendix).  
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Figure 4.7. Characterization of oestrogen-independent LCLs established from EREB2.5 cells expressing type 
1 EBNA-2 and chimaeras 2 and 7 
EREB2.5 cells transfected with OriP-p294 plasmids coding for type 1 EBNA-2 (A) or chimaeras 2 and 7 (B) and 
grown in the absence of oestrogen gave rise to continuously proliferating lymphoblastoid cell lines (LCLs). Protein 
samples were harvested at each month after transfection over a period of 6 months (A) or after 1.5 and 3 months (B) 
and analysed by western blotting. The anti-EBNA-2 antibody (PE2), detected the transfected type 1 (E2) and 
chimaeric (chim E2) EBNA-2 proteins as well as the endogenous ER-EBNA-2 (ER-E2). EBNA-LP immunoblotting 
was performed with the antibodies JF186 (type 1 specific) and 4D3 (recognises both types). At any time-point 
analysed, both antibodies detected a type 1 3-repeat EBNA-LP species (T1 3R ELP), expressed from the 
endogenous p554-4 plasmid, indicating that the plasmid was not lost from the cells. The number of repeats was 
judged by comparison to 293 cells transfected with a type 1 3-repeat EBNA-LP-expressing vector (T1ELP3R). In 
addition to this EBNA-LP species, a type 2 Y1Y2-truncated isoform of around 52 kDa (T2 ∆Y1Y2 ELP), expressed 
by the resident P3HR1 genome, was detected by the 4D3 antibody. Numbers alongside the EBNA-LP immunoblot 
panel represent protein molecular weight (in kDa). β-actin immunoblots ensure equal loading of the proteins. 1 
representative experiment of 3 is shown.  
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Since only a type 1 full-length EBNA-LP is present in the EREB2.5 assay, it might be that a type 
specific cooperation between EBNA-2 and EBNA-LP would be important for optimal 
proliferation in the EREB2.5 growth system and that the lack of a full-length type 2 EBNA-LP 
species could hamper the growth-promoting abilities of type 2 EBNA-2. To test this issue 
directly, OriP plasmids expressing either type 1 or type 2 EBNA-2 (section 2.3.3.2.2) were 
Amaxa-transfected into EREB2.5 cells, in the presence or absence of an OriP plasmid expressing 
a 3-repeat type 2 EBNA-LP (section 3.2.1.3.3) This experiment allows to determine whether the 
presence of a full-length type 2 EBNA-LP (homologous to the endogenous type 1 3-repeat 
EBNA-LP) would enable the type 2 EBNA-2 to sustain cell proliferation in an oestrogen-
independent fashion (Figure 4.8). Accumulation of proliferating cells was assessed each week 
after transfection and oestrogen withdrawal over a period of 3 weeks (Figure 4.8 A). Cells 
expressing type 1 or type 2 EBNA-2 alone displayed proliferation levels similar to those 
observed in Figure 4.2 C. Addition of the type 2 EBNA-LP did not produce any significant effect 
on growth of either type 1 or type 2 EBNA-2-expressing cells or control cells (Figure 4.8 A). 
There were no significant differences in the expression levels of EBNA-2 proteins comparing the 
type 1 and type 2 forms, as assessed by western blotting with the PE2 antibody (Figure 4.8 B). 
Immunoblotting with the 4D3 antibody confirmed good expression of the type 2 3-repeat EBNA-
LP from the transfected pSNOC vector. This EBNA-LP isoform displays a slightly higher 
molecular weight on SDS-PAGE compared to the endogenous type 1 3-repeat EBNA-LP (Figure 
4.8 B) because of the substantial differences (12 amino acids) in the primary amino acid 
sequences between type 1 and type 2 EBNA-LP. This experiment demonstrates that the inability 
of type 2 EBNA-2 to rescue growth of oestrogen-depleted EREB2.5 cells is not due to the 
absence of a full-length type 2 EBNA-LP in the system. Hence the assay functionally 
distinguishes between the ability of type 1 and type 2 EBNA-2 to sustain cell proliferation, 
regardless the type of EBNA-LP.  
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Figure 4.8. Cooperation between type 1 and type 2 EBNA-2 and EBNA-LP in the EREB2.5 growth system 
EREB2.5 cells were transfected with OriP-p294 plasmids expressing either type 1 (E2T1) or type 2 (E2T2) EBNA-
2, or with empty vector (e.v.), in the presence or absence of a pSNOC plasmid expressing a type 2 EBNA-LP with 3 
repeats (T2 ELP). Oestrogen was removed immediately after transfection. (A) Outgrowth of the cells was monitored 
over a period of 3 weeks, by counting live cells on a haemocytometer. Transfections were performed in duplicate 
and for each replica triplicate wells of cells were counted. Error bars indicate standard deviations. (B) 4 days after 
transfection, proteins were extracted from the cells and fractionated by SDS-PAGE. Western blot analysis was 
performed using PE2 and 4D3 antibodies in order to detect EBNA-2 and EBNA-LP respectively and confirmed 
equal levels of expression. The PE2 antibody, detected the transfected type 1 (T1 E2) and type 2 (T2 E2) EBNA-2 
proteins as well as the endogenous ER-EBNA-2 (ER-E2). EBNA-LP western blot showed that empty vector-
transfected cells express the 30 kDa type 1 full-length 3-repeat EBNA-LP (T1 3R), encoded by the p554-4 plasmid, 
and the 52 kDa Y1Y2-truncated EBNA-LP species (T2 ∆Y1Y2), expressed from the P3HR1 resident genome. The 
full-length type 2 3-repeat EBNA-LP protein (T2 3R), expressed from the pSNOC vector, is detected on the gel at 
approximately the same position of the endogenous type 1 3-repeat EBNA-LP (see main text for details). The levels 
of β-actin did not alter throughout the experiment. Duplicate samples for each transfection are shown. B95-8, 
AG876 and T2 ELP 3R (+) lanes represent positive controls for expression of EBNA-2, type 1 and type 2, and type 
2 3-repeat EBNA-LP, respectively. Numbers indicate apparent molecular weight (in kDa). 1 representative 
experiment of 2 is shown.  
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4.2.6  Analysis of the transformation phenotype and the gene regulation 
pattern induced by an EBV-BAC recombinant virus expressing EBNA-
2 chimaera 2 during infection 
 
The EREB2.5 growth assay, which was used to identify the ability of the C-terminal region of 
type 1 EBNA-2 to confer the proliferative capacity of type 1 EBNA-2 on to type 2 EBNA-2 
(chimaera 2, Figure 4.2), measures the ability of the EBNA-2 allele to maintain proliferation of 
an EBV-immortalised LCL. To test whether this region of type 1 EBNA-2 is sufficient to confer 
a type 1 growth-transformation phenotype and LMP-1/CXCR7 expression levels to a type 2 
EBNA-2 protein during infection of primary B lymphocytes, a recombinant EBV-BAC virus 
carrying the sequence coding for EBNA-2 chimaera 2 was generated.  
 
4.2.6.1  Generation and characterization of chimaera 2 EBNA-2 EBV-BAC 
recombinant virus 
The type 1 EBNA-2 ORF in the T1 E2 EBV-BAC construct [447] available in this laboratory 
was substituted with a chimaera 2 EBNA-2 sequence by RecA-based homologous recombination 
in E. coli, as described in section 2.3.3.3.3. The C2 E2 EBV-BAC construct was thereby 
obtained. This work was carried out by Prof. Paul Farrell and Claudio Elgueta. The integrity of 
this EBNA-2 EBV-BAC mutant was screened by PCR and restriction digestion analysis on 
pulsed field gels (section 2.3.3.3.3). Stable 293 cell clones containing the chimaera 2 EBNA-2 
BAC were established by Lipofectamine-mediated transfection and hygromycin selection, as 
described in section 2.2.6.4. Several 293 clonal cell lines were screened for the integrity of the 
EBV-BAC and for their ability to produce infectious virus. Episomal BAC DNA was recovered 
from growing 293 cells, amplified in E.coli and analysed by PCR with type specific primers 
(section 2.8.6), to ensure the presence of the chimaeric EBNA-2 ORF, and by pulsed field 
analysis of multiple restriction digests (Supplementary Figures 8 and 9, in the Appendix). The 
analysis revealed that all the 293 clones tested were positive for the presence of a chimaeric 
EBNA-2 ORF (Supplementary Figure 8, Appendix) and no rearrangements had occurred in other 
sites of the EBV-BACs constructs (Supplementary Figure 9, Appendix), as the restriction 
patterns were identical to those of the BAC DNA constructs originally transfected (see section 
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2.3.3.3.3). Production of infectious virus was tested by transient transfection of BZLF1 and 
BALF4 expression plasmids [457,458], as described in section 2.2.9, and the cell culture 
supernatants were used to infect Raji cells. A 293 clone carrying the type 1 EBNA-2 EBV-BAC 
was included in the analysis. Counts of GFP-positive cells, which represent a measure of 
infectivity, allowed identification of clones producing virus (Figure 4.9). One individual 293 
clone, carrying a correct C2 E2 EBV-BAC construct and able to produce good titres of virus, 
was chosen and used throughout all the experiments reported in this section. Analysis of the GFP 
expression of this cell line by flow cytometry confirmed that 100% of the cells analysed were 
GFP-positive and therefore ensured that the EBV-BAC construct (which contains a GFP 
cassette) was present in the whole cell population (Supplementary Figure 7 in the Appendix) 
 
 
 
 
Figure 4.9. 293-C2 E2 EBV-BAC clonal cell lines tested for virus production 
293-C2 E2 EBV-BAC clonal cell lines were transfected with BZLF1 and BALF4-expressing plasmids (section 
2.2.9). 10-fold serial dilutions of the culture supernatants were then used to infect Raji cells. Infectivity was assessed 
by counting the number of GFP-positive cells (Green Raji Units, GRU) on an inverted fluorescent microscope and is 
expressed as GRU/µl of viral preparation. 293-T1 E2 EBV BAC cell line was included as a positive control. Each 
viral preparation was titrated in duplicate. Error bars represent standard errors. 
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4.2.6.2  Regulation of LMP-1 and CXCR7 genes during infection of primary B cells 
with BAC-EBV expressing EBNA-2 chimaera 2 
In order to compare host and viral gene regulation associated with type 1 and chimaera 2 EBNA-
2 during infection of primary B cells, equal amounts (5000 GRUs) of the BAC-derived EBV 
recombinant viruses, expressing either type 1 or chimaera 2 EBNA-2, were used to infect 
aliquots of 2 x 106 human primary B cells. Similarly to the experiment reported in section 
3.2.3.2.2, proteins and RNA samples were prepared from the infected cells at early time-points 
following infection (1, 2, 4 and 8 days) and analysed by western blotting and RT-PCR, 
respectively. Western blot analysis for EBNA-2 indicated that the type 1 and chimaeric EBNA-2 
proteins were correctly expressed (Figure 4.10 A).  
RT-PCR analysis of LMP-1 mRNA showed that chimaera 2 induced LMP-1 mRNA expression 
as effectively as type 1 EBNA-2 (Figure 4.10 B). The C-terminal third of type 1 EBNA-2 is thus 
sufficient to confer wild-type type 1 LMP-1 expression levels when swapped in a type 2 EBNA-
expressing virus, during EBV infection.  
CXCR7 mRNA in chimera 2-infected cells was found to be initially slightly up-regulated at day 
1 post-infection, compared to mock cells, however at the later time-points CXCR7 mRNA was 
reduced to levels that were consistently and markedly lower that those detected in type 1 EBNA-
2-infected cells (Figure 4.10 B). Hence, the C-terminus of type 1 EBNA-2 does not seem to be 
sufficient to maintain wild-type type 1 expression levels of CXCR7, when placed in a type 2 
EBNA-2-expressing virus.  
As expected, cyclin D2 mRNA levels were not detected in mock-infected cells and were detected 
at equal levels in type 1 or chimaera 2 EBNA-2-infected cells (Figure 4.10 B). Substantial 
mRNA levels of the EBNA-2 target c-MYC, were detected in mock-infected cells and were 
maintaned thereafter at similar levels throughout the time-course in both type 1 and chimaera 2 
EBNA-2-infected cells, with only a slight increase detected at the day 2 time-point in both 
infections. This observation is consistent with the results presented in section 3.2.3.2.2, showing 
that the c-MYC gene is not differentially regulated by type 1 and type 2 EBNA-2 EBV-BAC 
viruses (Figure 3.25 B).  
Similarly to the results obtained in the infection assay with type 1 and type 2 EBNA-2 EBV-
BAC recombinant viruses (section 3.2.3.2.2, Figure 3.25 B), CXCR4 mRNA down-regulation 
occurred with almost identical kinetics following infection with either type 1 or chimaera 2 
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EBNA-2-expressing viruses (Figure 4.10 B). Similar expression patterns for the genes analysed 
were observed in another independent experiment, with minor variations in the overall levels of 
expression, perhaps due to variability related to different B cell donors being used in each 
experiment.  
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Figure 4.10. Regulation of viral and host genes during infection of primary B cells with BAC- EBV expressing 
type 1 EBNA-2 or chimaera 2 EBNA-2 
2 x 106 primary B lymphocytes were infected with 5000 GRUs of EBV-BAC viruses expressing either type 1 (T1) 
EBNA-2 or chimaera 2 (chim 2). Cells were harvested at 1, 2, 4 and 8 days post-infection and proteins and total 
RNA were extracted. Samples from uninfected cells, harvested at the day 0 time-point, were also analysed. (A) 
Whole protein extracts from each well of infected cells were loaded on an SDS-PAGE gel and subjected to western 
blot analysis using the anti-EBNA-2 antibody (PE2) and the anti-CXCR7 antibody. Protein apparent molecular 
weight (in kDa) is shown. The blots were re-probed for ß-actin to show the total amount of protein recovered from 
each sample. (B) RT-PCR analysis of total cell RNA using LMP-1, CXCR7, CXCR4, cyclin D2, c-MYC and 
GAPDH specific primers. RNA from an LCLs established with T1 EBNA-2 EBV-BAC was included in the 
analysis. p.i.: post-infection; ntc: no template control. 1 representative experiment of 2 is shown.  
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4.2.6.3  Detection of CXCR7 protein in chimaera 2 EBNA-2 EBV-BAC-infected 
primary B cells 
Total expression levels of CXCR7 were analysed at the protein level by western blotting during 
infection with chimaera 2 EBNA-2-expressing virus (Figure 4.10 A). CXCR7 protein was found 
to be up-regulated following infection with type 1 EBNA-2 expressing virus, compared to 
uninfected cells, with a strong induction at days 4 and 8, consistent with the experiment reported 
in Figure 3.25 (section 3.2.3.2.3). In this experiment, however, only the glycosylated species of 
CXCR7 (>150 kDa and around 76 kDa) could be detected but not the unmodified protein 
(approximately 50 kDa) (Figure 4.10 A). Likewise, CXCR7 protein levels were induced in cells 
infected with the chimaera 2-expressing virus, compared to mock-infected cells, since the early 
time-points analysed but the level of CXCR7 was less than in type 1 infected cells, especially at 
the 4 and 8 days time-points. Somewhat lower amounts of total proteins were recovered from 
chimaera 2 EBNA-2 infected cells, as indicated by the β-actin immunoblot, due to slower 
proliferation of these cells compared to type 1 EBNA-2-infected cells (see following section). 
However, even when taking into account β-actin levels, CXCR7 protein levels can be considered 
less abundant in chimaera 2 EBNA-2 infection, compared to type 1 EBNA-2-infected cells.  
 
Surface expression of CXCR7 in primary B cells infected with type 1 and chimaera 2 EBNA-2-
expressing recombinant EB viruses was detected by flow cytometry. Consistent with the results 
reported in section 3.2.3.2.3, only a small fraction of the infected cells analysed was positive for 
CXCR7 expression. Only moderate differences were detected between type 1 and chimaera 2 
EBNA-2 EBV-BAC virus-infected cells (15.3% and 8.6% of CXCR7-positive cells respectively, 
Figure 4.11). These observations were confirmed in another independent experiment. 
Collectively these analyses of CXCR7 protein expression levels indicate that there are only 
modest differences between type 1 and chimaera 2 EBNA-2 EBV-BAC-infections but there do 
appear to be some differences in regulation of CXCR7. 
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Figure 4.11. Detection of CXCR7 surface expression by flow cytometry in primary B cells infected with type 1 
and chimaera 2 EBNA-2 EBV-BAC 
1 x 106 primary B cells were either infected with 2500 GRU of the EBV-BAC recombinant viruses (expressing type 
1 or chimaera 2 EBNA-2) (B) or left uninfected (mock) (A). 2 days post-infection, cells were stained with the APC-
cross-linked anti-human CXCR7 antibody (CXCR7-APC), or with the APC-conjugated isotype control antibody 
(iso-APC) and analysed by flow cytometry. Mock-infected cells were stained at the day 0 time-point. The left hand-
side panels represent the scatterplots (forward and side scatter) of the mock (A) and virus (B) -infected cells. The 
oval (R3) defines the gated population. The histograms show the fluorescence of stained cells detected in the APC 
channel for either mock-infected (A) or virus-infected (B) cells. R4 represents the percentage of fluorescent cells 
and is set such that < 1 % of mock-infected cells are APC-postive when stained with the isotype antibody. Numbers 
displayed in each histogram plot indicate the percentage of APC-positive cells, which represents a measure of cells 
expressing surface CXCR7. The results shown here were obtained from the same experiment showed in figure 3.28. 
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4.2.6.4  Attempt to establish LCLs following infection of primary B cells with 
EBNA-2-chimaera 2 EBV-BAC virus 
To test whether chimaera 2 EBNA-2-recombinant virus is able to give rise to LCLs, primary B 
cells (106 cells) were infected with 5-fold serial dilutions of viral preparation, starting from 8000 
GRUs, as described in section 2.2.13 and their outgrowth was followed over time. During the 
first days following infection, upon microscopical observation, cells infected with the chimaeric 
EBNA-2-bearing virus displayed a cell morphology typical of activated virus-infected cells and a 
strong tendency to form clusters, similarly to type 1 EBNA-2 virus-infected B cells. However, 
live cell count analysis demonstrated that at already 1 week after infection, chimaera 2 EBNA-2-
infected cells were proliferating slightly less than type 1 EBNA-2 EBV-BAC-infected cells 
(Figure 4.12) and marked differences in proliferation levels were detected at 2 and 3 weeks post-
infection. For example, 3 weeks after infection, live cell counts for cells initially infected with 
1600 GRU of type 1 EBNA-2 EBV-BAC were approximately 9-fold higher than those displayed 
by cells infected with equal amounts of chimaera 2 EBNA-2 (Figure 4.12). Ultimately, no LCLs 
were established from chimaera 2 EBNA-2-virus-infected cells, even though culture conditions 
were identical to those applied to type 1 EBNA-2-LCLs. The latter cells could be expanded very 
easily and were transferred to tissue culture flasks within 6 weeks after the initial infection. 
Chimaera 2 EBNA-2 EB virus was unable to give rise to permanently growing LCLs following 
infection of primary B cells in 3 independent experiments. Thus, the results indicate that the C-
terminal region of type 1 EBNA-2, when swapped into a type 2 EBNA-2 EBV-BAC virus, is not 
sufficient to growth-transform primary B cells into permanently proliferating LCLs.  
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Figure 4.12. Live cell counts of type 1 and chimaera 2 EBNA-2 EBV-BAC transformants 
106 primary B cells were either left uninfected (mock) or infected with 5-fold serial dilutions of recombinant EBV-
BAC viruses (8000, 1600 and 320 GRUs) expressing either type 1 (T1) or chimaera 2 (C2) EBNA-2. Infected cells 
were maintained in culture over time in order to establish LCLs and cell proliferation levels were assessed by 
counting the number of live cells on a haemocytometer at each week post-infection (p.i.). Error bars represent 
standard deviations. Data from 1 representative experiment of 3 is shown.  
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To test whether the inability of the chimaera 2 EBNA-2 virus to growth-transform primary B 
cells is due to aberrant expression of the other EBV latent antigens, western blot analysis of 
chimaera 2 recombinant virus-infected cells, in comparison to type 1 EBNA-2 virus-expressing 
cells, was performed at 1 week post-infection (Figure 4.13). Because the experiment was 
perfomed only on a small scale (2 x 106 B cells and 5000 GRUs), limited amounts of the protein 
samples were available and only a restricted number of EBV-latent antigens could be succesfully 
detected by western blot analysis with repeated stripping and reprobing. Furthermore, because 
chimaera 2 EBNA-2-infected cells proliferate slighlty less than cells infected with type 1 EB 
virus, total protein extracts obtained from the former cells were slightly less abundant, as 
demonstrated by the ß-actin immunoblot (Figure 4.13). Hence expression levels of the EBV 
antigens tested are consistently somewhat lower in chimaera 2 EBNA-2-infected cells compared 
to type 1, and the total protein content of the samples was not enough to allow detection of some 
antigens (i.e. LMP-1, see later) by western blot. The immunoblot analysis for EBNA-2 revealed 
that the wild-type type 1 and chimaera 2 proteins were expressed at approximately equal levels 
(Figure 4.13), consistent with the experiment shown in figure 4.10 A. Similarly to the wild-type 
type 1 virus, the chimaeric recombinant EBV expresses 5- and a 4-repeat EBNA-LP, EBNA-1 
and EBNA-3C proteins of the expected size, with minor differences in abundancy (Figure 4.13). 
Very low levels of LMP-1 could be detected in type 1 EBNA-2-infected cells and only traces of 
the latent membrane protein were detected in chimaera 2 EBNA-2-infection. However, this 
difference is likely to be due to lower amounts of total proteins being recovered from chimaera 
2-infected samples. Similar results were obtained in an another experiment. In summary, the 
EBV-BAC virus expressing chimaera 2 EBNA-2 does indeed express EBV proteins of the 
correct size confirming that no second-site mutations have occurred in the genome of the 
chimaeric EBNA-2 recombinant virus.  
 
Taken together these results suggest that the C-terminus of type 1 EBNA-2, when swapped into a 
type 2 EBNA-2-expressing recombinant virus, is able to give approximately type 1 mRNA 
expression levels of LMP-1, but not of CXCR7, during primary infection and is not able to 
maintain long-term outgrowth of virus-infected B cells.  
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Figure 4.13. Western blot analysis of expression of latency-associated EBV proteins in type 1 and chimaera 2 
EBNA-2 EBV-BAC-infected primary B cells 
2 x 106 primary B cells were infected with 5000 GRU of either type 1 (T1) or chimaera 2 (C2) EBNA-2 EBV-BAC 
viruses and proteins were RIPA-extracted 1 week post-infection. Uninfected cells (mock) harvested at the day 0 
time-point were included in the analysis. Whole protein extracts prepared from each well of infected cells were 
fractionated by SDS-PAGE and analysed by immunoblotting with spefic antibodies in order to detect the EBV latent 
proteins EBNA-2, -LP, -1, -3A, -3C and LMP-1. The membranes were consecutively stripped and reprobed. ß-actin 
immunoblot shows the total amount of proteins (slighlty higer in type 1-infected cells, since they proliferate faster 
than chimaera 2-infected cells). Results from 1 representative experiment of 2 are shown.  
 
 
 
 
 
261 
 
4.3  Discussion 
The experiments presented in this chapter provide the first functional identification of the 
EBNA-2 protein regions that are the key determinants of the enhanced ability of the type 1 
EBNA-2 to promote B cell growth, compared to the type 2. For this, the EREB2.5 trans-
complementation system, that was previously used to map the domains of the type 1 EBNA-2 
required for B cell transformation [157,291,292,293], was adapted into an assay that 
discriminates between type 1 and type 2 EBNA-2–induced B cell proliferation [348]. From the 
EBNA-2 chimaeras tested in the EREB2.5 growth assay, chimaeras 2 and 7 indicated that the 
RG, CR7 and TAD are the minimum type 1 sequences required to confer a type 1 growth 
phenotype to a type 2 EBNA-2 protein in oestrogen-deprived EREB2.5 cells (Figure 4.2 B and 
C). This result was quite surprising and unexpected as most of the sequence variation between 
type 1 and type 2 EBNA-2 lies in the N-terminal half of the protein, mostly in the diversity 
region (Figure 4.2 A) and not in the C-terminal part. In fact, in the C-terminal region the 
sequence identity between the two types of EBNA-2 proteins is 62%, whereas in the N-terminal 
part this is 48% and only 30% in the diversity region. Importantly, in the EREB2.5 assay the 
growth phenotype correlated with the ability of the EBNA-2 proteins to induce LMP-1 and 
CXCR7 genes. Type 1 EBNA-2 and chimaeras 2 and 7 maintained high levels of expression of 
those genes, which in turn drive continuous proliferation of the cells leading to LCLs 
establishment (Figures 4.4), whereas in cells expressing type 2 EBNA-2, LMP-1 and CXCR7 
were not maintained at the physiological levels required for continuous proliferation, causing the 
cells to cease growth and ultimately die (Figure 4.4). These observations indicate that the C-
terminus of type 1 EBNA-2 protein confers the ability to give sufficient expression levels of 
those genes that are essential for EBV-LCL proliferation (LMP-1, CXCR7). In summary, the 
results obtained using the EREB2.5 growth assay indicate that the mechanism that accounts for 
the superior ability of type 1 EBNA-2 to sustain B cell growth, compared to the type 2, is higher 
induction of LMP-1 and CXCR7 mediated by the C-terminal part of the protein.  
 
The TAD of EBNA-2 is a strong transcriptional activator and is essential for EBNA-2-mediated 
activation of viral and cell genes and B cell transformation, since viruses lacking this domain are 
immortalisation-incompetent [305,308]. The TAD mediates transcriptional activation at EBNA-2 
target promoters by recruiting histone acetyltransferases (HAT) p300/CBP and PCAF [260] and 
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several host transcription factors, including TFIIH [328], TAF40, TFIIB [329] and co-activator 
p100 that interacts with TFIIE [330]. The RG sequence is involved in protein-protein and 
protein-nucleic acid interactions and is important for efficient B cell growth transformation 
[313]. The RG element down-regulates EBNA-2 activation of the LMP-1 promoter but not of the 
Cp [313]. The CR7 has been shown to be dispensable for B cell growth transformation, although 
is important for transcriptional cooperation with EBNA-LP [313]. In addition to CR7, the RG 
and TAD domains have also been shown to be involved in EBNA-2/EBNA-LP transcriptional 
cooperation. In fact, the TAD of EBNA-2 has been demonstrated to be required for EBNA-LP 
co-activation with EBNA-2 in the context of LMP-1 promoter-reporter assays and represents a 
specific binding site for EBNA-LP, as demonstrated by in vitro binding assays [141]. Moreover, 
the RG and CR7 elements are able to down-regulate the high intrinsic transcriptional activity of 
EBNA-2 TAD in the context of Gal4 DNA-binding fusions, suggesting a modulatory activity of 
these domains on EBNA-LP function [193]. EBNA-LP has been shown to enhance EBNA-2-
mediated transcriptional activation of both viral and cell promoters (LMP-1/LMP-2B, Cp and 
cyclin D2) [138,139,140,141,142]; the mechanism of cooperative function is not entirely clear 
but has been proposed to involve interaction with histone deacetylase 4 [192]. EBNA-2 and 
EBNA-LP proteins do not significantly associate in lymphoblasts, as demonstrated by co-
immunoprecipitation and immunofluorescence assays in previous studies [141,142] and it has 
therefore been suggested that EBNA-LP co-activation with EBNA-2 takes place only when 
transient unstable interactions are established, which would allow recruitment of positive 
transcriptional regulators to the EBNA-2 TAD at EBNA-2-specific promoters [141].  
 
The mapping studies in the EREB2.5 growth assay suggest that the difference in LMP-1/CXCR7 
activation and therefore in growth phenotype observed between type 1 and type 2 EBNA-2 is 
determined by different mechanisms of transcriptional activation, mediated by the TAD of 
EBNA-2 and modulated by cooperation with EBNA-LP, through the RG, CR7 and TAD EBNA-
2 elements. These results are consistent with the crucial roles played by the EBNA-2 TAD-
mediated transcriptional activation and the EBNA-LP cooperative function during the EBV-
driven B cell transformation process [139,140,308]. Future studies will include additional 
detailed mutational analysis of the RG, CR7 and TAD sequences in order to identify the amino 
acids that are the key determinants of the differing abilities of type 1 and type 2 EBNA-2 to 
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transactivate target genes, and therefore sustain B cell growth. At the biochemical level the 
differences between type 1 and type 2 transcriptional activation may be determined by 
differences in cell transcription factors or histone acetyltransferases recruited by type 1 EBNA-2 
TAD, compared to the type 2, resulting in higher induction of LMP-1 and CXCR7. It is 
noteworthy in this context that EBNA-2 regulation of the LMP-1 promoter occurs mainly 
through other cell transcription factors such as PU.1, rather than RBP-Jk 
[255,256,257,258,259,260]. It will be interesting to determine in the future whether a similar 
situation exists at the CXCR7 promoter. Future work will be devoted to investigate and compare 
the biochemical interactions established by the two EBNA-2 proteins with host transcriptional 
regulatory proteins, through their TAD domains, using for example tandem-affinity purification 
technique. Additionally, type 1 and type 2 RG and CR7 sequences may differ in their ability to 
cooperate with EBNA-LP and thereby modulate the transcriptional activity of the TAD. 
Although EBNA-LP co-activation function has been shown to occur at the LMP-1 promoter 
[139,140], it is not known whether this occurs also at the CXCR7 promoter. Therefore, further 
work will be required to elucidate the importance of EBNA-LP for EBNA-2-mediated 
transcriptional activation of the CXCR7 gene.  
 
Recent studies suggest that the type 1 RG element is highly methylated on its arginine residues, 
in either a symmetric or an asymmetric fashion [490]. Symmetrically dimethylated arginine 
(sDMA) residues have been shown to enable EBNA-2 binding to the survival motor neuron 
protein (SMN), which is involved in RNA metabolism and in transcriptional regulation by co-
activating the RNA-polymerase II transcription complex [261]. SMN has been also found to 
activate the LMP-1 promoter in the presence of EBNA-2 in reporter gene assays [261,333]. 
Asymmetric dimethylation of the RG sequence has been shown to promote EBNA-2 targeting at 
the viral promoters LMP-1, LMP-2A and Cp via association with RBP-Jk. [490]. Given the 
functional importance of methylation of the type 1 EBNA-2 RG element in LMP-1 regulation, it 
might be therefore interesting to investigate the methylation status of the type 2 EBNA-2 to 
assess whether different RG methylation patterns in type 1 and type 2 EBNA-2 may account for 
the different abilities of these two proteins to induce LMP-1 and therefore sustain B cell 
proliferation.  
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Most of the previous studies of EBNA-2 functional domains have involved the type 1 EBNA-2 
and only a few have compared the type 1 and the type 2 proteins. One study focussed on the 
interaction between EBNA-2 and hSNF5/Ini1, a component of the host chromatin remodelling 
complex SWI/SNF, and showed that this interaction takes place with both EBNA-2 alleles in a 
yeast two-hybrid system [315]. EBNA-2-hSNF5/Ini1 association maps to two key sites of 
EBNA-2 protein, one within the divergent domain (IPP286, where only one amino acid is 
different between type 1 and type 2 EBNA-2, see Supplementary Figure 1 in the Appendix) and 
one in the RBP-Jk binding domain (DQQ313, identical in the two EBNA-2 alleles, 
Supplementary Figure 1, Appendix). It also requires phosphorylation of a consensus CKII site at 
position 469, which displays an identical sequence in type 1 and type 2 EBNA-2 [314]. Those 
data suggest that interaction with hSNF5/Ini1 and chromatin modification, although important 
for growth-transformation of type 1 EBNA-2, is not likely to be the key mechanism that accounts 
for the differences in transcriptional activation and transforming phenotype between type 1 and 
type 2 EBNA-2. The mapping analysis performed in the present study is in line with those 
previous observations since chimaera 1, comprising the N-terminus of type 1 EBNA-2 (which 
contains the hSNF5/Ini1 binding sites) and the C-terminus of type 2 EBNA-2, did not display a 
type 1 growth phenotype in the EREB2.5 system (Figure 4.2 B and C). Furthermore, the result 
showing that a null growth phenotype is obtained with chimaera 1, which contains a type 1 RBP-
Jk binding domain (Figure 4.2 B and C), is in agreement with a previous study showing that type 
1 and type 2 EBNA-2 are equivalent in binding to RBP-Jk in EMSA assays [300], confirming 
that RBP-Jk-mediated transactivation of EBNA-2 target genes is not the key mechanism that 
accounts for the higher transforming ability of type 1 EBNA-2. In another study the TADs from 
type 1 and type 2 EBNA-2 were found to display similar levels of transcriptional activities in 
CAT assays when fused to the Gal4 DNA-binding domain [312]. Those findings suggested that 
additional portions of EBNA-2 protein contribute to transactivation. This is consistent with the 
results presented in the present study showing that a chimaeric type 2 EBNA-2 protein bearing 
type 1 TAD and NLS (chimaera 4) is not able to rescue proliferation of oestrogen-depleted 
EREB2.5 cells (Figure 4.2 B and C). This also further strengthens the idea that, in addition to the 
TAD-mediated transactivation, other mechanisms (i.e. transcriptional cooperation with EBNA-
LP) mediated by other portions of EBNA-2 (i.e. RG and CR7) are important for EBNA-2 
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transcriptional activation and may account for the differences in transactivation/B cell 
transformation phenotypes between the type 1 and type 2 proteins (Figure 4.2 B and C).  
 
Since EBNA-LP has been shown to exert a synergistic effect on EBNA-2-mediated induction of 
LMP-1 [139,140], it was important to clarify which EBNA-LP species are expressed in the 
EREB2.5 cell system (Figure 4.7). A type 1 3-repeat full-length EBNA-LP (encoded by the 
endogenous p554-4 plasmid, expressing the ER-EBNA-2) and a type 2 Y1Y2-truncated isoform, 
encoded by the resident P3HR1 EBV genome were detected (Figure 4.7). Similarly to the 
Daudi/P3HR1 cl.16:ER-EBNA-2 system (Figures 3.5 and 3.6), it might be speculated that the 
absence of a full-length type 2 EBNA-LP could account for the null growth phenotype and the 
weaker induction of LMP-1/CXCR7 observed in the presence of type 2 EBNA-2. However, the 
experiment illustrated in Figure 4.8 clearly demonstrates that this is not the case, since even in 
the presence of a full-length type 2 EBNA-LP (with 3 W repeat domains) the inability of type 2 
EBNA-2 at maintaining cell proliferation was not complemented. Therefore the EREB2.5 
growth assay functionally distinguishes between the ability of type 1 and type 2 EBNA-2 to 
sustain cell proliferation, which is likely to be enhanced by cooperation with EBNA-LP but is 
not influenced by the type of EBNA-LP present in the system. A role in protection from caspase-
induced apoptosis has been proposed for the Y1Y2-truncated type 2 EBNA-LP species in BL 
cell lines [194] but the significance of this function in the EREB2.5 growth assay has not been 
determined during this thesis work.  
 
Expression of a full-length type 1, but not type 2, EBNA-LP protein in EREB2.5 assay is a 
feature common to two other systems used in this study, the Daudi/P3HR1 cl.16:ER-EBNA-2 
cell lines and the infection assays with the EBV-BAC recombinant viruses. The finding that the 
inability to maintain long-term growth in the EREB2.5 assay by type 2 EBNA-2 is not affected 
by the type of EBNA-LP present (Figure 4.8) is consistent with results obtained in the functional 
assay for EBNA-LP in Daudi cells (Figure 3.10), which showed that the weaker induction of 
LMP-1 is independent of the type of EBNA-LP expressed in the cells. Collectively the data 
support the idea that the growth phenotype (Figure 3.29) and LMP-1 expression levels (Figure 
3.25 B) induced by type 2 EBNA-2-expressing BAC virus during primary infection (section 
3.2.3.2) are not affected by the absence of a type 2 EBNA-LP.  
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The finding that type 2 EBNA-2 cannot rescue proliferation of oestrogen-starved EREB2.5 cells 
when expressed in trans in the EREB2.5 assay (Figure 4.2 B and C) is somehow surprising, if 
one considers that a type 2 EBV virus is able to eventually establish LCLs upon infection of 
primary B cells, albeit with very low efficiency (section 3.2.3.2.4 and [414]). In the previously 
published studies demonstrating the different transforming phenotype of type 1 and type 2 EBV 
using primary B cell infection experiments with either wild-type or recombinant type 1 and type 
2 EBV viruses [155,414], the cell dilution was shown to be a critical factor for type 2 EBNA-2 
viruses to growth-transform resting B cells. However, experiments previously performed in this 
laboratory with the EREB2.5 system, showed that different cell concentrations did not influence 
the null growth phenotype of type 2 EBNA-2. The difference in growth phenotype determined 
by type 2 EBNA-2 during infection and in the EREB2.5 trans-complementation assay might be 
ascribed either to the truncated EBNA-LP protein present in the latter assay, or to additional 
factors linked to the virus-B cell interaction occurring during the process of infection. These 
include virus attachment to the cell, signalling induced by gp340/220–CD21 binding, virus entry 
into the cell, activation of B cells, cell cycle entry, EBV genome circularization, amplification of 
EBV genomes in the infected cells, latency promoter usage switch (Wp/Cp), clonal expansion 
and finally maintenance of the immortalised state of the LCL [52]. All these early events might 
act as compensatory mechanisms for the poor ability of type 2 EBNA-2 to induce B cell 
proliferation. For example, while most of the established LCLs usually express low levels of 
only one or a few EBNA-LP species, during initial infection of primary B cells by EBV several 
isoforms of EBNA-LP are expressed at very high levels and this might help to complement the 
low transactivation and transformation potential of the type 2 EBNA-2. Moreover, LCL 
outgrowth following initial EBV infection of naïve resting B cells is a stochastic event whereby a 
few cells with the correct levels of expression of those genes required for B cell proliferation 
(e.g. CXCR7, LMP-1) are selected and clonally expanded. In the infection experiment with type 
1 and type 2 EBNA-2 EBV-BACs (Figure 3.25 B), while type 1 infected cells maintained high 
levels of CXCR7 mRNA, in type 2 infected cells induction of this gene was weaker and less 
consistent, but was not completely eliminated. Similarly, LMP-1 mRNA was promptly up-
regulated by type 1 EBNA-2, whereas there was a lag in the induction of this gene in type 2 
EBNA-2-infected cells and overall expression levels were markedly lower compared to type 1 
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infection. Therefore it seems likely that slower and lower expression of LMP-1/CXCR7 induced 
by type 2 EBNA-2-expressing virus during the initial stages of infection accounts for the low 
transforming efficiency displayed by this viral type. However, once a few cells, infected with 
type 2 EBV, eventually express the correct levels of LMP-1/CXR7, these cells are selected and 
can be amplified to give rise to an LCL. In fact, in both type 1 and type 2 established LCLs, 
LMP-1 and CXCR7 expression levels were ultimately approximately similar (Figure 3.25 B and 
[348]).  
 
The result that the chimaera 2 EBNA-2 expressing EBV-BAC virus failed to transform primary 
B cells into LCLs (Section 4.2.6.4) was unexpected because the EBNA-2 chimaera 2 protein was 
found to be able to maintain growth of oestrogen-starved EREB2.5 cells (Figure 4.2). 
Collectively, the results obtained regarding the chimaera 2 EBNA-2 mutant indicate that the type 
1 C-terminus of EBNA-2, when swapped into a type 2 protein, is able to maintain the 
immortalised state of EBV-LCLs but is not sufficient to growth-transform primary B cells into 
LCLs. The defective transforming phenotype displayed by the EBNA-2 mutant virus is not due 
to rearrangements in the EBV-BAC genome occurred during the cloning process (Figure 2.18 
and Supplementary Figure 8 in the Appendix) or to lack of expression of EBV latent antigens 
(Figure 4.13). RT-PCR analysis of EBNA-2 target RNAs during primary infection indicated that 
the chimaeric EBNA-2 virus was able to induce approximately type 1 levels of LMP-1 mRNA 
during the early stages of infection (1 week post-infection, Figure 4.10 B) and this might account 
for the initial phase of proliferation observed during the first 1-2 weeks post-infection (Figure 
4.12). However, CXCR7 mRNA levels were substantially inferior to those induced in cells 
infected with the wild-type type 1 EBNA-2-expressing virus (Figure 4.10 B). Thus, insufficient 
levels of CXCR7 mRNA may be one of the reasons why chimaera 2 EBNA-2 virus is not able to 
permanently transform primary B cells into LCLs. This observation further reinforces the idea 
that CXCR7 is an essential gene for perpetual proliferation of EBV-LCLs, but also raises the 
question why chimaera 2 EBNA-2 is able to induce sufficient levels of CXCR7 in the EREB2.5 
LCL but not during primary B cells infection. In fact, the inability of the chimaera 2 EBNA-2-
expressing virus to maintain type 1 levels of CXCR7 mRNA and therefore continuous growth of 
the cells is in contrast to the results obtained in the EREB2.5 growth assay, where chimaera 2 
EBNA-2 was able to induce approximately wild-type type 1 levels of CXCR7 mRNA and 
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thereby rescue proliferation of oestrogen-deprived EREB2.5 cells (Figure 4.4). There are critical 
differences between the trans-complementation approach in the EREB2.5 cell line and the 
growth-transformation assays using primary B cells. The former assay only determines the 
ability of an ectopically expressed mutant EBNA-2 proteins to rescue long-term growth of EBV-
immortalised LCLs, whereas the latter system measures the ability of recombinant viruses 
carrying the mutated EBNA-2 genes to both initiate and maintain immortalisation of primary B 
cells. As mentioned before, the process of transformation of B cells into LCLs is a complex 
phenomenon involving many stages (see before) therefore it is likely that some of the events 
related to the virus-B cell interaction process may be responsible for the inability of the chimaera 
2 EBNA-2 virus to maintain wild-type type 1 levels of CXCR7 and may therefore hinder the 
ability of this virus to growth-transform primary B cells. It is possible that CXCR7 regulation 
during primary infection might be more complex than it is present in established EBV-LCLs. For 
example, the interplay between CXCR7 and CXCR4 might be of particular relevance. In fact, 
CXCR4 protein and RNA expression levels are quite high in resting uninfected B cells but are 
rapidly repressed upon EBV infection and are ultimately very low in EBV-LCLs (Figures 3.25 B 
and 4.10 B and [472,473]). Therefore, the concomitant modulation of CXCR4 that takes place 
during the early stages of infection, but not in an established EBV-LCL, may be relevant for 
regulation of CXCR7 by EBNA-2 and this will certainly merit further investigation. It is also 
quite possible that some epigenetic modifications of the CXCR7 promoter required for its long-
term activity, have already been made in the EREB2.5 LCL but are not established by EBNA-2 
chimaera 2 in the context of a primary B cell infection.  
Additionally, as mentioned before, the differing phenotypes obtained with the chimaeric EBNA-
2 protein in primary infection experiments and in the EREB2.5 assay might be due to the 
presence of the truncated EBNA-LP protein in the latter system. To test whether this is the case, 
an OriP plasmid expressing a type 2 truncated EBNA-LP protein could be transfected into 
primary B cells infected with a chimaera 2 EBNA-2 EBV-BAC, within 1-2 weeks after initial 
infection, prior to loss of proliferation observed in these infected cells (Figure 4.12). This 
experiment would allow one to determine whether a type 2 Y1Y1-truncated EBNA-LP could 
rescue the inability of the EBNA-2 chimaera 2 EBV-BAC to maintain sufficient CXCR7 mRNA 
expression levels and permanent proliferation of the infected B cells. If this were true, then it 
would be interesting to investigate the underlying mechanism. This is unlikely to involve 
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transcriptional cooperation with EBNA-2, because the majority of EBNA-LP cooperative 
function has been mapped to the W region whereas the Y1Y2 domains have been suggested to be 
dispensable for this function [139,140]. In this respect, the Y1Y2-truncated EBNA-LP would be 
functionally equivalent to the full-length type 1 EBNA-LP isoforms already encoded by the 
EBV-BAC viruses. An alternative mechanism to take into account could be protection from 
apoptosis through inibition of protein phosphatase 2A, a novel function attributed to Y1Y2-
truncated EBNA-LP proteins in BL cell lines [194]. It might be also interesting to test whether 
the growth efficiency of chimaera 2 EBNA-2 EBV-BAC virus could be improved by culturing 
the infected lymphocytes on irradiated human diploid fibroblasts, a strategy often used to provide 
paracrine B cell growth factors that can enhance B cell proliferation [457,491].  
 
Differential regulation of CXCR7 mRNA by type 1 and chimaera 2 EBNA-2 EBV-BAC was not 
consistent with the protein expression data obtained by western blot and flow cytometry (section 
4.2.6.3) showing that there are no major differences in both total and surface CXCR7 protein 
expression levels in cells infected with type 1 and chimaera 2 EBNA-2 EBV-BAC. However, as 
discussed in section 3.3, not very much is known so far about the regulation of CXCR7 protein 
in B cells and it is possible that several isoforms are present, perhaps due to various post-
translational protein modification mechanisms. There are also considerable uncertainties about 
the extent to which particular CXCR7 antibodies may recognise sub-populations of the the 
protein (section 1.8.4 and [390,480]). 
 
In summary, the data reported in this chapter demonstrates that the C-terminal region of type 1 
EBNA-2, when swapped into a type 2 protein, is the key determinant of the differing abilities of 
type 1 and type 2 EBNA-2 to sustain EBV-LCL cell proliferation and is able to induce sufficient 
levels of genes (LMP-1 and CXCR7) required for continuous proliferation of EBV-infected 
LCLs. However, when the C-terminus of type 1 EBNA-2 was swapped into a type 2 EBNA-2-
expressing EBV-BAC virus and tested in primary B cell infection assays, no permanently 
growing LCLs could be established. This mutant EBNA-2 virus was able to induce, during early 
stages of infection, approximately wild-type type 1 expression levels of LMP-1 mRNA, but not 
of CXCR7, suggesting that lack of sufficient levels of CXCR7 may account for the deficient 
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growth phenotype and that regulation of CXCR7 by EBNA-2 might be more complex in the 
context of primary B cell infection compared to immortalised EBV-LCLs.  
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5  Final discussion: summary and future directions 
 
This study shed light on the mechanism underlying a remarkable functional difference between 
type 1 and type 2 EBV, namely the poorer in vitro transforming ability of type 2 strains of EBV, 
compared to type 1. The greater transforming activity of type 1 EBV was found to correlate with 
a stronger and more rapid induction of the viral oncogene LMP-1 and the cell gene CXCR7 
(which are both required for proliferation of EBV-LCLs) during infection of primary B cells with 
EBV-BAC recombinant viruses. The enhanced ability of type 1 EBNA-2 to induce LMP-1 and 
CXCR7 genes was also confirmed using BL cell lines with oestrogen-regulated type 1 and type 2 
EBNA-2 proteins. In order to identify the regions of the EBNA-2 protein that may account for 
the enhanced ability of type 1 EBNA-2 EBV to promote B cell proliferation, a functional assay 
based on the EREB2.5 cell line, which allows discrimination between type 1 and type 2 EBNA-
2-induced EBV-LCL growth, was used. Surprisingly, although the major sequence differences 
between type 1 and type 2 EBNA-2 lie in N-terminal parts of the protein, the superior ability of 
type 1 EBNA-2 to sustain proliferation of EBV-infected lymphoblasts is mostly determined by 
the C-terminus of EBNA-2. Substitution of the C-terminus of type 1 EBNA-2 into the type 2 
protein was sufficient to confer a type 1 growth phenotype as well as type 1 expression levels of 
LMP-1 and CXCR7 in the EREB2.5 cell growth assay. Within this region, the RG, CR7 and 
TAD domains are the minimum type 1 sequences required. Sequencing the C-terminus of 
EBNA-2 from additional EBV isolates showed high sequence identity within type 1 isolates or 
within type 2 isolates, indicating that the functional differences mapped are typical of EBV type 
sequences. However, when a recombinant virus expressing EBNA-2 chimaera 2 was tested in 
primary B cell infection assays, it induced type 1 expression levels of LMP-1 and a transient 
initial phase of cell proliferation, but was not able to maintain sufficient levels of CXCR7 or 
sustain long-term proliferation of the infected cells. The data suggests that EBNA-2-dependent 
regulation of CXCR7 in primary infection might be more complex than in EBV-LCLs, perhaps 
due to interplay with CXCR4. These additional levels of complexity will merit further 
investigation, but they do not affect the conclusion that the C-terminal third of the EBNA-2 
protein is the key determinant of the superior ability of type 1 EBNA-2 to maintain proliferation 
of EBV-LCLs, compared to type 2 EBNA-2.  
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The results obtained during the course of this thesis provide the first specific insight into the 
mechanism of EBV type differences and will be important for future studies of the physiological 
significance of the EBV types in normal infection and disease. In this respect, several questions 
about type 2 EBV biology should be addressed. First of all, why has EBV evolved as two viral 
subtypes? What is the significance in vivo of the defective in vitro transforming phenotype 
displayed by type 2 EBV? Are type 2 strains of EBV less lymphomagenic than type 1 in vivo? 
Finally, why has type 2 EBV evolved to be a low-competent transforming virus and how can this 
virus then efficiently colonize the host?  
 
Strain variability comparable to that found in the EBV EBNA-2 gene can also be found in other 
herpesviruses. The K1 gene of KSHV, which encodes for a transforming signalling protein 
functionally similar to EBV LMP-1 and HVS Stp, displays very high levels of sequence 
divergence relative to those observed in other portions of the KSHV genome. Based on K1 
sequence variation, 4 major subtypes (A, B, C and D) have been defined [492,493]. However, in 
contrast to the EBNA-2 alleles, which appear to be higly conserved among isolates of the same 
type (see Tables 4.1 and 4.2), KSHV K1 display high sequence divergence among individual 
isolates from the same subtype [494]. The hypervariability in the K1 gene is such that at least 13 
K1 variants can be identified [494]. Nearly 85% of the nucleotide changes in K1 variants are 
non-synonymous, suggesting that, rather than simple incorporation of random mutations, there is 
a highly selective biological mechanism at the protein level that is driving the evolution of these 
4 subtypes, and this is very likely to be due to host immune pressure. Interestingly, similarly to 
EBV type 1 and type 2, the 4 subtypes of KSHV display specific patterns of geographical 
distribution. The A and C subgroups have been isolated from KSHV-infected subjects in Europe, 
the United States, Asia and the Middle East, whereas the type D subgroup is found primarily in 
south Asia, Australia and the Pacific islands. Interestingly, type B is found almost exclusively in 
Central and Southern Africa and in African emigrants, a geographical pattern reminiscent of that 
of type 2 EBV [495]. These observations suggest that KSHV is an ancient human virus and that 
the separation of the viral groups A/C, B, and D is likely to have arisen from isolation and 
founder effects associated with the spread of modern human populations from Africa in 
paleolitic times [494,495]. In contrast to the EBV types, there does not seem to be any specific 
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association between KSHV subtypes and in vitro or in vivo phenotypes, despite K1 protein being 
important for cell transformation [15,492].  
Sequence variation in the Stp gene of HVS, defines subtypes A, B and C. Subgroup A and C 
strains immortalise common marmoset lymphocytes, but none of the subgroup B strains is 
immortalisation-competent in in vitro assays. Hence, the Stp gene can be considered similar to 
EBV EBNA-2, in that the sequence polymorphism in this genes defines the HVS viral subtypes 
and their tranforming phenotype in vitro. In contrast to EBNA-2, but similarly to the 
hypervariability found in KSHV K1, HVS Stp C type gene also displays considerable amino acid 
heterogeneity (up to 15%) among different isolates [496]. Both HSV Stp and KSHV K1 proteins 
are encoded by two distinct ORFs at the 5’ end of the viral genomes, a position in close 
proximity to the terminal repeats which represent a highly mutagenic region due to the presence 
of repetitive sequences that may undergo to homologous recombination at a high frequency [15].  
Remarkably, like EBV, a clear classification of HHV-6 into African (A) and non-African (B) 
subgroups has also been demonstrated, with sequence variability found within the nuclear 
regulatory protein IE1 (63% nucleotide identity between A and B types) and the glycoproteins 
gB and gH [497,498]. Although the HHV-6 variants are closely related, they are distinct viruses 
from a molecular and biological point of view. In fact, they differ with respect to their cell 
tropisms, interactions with cells and signaling pathways of the immune system, DNA sequences, 
and epidemiology [498,499,500,501]. Because of these differences, HHV-6 A and B have been 
suggested to be considered distinct herpesvirus species, however, they have not yet been 
formally recognised as such [501,502]. 
Among rhesus lymphocryptoviruses (LCVs), two viral types, similar to type 1 and type 2 EBV 
have been identified. These rhesus LCV strains displayed genetic polymorphism in their EBNA-
2 genes (approximately 40% amino acid identity) comparable to those occurring between type 1 
and type 2 EBV EBNA-2 (approximately 55% of amino acid identity) [294,503]. Similarly to 
type 1 and type 2 EBV, both types of LCVs have oncogenic potential as the first two isolates 
identified were derived from B cell lymphoma biopsies from rhesus monkeys. Interestingly, one 
cell line harbouring the type 2 rhesus LCV grew very slowly in tissue culture and viral progeny 
from this line immortalised rhesus monkey primary B cells with difficulty, analogous to the 
situation observed for type 2 EBV. However, it is not possible to determine whether this in vitro 
growth phenotype represents a significant difference since only a single isolate from each type of 
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rhesus LCV was compared. Furthermore, the type 2 rhesus LCV isolate grown in tissue culture 
had a C-terminal deletion in the EBNA-2 gene, encompassing the nuclear localization signal, 
that was not common in other type 2 strains isolated from the same community of rhesus 
monkeys [503]. Thus, it is possible that the reduced in vitro growth phenotype of this type 2 
rhesus LCV isolate is due to this deletion, rather than the type 2 sequence in the rest of the gene. 
Nevertheless, the similar evolution of type 1 and type 2 EBV in human and non-human primates 
suggests that the type specific polymorphisms in EBNA-2 are not random, and that each allele 
instead confers a selective advantage in vivo. Hence there appears to be a common selective 
pressure in human and non human primate hosts for the evolution of two LCV types. EBV, like 
all herpesviruses, has co-evolved with its host and it is likely that the selective pressure driving 
the evolution of the two viral types is to be found in the host, as suggested for the evolution of 
the KSHV subgroups (see before). Candidate factors may be both genetic and environmental, 
including SNPs or polymorphisms in host genes, HLA alleles, co-infections with other 
pathogens, nutrition and maturity and status of the immune system. For example, it might be 
possible that the allelic variability in the EBNA-2 gene has evolved to either mimic or avoid a 
particular HLA repertoire that allows preferential viral entry and survival only in genetically 
appropriate host cells. EBNA-2 has been shown to elicit EBV-specific cytotoxic T cell 
responses, but so far it is not fully understood whether the type 1 / type 2 polymorphism in this 
gene may influence the outcome of host CTL responses [440,443,444]. Therefore host HLA-DR 
haplotypes may not be the selective pressure that has pushed EBV to evolve as two distinct viral 
types. So why are there two EBV types and what is the significance in vivo of the differences in 
growth properties ascribed to the two EBV types in vitro? Despite the clear difference in growth 
phenotype in vitro between type 1 and type 2 EBV, no type specific disease associations have 
been demonstrated so far. Extensive literature exists on the prevalence of type 1 and type 2 
strains in EBV-associated tumours but it indicates that this simply reflects the patterns of 
geographical distribution of these strains in the normal population [413,423,424] (reviewed in 
section 1.9). It is indeed surprising that type 2 EBV strains display a very poor B cell 
transformation phenotype in vitro, yet are still able to colonize the host in vivo 
[419,420,421,422]. To establish a persistent infection in vivo, EBV exploits the normal B cell 
differentiation pathway and thereby gains access to the long-lived memory B cell compartment, 
where the virus can persist [85]. The virus initially infects naïve B cells and causes them to 
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proliferate as activated B-blasts under the influence of the growth-promoting latency III gene 
expression program, in a similar fashion to what occurs in vitro [85,86,87]. The EBV-infected B-
blasts subsequently migrate into germinal centres and differentiate to become resting memory B 
cells. Certainly the critical step for the virus to gain access to its reservoir (memory B cell pool) 
is to initially establish an efficient growth-promoting program in the newly infected naïve B cells 
(reviewed in section 1.5.4.1). So how can type 2 EBV achieve this? Clues for understanding why 
type 2 EBV strains have evolved and are successful in establishing persistent infection despite 
their poor transformation potential might be also obtained if one considers the peculiar 
geographical distribution of type 2 EBV strains. In fact, type 2 EBV is not as widespread as type 
1, but seems to be able to colonize only human hosts from some specific parts of the world (i.e. 
Central Africa), suggesting that an additional factor is present in these areas that may provide a 
helper function for type 2 EBV to successfully infect the host and establish persistence. 
Interestingly, the areas where type 2 EBV is detected largely correspond to malaria holoendemic 
regions [349]. Malaria is a mosquito-borne disease and its holoendemic form is caused by the 
parasite Plasmodium falciparum. Malaria is holoendemic in most regions of Equatorial Africa, 
where there is a stable transmission of P. falciparum, characterized by recurrent exposure and 
repeated acute infections throughout the year [119]. In these regions P. falciparum is highly 
prevalent in children below 5 years of age [504] and this is approximately the same age at which 
primary EBV infection is most likely to occur. Both EBV and P. falciparum malaria have been 
identified as co-factors for the aetiology of the endemic subtype of Burkitt’s Lymphoma, the 
most common childhood cancer in Equatorial Africa [119]. It is believed that the two pathogens 
interact at the B cell level and this may contribute to the pathogenesis of BL [119]. In fact, 
chronic P. falciparum malaria infection induces a constant antigenic stimulation of the B cell 
compartment which promotes EBV infection of B cells [119]. This might therefore represent a 
favourable environment that enables infection of the B cell compartment by low-efficiency 
transforming EBV strains, such as type 2 strains.  
Several studies have suggested that P. falciparum acts as a B cell mitogen and promotes B cell 
proliferation in vitro [505,506,507,508,509,510] and recently a P. falciparum protein expressed 
on the surface of infected erythrocytes, was shown to act as a polyclonal B cell activator of B 
cells [509]. Furthermore, administration of extracts from cultured P. falciparum to peripheral 
blood lymphocytes ex vivo enhances the frequency of spontaneous establishment of EBV-LCLs 
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[510] and the number of EBV-infected B cells is increased in children during an episode of acute 
P. falciparum malaria [511]. Recently, it has been recognised that Toll-like receptor (TLR) 
signalling may serve as third signal required for optimal B cell-activation, in addition to antigen 
binding to the B cell receptor (BCR) and CD40 stimulation [512]. Stimulation of TLR7 and 
TLR9 pathways with synthetic ligands (R837 and R848) and CpG DNA respectively have been 
shown to drive activation and proliferation of B cells [513,514,515]. Importantly, P. falciparum 
has been demonstrated to express a TLR9-ligand during blood stage malaria and malaria pigment 
hemozoin has been shown to activate TLR9 [516,517]. Furthermore, a study by Iskra et al. 
showed that the TLR9-ligand CpG DNA synergistically augments EBV-induced B cell 
proliferation and transformation in vitro. In addition, ligands for TLR2/7/8 or whole bacteria 
were demonstrated to have a superadditive effect on proliferation of EBV-infected B cells [518]. 
Collectively, these observations suggest that microbial agents present during EBV infection, 
such as P. falciparum malaria, might have an effect on EBV-induced B cell transformation. It is 
therefore possible that the chronic antigenic stimulation of B cells induced by P. falciparum 
(CIDR1α or TLR ligands) in malaria holoendemic areas might complement the poor B cell 
transformation potential of type 2 EBV, allowing this viral strain to colonize the B cell 
compartment of the host in these regions as effectively as type 1 EBV strains. Additionally, the 
cytokine milieu produced during malaria infection may also offer a compensatory mechanism for 
the inefficient primary B cell transformation capability of type 2 EBV. The cytokine IL-10, for 
example, is highly produced during malaria infection and has been found to act as a B cell 
stimulatory factor [519,520,521]. These speculations are further corroborated by epidemiological 
data showing that in HIV-positive patients in Western communities type 2 EBV strains are 
detected at much higher frequency (30%) than in healthy carriers from the same geographical 
areas, in which type 2 EBV prevalence is <3% [419,429,430]. This supports the idea that type 2 
EBV may be successful at colonizing hosts only in the presence of multiple microbial infection, 
a situation frequently observed in patients with a compromised immune system, which can lead 
to chronic stimulation of the host B cell pool. To shed light on the in vivo physiology of type 2 
strains of EBV, it would be interesting in the future to investigate the interplay between 
P.falciparum’s B cell mitogenic activity, the role of TLRs in promoting B cell proliferation, 
EBV-mediated B cell transformation and EBV types.  
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6 Appendix 
 
6.1 Type 1 and type 2 EBNA-2 protein sequences 
 
 
 
Supplementary Figure 6.1. Amino acid sequence alignment of type 1 and type 2 EBNA-2 proteins 
The predicted amino acid sequences of type 1 and type 2 EBNA-2 were derived from the B95-8 (GenBank 
accession number AJ507799) and AG876 (GenBank accession number NC009334) EBV strains respectively.  
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6.2 Optimization of Neon transfection protocols in B cell lines  
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Supplementary Figure 6.2. Standard Neon transfection protocols tested for Daudi (A), P3HR1 cl.16 (B), 
DG75 (C) and BJAB (D) B cell lines 
To determine the best electroporation parameters for each B cell line, aliquots of 2 x 106 cells were transfected with 
5 µg of a GFP-expression plasmid (pMAX GFP, Amaxa) using a range of 24 standard transfection protocols 
provided by the Neon transfection system (Invitrogen), as described in section 2.2.6.3. 24 hours after transfection, 
the cells were analysed by flow cytometry. Transfection efficiency was assessed by measuring the percentage of 
viable cells (determined by the side versus forward scatter profile) and the percentage of GFP-positive cells 
(determined by fluorescence intensity detected in the green channel). Transfection protocols number 9, 8, 11 and 14 
gave the best transfection efficiencies for Daudi, P3HR1 cl.16 DG75 and BJAB cell lines respectively. 
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6.3 Titration of OriP-p294 and pSNOC plasmids expressing EBNA-
2 and EBNA-LP respectively in EBV-negative DG75 cells using 
the Neon transfection system 
 
 
 
Supplementary Figure 6.3. Western blot analysis of EBNA-2 and EBNA-LP expression levels in Neon-
transfected DG75 cells 
2 x 106 DG75 cells (EBV-negative) were transfected with Neon transfection protocol number 11 (see section 2.2.6.3 
and Supplementary Figure 2) with 2-fold serial dilutions (880, 440, 220, 110, 55 and 27.5 nmol) of the plasmids 
OriP-p294 E2 T1 (~14 kb) and pSNOC T1 ELP 3R (8420 bp), which express type 1 EBNA-2 and type 1 3-repeat 
EBNA-LP respectively. The experiment was performed in duplicate. 24 hours after transfection cells were harvested 
and protein extracts were analysed by western blotting using the PE2 and 4D3 antibodies, in order to detect 
expression levels of EBNA-2 and EBNA-LP respectively. ß-actin immunoblot was included in the analysis to ensure 
equal loading of the proteins. EBNA-2 was detected only when 2, 4 or 8 µg of plasmid were transfected, using 
exposure times routinely used for the PE2 antibody. EBNA-LP could be detected at any plasmid dose used. The 
analysis revealed that 220 and 440 nmol are the minimum plasmid doses required to detect EBNA-2 expression on a 
western blot and to give good expression levels of EBNA-LP. Therefore, these plasmid doses were used in the 
subsequent transfection experiments in Daudi and P3HR1 cl.16 cell lines, aimed to set up a functional assay for 
cooperation between type 1 / type 2 EBNA-2 and type 1 / type 2 EBNA-LP (section 3.2.1.3.2).  
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6.4 cDNA sequence of a 3-repeat EBNA-LP from the Jijoye strain 
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Supplementary Figure 6.4. Nucleotide sequence alignment of EBNA-LP coding sequence from Jijoye, B95-8 
(type 1 prototype) and AG876 (type 2 prototype) EBV strains 
The sequence coding for a 3-repeat EBNA-LP is shown. Clones 3, 7, 5 and 2 represent 4 different cDNA clones 
obtained from the Jijoye strain (section 3.2.1.3.3). Nucleotides identical between all the sequences are highlighted in 
yellow whereas nucleotides identical only between some of the sequences are coloured in blue. Boxed regions 
represent the W1, W2, Y1 and Y2 exons. Jijoye EBNA-LP sequence is type 2 in the W1 repeated exons and type 1 
in the unique Y1 and Y2 exons. AG876 (GenBank NC009334) and B95-8 (GenBank NC007605) EBNA-LP 
sequences are included in the alignment. 
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6.5 Purity of human primary B cells isolated from buffy coat 
residues  
 
 
 
Supplementary Figure 6.5. Flow cytometry analysis of CD20 surface expression of human primary B cells 
purified from buffy coat using RosetteSEP method (StemCell Technologies) 
Human primary B cells were isolated from buffy coats as described in section 2.2.12 and then live-stained for the 
surface marker CD20 (section 2.6.1) in order to determine the purity of the B cell population. (A) Dot plot 
displaying the forward and side scatter profile of the cells analysed. The gated population is marked by the oval 
(R3). (B) Histograms showing fluorescence of cells either left unstained (top panel), or stained with FITC-labelled 
isotype control antibody (middle panel) and with FITC-conjugated anti-CD20 antibody (bottom panel). R4 
represents the percentage of fluorescent cells and is set at <1% in unstained cells. CD20 expression indicated that the 
purity of the isolated B cells is 94%. 
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6.6 Titration of AG876 and B95-8 viral preparations 
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Supplementary Figure 6.6. Flow cytometry analysis of intracellular expression of EBNA-2 in human primary 
B cell infected with B95-8 and AG876 EBV virus 
2-fold serial dilutions (200, 100, 50, 25 and 12.5 µl) of B95-8 and AG876 concentrated viral preparations were used 
to infect aliquots of 2 x 106 primary B cells. 48 hours after infection, cells were fixed, permeabilized and stained for 
EBNA-2, as described in section 2.6.2. The PE2 antibody was used as a primary antibody at a 1:50 dilution followed 
by a FITC-coupled secondary antibody. (A) Dot plot of the forward and side scatter profile of the cell populations 
analysed. The gated population is marked by the oval (R3). (B) and (C) Histogram plots showing the fluorescence 
of stained cells detected in the FITC channel for either mock-infected cells (B) or cells infected with a range of 
amounts of B95-8 (left panels) and AG876 (right panels) viral preparations (C). Positive fluorescence boundaries 
are marked by horizontal lines (R4) and are set in order to give <1% of FITC-positive mock-infected cells. Numbers 
displayed in the top right corner of each histogram plot indicate the percentage of FITC-positive cells, which 
represent a measure of EBNA-2-positive cells (reported in figure 3.20). Doses of viruses used for infection are 
shown on the right hand-side of the histograms. 
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6.7 Measurement of GFP content in 293 stable cell lines carrying 
mutant EBNA-2 EBV-BAC constructs  
 
 
 
Supplementary Figure 6.7. Flow cytometry analysis of 293-T2 E2 EBV-BAC and 293-C2 E2 EBV-BAC cell 
lines 
The 293 stable cell lines transfected with the EBNA-2 EBV-BAC mutant constructs, which comprise a GFP 
cassette, were analysed by flow cytometry in order to detect GFP expression. (A) Dot plot of the forward and side 
scatter profile of the cell populations analysed. The gated population is marked by the oval (R3). (B) Histograms 
showing the fluorescence detected in the green channel for either untransfected 293 cells or 293 cells stably 
transfected with type 2 (T2) and chimaera 2 (C2) EBNA-2 (E2) EBV-BAC. 100% of both cell populations analysed 
were GFP-positive, demonstrating that the cell lines stably carry the BAC constructs. 
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6.8 Characterization of EBNA-2 EBV-BAC mutants recovered 
from 293 virus-producer clonal cell lines 
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Supplementary Figure 6.8. PFGE analysis of EcoRI and EcoRV restriction digests of type 1 (T1), type 2 (T2) 
and chimaera 2 (C2) EBNA-2 (E2) EBV-BACs recovered from 293 virus-producer cell lines.  
Episomal BAC DNA was recovered from 293 clonal cell lines by preparation of low molecular weight DNA 
(section 2.3.3.1.2) and amplification in E. Coli (section 2.3.3.1.11). Small scale preparations of the BAC DNA were 
carried out from 2 single colonies, as described in section 2.3.3.1.13. 5 µl of EBV-BAC DNA preparations were 
digested with EcoRI (A) and EcoRV (B) restriction endonucleases and analysed on a pulsed field gel. The EcoRI 
and EcoRV patterns shown here are identical to those of the original BACs used to establish the 293 clones (Figure 
2.11), demonstrating that the BACs had not suffered any alterations or rearrangements in the 293 cells. (A) EcoRI 
digest. The ~ 46.4 kb band detected in the type 1 EBNA-2 EBV-BAC (T1 E2) and corresponding to a DNA 
fragment that comprises the BamHI W repeat region and the EBNA-2 ORF, was absent in the 2 mutant EBNA-2 
BAC constructs. It was replaced either by a double band of ~ 20 kb size in the type 2 EBNA-2 EBV-BAC (T2 E2) 
or 2 bands of ~ 25.8 and 20.6 kb in the chimaera 2 EBNA-2 EBV-BAC (C2 E2) construct. This is because of the 
insertion of an extra EcoRI site in front of the ATG in the mutant EBNA-2 ORFs (described in section 2.3.3.3.3). 
The size of the ~20 kb doublet produced in the T2 E2 construct indicates that 2 BamHI W repeats (~ 6 kb) had been 
lost (see section 2.3.3.3.3). (B) EcoRV digest. The ~ 34 kb band detected in the type 1 EBNA-2 EBV-BAC (T1 E2) 
sample was replaced by a ~ 28 kb fragment in the type 2 EBNA-2 EBV-BAC (T2 E2) preparations analysed, 
confirming the loss 2 BamHI W repeats of ~ 6 kb, compared to the type 1 BAC. The EcoRV digestion pattern of the 
chimaera 2 EBNA-2 (C2 E2) construct is identical to that of the type 1 EBNA-2 BAC. Either 1 (293-T1 and T2 E2 
EBV-BAC) or 4 (293-C2 E2 EBV-BAC) individual 293 clonal cell lines were screened. 2 DNA mini-preparations 
for each 293 clone tested were analysed. M: size marker lambda DNA-monoCut Mix (NEB). Size of the marker 
DNA fragments are shown. 
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6.9 Characterization of EBNA-2 chimaera 2 EBV-BAC mutants 
recovered from 293 virus-producer clonal cell lines 
 
 
 
 
Supplementary Figure 6.9. PCR analysis of type 1 and chimaera 2 EBNA-2 EBV-BACs 
0.25 µl of miniprep EBV-BAC DNA recovered from clonal 293 producer cell lines were analysed by PCR as 
described in section 2.3.3.3.3 (Figure 2.19) in order to identify chimaera 2 EBNA-2 (C2 E2) positive clones. 4 
clonal cell lines stably transfected with the chimaera 2 EBNA-2 EBV-BAC constructs were tested (clones 2A, 2D, 
7.21 and 7B), and 3 DNA small scale preparations for each clone were screened by PCR. EBV-BAC carrying the 
type 1 EBNA-2 (T1 E2) was included in the analysis as negative control. Detection of the 170 bp PCR product in all 
the C2 E2 samples confirmed that all the cell lines tested were positive for the presence of the chimaeric EBNA-2 
ORF in the EBV-BAC constructs. pBS E2 C2: positive control, EBNA-2 chimaera 2 sequence in pBluescript vector 
background. ntc: no template control. M: 100 bp size marker (NEB). 
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6.10 Validation of the anti-human CXCR7 antibody (ProteinTech, 
IL, USA) 
 
 
 
Supplementary Figure 6.10. Characterization of the anti-human CXCR7 antibody (ProteinTech, IL, USA) in 
the EREB2.5 cell line 
(A) EREB2.5 cells were starved of oestrogen for 5 days and then re-stimulated with 1 µM oestrogen for 1, 4, 8 and 
24 hours. At these time-points, cells were harvested and protein extracts were prepared by RIPA-extraction and 
analysed by western blotting with the anti-human CXCR7 antibody. Protein samples from EREB2.5 cells grown in 
the presence of oestrogen were included in the analysis as positive control. The antibody detects a band of 
approximately 50 kDa (unmodified CXCR7 protein), and also several species of higher molecular weight, which are 
likely to be glycosylated isoforms of the receptor. Due to high basal levels of expression of CXCR7, no differences 
in expression levels of the receptor were observed upon inactivation of ER-EBNA-2 and throughout the time-course 
of oestrogen re-stimulation. (B) To ensure that the high molecular weight bands detected by the anti-CXCR7 
antibody represent glycosylated species of the receptor, the glycosylation inhibitor tunicamycin (Sigma) was used. 
EREB2.5 cells were oestrogen-starved for 5 days and then re-stimulated with 1 µM oestrogen in the presence or 
absence of tunicamycin (1 µg/µl) for 24 hours. The presence of tunicamycin reduced the amount of high molecular 
weight CXCR7 species, indicating that these are glycosylated isoforms of the receptor. The experiments shown in 
this figure were carried out by Claudio Elgueta. 
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6.11  PCR-genotyping of Daudi EBV strain 
 
 
Supplementary Figure 6.11. PCR-typing of EBNA-3 loci of Daudi EBV strain reveals they are type 1. 
1 µg of genomic DNA extracted from Daudi cells was PCR-amplified with primer pairs specific for either EBNA-
3A (A), EBNA-3B (B) or EBNA-3C (C) loci. Primer pairs (described in section 2.8.11 and [405]) anneal to type-
common sequences and give rise to amplicons of type specific size (EBNA-3A type 1: 276 bp, type 2: 237 bp; 
EBNA-3B type 1: 125 bp, type 2: 149 bp; EBNA-3C type 1: 153 bp, type 2: 246 bp). DG75 cell lines served as 
negative control. B95-8 and AG876 were used as positive controls for type 1 and type 2 respectively. M: size 
marker; ntc: no template control.  
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6.12  Episome rescue from oestrogen-independent EREB2.5 LCLs 
 
 
 
Supplementary Figure 6.12. Agarose gel analysis of EcoRI restriction digests of low molecular weight DNA 
recovered from oestrogen-independent EREB2.5 LCLs carrying OriP-p294 E2T1 plasmid 
Episomal BAC DNA was recovered from oestrogen-independent EREB2.5 cell lines transfected with the OriP-p294 
E2T1 plasmid, expressing type 1 EBNA-2, by preparation of low molecular weight (MW) DNA (section 2.3.3.1.2) 
and amplification in E. Coli (section 2.3.3.1.11). Small scale preparations of the plasmid DNA were performed from 
several single colonies, as described in section 2.3.3.1.13. 5 µl of DNA preparations were digested with EcoRI 
restriction endonuclease and analysed on a 1% agarose gel. The plasmids OriP-p294 E2T1 and p554-4 digested with 
EcoRI served as positive controls. Only the OriP-p294 plasmid is recovered from the LCLs, but not the p554-4 
vector, suggesting the latter has become integrated into the cells. n.d.: non-digested plasmid. 1 kb and 100 bp M: 
DNA size markers (NEB). 
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6.13  OriP-p294 plasmids do not express any EBNA-LP isoform 
 
 
 
Supplementary Figure 6.13. Western blot analysis of EBNA-LP expression in EREB2.5 (A) and DG75 (B) 
cells transiently transfected with OriP-p294 plasmids 
6 x 106 cells were Amaxa-transfected with 5µg of OriP-p294 vectors carrying either type 1 EBNA-2 (E2T1), type 2 
EBNA-2 (E2T2) or no EBNA-2 (e.v.) sequences. A 2-repeat EBNA-LP expressing vector was also transfected as 
positive control [ELP 2R (+)]. 4 days after transfection cells were harvested, proteins were extracted with RIPA 
lysis buffer and subjected to western blot analysis using the JF186 antibody, specific for type 1 EBNA-LP. No 
EBNA-LP is expressed from the OriP-p294 plasmids in either EREB2.5 cells (which express already an endogenous 
3-repeat EBNA-LP, encoded by the p554-5 vector) (A) or in the EBV-negative cell line DG75 (B). Numbers on the 
left hand-side of the EBNA-LP immunoblot panel represent apparent protein molecular weight in kDa. β-actin 
immunoblot was performed to ensure equal protein loading on the gel. B95-8 and AG876: positive and negative 
controls respectively for EBNA-LP expression. EREB2.5 n.t. and DG75 n.t.: non-transfected cells. 3R and 2R: 3-
repeat and 2-repeat EBNA-LP isoforms.  
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